testosterone patients referred dysfunction erectile
testosterone patients referred dysfunction
testosterone screened basis desire gynecomastia
testosterone gynecomastia
testosterone heptylate consisted hyperprolactinemia
heptylate consisted hyperprolactinemia
bromocriptine hypogonadism
bromocriptine hypogonadism consisted hyperprolactinemia
testosterone heptylate consisted hypogonadism
heptylate consisted hypogonadism
testosterone determination discovered tumors pituitary
testosterone determination discovered tumors
testosterone levels Most seemed result luteinizing dysfunction hypothalamic
testosterone levels Most seemed result luteinizing dysfunction
testosterone levels Most seemed result have role dysfunction erectile
testosterone levels Most seemed result have role dysfunction
testosterone prolactin cannot erectile
testosterone prolactin cannot dysfunction
testosterone desire gynecomastia
vasopressin gene expression Upregulation insipidus diabetes
vasopressin gene expression Upregulation insipidus
lithium nuclei gene expression Upregulation insipidus diabetes
lithium nuclei gene expression Upregulation insipidus
lithium polyuria
Li lithium polyuria
arginine gene expression investigated lithium polyuria
vasopressin gene expression investigated lithium polyuria
AVP gene expression investigated lithium polyuria
AVP elevation contribute dehydration
AVP expression upregulation elevation contribute dehydration
Li SON expression upregulation elevation contribute dehydration induced rat insipidus diabetes
Li SON expression upregulation elevation contribute dehydration induced rat insipidus
AVP elevation contribute dehydration induced rat insipidus diabetes
AVP elevation contribute dehydration induced rat insipidus
AVP expression upregulation elevation contribute dehydration induced rat insipidus diabetes
AVP expression upregulation elevation contribute dehydration induced rat insipidus
Li SON expression upregulation elevation contribute dehydration
lidocaine man bolus resulted depression
lidocaine represented had conditions predisposed development bradyarrhythmias
UM administered tachycardias ventricular
UM administered tachycardias
272 administered tachycardias ventricular
272 administered tachycardias
N 272 administered tachycardias ventricular
N 272 administered tachycardias
N N 272 administered tachycardias ventricular
N N 272 administered tachycardias
dimethylpropranolol N 272 administered tachycardias ventricular
dimethylpropranolol N 272 administered tachycardias
UM converted tachycardia ventricular
UM converted tachycardia
272 converted tachycardia ventricular
272 converted tachycardia
oxygen therapy cystitis hemorrhagic
oxygen therapy cystitis
cyclophosphamide control therapy cystitis hemorrhagic
cyclophosphamide control therapy cystitis
cyclophosphamide therapy granulomatosis Wegener
cyclophosphamide therapy granulomatosis Wegener '
cyclophosphamide therapy granulomatosis s
cyclophosphamide therapy granulomatosis
cyclophosphamide due case cystitis hemorrhagic
cyclophosphamide due case cystitis
prostaglandin F irrigation treatment failed control hemorrhage
F irrigation treatment failed control hemorrhage
2 alpha F irrigation treatment failed control hemorrhage
alpha F irrigation treatment failed control hemorrhage
cyclophosphamide treatment alternative offer cystitis hemorrhagic
cyclophosphamide treatment alternative offer cystitis
cisplatin striking BACKGROUND rate effects neurotoxic
CDDP BACKGROUND rate effects neurotoxic
carboplatin advantages striking BACKGROUND rate effects neurotoxic
CBDCA advantages striking BACKGROUND rate effects neurotoxic
CBDCA higher schedules drugs neurotoxic
CDDP caused those similar neurotoxic
CDDP caused those similar probable induced neurotoxicity
CBDCA neurotoxic
CBDCA neurotoxic similar probable induced neurotoxicity
steroids efficacy seizures
steroids demonstrate actions relevance host disorders neurological
steroids demonstrate actions relevance host disorders neurological and
steroids demonstrate actions relevance host disorders neurological psychiatric
steroids demonstrate actions relevance host disorders
steroid modulate effects cocaine engendered administration kindling seizure
gamma modulate effects cocaine engendered administration kindling seizure
aminobutyric acid gamma modulate effects cocaine engendered administration kindling seizure
acid gamma modulate effects cocaine engendered administration kindling seizure
GABA receptor acid gamma modulate effects cocaine engendered administration kindling seizure
Allopregnanolone tested ability suppress expression development seizures
3 alpha Allopregnanolone tested ability suppress expression development seizures
alpha Allopregnanolone tested ability suppress expression development seizures
hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
5 alpha hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
alpha hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
pregnan alpha hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
20 one hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
one hydroxy alpha Allopregnanolone tested ability suppress expression development seizures
pregnanolone Allopregnanolone tested ability suppress expression development seizures
3 alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
5 beta hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
beta hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
pregnan beta hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
20 one hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
one hydroxy alpha pregnanolone Allopregnanolone tested ability suppress expression development seizures
allopregnanolone alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
ganaxolone Allopregnanolone tested ability suppress expression development seizures
3 alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
hydroxy alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
3 beta alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
beta alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
methyl alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
5 alpha alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
alpha alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
pregnan alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
20 alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
one alpha derivative ganaxolone Allopregnanolone tested ability suppress expression development seizures
allopregnanolone suppressed expression seizures
GABA modulators suppressed expression seizures
ganaxolone allopregnanolone suppressed expression seizures
propranolol toxicity
propranolol toxicity result developed an Alzheimer
propranolol toxicity
propranolol toxicity result developed an Alzheimer dementia
Bradykinin antagonists inhibitors vincristine induced hyperalgesia model chemotherapy diabetic
Bradykinin antagonists inhibitors vincristine induced hyperalgesia model neuropathy
Bradykinin antagonists inhibitors vincristine induced hyperalgesia
nitric synthase antagonists inhibitors vincristine induced hyperalgesia model chemotherapy diabetic
nitric synthase antagonists inhibitors vincristine induced hyperalgesia model neuropathy
oxide synthase antagonists inhibitors vincristine induced hyperalgesia model chemotherapy diabetic
oxide synthase antagonists inhibitors vincristine induced hyperalgesia model neuropathy
nitric synthase antagonists inhibitors vincristine induced hyperalgesia
oxide synthase antagonists inhibitors vincristine induced hyperalgesia
vincristine induced hyperalgesia model chemotherapy diabetic
vincristine induced hyperalgesia model neuropathy
HOE bradykinin antagonists action influence model diabetic
HOE bradykinin antagonists action influence model diabetic streptozotocin
HOE bradykinin antagonists action influence model diabetic streptozotocin induced
HOE bradykinin antagonists action influence model diabetic and
HOE bradykinin antagonists action influence model diabetic neuropathy toxic
HOE bradykinin antagonists action influence model diabetic neuropathy vincristine
HOE bradykinin antagonists action influence model diabetic neuropathy vincristine induced
HOE bradykinin antagonists action influence model diabetic neuropathy
140 HOE bradykinin antagonists action influence model diabetic
140 HOE bradykinin antagonists action influence model diabetic streptozotocin
140 HOE bradykinin antagonists action influence model diabetic streptozotocin induced
140 HOE bradykinin antagonists action influence model diabetic and
140 HOE bradykinin antagonists action influence model diabetic neuropathy toxic
140 HOE bradykinin antagonists action influence model diabetic neuropathy vincristine
140 HOE bradykinin antagonists action influence model diabetic neuropathy vincristine induced
140 HOE bradykinin antagonists action influence model diabetic neuropathy
des HOE action influence model diabetic
des HOE action influence model diabetic streptozotocin
des HOE action influence model diabetic streptozotocin induced
des HOE action influence model diabetic and
des HOE action influence model diabetic neuropathy toxic
des HOE action influence model diabetic neuropathy vincristine
des HOE action influence model diabetic neuropathy vincristine induced
des HOE action influence model diabetic neuropathy
Arg HOE action influence model diabetic
Arg HOE action influence model diabetic streptozotocin
Arg HOE action influence model diabetic streptozotocin induced
Arg HOE action influence model diabetic and
Arg HOE action influence model diabetic neuropathy toxic
Arg HOE action influence model diabetic neuropathy vincristine
Arg HOE action influence model diabetic neuropathy vincristine induced
Arg HOE action influence model diabetic neuropathy
10 HOE action influence model diabetic
10 HOE action influence model diabetic streptozotocin
10 HOE action influence model diabetic streptozotocin induced
10 HOE action influence model diabetic and
10 HOE action influence model diabetic neuropathy toxic
10 HOE action influence model diabetic neuropathy vincristine
10 HOE action influence model diabetic neuropathy vincristine induced
10 HOE action influence model diabetic neuropathy
HOE action influence model diabetic
HOE action influence model diabetic streptozotocin
HOE action influence model diabetic streptozotocin induced
HOE action influence model diabetic and
HOE action influence model diabetic neuropathy toxic
HOE action influence model diabetic neuropathy vincristine
HOE action influence model diabetic neuropathy vincristine induced
HOE action influence model diabetic neuropathy
140 HOE action influence model diabetic
140 HOE action influence model diabetic streptozotocin
140 HOE action influence model diabetic streptozotocin induced
140 HOE action influence model diabetic and
140 HOE action influence model diabetic neuropathy toxic
140 HOE action influence model diabetic neuropathy vincristine
140 HOE action influence model diabetic neuropathy vincristine induced
140 HOE action influence model diabetic neuropathy
NO synthase constitutive inhibitor influence model diabetic
NO synthase constitutive inhibitor influence model diabetic streptozotocin
NO synthase constitutive inhibitor influence model diabetic streptozotocin induced
NO synthase constitutive inhibitor influence model diabetic and
NO synthase constitutive inhibitor influence model diabetic neuropathy toxic
NO synthase constitutive inhibitor influence model diabetic neuropathy vincristine
NO synthase constitutive inhibitor influence model diabetic neuropathy vincristine induced
NO synthase constitutive inhibitor influence model diabetic neuropathy
NO synthase inhibitor constitutive inhibitor influence model diabetic
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin induced
NO synthase inhibitor constitutive inhibitor influence model diabetic and
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy toxic
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine induced
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy
NO synthase inhibitor constitutive inhibitor influence model diabetic
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin
NO synthase inhibitor constitutive inhibitor influence model diabetic streptozotocin induced
NO synthase inhibitor constitutive inhibitor influence model diabetic and
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy toxic
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy vincristine induced
NO synthase inhibitor constitutive inhibitor influence model diabetic neuropathy
bradykinin antagonists action influence model diabetic
bradykinin antagonists action influence model diabetic streptozotocin
bradykinin antagonists action influence model diabetic streptozotocin induced
bradykinin antagonists action influence model diabetic and
bradykinin antagonists action influence model diabetic neuropathy toxic
bradykinin antagonists action influence model diabetic neuropathy vincristine
bradykinin antagonists action influence model diabetic neuropathy vincristine induced
bradykinin antagonists action influence model diabetic neuropathy
bradykinin receptors inhibition confirm paper results RESULTS reduces hyperalgesia diabetic
bradykinin receptors inhibition confirm paper results RESULTS reduces hyperalgesia
NO synthase inducible confirm paper results RESULTS reduces hyperalgesia diabetic
NO synthase inducible confirm paper results RESULTS reduces hyperalgesia
NO activity neuronal inducible confirm paper results RESULTS reduces hyperalgesia diabetic
NO activity neuronal inducible confirm paper results RESULTS reduces hyperalgesia
bradykinin inducible products involved hyperalgesia
NO activation inducible products involved hyperalgesia
NO activation inducible products involved hyperalgesia
des HOE activity L 140 neuropathy toxic
des HOE activity L 140 neuropathy
Arg 140 neuropathy toxic
Arg 140 neuropathy
10 140 neuropathy toxic
10 140 neuropathy
HOE 140 neuropathy toxic
HOE 140 neuropathy
140 neuropathy toxic
140 neuropathy
HOE activity L 140 neuropathy toxic
HOE activity L 140 neuropathy
140 HOE activity L 140 neuropathy toxic
140 HOE activity L 140 neuropathy
bradykinin activity participates streptozotocin induced hyperalgesia
bradykinin activity participates seemed bradykinin hyperalgesia
bradykinin seemed participates streptozotocin induced hyperalgesia
bradykinin hyperalgesia
NO synthase participates streptozotocin induced hyperalgesia
NO synthase participates seemed bradykinin hyperalgesia
NO pathway neuronal seemed participates streptozotocin induced hyperalgesia
NO pathway neuronal seemed bradykinin hyperalgesia
NO inhibitors antagonists doses administration effective alleviation pain neuropathic
NO inhibitors antagonists doses administration effective alleviation pain
bradykinin antagonists doses administration effective alleviation pain neuropathic
bradykinin antagonists doses administration effective alleviation pain
lithium anticonvulsants use type diagnosis structured Patients experienced compared switch manic
lithium anticonvulsants use type diagnosis structured Patients experienced compared switch manic hypomanic
lithium anticonvulsants use type diagnosis II vs DSM
lithium anticonvulsants use type diagnosis II vs IV
lithium anticonvulsants use type diagnosis II vs bipolar
lithium anticonvulsants use type diagnosis II vs I
lithium anticonvulsants use type diagnosis II bipolar
lithium anticonvulsants use type diagnosis II
lithium anticonvulsants use type diagnosis number episodes manic
captopril sensitivity Contribution treated rats hypertensive
captopril treated rats hypertensive
captopril treated contributes importantly effect hypertensive
hexamethonium infusion resulted decline eliminated increase
hexamethonium infusion resulted decline eliminated MAP in
hexamethonium infusion resulted decline eliminated MAP
Pethidine associated pethidine control postoperative
Pethidine associated pethidine control pain
pethidine control postoperative
pethidine control pain
pethidine doses received male year controlled pump management control postoperative
pethidine doses received male year controlled pump management control pain
cyproterone women thromboembolism risk venous
cyproterone women thromboembolism
acetate cyproterone women thromboembolism risk venous
acetate cyproterone women thromboembolism
ethinylestradiol acetate cyproterone women thromboembolism risk venous
ethinylestradiol acetate cyproterone women thromboembolism
cyproterone ethinylestradiol women thromboembolism venous
cyproterone ethinylestradiol women thromboembolism
acetate ethinylestradiol women thromboembolism venous
acetate ethinylestradiol women thromboembolism
cyproterone ethinylestradiol women thromboembolism VTE
acetate ethinylestradiol women thromboembolism VTE
CPA EE ethinylestradiol women thromboembolism venous
CPA EE ethinylestradiol women thromboembolism
CPA EE ethinylestradiol women thromboembolism VTE
ethinylestradiol women thromboembolism venous
ethinylestradiol women thromboembolism
ethinylestradiol women thromboembolism VTE
EE ethinylestradiol women thromboembolism venous
EE ethinylestradiol women thromboembolism
EE ethinylestradiol women thromboembolism VTE
levonorgestrel women years COCs 1 women risk VTE
CPA EE women risk VTE
EE women risk VTE
CPA EE taking similar risk VTE
EE taking similar risk VTE
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal breast
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal head
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers
fluorouracil IMPORTANCE mainstay treatment colorectal
fluorouracil IMPORTANCE mainstay treatment colorectal breast
fluorouracil IMPORTANCE mainstay treatment colorectal and
fluorouracil IMPORTANCE mainstay treatment colorectal head
fluorouracil IMPORTANCE mainstay treatment colorectal and
fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
fluorouracil IMPORTANCE mainstay treatment colorectal cancers
5 fluorouracil IMPORTANCE mainstay treatment colorectal
5 fluorouracil IMPORTANCE mainstay treatment colorectal breast
5 fluorouracil IMPORTANCE mainstay treatment colorectal and
5 fluorouracil IMPORTANCE mainstay treatment colorectal head
5 fluorouracil IMPORTANCE mainstay treatment colorectal and
5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal breast
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal and
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal head
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal and
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
FU 5 fluorouracil IMPORTANCE mainstay treatment colorectal cancers
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment tumors
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal breast
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal head
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal and
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers neck
Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment colorectal cancers
5 Fluoropyrimidines fluorouracil IMPORTANCE mainstay treatment tumors
fluorouracil IMPORTANCE mainstay treatment tumors
5 fluorouracil IMPORTANCE mainstay treatment tumors
FU 5 fluorouracil IMPORTANCE mainstay treatment tumors
capecitabine safety gain populations patients disease age renal
capecitabine safety gain populations patients disease age and
capecitabine safety gain populations patients disease age kidney
capecitabine safety gain populations patients disease
Capecitabine has given patients dysfunctions age hepatic
Capecitabine has given patients dysfunctions age and
Capecitabine has given patients dysfunctions age renal
Capecitabine has given patients dysfunctions
Haloperidol induced parkinsonian
AIDA doses 5 microg rigidity muscle
AIDA doses 5 microg rigidity
metocurine abolished rigidity
AZT induced anemia patients AIDS
AZT therapy induced anemia patients AIDS
antidepressant fluoxetine exposure disease patients disability motor
antidepressant fluoxetine exposure disease patients disability
antidepressant fluoxetine exposure disease Parkinson idiopathic
antidepressant fluoxetine exposure disease Parkinson
antidepressant fluoxetine exposure disease Parkinson '
antidepressant fluoxetine exposure disease s
antidepressant fluoxetine exposure disease
fluoxetine exposure disease Parkinson idiopathic
fluoxetine exposure disease Parkinson
fluoxetine exposure disease Parkinson '
fluoxetine exposure disease s
fluoxetine exposure disease
dopamine capacity fluoxetine patients Parkinson
dopamine capacity fluoxetine patients Parkinson '
dopamine capacity fluoxetine patients s
dopamine capacity fluoxetine patients disease
fluoxetine patients Parkinson
fluoxetine patients Parkinson '
fluoxetine patients s
fluoxetine patients disease
interferon therapy hemolysis
ribavirin reduction timing C chronic
ribavirin reduction timing C hepatitis
ribavirin reduction timing C
ribavirin interferon therapy hemolysis patients timing C chronic
ribavirin interferon therapy hemolysis patients timing C hepatitis
ribavirin interferon therapy hemolysis patients timing C
interferon therapy hemolysis patients timing C chronic
interferon therapy hemolysis patients timing C hepatitis
interferon therapy hemolysis patients timing C
ribavirin reduction timing patients hemolysis
ribavirin interferon therapy hemolysis
ribavirin reduction timing examined patients hemolysis
ribavirin reduction patients 10 continue < g values decreased anemia
rifampicin administration developed failure renal
rifampicin administration developed failure
Cocaine use associated vasoconstriction vasculitis
Cocaine use associated complications neurovascular
Cocaine use associated complications
cocaine use associated SAH underwent patients found evidence narrowing evidence narrowing vasculitis
Nicotine appear enhance thrombosis
fluorouracil therapy associated toxicity cardiac
fluorouracil therapy associated toxicity
5 therapy associated toxicity cardiac
5 therapy associated toxicity
FU 5 therapy associated toxicity cardiac
FU 5 therapy associated toxicity
5 infusion treatment tumors
FU infusion treatment tumors
5 infusion associated patients disease coronary
5 infusion associated patients disease artery
5 infusion associated patients disease
- infusion associated patients disease coronary
- infusion associated patients disease artery
- infusion associated patients disease
FU infusion associated patients disease coronary
FU infusion associated patients disease artery
FU infusion associated patients disease
Papaverine hydrochloride direct vasodilator used manage vasospasm
hydrochloride direct vasodilator used manage vasospasm
papaverine cases described dysfunction cranial
papaverine cases described dysfunction nerve
papaverine cases described dysfunction
papaverine received vasospasm
papaverine used manage vasospasm
papaverine treatment vasospasm
papaverine avoid deficits cranial
papaverine avoid deficits nerve
papaverine avoid deficits
ibuprofen use associated described child developed syndrome vanishing
ibuprofen use associated described child developed syndrome bile
ibuprofen use associated described child developed syndrome duct
ibuprofen use associated described child developed syndrome
ursodeoxycholic acid therapy unrelenting disease cholestatic
ursodeoxycholic acid therapy unrelenting disease
acid therapy unrelenting disease cholestatic
acid therapy unrelenting disease
tacrolimus acid therapy unrelenting cirrhosis
prednisone acid therapy unrelenting cirrhosis
prednisone acid therapy unrelenting disease cholestatic
prednisone acid therapy unrelenting disease
ursodeoxycholic acid therapy unrelenting cirrhosis
acid therapy unrelenting cirrhosis
tacrolimus acid therapy unrelenting disease cholestatic
tacrolimus acid therapy unrelenting disease
atorvastatin effects Anti hypertension
superoxide production increased deficiency Dexamethasone characterized hypertension
O superoxide production increased deficiency Dexamethasone characterized hypertension
2 - O superoxide production increased deficiency Dexamethasone characterized hypertension
- O superoxide production increased deficiency Dexamethasone characterized hypertension
nitric oxide associated dysfunction characterized hypertension
oxide associated dysfunction characterized hypertension
NO oxide associated dysfunction characterized hypertension
Atorvastatin possesses reduced O production forms hypertension
Ato possesses reduced O production forms hypertension
O production forms hypertension
2 O production forms hypertension
NO availability improve reported properties possesses reduced O production forms hypertension
lamivudine monotherapy cirrhosis
lamivudine monotherapy cirrhosis improvement patient virus hepatitis
lamivudine monotherapy cirrhosis improvement patient virus B
lamivudine administration cirrhosis
clozapine commencement developed year schizophrenia
clozapine remains standard treatment psychosis
alcohol consumption patients failure Acute
alcohol consumption patients failure liver
alcohol consumption patients failure
paracetamol ingesting failure Acute
paracetamol ingesting failure liver
paracetamol ingesting failure
alcohol development hepatotoxicity
alcohol consumers developed failure liver
alcohol consumers developed failure
alcohol consumption days paracetamol 3 developed failure liver
alcohol consumption days paracetamol 3 developed failure
alcohol consumption g factors patients possible failure liver
alcohol consumption g factors patients possible failure
aminoglycoside treatment effects Nephrotoxic
aminoglycosides act nephrotoxicants level inducing impairment
aminoglycosides act nephrotoxicants level inducing impairment reabsorption of
aminoglycosides act nephrotoxicants level inducing impairment reabsorption renal
aminoglycosides act nephrotoxicants level inducing impairment reabsorption
D developed patients arthritis rheumatoid
D developed patients arthritis
penicillamine D developed patients arthritis rheumatoid
penicillamine D developed patients arthritis
glyceryl trinitrate Effect sphincter
glyceryl trinitrate Effect spasm of
glyceryl trinitrate Effect spasm Oddi
glyceryl trinitrate Effect spasm
trinitrate Effect sphincter
trinitrate Effect spasm of
trinitrate Effect spasm Oddi
trinitrate Effect spasm
morphine Effect sphincter
morphine Effect spasm of
morphine Effect spasm Oddi
morphine Effect spasm
prostigmine evoked spasm Effect sphincter
prostigmine evoked spasm of
prostigmine evoked spasm Oddi
prostigmine evoked spasm
glyceryl trinitrate effect induced evaluated sphincter
glyceryl trinitrate effect induced evaluated sphincter spasm of
glyceryl trinitrate effect induced evaluated sphincter spasm Oddi
glyceryl trinitrate effect induced evaluated sphincter spasm
trinitrate effect induced evaluated sphincter
trinitrate effect induced evaluated sphincter spasm of
trinitrate effect induced evaluated sphincter spasm Oddi
trinitrate effect induced evaluated sphincter spasm
morphine trinitrate effect induced evaluated sphincter
morphine trinitrate effect induced evaluated sphincter spasm of
morphine trinitrate effect induced evaluated sphincter spasm Oddi
morphine trinitrate effect induced evaluated sphincter spasm
glyceryl trinitrate effect induced evaluated patients sphincter
glyceryl trinitrate effect induced evaluated patients sphincter dyskinesia of
glyceryl trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
glyceryl trinitrate effect induced evaluated patients sphincter dyskinesia
trinitrate effect induced evaluated patients sphincter
trinitrate effect induced evaluated patients sphincter dyskinesia of
trinitrate effect induced evaluated patients sphincter dyskinesia Oddi
trinitrate effect induced evaluated patients sphincter dyskinesia
prostigmine morphine trinitrate effect induced evaluated sphincter
prostigmine morphine trinitrate effect induced evaluated sphincter spasm of
prostigmine morphine trinitrate effect induced evaluated sphincter spasm Oddi
prostigmine morphine trinitrate effect induced evaluated sphincter spasm
morphine administration prostigmine induced Sphincter
morphine administration prostigmine induced Sphincter spasm of
morphine administration prostigmine induced Sphincter spasm Oddi
morphine administration prostigmine induced Sphincter spasm
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter spasm of
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter spasm Oddi
morphine subcutaneously intramuscularly 0 prostigmine induced Sphincter spasm
prostigmine induced Sphincter
prostigmine induced Sphincter spasm of
prostigmine induced Sphincter spasm Oddi
prostigmine induced Sphincter spasm
prostigmine intramuscularly 0 prostigmine induced Sphincter
prostigmine intramuscularly 0 prostigmine induced Sphincter spasm of
prostigmine intramuscularly 0 prostigmine induced Sphincter spasm Oddi
prostigmine intramuscularly 0 prostigmine induced Sphincter spasm
glyceryl trinitrate effectiveness evidence sphincter
glyceryl trinitrate effectiveness evidence sphincter spasm of
glyceryl trinitrate effectiveness evidence sphincter spasm Oddi
glyceryl trinitrate effectiveness evidence sphincter spasm
trinitrate effectiveness evidence sphincter
trinitrate effectiveness evidence sphincter spasm of
trinitrate effectiveness evidence sphincter spasm Oddi
trinitrate effectiveness evidence sphincter spasm
morphine trinitrate effectiveness evidence sphincter
morphine trinitrate effectiveness evidence sphincter spasm of
morphine trinitrate effectiveness evidence sphincter spasm Oddi
morphine trinitrate effectiveness evidence sphincter spasm
glyceryl trinitrate able relevance treatment sphincter
glyceryl trinitrate able relevance treatment sphincter dyskinesia of
glyceryl trinitrate able relevance treatment sphincter dyskinesia Oddi
glyceryl trinitrate able relevance treatment sphincter dyskinesia
trinitrate able relevance treatment sphincter
trinitrate able relevance treatment sphincter dyskinesia of
trinitrate able relevance treatment sphincter dyskinesia Oddi
trinitrate able relevance treatment sphincter dyskinesia
dobutamine stress spasm due ischemia Myocardial
dobutamine stress spasm due ischemia
Dobutamine echocardiography test ischemia myocardial
Dobutamine echocardiography test ischemia
dobutamine induced ischemia myocardial
dobutamine induced ischemia
acetylcholine injection induced documented stenosis coronary
acetylcholine injection induced documented stenosis artery
acetylcholine injection induced documented stenosis
milrinone treatment Vasopressin hypotension failure heart
milrinone treatment Vasopressin hypotension failure
Vasopressin hypotension failure heart
Vasopressin hypotension failure
milrinone treatment failure heart
milrinone treatment failure
milrinone treatment hypotension failure heart
milrinone treatment hypotension failure
milrinone effect inhibiting restored patients failure heart
milrinone effect inhibiting restored patients failure
vasopressin doses restored patients failure heart
vasopressin doses restored patients failure
metronidazole treat infection
tyrosine phosphatase nephrosis
PAN injection days as include phase proteinuria associated effacement phase proteinuria associated glomerulosclerosis
Nitro ester protector ototoxicity
L Nitro ester protector ototoxicity
arginine ester protector ototoxicity
methyl ester protector ototoxicity
ester protector ototoxicity
gentamicin ototoxicity
gentamicin caused loss high
gentamicin caused loss frequency
gentamicin caused loss hearing
gentamicin caused loss
nitro act high
nitro act high loss frequency
nitro act high loss hearing
nitro act high loss
L nitro act high
L nitro act high loss frequency
L nitro act high loss hearing
L nitro act high loss
arginine ester act high
arginine ester act high loss frequency
arginine ester act high loss hearing
arginine ester act high loss
methyl ester act high
methyl ester act high loss frequency
methyl ester act high loss hearing
methyl ester act high loss
ester act high
ester act high loss frequency
ester act high loss hearing
ester act high loss
L ester act high
L ester act high loss frequency
L ester act high loss hearing
L ester act high loss
NAME L ester act high
NAME L ester act high loss frequency
NAME L ester act high loss hearing
NAME L ester act high loss
nitric oxide inhibitor nitro act high
nitric oxide inhibitor nitro act high loss frequency
nitric oxide inhibitor nitro act high loss hearing
nitric oxide inhibitor nitro act high loss
oxide inhibitor nitro act high
oxide inhibitor nitro act high loss frequency
oxide inhibitor nitro act high loss hearing
oxide inhibitor nitro act high loss
NO oxide inhibitor nitro act high
NO oxide inhibitor nitro act high loss frequency
NO oxide inhibitor nitro act high loss hearing
NO oxide inhibitor nitro act high loss
Aminoglycoside antibiotics used inhibitor nitro act high
Aminoglycoside antibiotics used inhibitor nitro act high loss frequency
Aminoglycoside antibiotics used inhibitor nitro act high loss hearing
Aminoglycoside antibiotics used inhibitor nitro act high loss
NO production involves need problem ototoxicity
NO production involves mechanism ototoxic
NO inhibitors use assess need problem ototoxicity
NO inhibitors use assess need involves mechanism ototoxic
aminoglycoside prevention assess need problem ototoxicity
aminoglycoside prevention assess need involves mechanism ototoxic
NO production involves need assess prevention loss sensorineural
NO production involves need assess prevention loss hearing
NO production involves need assess prevention loss
NO inhibitors use assess prevention loss sensorineural
NO inhibitors use assess prevention loss hearing
NO inhibitors use assess prevention loss
aminoglycoside prevention loss sensorineural
aminoglycoside prevention loss hearing
aminoglycoside prevention loss
L induced loss hearing
L induced loss
NAME gentamicin L induced loss hearing
NAME gentamicin L induced loss
NAD diet Influence precursors hepatotoxicity
poly polymerase inhibitor amide effects demonstrated mice suffering acetaminophen hepatitis
ADP polymerase inhibitor amide effects demonstrated mice suffering acetaminophen hepatitis
ribose ADP polymerase inhibitor amide effects demonstrated mice suffering acetaminophen hepatitis
poly polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury liver
poly polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury
ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury liver
ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury
ribose ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury liver
ribose ADP polymerase inhibitor amide effects demonstrated mice suffering suggesting involves injury
nicotinic amide effects demonstrated mice suffering acetaminophen hepatitis
acid amide effects demonstrated mice suffering acetaminophen hepatitis
amide effects demonstrated mice suffering acetaminophen hepatitis
nicotinic amide effects demonstrated mice suffering suggesting involves injury liver
nicotinic amide effects demonstrated mice suffering suggesting involves injury
acid amide effects demonstrated mice suffering suggesting involves injury liver
acid amide effects demonstrated mice suffering suggesting involves injury
amide effects demonstrated mice suffering suggesting involves injury liver
amide effects demonstrated mice suffering suggesting involves injury
NAD precursors diet substrate acts hepatitis
oxaloacetate transaminase transaminase quantified injuries Liver
oxaloacetate transaminase transaminase quantified injuries
pyruvate transaminase quantified injuries Liver
pyruvate transaminase quantified injuries
glutamate activities quantified injuries Liver
glutamate activities quantified injuries
glutamate transaminase transaminase quantified injuries Liver
glutamate transaminase transaminase quantified injuries
NAA given observed reduction hepatitis
NAD depletion reduced reduced AAP hepatitis
NAA reduced AAP hepatitis
NAA application see avoid damage hepatic
NAA application see avoid damage
Cyclophosphamide induced behavioral model pain visceral
Cyclophosphamide induced behavioral model pain
acrolein produce known agent Cyclophosphamide used induce cystitis
Morphine dose reversed disorders behavioral
Morphine dose reversed disorders
morphine administration time observed modifications edema
CP model induced model pain visceral
CP model induced model pain
ergot history discussion includes discovery epidemics gangrene
ergot preparations continue play persists fire danger Anthony St
ergot preparations continue play persists fire danger Anthony
ergot preparations continue play persists fire danger '
ergot preparations continue play persists fire s
ergot preparations continue play persists fire
calcium blockers advent continue play therapy migraine
calcium blockers advent continue play persists fire danger Anthony St
calcium blockers advent continue play persists fire danger Anthony
calcium blockers advent continue play persists fire danger '
calcium blockers advent continue play persists fire s
calcium blockers advent continue play persists fire
carbamazepine therapy institution atonic Myoclonic
carbamazepine therapy institution atonic
carbamazepine therapy institution atonic and
carbamazepine therapy institution atonic seizures absence
carbamazepine therapy institution atonic seizures
carbamazepine treated years aged children had reaction characterized onset absence atypical myoclonic
carbamazepine treated years aged children had reaction characterized onset absence atypical
carbamazepine treated years aged children had reaction characterized onset absence
carbamazepine treated years aged children had reaction characterized onset absence and
carbamazepine treated years aged children had reaction characterized onset absence /
carbamazepine treated years aged children had reaction characterized onset absence or
carbamazepine treated years aged children had reaction characterized onset absence seizures atonic
carbamazepine treated years aged children had reaction characterized onset absence seizures motor minor
carbamazepine treated years aged children had reaction characterized onset absence seizures motor
carbamazepine treated years aged children had reaction characterized onset absence seizures
carbamazepine epilepsy
carbamazepine discontinued returned had resolve seizures
carbamazepine discontinued returned had persist seizures
carmofur result syndrome organic
carmofur result syndrome personality
carmofur result syndrome
Raloxifene Evaluation Outcomes METHODS enrolled 7 women osteoporosis
Raloxifene increase 9 7 2 3 % % CI cancer endometrial
Raloxifene increase 9 7 2 3 % % CI cancer
Raloxifene increase 9 7 2 3 % % CI hyperplasia endometrial
Raloxifene increase 9 7 2 3 % % CI hyperplasia
Raloxifene increase 9 7 2 3 % % CI disease gallbladder
Raloxifene increase 9 7 2 3 % % CI disease
Raloxifene increase cataracts
Raloxifene associated was risk cataracts cancer endometrial
Raloxifene associated was risk cataracts cancer
Raloxifene associated was risk cataracts hyperplasia endometrial
Raloxifene associated was risk cataracts hyperplasia
Raloxifene associated was risk cataracts disease gallbladder
Raloxifene associated was risk cataracts disease
Raloxifene associated was risk cataracts
Clarithromycin associated failure chronic
Clarithromycin associated failure renal
Clarithromycin associated failure
macrolide antibiotic occurring hallucinations visual
macrolide antibiotic occurring hallucinations
clarithromycin face failure chronic
clarithromycin face failure renal
clarithromycin face failure
aluminum intoxication combination dose clarithromycin face failure chronic
aluminum intoxication combination dose clarithromycin face failure renal
aluminum intoxication combination dose clarithromycin face failure
aluminum intoxication combination facilitated appearance effect neurotoxic
clarithromycin dose combination facilitated appearance effect neurotoxic
verapamil effect ulcers
verapamil effect rats atherosclerotic
verapamil effect ulcers gastric
verapamil effect ulcers hemorrhagic
histamine release diffusion generation modulating rats atherosclerosis
histamine release diffusion generation modulating hemorrhage ulcer
histamine release diffusion generation modulating hemorrhage gastric
histamine release diffusion generation modulating hemorrhage
verapamil model ulcer
histamine concentration diffusion areas ulcer
luminal content diffusion areas ulcer
calcium concentration parameters atherosclerotic
calcium concentration parameters obtained rats atherosclerotic
histamine release diffusion observed accompanied ulcers
luminal content diffusion observed accompanied ulcers
histamine correlation found rats atherosclerotic
histamine histamine ulcer
histamine hemorrhage gastric
histamine hemorrhage
verapamil dose ulcer
verapamil dose ulcer hemorrhagic
verapamil ameliorated release diffusion ulcer
verapamil ameliorated release diffusion ulcer produce Atherosclerosis
histamine release diffusion ulcer produce Atherosclerosis
histamine release diffusion ulcer
verapamil ameliorated release diffusion ulcer gastric
verapamil ameliorated release diffusion ulcer hemorrhagic
histamine release diffusion ulcer gastric
histamine release diffusion ulcer hemorrhagic
paracetamol survivors transplant induced injury acute
paracetamol survivors transplant induced injury liver
paracetamol survivors transplant induced injury
paracetamol caused induced injury liver
paracetamol caused induced injury
paracetamol caused higher age age died disease liver
paracetamol caused higher age age died disease
heparin induced aggregation platelet
heparin induced aggregation
heparin require aggregation platelet
heparin require aggregation
chlorpropamide treated diabetes 65 year woman adult
chlorpropamide treated diabetes onset
chlorpropamide treated diabetes
Diabenese diabetes 65 year woman adult
Diabenese diabetes onset
Diabenese diabetes
chlorpropamide therapy discontinuation resolved neuropathy had diabetes 65 year woman adult
chlorpropamide therapy discontinuation resolved neuropathy had diabetes onset
chlorpropamide therapy discontinuation resolved neuropathy had diabetes
dexamethasone saline pretreated patients determined myalgia
dexamethasone group patients complained differ Incidence myalgia
dexamethasone group patients complained myalgia
dexamethasone group patients complained reported myalgia
dexamethasone Administration IMPLICATIONS induced myalgia postoperative
dexamethasone Administration IMPLICATIONS induced myalgia
dexamethasone Pretreatment justified prevent myalgia postoperative
dexamethasone Pretreatment justified prevent myalgia
carboplatin injection Severe toxicity ocular
carboplatin injection Severe toxicity ocular and
carboplatin injection Severe toxicity ocular orbital
carboplatin injection Severe toxicity
carboplatin glioblastomas
carboplatin said have effects cisplatin known toxicity ocular
carboplatin said have effects cisplatin known toxicity ocular and
carboplatin said have effects cisplatin known toxicity ocular orbital
carboplatin said have effects cisplatin known toxicity
cisplatin known toxicity ocular
cisplatin known toxicity ocular and
cisplatin known toxicity ocular orbital
cisplatin known toxicity
carboplatin injection experienced case ocular
carboplatin injection experienced case ocular and
carboplatin injection experienced case ocular toxicity orbital
carboplatin injection experienced case ocular toxicity
carboplatin injection received glioblastomas
carboplatin toxicity
carboplatin injection performing aware toxicity ocular
carboplatin injection performing aware toxicity
xanthine oxidase Role hypertension
nitric oxide associated hypertension
oxide associated hypertension
nitric oxide associated hypertension GC HT
oxide associated hypertension GC HT
xanthine oxidase role studied dexamethasone hypertension
xanthine oxidase role studied dexamethasone hypertension dex HT
Allopurinol prevent HT
allopurinol failed prevent hormone induced hypertension
allopurinol failed together suggests determinant HT
estradiol - therapy estrogen women atherosclerosis
- therapy estrogen women atherosclerosis
and - therapy estrogen women atherosclerosis
testosterone esters - therapy estrogen women atherosclerosis
esters - therapy estrogen women atherosclerosis
estrogen women atherosclerosis
alcohol use diabetes
cholesterol level diabetes
pilocarpine model characterized period epilepticus status
pilocarpine model characterized period epilepticus
PILO model characterized period epilepticus status
PILO model characterized period epilepticus
pilocarpine model epilepsy
PILO model epilepsy
pilocarpine model characterized period epilepticus followed seizures
PILO model characterized period epilepticus followed seizures
pilocarpine model characterized period epilepticus followed seizures damage brain
pilocarpine model characterized period epilepticus followed seizures damage
PILO model characterized period epilepticus followed seizures damage brain
PILO model characterized period epilepticus followed seizures damage
dopamine agonist hyperprolactinemia
cabergoline induced hyperprolactinemia
cabergoline treated hyperprolactinemia
risperidone males Manual bipolar
risperidone males disorder
risperidone males Manual bipolar Mental
risperidone males Manual bipolar Disorders
cabergoline treated RESULTS males disorder psychoses
cabergoline treated RESULTS males Manual bipolar Mental
cabergoline treated RESULTS males Manual bipolar Disorders
risperidone males disorder psychoses
cabergoline treated RESULTS males Manual bipolar
cabergoline treated RESULTS males disorder
Cabergoline useful treatment hyperprolactinemia
topiramate prevention impairments memory
topiramate prevention impairments memory and
topiramate prevention impairments memory learning
topiramate prevention impairments
Cocaine causes impairments memory
Cocaine causes impairments memory and
Cocaine causes impairments memory learning
Cocaine causes impairments
cocaine toxicity
cocaine brain induced status association stress increase toxicity
cocaine administration model evaluated activity stress activity effect topiramate therapy addiction cocaine
cocaine administration model evaluated activity stress activity effect topiramate therapy addiction
nitric synthase stress activity effect topiramate therapy addiction cocaine
nitric synthase stress activity effect topiramate therapy addiction
oxide synthase stress activity effect topiramate therapy addiction cocaine
oxide synthase stress activity effect topiramate therapy addiction
topiramate therapy addiction cocaine
topiramate therapy addiction
penicillin analysis activity epileptiform
penicillin analysis activity
Penicillin model model research epilepsy
penicillin analysis activity epileptiform
penicillin analysis activity
penicillin activity analyzed periods epileptiform
penicillin activity analyzed periods activity
diclofenac tolerability results tolerability etoricoxib patients rheumatoid
diclofenac tolerability results tolerability etoricoxib patients arthritis
sodium tolerability results tolerability etoricoxib patients rheumatoid
sodium tolerability results tolerability etoricoxib patients arthritis
etoricoxib patients rheumatoid
etoricoxib patients arthritis
etoricoxib tolerability results tolerability etoricoxib patients rheumatoid
etoricoxib tolerability results tolerability etoricoxib patients arthritis
diclofenac etoricoxib compare patients arthritis rheumatoid
diclofenac etoricoxib compare patients arthritis
diclofenac etoricoxib compare patients arthritis RA
etoricoxib compare patients arthritis rheumatoid
etoricoxib compare patients arthritis
etoricoxib compare patients arthritis RA
diclofenac mg daily received diagnosed enrolled RA
etoricoxib daily received diagnosed enrolled RA
etoricoxib lower rate due AEs GI
etoricoxib lower rate due AEs
diclofenac etoricoxib higher incidence discontinuations related oedema
diclofenac etoricoxib % 0 001 01 oedema
diclofenac etoricoxib higher incidence discontinuations hypertension
diclofenac etoricoxib % 0 001 hypertension
Etoricoxib mg demonstrated discontinuing treatment higher AEs GI
Etoricoxib mg demonstrated discontinuing treatment higher AEs
Etoricoxib mg demonstrated discontinuing treatment higher common discontinuations AEs GI
Etoricoxib mg demonstrated discontinuing treatment higher common discontinuations AEs
etoricoxib higher AEs GI
etoricoxib higher AEs
etoricoxib higher common discontinuations AEs GI
etoricoxib higher common discontinuations AEs
Metformin hydrochloride discontinued resolved jaundice
hydrochloride discontinued resolved jaundice
metformin initiation wk jaundice
metformin example represents believe onset wk jaundice
metformin initiation wk onset believe reported associated hepatotoxicity
metformin example represents believe reported associated hepatotoxicity
Methamphetamine stimulant increases produce effects dysrhythmias hallucinations
Methamphetamine stimulant increases produce effects dysrhythmias behavior violent
Methamphetamine stimulant increases produce effects dysrhythmias behavior
Methamphetamine stimulant increases produce effects dysrhythmias cardiac
Methamphetamine stimulant increases produce effects dysrhythmias
Methamphetamine stimulant increases produce effects dysrhythmias hypertension
methamphetamine abusing patients present hygiene caries mouth meth
methamphetamine abusing patients present hygiene caries mouth
methamphetamine abusing patients present wear tooth
methamphetamine abusing patients present wear
methamphetamine abusing patients present hygiene caries xerostomia
methamphetamines abusing patients manage recognize help presented case showing manifestations mouth meth
methamphetamines abusing patients manage recognize help presented case showing manifestations mouth
Flestolol produced induced tachycardia
Flestolol reduced tachyarrhythmia supraventricular
Flestolol reduced tachyarrhythmia
flestolol infusion found safe pain chest
flestolol infusion found safe pain
flestolol infusion found patients angina unstable
flestolol infusion found patients angina
etoposide enhancing protects myelosuppression
daunorubicin etoposide enhancing protects myelosuppression
doxorubicin etoposide enhancing protects myelosuppression
Dexrazoxane protects myelosuppression
daunorubicin cleavage limit myelosuppression toxicity cardiac
daunorubicin cleavage limit myelosuppression toxicity
etoposide daunorubicin cleavage limit myelosuppression
etoposide daunorubicin cleavage limit myelosuppression toxicity cardiac
etoposide daunorubicin cleavage limit myelosuppression toxicity
daunorubicin cleavage limit myelosuppression
epipodophyllotoxin etoposide daunorubicin cleavage limit myelosuppression
doxorubicin daunorubicin cleavage limit myelosuppression toxicity cardiac
doxorubicin daunorubicin cleavage limit myelosuppression toxicity
epipodophyllotoxin etoposide daunorubicin cleavage limit myelosuppression toxicity cardiac
epipodophyllotoxin etoposide daunorubicin cleavage limit myelosuppression toxicity
doxorubicin daunorubicin cleavage limit myelosuppression
anthracyclines daunorubicin cleavage limit myelosuppression
anthracyclines daunorubicin cleavage limit myelosuppression toxicity cardiac
anthracyclines daunorubicin cleavage limit myelosuppression toxicity
anthracycline induced cardiotoxicity
Dexrazoxane recommended anthracycline induced cardiotoxicity
ICRF Dexrazoxane recommended anthracycline induced cardiotoxicity
187 ICRF Dexrazoxane recommended anthracycline induced cardiotoxicity
dexrazoxane coadministration toxicity hematologic
dexrazoxane coadministration toxicity
dexrazoxane determined investigated toxicity hematologic
dexrazoxane determined investigated toxicity
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression cytotoxicity
etoposide daunorubicin reduced loss myelosuppression
etoposide daunorubicin reduced antagonized dexrazoxane myelosuppression
dexrazoxane doses reduced loss myelosuppression weight
dexrazoxane doses reduced loss
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression loss weight
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression loss
dexrazoxane antagonized reduced loss myelosuppression weight
dexrazoxane antagonized reduced loss
dexrazoxane myelosuppression loss weight
dexrazoxane myelosuppression loss
daunorubicin reduced loss myelosuppression
daunorubicin reduced antagonized dexrazoxane myelosuppression
doxorubicin cytotoxicity
doxorubicin cytotoxicity myelosuppression dexrazoxane antagonized reduced loss myelosuppression
doxorubicin cytotoxicity myelosuppression
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression cytotoxicity
dexrazoxane myelosuppression cytotoxicity
daunorubicin reduced antagonized dexrazoxane myelosuppression cytotoxicity
dexrazoxane doses reduced loss myelosuppression
dexrazoxane doses reduced antagonized dexrazoxane myelosuppression
dexrazoxane antagonized reduced loss myelosuppression
dexrazoxane myelosuppression
etoposide doses combining metastases
dexrazoxane doses combining metastases patients trials ongoing aim improving toxicity hematologic
dexrazoxane doses combining metastases patients trials ongoing aim improving toxicity
dexrazoxane doses combining metastases
dacarbazine therapy melanoma
DTIC therapy melanoma
dacarbazine therapy melanoma
DTIC therapy melanoma
paracetamol cause cancer necrosis renal
paracetamol cause cancer necrosis papillary
paracetamol cause cancer necrosis
paracetamol cause cancer urothelial
paracetamol cause cancer
paracetamol phenacetin consumption associated cancer
paracetamol phenacetin consumption associated cancer pelvis of
paracetamol phenacetin consumption associated cancer pelvis the
paracetamol phenacetin consumption associated cancer pelvis renal
paracetamol phenacetin consumption associated cancer pelvis
paracetamol phenacetin consumption associated cancer pelvis ureter
paracetamol phenacetin consumption associated cancer pelvis or
paracetamol phenacetin consumption associated cancer pelvis bladder
paracetamol phenacetin consumption associated cancer necrosis renal
paracetamol phenacetin consumption associated cancer necrosis papillary
paracetamol phenacetin consumption associated cancer necrosis
phenacetin consumption associated cancer
phenacetin consumption associated cancer pelvis of
phenacetin consumption associated cancer pelvis the
phenacetin consumption associated cancer pelvis renal
phenacetin consumption associated cancer pelvis
phenacetin consumption associated cancer pelvis ureter
phenacetin consumption associated cancer pelvis or
phenacetin consumption associated cancer pelvis bladder
phenacetin increased cancer
phenacetin increased cancer pelvis of
phenacetin increased cancer pelvis the
phenacetin increased cancer pelvis renal
phenacetin increased cancer pelvis
phenacetin increased cancer pelvis and
phenacetin increased cancer pelvis bladder
phenacetin increased increased cancer ureteric
phenacetin increased increased cancer
paracetamol consumption necrosis renal
paracetamol consumption necrosis papillary
paracetamol consumption necrosis
paracetamol consumption any cancers
paracetamol consumption substantiate was suggestion association cancer
paracetamol consumption substantiate was suggestion association cancer ureter of
paracetamol consumption substantiate was suggestion association cancer ureter the
paracetamol consumption substantiate was suggestion association cancer ureter
isosorbide dinitrate administration wall infarction suffered old necrosis
dinitrate administration wall infarction suffered old necrosis
amiodarone presenting coma myxedemic
amiodarone presenting coma
amiodarone patient congestive
amiodarone patient heart
amiodarone patient failure
amiodarone secondary report coma myxedema
amiodarone secondary report coma
amiodarone secondary hypothyroidism failure patient heart congestive
amiodarone secondary hypothyroidism failure patient heart
amiodarone secondary hypothyroidism failure
amiodarone secondary hypothyroidism failure CHF
amiodarone therapy coma myxedema
amiodarone therapy coma
amiodarone CHF
amiodarone usage given patients CHF
Simvastatin ezetimibe failure hepatic
Simvastatin ezetimibe failure
ezetimibe failure hepatic
ezetimibe failure
ezetimibe published events hepatotoxic
simvastatin mg necessitating developed failure fulminant
simvastatin mg necessitating developed failure hepatic
simvastatin mg necessitating developed failure
simvastatin maintained evidence hepatotoxicity
escitalopram Simvastatinezetimibe taking depression
Simvastatinezetimibe taking depression
escitalopram Simvastatinezetimibe discontinued excluded causes hepatotoxicity
uridine glucoronosyltransferases undergoes inhibited glucuronidation resulting exposure hepatotoxicity
diphosphate glucoronosyltransferases undergoes inhibited glucuronidation resulting exposure hepatotoxicity
simvastatin exposure hepatotoxicity
Ezetimibe undergoes inhibited glucuronidation resulting exposure hepatotoxicity
simvastatin acid glucuronidation resulting exposure hepatotoxicity
hydroxy acid glucuronidation resulting exposure hepatotoxicity
acid glucuronidation resulting exposure hepatotoxicity
simvastatin report ezetimibe failure liver
simvastatin report ezetimibe failure
ezetimibe failure liver
ezetimibe failure
simvastatin exposure mechanism simvastatinezetimibe induced hepatotoxicity
ezetimibe inhibition exposure mechanism simvastatinezetimibe induced hepatotoxicity
methotrexate toxicity high posterior syndrome leukoencephalopathy
methotrexate toxicity high posterior stroke
methotrexate toxicity high posterior syndrome secretion inappropriate
methotrexate toxicity high posterior syndrome secretion antidiuretic
methotrexate toxicity high posterior syndrome secretion hormone
methotrexate toxicity high posterior syndrome secretion
methotrexate toxicity high posterior stroke epilepsy temporal
methotrexate toxicity high posterior stroke epilepsy lobe
methotrexate toxicity high posterior stroke epilepsy
methotrexate toxicity
serotonin secondary inhibitors incontinence
steroids resolved angioedema
diphenhydramine hydrochloride steroids resolved angioedema
LEV treated FINDINGS 28 year man suffering epilepsy idiopathic
LEV treated FINDINGS 28 year man suffering epilepsy
LEV treated FINDINGS 28 year man suffering seizures
valproate added LEV treated FINDINGS 28 year man suffering seizures
VPA valproate added LEV treated FINDINGS 28 year man suffering seizures
valproate added LEV treated FINDINGS 28 year man suffering epilepsy idiopathic
valproate added LEV treated FINDINGS 28 year man suffering epilepsy
VPA valproate added LEV treated FINDINGS 28 year man suffering epilepsy idiopathic
VPA valproate added LEV treated FINDINGS 28 year man suffering epilepsy
LEV discontinuation improved decreased frequency seizure
folic acid activity induces SLE acid epilepsy
acid activity induces SLE acid epilepsy
folic acid epilepsy
acid epilepsy
folic acid effect study containing determine rate defects birth
folic acid effect study containing determine rate defects
acid effect study containing determine rate defects birth
acid effect study containing determine rate defects
folic acid effect study containing supplementation women epileptic
acid effect study containing supplementation women epileptic
folic acid effect study containing determine rate defects epilepsy
acid effect study containing determine rate defects epilepsy
folic acid women epileptic
acid women epileptic
folic acid women developed epilepsy
acid women developed epilepsy
carbamazepine treated woman epileptic
folic acid carbamazepine treated woman epileptic
acid carbamazepine treated woman epileptic
folic acid dose barrier triggered disease autoimmune
folic acid dose barrier triggered disease
acid dose barrier triggered disease autoimmune
acid dose barrier triggered disease
folic acid dose barrier triggered disease CONCLUSIONS patient epileptic
acid dose barrier triggered disease CONCLUSIONS patient epileptic
folic acid dose all disease autoimmune
folic acid dose all disease
acid dose all disease autoimmune
acid dose all disease
folic acid healthy women epileptic
acid healthy women epileptic
folic acid dose increase risk seizures epileptic
folic acid dose increase risk seizures
acid dose increase risk seizures epileptic
acid dose increase risk seizures
nimesulide Tolerability urticaria
paracetamol nimesulide Tolerability urticaria
NSAID Tolerability urticaria
nimesulide paracetamol number history induced urticaria
paracetamol number history induced urticaria
NSAID history induced urticaria
nimesulide procedure applied patients history angioedema urticaria
paracetamol nimesulide procedure applied patients history angioedema urticaria
NSAID angioedema urticaria
NSAID history subjects % urticaria
NSAID history subjects % induced angioedema urticaria
NSAID history subjects % induced alone with urticaria
nimesulide tolerability confirm patients experienced angioedema urticaria
paracetamol nimesulide tolerability confirm patients experienced angioedema urticaria
NSAIDs caused angioedema urticaria
NSAID history increased increased history urticaria
enflurane delineated foci Epileptic
enflurane prove activator foci epileptic
MZ dose age myocardiopathy
MZ dose age myocardiopathy MP
MZ dose age myocardiopathy duration test regurgitation mitral
MZ dose age myocardiopathy duration test regurgitation
MZ dose age myocardiopathy duration test regurgitation MR
MZ dose age stroke
MZ use caused hypoxia presented hypoxia due obstruction airway
MZ use caused hypoxia presented hypoxia due obstruction
MZ doses MR MP
MZ doses MR
streptomycin effects neurotoxic
lidocaine relieved spasm
sodium pentothal infused minimize ischaemia cerebral
sodium pentothal infused minimize ischaemia
pentothal infused minimize ischaemia cerebral
pentothal infused minimize ischaemia
lidocaine given counteract vasospasm
benztropine Ethopropazine parkinsonism
Ethopropazine parkinsonism
fluphenazine enanthate outpatients schizophrenic
enanthate outpatients schizophrenic
ethopropazine compared benztropine treatment parkinsonism induced enanthate outpatients schizophrenic
benztropine treatment parkinsonism induced enanthate outpatients schizophrenic
benztropine treatment parkinsonism
ethopropazine compared benztropine treatment parkinsonism
procyclidine efficacious found effective symptoms parkinsonian
procyclidine efficacious found effective symptoms
benztropine Ethopropazine found effective symptoms parkinsonian
benztropine Ethopropazine found effective symptoms
Ethopropazine found effective symptoms parkinsonian
Ethopropazine found effective symptoms
procyclindine treatment condition had increase dyskinesia tardive
procyclindine treatment condition had increase dyskinesia
ethopropazine patients anxiety
procyclindine treatment condition anxiety depression
ethopropazine patients anxiety depression
procyclindine treatment condition anxiety
ethopropazine patients anxiety condition had increase dyskinesia tardive
ethopropazine patients anxiety condition had increase dyskinesia
benztropine drug choice treatment neuroleptic symptoms parkinsonian
benztropine drug choice treatment neuroleptic symptoms
cimetidine was liver
cimetidine was liver or
cimetidine was liver disease kidney
cimetidine was liver disease
cimetidine levels had disease liver
cimetidine levels had disease liver or
cimetidine levels had disease kidney
cimetidine levels had disease
terbutaline treatment labor preterm
terbutaline treatment labor
terbutaline labor preterm
terbutaline labor
cisplatin study therapy cancers head
cisplatin study therapy cancers head and
cisplatin study therapy cancers head neck
cisplatin study therapy cancers
paclitaxel cisplatin study therapy cancers head
paclitaxel cisplatin study therapy cancers head and
paclitaxel cisplatin study therapy cancers head neck
paclitaxel cisplatin study therapy cancers
cisplatin combination used reported cancer head
cisplatin combination used reported cancer head and
cisplatin combination used reported cancer head neck
cisplatin combination used reported cancer
cisplatin combination used improved duration patients ovarian
cisplatin combination used improved duration patients cancer
paclitaxel reported used improved duration patients ovarian
paclitaxel reported used improved duration patients cancer
Taxol Bristol paclitaxel reported used improved duration patients ovarian
Taxol Bristol paclitaxel reported used improved duration patients cancer
paclitaxel combination used improved duration patients ovarian
paclitaxel combination used improved duration patients cancer
paclitaxel reported cancer head
paclitaxel reported cancer head and
paclitaxel reported cancer head neck
paclitaxel reported cancer
Taxol Bristol paclitaxel reported cancer head
Taxol Bristol paclitaxel reported cancer head and
Taxol Bristol paclitaxel reported cancer head neck
Taxol Bristol paclitaxel reported cancer
paclitaxel combination used reported cancer head
paclitaxel combination used reported cancer head and
paclitaxel combination used reported cancer head neck
paclitaxel combination used reported cancer
cisplatin escalating response determine trial initiated stimulating untreated head
cisplatin escalating response determine trial initiated stimulating untreated head and
cisplatin escalating response determine trial initiated stimulating untreated head carcinoma neck
cisplatin escalating response determine trial initiated stimulating untreated head carcinoma
cisplatin escalating response toxicity
paclitaxel doses escalating response toxicity
paclitaxel doses escalating response determine trial initiated stimulating untreated head
paclitaxel doses escalating response determine trial initiated stimulating untreated head and
paclitaxel doses escalating response determine trial initiated stimulating untreated head carcinoma neck
paclitaxel doses escalating response determine trial initiated stimulating untreated head carcinoma
paclitaxel doses escalating incorporate permitted permits toxicity
cisplatin first advanced head
cisplatin first advanced head and
cisplatin first advanced head neck
cisplatin first advanced cancer
Paclitaxel cisplatin first advanced head
Paclitaxel cisplatin first advanced head and
Paclitaxel cisplatin first advanced head neck
Paclitaxel cisplatin first advanced cancer
desferrioxamine receiving toxicity Ocular
desferrioxamine receiving toxicity Ocular and
desferrioxamine receiving toxicity Ocular auditory
desferrioxamine receiving toxicity
desferrioxamine receiving period monitored detection toxicity audiovisual
desferrioxamine receiving period monitored detection toxicity
dyschromatopsy
dyschromatopsy characterized pigmentary
dyschromatopsy characterized pigmentary deposits retinal
dyschromatopsy characterized pigmentary deposits
dyschromatopsy characterized origin toxicity Visual
dyschromatopsy characterized origin toxicity
dyschromatopsy characterized associated loss a
dyschromatopsy characterized associated loss
dyschromatopsy characterized associated loss acuity of
dyschromatopsy characterized associated loss acuity visual
dyschromatopsy characterized associated loss acuity
Desferrioxamine withdrawal resulted patient reversal loss hearing
Desferrioxamine withdrawal resulted patient reversal loss
aluminium
desferrioxamine doses receiving patients appeared coincided normalization levels ferritin aluminium
aluminium ferritin levels normalization coincided appeared toxicity
desferrioxamine doses receiving patients appeared toxicity
desferrioxamine receiving patients complication toxicity audiovisual
desferrioxamine receiving patients complication toxicity
Doxorubicin induces self nephropathy
Doxorubicin induces self nephropathy characterized glomerular
Doxorubicin induces self nephropathy characterized and
Doxorubicin induces self nephropathy characterized lesions late
Doxorubicin induces self nephropathy characterized lesions onset
Doxorubicin induces self nephropathy characterized lesions tubular
Doxorubicin induces self nephropathy characterized lesions
citrate activity glomerular
citrate activity glomerular and
citrate activity glomerular lesions tubular
citrate activity glomerular lesions
superoxide function encoded reduction induced lesions renal
superoxide function encoded reduction induced lesions
doxorubicin encoded reduction induced lesions renal
doxorubicin encoded reduction induced lesions
Ginsenoside Rg restores impairment
Ginsenoside Rg restores impairment learning of
Ginsenoside Rg restores impairment learning
Rg restores impairment
Rg restores impairment learning of
Rg restores impairment learning
1 Rg restores impairment
1 Rg restores impairment learning of
1 Rg restores impairment learning
Rg ameliorate impairment learning
Rg ameliorate impairment
1 Rg ameliorate impairment learning
1 Rg ameliorate impairment
ginsenoside extracted Rg ameliorate impairment learning
ginsenoside extracted Rg ameliorate impairment
Rg effect investigate learning
Rg effect investigate learning impairment
1 Rg effect investigate learning
1 Rg effect investigate learning impairment
zidovudine individuals use toxicity didanosine antibody HIV
zidovudine individuals use toxicity didanosine antibody
zidovudine individuals positive
AZT zidovudine individuals use toxicity didanosine antibody HIV
AZT zidovudine individuals use toxicity didanosine antibody
AZT zidovudine individuals positive
didanosine toxicity
ddI didanosine toxicity
zidovudine individuals use toxicity
AZT zidovudine individuals use toxicity
didanosine antibody HIV
didanosine antibody
didanosine toxicity use individuals positive
ddI didanosine antibody HIV
ddI didanosine antibody
ddI didanosine toxicity use individuals positive
didanosine normal returned mild developed characteristic diabetes
ketamine induced analgesia
morphine ketamine induced analgesia
morphine ketamine predominance reflected Latency loss righting reflex rigidity
ketamine predominance reflected Latency loss righting reflex rigidity
Naloxone inhibited effects cataleptic
naloxone ID asymmetry latency rigidity
naloxone ID asymmetry latency differences argue suggest mechanisms catalepsy
carboplatin cancer ovarian
carboplatin cancer
Paclitaxel combined carboplatin cancer ovarian
Paclitaxel combined carboplatin cancer
carboplatin administered women cancer ovarian
carboplatin administered women cancer
paclitaxel dose determine study phase infusion combination carboplatin administered women cancer ovarian
paclitaxel dose determine study phase infusion combination carboplatin administered women cancer
Taxol Bristol paclitaxel dose determine study phase infusion combination carboplatin administered women cancer ovarian
Taxol Bristol paclitaxel dose determine study phase infusion combination carboplatin administered women cancer
paclitaxel doses escalated phase infusion combination carboplatin administered women cancer ovarian
paclitaxel doses escalated phase infusion combination carboplatin administered women cancer
interferon therapy treatment infection HCV
interferon therapy treatment infection
ribavirin interferon therapy treatment infection HCV
ribavirin interferon therapy treatment infection
ribavirin result decrease problematic patients those comorbid disorders renal
ribavirin result decrease problematic patients those comorbid disorders renal or
ribavirin result decrease problematic patients those comorbid disorders renal cardiovascular
ribavirin result decrease problematic patients those comorbid disorders
ribavirin result hemolysis
ribavirin result decrease problematic patients infection HCV
ribavirin result decrease problematic patients infection
ribavirin result decrease problematic anemia
ribavirin anemia
ribavirin associated anemia
Viramidine has potential maintain decreasing risk anemia hemolytic
Viramidine has potential maintain decreasing risk anemia
Viramidine has potential maintain decreasing patients C chronic
Viramidine has potential maintain decreasing patients C hepatitis
Viramidine has potential maintain decreasing patients C
ribavirin prodrug liver has potential maintain decreasing patients C chronic
ribavirin prodrug liver has potential maintain decreasing patients C hepatitis
ribavirin prodrug liver has potential maintain decreasing patients C
ribavirin efficacy maintain decreasing patients C chronic
ribavirin efficacy maintain decreasing patients C hepatitis
ribavirin efficacy maintain decreasing patients C
p shown factor digluconate associated cystitis
choloroaniline factor digluconate associated cystitis
Picloxydine irrigations appeared have incidence cystitis
doxorubicin model damage diagnosis investigated examined development disorders cardiac
doxorubicin model damage diagnosis investigated examined development disorders
DOX doxorubicin model damage diagnosis investigated examined development disorders cardiac
DOX doxorubicin model damage diagnosis investigated examined development disorders
DOX rats Eighteen died toxicity
DOX given rats hearts evaluation revealed degrees fibrosis
DOX injury ischemic
DOX injury
DOX was is induced cardiotoxicity
DOX indicates rats cTnT induced cardiotoxicity
docetaxel cancer prostate
docetaxel cancer
thalidomide docetaxel cancer prostate
thalidomide docetaxel cancer
docetaxel treated cancer prostate
docetaxel treated cancer
thalidomide treated cancer prostate
thalidomide treated cancer
docetaxel treatment cancer prostate
docetaxel treatment cancer
thalidomide addition docetaxel treatment cancer prostate
thalidomide addition docetaxel treatment cancer
Tramadol opioid used treat pain
Tramadol opioid used treat pain pain
Tramadol opioid used treat pain cancer
paroxetine hydrochloride patient tetraparetic
dosulepine paroxetine hydrochloride patient tetraparetic
hydrochloride patient tetraparetic
dosulepine paroxetine hydrochloride patient pain chronic
dosulepine paroxetine hydrochloride patient pain
hydrochloride patient pain chronic
hydrochloride patient pain
paroxetine hydrochloride patient pain chronic
paroxetine hydrochloride patient pain
telithromycin mg PO treat infection upper
telithromycin mg PO treat infection respiratory
telithromycin mg PO treat infection tract
telithromycin mg PO treat infection
telithromycin cause score 8 scale adverse
telithromycin cause score 8 scale drug
telithromycin cause score 8 scale reaction
tacrolimus mapping imaging neurotoxicity
tacrolimus developed complications neurologic
tacrolimus developed complications
tacrolimus lesions outcomes predicting useful Diffusion induced neurotoxicity
iopentol lower Frequencies fibrillation ventricular
iopentol lower Frequencies fibrillation
iohexol iopentol lower Frequencies fibrillation ventricular
iohexol iopentol lower Frequencies fibrillation
methamphetamine Attenuation neurotoxicity
lipopolysaccharide pretreatment mice neurotoxicity
methamphetamine induced damage dopaminergic
methamphetamine induced damage terminal
methamphetamine induced damage
dopamine induced modulating neurotoxicity
methamphetamine modulating neurotoxicity
lipopolysaccharide roles neurotoxicity
Lipopolysaccharide pretreatment affect temperature hyperthermia
dopamine neurotoxicity
methamphetamine exerting concluded dopamine neurotoxicity
lipopolysaccharide pretreatment concluded dopamine neurotoxicity
levobupivacaine bupivacaine rats toxicity
bupivacaine rats toxicity
ropivacaine bupivacaine rats toxicity
levobupivacaine bupivacaine toxicity
bupivacaine toxicity
ropivacaine bupivacaine toxicity
bupivacaine those larger similar doses seizures
bupivacaine those larger smaller doses levobupivacaine produced dysrhythmias asystole
bupivacaine those larger smaller doses levobupivacaine produced dysrhythmias
levobupivacaine toxicity
levobupivacaine bupivacaine induced that treatment susceptible appears conclude intermediate toxicity
bupivacaine ropivacaine that intermediate conclude appears arrest cardiac
bupivacaine ropivacaine that intermediate conclude appears arrest
bupivacaine induced that treatment susceptible appears arrest cardiac
bupivacaine induced that treatment susceptible appears arrest
bupivacaine ropivacaine that intermediate toxicity
bupivacaine induced that treatment susceptible appears conclude intermediate toxicity
ropivacaine that intermediate toxicity
ropivacaine rate administered intermediate toxicity
dyazide therapy complicating nephrolithiasis
hydrochlorothiazide years reported case nephrolithiasis
triamterene therapy years reported case nephrolithiasis
triamterene nephrolithiasis case reported years therapy hypertension
hydrochlorothiazide years therapy hypertension
triamterene therapy hypertension
tacrolimus treatment associated dermatitis
tacrolimus describe eruptions
tacrolimus ointment dermatitis facial
tacrolimus ointment dermatitis
tacrolimus describe herein patients developed rosacea
tacrolimus describe eruptions dermatitis
tacrolimus immunomodulators use regarded cause dermatitis
dexamethasone myeloma
cyclophosphamide definition XI dexamethasone myeloma
bortezomib definition XI dexamethasone myeloma
dexamethasone transplantation patients myeloma multiple
dexamethasone transplantation patients myeloma
dexamethasone transplantation patients myeloma MM
cyclophosphamide dose evaluate dexamethasone transplantation patients myeloma multiple
cyclophosphamide dose evaluate dexamethasone transplantation patients myeloma
cyclophosphamide dose evaluate dexamethasone transplantation patients myeloma MM
bortezomib evaluate dexamethasone transplantation patients myeloma multiple
bortezomib evaluate dexamethasone transplantation patients myeloma
bortezomib evaluate dexamethasone transplantation patients myeloma MM
dexamethasone combination bortezomib treatment patients MM
cyclophosphamide m combination bortezomib treatment patients MM
bortezomib treatment patients MM
CsA treated group worst showed analysis grade fibrosis
SRL CsA treated group worst showed analysis grade fibrosis
SRL combination 506 showed degree fibrosis
FK 506 showed degree fibrosis
506 showed degree fibrosis
metoprolol treatment SR block shock cardiogenic
metoprolol treatment SR block shock
verapamil SR block shock cardiogenic
verapamil SR block shock
dopamine agents doses uses block heart
dopamine agents doses uses block
atropine doses uses block heart
atropine doses uses block
dopamine agents doses uses block remain hypotensive
dobutamine dopamine agents doses uses block heart
dobutamine dopamine agents doses uses block
atropine doses uses block remain hypotensive
dobutamine dopamine agents doses uses block remain hypotensive
calcium chloride use resolved hypotension
chloride use resolved hypotension
calcium chloride use resolved hypotension block heart
calcium chloride use resolved hypotension block
chloride use resolved hypotension block heart
chloride use resolved hypotension block
paclitaxel cancer Chemotherapy non
paclitaxel cancer small
paclitaxel cancer cell
paclitaxel cancer lung
paclitaxel cancer
Paclitaxel demonstrated types ovarian
Paclitaxel demonstrated types and
Paclitaxel demonstrated types carcinoma breast
Paclitaxel demonstrated types carcinoma
Taxol Bristol Paclitaxel demonstrated types ovarian
Taxol Bristol Paclitaxel demonstrated types and
Taxol Bristol Paclitaxel demonstrated types carcinoma breast
Taxol Bristol Paclitaxel demonstrated types carcinoma
Paclitaxel demonstrated types tumor
Taxol Bristol Paclitaxel demonstrated types tumor
paclitaxel infusions trials patients IIIB non
paclitaxel infusions trials cell small
paclitaxel infusions trials cell
paclitaxel infusions trials cell cancer lung
paclitaxel infusions trials cell cancer
paclitaxel infusions trials NSCLC
paclitaxel infusion efficacy investigated IIIB NSCLC
paclitaxel infusion efficacy toxicity
Paclitaxel agent 3 infusion proving effective superior terms incidence toxicity
paclitaxel combined drugs active NSCLC
paclitaxel comparing studies remain indicated studies paclitaxel combined drugs active NSCLC
Cyclosporin A caused reduction hypertrophy
A caused reduction hypertrophy
CsA A caused reduction hypertrophy
macrolide rapamycin A caused reduction hypertrophy
rapamycin A caused reduction hypertrophy
Fujimycine A caused reduction hypertrophy
FK Fujimycine A caused reduction hypertrophy
506 FK Fujimycine A caused reduction hypertrophy
FK CsA toxicity
506 toxicity
CsA toxicity
HCBD produced damage discriminated both damage glomerular
HCBD produced damage discriminated both damage
BEA HCBD produced damage discriminated both damage glomerular
BEA HCBD produced damage discriminated both damage
PAN produced damage glomerular
PAN produced damage
droperidol dose administration minutes developed protrusion year man allergies drug
droperidol dose administration minutes developed protrusion year man allergies
droperidol dose administration minutes developed protrusion year man allergies angioedema tongue
droperidol dose administration minutes developed protrusion year man allergies angioedema tongue swelling
ciprofloxacin suspect infection urinary
ciprofloxacin suspect infection tract
ciprofloxacin suspect infection
ethambutol map pattern degeneration axonal
ethambutol map pattern degeneration
Ethambutol agent used treat tuberculosis
EMB management terms important manage patients impairment renal
EMB management terms important manage patients impairment
ethambutol dosing manage patients impairment renal
ethambutol dosing manage patients impairment
dopamine formation dopa Mediation bradycardia
L bradycardia
dopa Mediation bradycardia
DL dopa Threo enhanced bradycardia
Threo enhanced bradycardia
dihydroxyphenylserine had enhanced bradycardia
L Threo enhanced bradycardia
dopa Threo enhanced bradycardia
dopamine 63 beta have effect hypotension
dopamine 63 beta have effect hypotension bradycardia
L effect dopa hypotension
dopa hypotension
FLA beta have effect hypotension bradycardia
63 beta have effect hypotension bradycardia
L effect dopa hypotension bradycardia
dopa hypotension bradycardia
FLA beta have effect hypotension
63 beta have effect hypotension
L restored bradycardia
dopa L restored bradycardia
5 decreased decreased bradycardia
HTP decreased decreased bradycardia
L stimulation enhances bradycardia
dopa enhances bradycardia
isoflurane anaesthesia fusion postero underwent patients using measured evaluate effect E trimethaphan induced hypotension
methylprednisolone do injury spinal
methylprednisolone do injury cord
methylprednisolone do injury
methylprednisolone became Studies Spinal
methylprednisolone became Studies Cord
methylprednisolone became Studies Injury
methylprednisolone became injury spinal
methylprednisolone became injury cord
methylprednisolone became injury
corticosteroid myopathy
steroid myopathy recovers recording protection offers injury spinal
steroid myopathy recovers recording protection offers injury cord
steroid myopathy recovers recording protection offers injury
steroid myopathy recovery recording protection offers injury spinal
steroid myopathy recovery recording protection offers injury cord
steroid myopathy recovery recording protection offers injury
steroid myopathy
steroid myopathy recovers recording recovery myopathy
steroid myopathy recovery recording recovers myopathy
steroid myopathy
methylprednisolone offers injury spinal
methylprednisolone offers injury cord
methylprednisolone offers injury
corticosteroid myopathy
Simvastatin induced syndrome myonecrosis associated hypothyroidism
Simvastatin induced syndrome myonecrosis
simvastatin thyroxine taking male hypothyroid
simvastatin thyroxine presented syndrome myonecrosis
thyroxine taking male hypothyroid
thyroxine presented syndrome myonecrosis
thyroxine presented syndrome compartment
thyroxine presented syndrome
fucoidan treatment Effect hemorrhage intracerebral
fucoidan treatment Effect hemorrhage
fucoidan reported reduce damage brain
fucoidan reported reduce damage
fucoidan reported model hemorrhage intracerebral
fucoidan reported model hemorrhage
Fucoidan treated exhibited tended have inflammation
Fucoidan treated exhibited had hematomas
Fucoidan treated exhibited tended have inflammation vicinity hematoma
Steroid treatment meshwork similar those reported glaucoma glaucoma open
Steroid treatment meshwork similar those reported glaucoma glaucoma angle
Steroid treatment meshwork similar those reported glaucoma glaucoma
Steroid treatment meshwork similar those reported glaucoma corticosteroid
Steroid treatment meshwork similar those reported glaucoma
oxygen species implicated induced antioxidants reducing proteinuria
oxygen species implicated induced nephropathy
Remifentanil pretreatment reduces myoclonus
remifentanil kg pretreatment effect compare incidence myoclonus
remifentanil group lower incidence myoclonus
remifentanil microg Pretreatment CONCLUSION reduced effects sedation apnea
etomidate induction reduced effects sedation nausea
remifentanil microg Pretreatment CONCLUSION reduced myoclonus
etomidate induction reduced effects sedation pruritus
remifentanil microg Pretreatment CONCLUSION reduced effects sedation pruritus
etomidate induction reduced effects sedation apnea
remifentanil microg Pretreatment CONCLUSION reduced effects sedation nausea
paracetamol overdose
paracetamol overdose survived increased patients failure due hepatitis viral
paracetamol overdose survived increased patients failure due hepatitis
Reserpine produced dyskinesia orofacial
Reserpine produced dyskinesia
Reserpine produced tremor suggestive disease Parkinson
Reserpine produced tremor suggestive disease Parkinson '
Reserpine produced tremor suggestive disease s
Reserpine produced tremor suggestive disease
MK 801 administered induced catalepsy
801 administered induced catalepsy
MK injection produced increase tremor
801 injection produced increase tremor
apomophine injection followed administered Reserpine produce dyskinesia oral
apomophine injection followed administered Reserpine produce dyskinesia
Reserpine produce dyskinesia oral
Reserpine produce dyskinesia
MK 801 attenuated catalepsy
801 attenuated catalepsy
MK 801 attenuated catalepsy tremor
801 attenuated catalepsy tremor
MK increases tremor catalepsy
801 increases tremor catalepsy
MK increases tremor
801 increases tremor
reserpine produces considered parkinsonian
NMDA produced blockage restore signs vacuous chewing movements catalepsy
NMDA produced blockage restore signs vacuous chewing movements tremor
magnesium toxicity
nifedipine potentiate toxicity
Selegiline hypotension disease Parkinson
Selegiline hypotension disease Parkinson '
Selegiline hypotension disease s
Selegiline hypotension disease
L day selegiline receive randomized patients mortality found trial Parkinson
L day selegiline receive randomized patients mortality found trial Parkinson '
L day selegiline receive randomized patients mortality found trial s
L day selegiline receive randomized patients mortality found trial Disease
dopa OBJECTIVES trial Parkinson
dopa OBJECTIVES trial Parkinson '
dopa OBJECTIVES trial s
dopa OBJECTIVES trial Disease
L day selegiline receive randomized patients disease Parkinson
L day selegiline receive randomized patients disease Parkinson '
L day selegiline receive randomized patients disease s
L day selegiline receive randomized patients disease
dopa OBJECTIVES trial found mortality patients disease Parkinson
dopa OBJECTIVES trial found mortality patients disease Parkinson '
dopa OBJECTIVES trial found mortality patients disease s
dopa OBJECTIVES trial found mortality patients disease
L day selegiline receive randomized patients disease PD
dopa OBJECTIVES trial found mortality patients disease PD
L taking those dopa OBJECTIVES trial Parkinson
L taking those dopa OBJECTIVES trial Parkinson '
L taking those dopa OBJECTIVES trial s
L taking those dopa OBJECTIVES trial Disease
dopa L taking those dopa OBJECTIVES trial Parkinson
dopa L taking those dopa OBJECTIVES trial Parkinson '
dopa L taking those dopa OBJECTIVES trial s
dopa L taking those dopa OBJECTIVES trial Disease
L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson
L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson '
L taking those dopa OBJECTIVES trial found mortality patients disease s
L taking those dopa OBJECTIVES trial found mortality patients disease
dopa L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson
dopa L taking those dopa OBJECTIVES trial found mortality patients disease Parkinson '
dopa L taking those dopa OBJECTIVES trial found mortality patients disease s
dopa L taking those dopa OBJECTIVES trial found mortality patients disease
L taking those dopa OBJECTIVES trial found mortality patients disease PD
dopa L taking those dopa OBJECTIVES trial found mortality patients disease PD
selegiline receive randomized patients mortality found trial Parkinson
selegiline receive randomized patients mortality found trial Parkinson '
selegiline receive randomized patients mortality found trial s
selegiline receive randomized patients mortality found trial Disease
selegiline receive randomized patients disease Parkinson
selegiline receive randomized patients disease Parkinson '
selegiline receive randomized patients disease s
selegiline receive randomized patients disease
selegiline receive randomized patients disease PD
L selegiline therapy associated hypotension systolic
L selegiline therapy associated hypotension orthostatic
L selegiline therapy associated hypotension
dopa associated hypotension systolic
dopa associated hypotension orthostatic
dopa associated hypotension
selegiline receiving patients PD
selegiline marked six patients PD
L selegiline finding confirms associated hypotension orthostatic
L selegiline finding confirms associated hypotension
dopa associated hypotension orthostatic
dopa associated hypotension
apomorphine dose administration dyskinesia study included patients had disease Parkinson
apomorphine dose administration dyskinesia study included patients had disease Parkinson '
apomorphine dose administration dyskinesia study included patients had disease s
apomorphine dose administration dyskinesia study included patients had disease
levodopa stimulation dyskinesias disease Parkinson
levodopa stimulation dyskinesias disease Parkinson '
levodopa stimulation dyskinesias disease s
levodopa stimulation dyskinesias disease
Dopamine essential development methamphetamine induced neurotoxicity
dopamine mediates methamphetamine toxicity
dopamine mediates drugs interfere toxicity
dopamine mediates drugs interfere enhance toxicity
DA dopamine mediates methamphetamine toxicity
DA dopamine mediates drugs interfere toxicity
DA dopamine mediates drugs interfere enhance toxicity
DA toxicity interfere drugs mediates methamphetamine toxicity
DA toxicity
DA toxicity interfere enhance toxicity
DA neurotransmission increase drugs enhance interfere drugs mediates methamphetamine toxicity
DA neurotransmission increase drugs enhance interfere toxicity
DA neurotransmission increase drugs enhance toxicity
methamphetamine toxicity
methamphetamine mediates drugs interfere toxicity
methamphetamine mediates drugs interfere enhance toxicity
METH methamphetamine toxicity
METH methamphetamine mediates drugs interfere toxicity
METH methamphetamine mediates drugs interfere enhance toxicity
DA confounded neurotoxicity
L ability dihydroxyphenylalanine show confounded neurotoxicity
dihydroxyphenylalanine show confounded neurotoxicity
alpha tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
methyl tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
para methyl tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
tyrosine effect reverse dihydroxyphenylalanine show confounded neurotoxicity
DA deficient engineered mice develop METH neurotoxicity
METH deficits dopaminergic
METH deficits
DA deficits develop METH deficits dopaminergic
DA deficits develop METH deficits
DA essential neurotoxicity
DA mechanisms warrant suggest demonstrate essential neurotoxicity
Cocaine induced disorder rates symptoms psychiatric
cocaine induced disorder rates symptoms psychiatric
cocaine induced disorder CIMD
cocaine outpatients cocaine induced disorder CIMD
cocaine compared measures symptoms psychiatric
cocaine outpatients cocaine compared measures symptoms psychiatric
salicylates calcium treated arthritis rheumatoid
salicylates calcium treated arthritis
naproxen therapy institution developed year man arthritis rheumatoid
naproxen therapy institution developed year man arthritis
fenoprofen calcium treated arthritis man year developed necrosis renal
fenoprofen calcium treated arthritis man year developed necrosis papillary
fenoprofen calcium treated arthritis man year developed necrosis
calcium treated arthritis man year developed necrosis renal
calcium treated arthritis man year developed necrosis papillary
calcium treated arthritis man year developed necrosis
fenoprofen calcium treated arthritis man year developed necrosis RPN
calcium treated arthritis man year developed necrosis RPN
sulindac calcium treated arthritis rheumatoid
sulindac calcium treated arthritis
salicylates calcium treated arthritis man year developed necrosis renal
salicylates calcium treated arthritis man year developed necrosis papillary
salicylates calcium treated arthritis man year developed necrosis
salicylates calcium treated arthritis man year developed necrosis RPN
fenoprofen calcium treated arthritis rheumatoid
fenoprofen calcium treated arthritis
calcium treated arthritis rheumatoid
calcium treated arthritis
sulindac calcium treated arthritis man year developed necrosis renal
sulindac calcium treated arthritis man year developed necrosis papillary
sulindac calcium treated arthritis man year developed necrosis
sulindac calcium treated arthritis man year developed necrosis RPN
gold salts calcium treated arthritis man year developed necrosis renal
gold salts calcium treated arthritis man year developed necrosis papillary
gold salts calcium treated arthritis man year developed necrosis
gold salts calcium treated arthritis man year developed necrosis RPN
gold salts calcium treated arthritis rheumatoid
gold salts calcium treated arthritis
sulindac advantages discuss antiinflammatory linking RPN
sulindac advantages discuss patients experienced toxicity renal
sulindac advantages discuss patients experienced toxicity
All induced leukemia acute
All induced leukemia promyelocytic
All induced leukemia
trans All induced leukemia acute
trans All induced leukemia promyelocytic
trans All induced leukemia
retinoic acid trans All induced leukemia acute
retinoic acid trans All induced leukemia promyelocytic
retinoic acid trans All induced leukemia
acid trans All induced leukemia acute
acid trans All induced leukemia promyelocytic
acid trans All induced leukemia
all acid associated leukemia acute
all acid associated leukemia promyelocytic
all acid associated leukemia
trans acid associated leukemia acute
trans acid associated leukemia promyelocytic
trans acid associated leukemia
retinoic acid associated leukemia acute
retinoic acid associated leukemia promyelocytic
retinoic acid associated leukemia
acid associated leukemia acute
acid associated leukemia promyelocytic
acid associated leukemia
all acid associated nodosum APL
trans acid associated nodosum APL
retinoic acid associated nodosum APL
acid associated nodosum APL
ATRA acid associated leukemia acute
ATRA acid associated leukemia promyelocytic
ATRA acid associated leukemia
ATRA acid associated nodosum APL
ATRA therapy developed patients APL
ATRA therapy developed nodules painful
steroid use effective induced nodosum erythema
steroid use effective induced nodosum
ziprasidone dose developed history schizophrenia
Caffeine induced arrhythmia cardiac
Caffeine induced arrhythmia
caffeine concentration containing consuming developed describe 25 prolapse mitral
caffeine concentration containing consuming developed describe 25 prolapse valve
caffeine concentration containing consuming developed describe 25 prolapse
acetylcholine subunits alpha necessary induced seizures
nicotine necessary induced hypolocomotion
acetylcholine subunits alpha necessary induced hypolocomotion
acetylcholine receptors Binding series behaviors go seizures
acetylcholine receptors Binding series behaviors go exploration tremors
nicotine Binding series behaviors go seizures death
acetylcholine receptors Binding series behaviors go seizures death
nicotine Binding series behaviors go exploration tremors
nicotine examined homozygous seizures hypolocomotion
nicotine mediators induced hypolocomotion
dopamine explored success risk defects visual
dopamine explored success risk defects field
dopamine explored success risk defects
dopamine explored success risk defects VFD
DA dopamine explored success risk defects visual
DA dopamine explored success risk defects field
DA dopamine explored success risk defects
DA dopamine explored success risk defects VFD
dopamine explored success treating abuse substance
dopamine explored success treating abuse
DA dopamine explored success treating abuse substance
DA dopamine explored success treating abuse
cocaine GVG effects dopamine explored success treating abuse substance
cocaine GVG effects dopamine explored success treating abuse
GVG effects dopamine explored success treating abuse substance
GVG effects dopamine explored success treating abuse
cocaine GVG effects dopamine explored success risk defects visual
cocaine GVG effects dopamine explored success risk defects field
cocaine GVG effects dopamine explored success risk defects
cocaine GVG effects dopamine explored success risk defects VFD
alcohol intake admitted Five patients pain
alcohol intake admitted Five patients seven patients pain
tamoxifen used treatment breast
tamoxifen used treatment cancer
tamoxifen used proposed prevention cancer breast
tamoxifen used proposed prevention cancer
tamoxifen use investigated women treated cancer breast
tamoxifen use investigated women treated cancer
tamoxifen received had Women had disease advanced
tamoxifen received had Women had disease
tamoxifen role suggest used proposed prevention breast
tamoxifen role suggest used proposed prevention cancer
tamoxifen cancer breast
tamoxifen cancer
tamoxifen treatment cancer breast
tamoxifen treatment cancer
calcium blockers exposed fetuses alterations Cardiovascular
calcium blockers exposed fetuses alterations
calcium blocker induced alterations cardiovascular
calcium blocker induced alterations
calcium blockers induce malformations cardiovascular
calcium blockers induce malformations
calcium blockers one administered examined malformations cardiovascular
calcium blockers one administered examined malformations
calcium blockers each observed incidence malformations cardiovascular
calcium blockers each observed incidence malformations
CYP observed increased mice inflammation bladder
CYP observed increased mice inflammation
RAPA conversion effects evaluate patients undergoing cyclosporine toxicity
tacrolimus cyclosporine toxicity
Tac tacrolimus cyclosporine toxicity
cyclosporine toxicity
CsA cyclosporine toxicity
CsA CsA hepatotoxicity
CsA hepatotoxicity
Tac nephrotoxicity CsA CsA disorder posttransplant
Tac nephrotoxicity CsA CsA disorder lymphoproliferative
Tac nephrotoxicity CsA CsA disorder
Tac nephrotoxicity CsA CsA disorder PTLD
Tac toxicity CsA disorder posttransplant
Tac toxicity CsA disorder lymphoproliferative
Tac toxicity CsA disorder
Tac toxicity CsA disorder PTLD
CsA CsA dysmorphism facial
CsA CsA dysmorphism
CsA dysmorphism facial
CsA dysmorphism
Tac nephrotoxicity CsA CsA hepatotoxicity
Tac toxicity CsA hepatotoxicity
Tac nephrotoxicity CsA CsA dysmorphism facial
Tac nephrotoxicity CsA CsA dysmorphism
Tac toxicity CsA dysmorphism facial
Tac toxicity CsA dysmorphism
Tac nephrotoxicity CsA CsA toxicity
Tac toxicity
CsA CsA disorder posttransplant
CsA CsA disorder lymphoproliferative
CsA CsA disorder
CsA CsA disorder PTLD
CsA disorder posttransplant
CsA disorder lymphoproliferative
CsA disorder
CsA disorder PTLD
CsA CsA toxicity
CsA toxicity
creatinine + decrease was nephrotoxicity
RAPA discontinued patients pneumonia ulcers aphtous
RAPA discontinued patients pneumonia ulcers
RAPA discontinued patients pneumonia PTLD
RAPA discontinued patients pneumonia
RAPA levels converting monitored However given immunosuppression antiviral prophylaxis Pneumocystis
RAPA levels converting monitored However given immunosuppression antiviral prophylaxis carinii
RAPA levels converting monitored However given immunosuppression antiviral prophylaxis pneumonia
heroin dependence methadone treated patients prolongation Syncope
heroin dependence methadone treated patients prolongation Syncope QT
heroin dependence methadone treated patients prolongation
methadone users reported Prolongation interval ECG patients pointes torsade
methadone users reported Prolongation interval ECG patients pointes de
methadone users reported Prolongation interval ECG patients pointes
methadone users reported Prolongation TdP
heroin addicts faint attribute underestimate incidence TdP
methadone effect caused attribute underestimate incidence TdP
heroin addicts faint attribute episodes syncope
heroin addicts population associated prolongation reporting syncope
heroin addicts population associated prolongation QT
heroin addicts population associated prolongation
acetylcholine expression caused dysfunction muscle
acetylcholine expression caused dysfunction
Prednisolone induced caused more atrophy
acetylcholine expression caused more atrophy
d curves fatigability nerve tensions tensions tetanic
tubocurarine fatigability nerve tensions tensions tetanic
prednisolone dysfunction neuromuscular
prednisolone dysfunction
acetylcholine expression changes dose dose atrophy muscle
acetylcholine expression changes dose dose atrophy
steroid injection syndrome Cauda
steroid injection syndrome equina
steroid injection syndrome
steroid injections therapy methods radiculopathy
triamcinolone injection caused syndrome cauda
triamcinolone injection caused syndrome equina
triamcinolone injection caused syndrome
steroid injection scheduled woman back low
steroid injection scheduled woman back
steroid injection scheduled woman back and
steroid injection scheduled woman back pain right
steroid injection scheduled woman back pain leg
steroid injection scheduled woman back pain
steroid injections vigilance deterioration neurologic
steroid injections vigilance deterioration
uric acid dL buffer compared effects nephrotoxic
acid dL buffer compared effects nephrotoxic
suprofen mg dose effects nephrotoxic
uric acid distribution altering causes declines acute
uric acid distribution altering causes declines
uric acid distribution altering causes declines function in
uric acid distribution altering causes declines function renal
uric acid distribution altering causes declines function
acid distribution altering causes declines acute
acid distribution altering causes declines
acid distribution altering causes declines function in
acid distribution altering causes declines function renal
acid distribution altering causes declines function
captopril Effect proteinuria rats hypertensive
captopril Effect proteinuria
aminonucleoside existing captopril Effect proteinuria rats hypertensive
captopril treatment patients hypertensive
captopril treatment effect Proteinuria
captopril reproducing abnormality renal
captopril reproducing abnormality
captopril administration failed aggravate pre proteinuria
captopril treatment failed potentiate development proteinuria
haloperidol efficacy studies model disease Parkinson
haloperidol efficacy studies model disease Parkinson '
haloperidol efficacy studies model disease s
haloperidol efficacy studies model disease
risperidone reduction syndrome Withdrawal
risperidone reduction syndrome emergent
risperidone reduction syndrome rabbit
risperidone reduction syndrome
dopamine antagonist serotonin mechanism withdrawal
dopamine antagonist serotonin mechanism related RS emergent
dopamine antagonist serotonin mechanism related RS
dopamine antagonist serotonin mechanism development RS
serotonin mechanism withdrawal
serotonin mechanism related RS emergent
serotonin mechanism related RS
serotonin system influence suggesting mechanism withdrawal
serotonin system influence suggesting mechanism related RS emergent
serotonin system influence suggesting mechanism related RS
risperidone profile related mechanism withdrawal
risperidone profile related RS emergent
risperidone profile related RS
serotonin mechanism development RS
serotonin system influence suggesting mechanism development RS
adriamycin mitochondria impairment cardiomyopathy
adriamycin cancer
ADR adriamycin cancer
adriamycin use limited due toxicity cardiovascular
adriamycin use limited due toxicity
ADR adriamycin use limited due toxicity cardiovascular
ADR adriamycin use limited due toxicity
ADR treatment caused arrhythmias cardiovascular
ADR treatment caused arrhythmias
ADR treatment caused indicated underwent swelling
NRA hyperactivity
0160 NRA hyperactivity
clozapine hyperactivity
cephalosporins receiving patients described anemia hemolytic
cephalosporins receiving patients described anemia
penicillins cephalosporins receiving patients described anemia hemolytic
penicillins cephalosporins receiving patients described anemia
cefotetan receiving developed anemia
epinephrine treatment priapism
cortisol humans transport L induced hypertension
L induced hypertension
arginine transport L induced hypertension
cortisol implicated arginine induced hypertension
L arginine induced hypertension
arginine induced hypertension
nitric system implicated arginine induced hypertension
oxide system implicated arginine induced hypertension
cortisol conclude associated increases
cortisol conclude associated increases pressure in
cortisol conclude associated increases pressure blood
cortisol conclude associated increases pressure
l abnormalities associated increases
l abnormalities associated increases pressure in
l abnormalities associated increases pressure blood
l abnormalities associated increases pressure
arginine system l abnormalities associated increases
arginine system l abnormalities associated increases pressure in
arginine system l abnormalities associated increases pressure blood
arginine system l abnormalities associated increases pressure
Oxytocin attributed loss blood
Oxytocin attributed loss
oxytocin response Hypotension associated decrease increase volume stroke
clotiazepam administration onset developed necrosis extensive
clotiazepam administration onset developed necrosis hepatocellular
clotiazepam administration onset developed necrosis
thienodiazepine derivative clotiazepam administration onset developed hepatitis
thienodiazepine derivative clotiazepam administration onset developed necrosis extensive
thienodiazepine derivative clotiazepam administration onset developed necrosis hepatocellular
thienodiazepine derivative clotiazepam administration onset developed necrosis
benzodiazepines administration interfere induce relapse hepatitis
benzodiazepines hepatotoxicity is suggests shows induce hepatitis
benzodiazepines hepatotoxicity
pentamidine tachycardia ventricular
pentamidine tachycardia
Pentamidine isethionate associated tachyarrhythmias ventricular
Pentamidine isethionate associated tachyarrhythmias
isethionate associated tachyarrhythmias ventricular
isethionate associated tachyarrhythmias
magnesium levels serum related induce hypomagnesemia
Pentamidine induced related induce hypomagnesemia
magnesium levels serum related pointes torsade
magnesium levels serum related pointes de
magnesium levels serum related pointes
magnesium supplementation advocated observed prolongation QTc
magnesium supplementation advocated observed prolongation interval
magnesium supplementation advocated observed prolongation
Warfarin induced hemorrhage
warfarin therapy man 28 case sustained developed pain
warfarin therapy man 28 case sustained developed pain contracture
warfarin form represents induced Anticoagulant induced characterized pain
warfarin form represents induced Anticoagulant induced characterized region degrees contracture
warfarin form represents induced Anticoagulant induced neuropathy peripheral
warfarin form represents induced Anticoagulant induced neuropathy
warfarin form represents induced Anticoagulant induced characterized region degrees impairment motor
warfarin form represents induced Anticoagulant induced characterized region degrees impairment motor and
warfarin form represents induced Anticoagulant induced characterized region degrees impairment motor sensory
warfarin form represents induced Anticoagulant induced characterized region degrees impairment
calcium chloride induced tetany
chloride induced tetany
diltiazem infusion developed arrest respiratory
diltiazem infusion developed arrest
calcium chloride administration resolved tetany
chloride administration resolved tetany
calcium chloride remedy accompany life tetany
chloride remedy accompany life tetany
glutamate uptake dyskinesia orofacial
glutamate uptake dyskinesia
glutamate uptake decrease correlates increase incidence diskinesia orofacial
glutamate uptake decrease correlates increase incidence diskinesia
bupropion release associated deprivation sleep
bupropion release associated deprivation
bupropion use sleep
bupropion use deprivation
bupropion risk add deprivation sleep
bupropion risk add deprivation
morphine therapy patients cancer
ketamine patients cancer
morphine responsive Pain
N aspartate effective improving analgesia pain neuropathic
N aspartate effective improving analgesia pain
methyl N aspartate effective improving analgesia pain neuropathic
methyl N aspartate effective improving analgesia pain
D methyl N aspartate effective improving analgesia pain neuropathic
D methyl N aspartate effective improving analgesia pain
aspartate effective improving analgesia pain neuropathic
aspartate effective improving analgesia pain
NMDA antagonists effective improving analgesia pain neuropathic
NMDA antagonists effective improving analgesia pain
ketamine antagonists effective improving analgesia syndromes pain
ketamine antagonists effective improving analgesia pain neuropathic
ketamine antagonists effective improving analgesia pain
N aspartate effective improving analgesia syndromes pain
methyl N aspartate effective improving analgesia syndromes pain
D methyl N aspartate effective improving analgesia syndromes pain
aspartate effective improving analgesia syndromes pain
NMDA antagonists effective improving analgesia syndromes pain
ketamine doses bolus given patients unrelieved pain
morphine study unrelieved patients cancer
morphine study unrelieved pain
ketamine doses bolus given patients cancer
Ketamine reduced intensity pain
morphine analgesia pain neuropathic
morphine analgesia pain
Ketamine improve analgesia syndromes pain
Ketamine improve analgesia pain neuropathic
Ketamine improve analgesia pain
morphine analgesia syndromes pain
tacrolimus cyclosporine toxicity
cyclosporine toxicity
methadone responses Pain
methadone stabilized addicts opioid
methadone stabilized addicts
methadone stabilized addicts sample tolerance pain
ketorolac agents pressor examined pain
hydromorphone doses administration examined pain
amiodarone administration tachycardia supraventricular
amiodarone administration tachycardia
amiodarone administration Wolff
amiodarone administration Parkinson
amiodarone administration syndrome White
amiodarone administration syndrome
amiodarone administration boy cardiomyopathy primary
amiodarone administration boy cardiomyopathy
amiodarone dosage Reduction resulted disappearance persistence bradycardia sinus
amiodarone dosage Reduction resulted disappearance persistence bradycardia
phenobarbital therapy term Hepatonecrosis
PB treated epilepsy
PB one consequence arrest cardiac
PB one consequence arrest
PB other bronchopneumonia
PB diagnosis dysfunction chronic
PB diagnosis dysfunction hepatic
PB diagnosis dysfunction enzyme
PB diagnosis dysfunction
sirolimus mofetil mycophenolate have nephrotoxicity
rapamycin mofetil mycophenolate have nephrotoxicity
mycophenolate have nephrotoxicity
mofetil mycophenolate have nephrotoxicity
adenosine characterization antagonist disease Parkinson
adenosine characterization antagonist disease Parkinson '
adenosine characterization antagonist disease s
adenosine characterization antagonist disease
A A adenosine characterization antagonist disease Parkinson
A A adenosine characterization antagonist disease Parkinson '
A A adenosine characterization antagonist disease s
A A adenosine characterization antagonist disease
2 A adenosine characterization antagonist disease Parkinson
2 A adenosine characterization antagonist disease Parkinson '
2 A adenosine characterization antagonist disease s
2 A adenosine characterization antagonist disease
A adenosine characterization antagonist disease Parkinson
A adenosine characterization antagonist disease Parkinson '
A adenosine characterization antagonist disease s
A adenosine characterization antagonist disease
A antagonist disease Parkinson
A antagonist disease Parkinson '
A antagonist disease s
A antagonist disease
1 antagonist disease Parkinson
1 antagonist disease Parkinson '
1 antagonist disease s
1 antagonist disease
receptor antagonist disease Parkinson
receptor antagonist disease Parkinson '
receptor antagonist disease s
receptor antagonist disease
antagonist disease Parkinson
antagonist disease Parkinson '
antagonist disease s
antagonist disease
adenosine A characterization described antagonist models disease Parkinson
adenosine A characterization described antagonist models disease Parkinson '
adenosine A characterization described antagonist models disease s
adenosine A characterization described antagonist models disease
A characterization described antagonist models disease Parkinson
A characterization described antagonist models disease Parkinson '
A characterization described antagonist models disease s
A characterization described antagonist models disease
2 A A characterization described antagonist models disease Parkinson
2 A A characterization described antagonist models disease Parkinson '
2 A A characterization described antagonist models disease s
2 A A characterization described antagonist models disease
A A characterization described antagonist models disease Parkinson
A A characterization described antagonist models disease Parkinson '
A A characterization described antagonist models disease s
A A characterization described antagonist models disease
A antagonist models disease Parkinson
A antagonist models disease Parkinson '
A antagonist models disease s
A antagonist models disease
1 antagonist models disease Parkinson
1 antagonist models disease Parkinson '
1 antagonist models disease s
1 antagonist models disease
receptor antagonist models disease Parkinson
receptor antagonist models disease Parkinson '
receptor antagonist models disease s
receptor antagonist models disease
antagonist models disease Parkinson
antagonist models disease Parkinson '
antagonist models disease s
antagonist models disease
haloperidol models akinesia
MPTP rotation models akinesia
MPTP rotation models catalepsy
reserpine model catalepsy
6 rat akinesia models catalepsy
hydroxydopamine model models catalepsy
6 hydroxydopamine model models catalepsy
OHDA 6 hydroxydopamine model models catalepsy
reserpine model catalepsy models mouse = 17 has number models disease Parkinson
reserpine model catalepsy models mouse = 17 has number models disease Parkinson '
reserpine model catalepsy models mouse = 17 has number models disease s
reserpine model catalepsy models mouse = 17 has number models disease
MPTP rotation models mouse = 17 has number models disease Parkinson
MPTP rotation models mouse = 17 has number models disease Parkinson '
MPTP rotation models mouse = 17 has number models disease s
MPTP rotation models mouse = 17 has number models disease
haloperidol models mouse = 17 has number models disease Parkinson
haloperidol models mouse = 17 has number models disease Parkinson '
haloperidol models mouse = 17 has number models disease s
haloperidol models mouse = 17 has number models disease
6 rat akinesia models mouse = 17 has number models disease Parkinson
6 rat akinesia models mouse = 17 has number models disease Parkinson '
6 rat akinesia models mouse = 17 has number models disease s
6 rat akinesia models mouse = 17 has number models disease
hydroxydopamine model models mouse = 17 has number models disease Parkinson
hydroxydopamine model models mouse = 17 has number models disease Parkinson '
hydroxydopamine model models mouse = 17 has number models disease s
hydroxydopamine model models mouse = 17 has number models disease
6 hydroxydopamine model models mouse = 17 has number models disease Parkinson
6 hydroxydopamine model models mouse = 17 has number models disease Parkinson '
6 hydroxydopamine model models mouse = 17 has number models disease s
6 hydroxydopamine model models mouse = 17 has number models disease
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease Parkinson
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease Parkinson '
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease s
OHDA 6 hydroxydopamine model models mouse = 17 has number models disease
6 rat akinesia
hydroxydopamine model models akinesia
6 hydroxydopamine model models akinesia
OHDA 6 hydroxydopamine model models akinesia
Gentamicin nephropathy
penicillin gentamicin died failure acute
penicillin gentamicin died failure renal
penicillin gentamicin died failure
gentamicin concentration reached developed anuria
Carbamazepine induced dysfunction cardiac
Carbamazepine induced dysfunction
carbamazepine associated dysfunction cardiac
carbamazepine associated dysfunction
carbamazepine overdose
carbamazepine used treatment neurologic conditions psychiatric
Tamoxifen drug prescribed chemotherapy cancer breast
Tamoxifen drug prescribed chemotherapy cancer
TAM Tamoxifen drug prescribed chemotherapy cancer breast
TAM Tamoxifen drug prescribed chemotherapy cancer
alpha concentrations prevented effect hemolytic
tocopherol acetate indicating prevented effect hemolytic
alpha concentrations prevented indicating related TAM hemolysis
tocopherol acetate indicating related TAM hemolysis
alpha tocopherol acetate indicating prevented effect hemolytic
T alpha tocopherol acetate indicating prevented effect hemolytic
alpha tocopherol acetate indicating related TAM hemolysis
T alpha tocopherol acetate indicating related TAM hemolysis
alpha tocopherol acetate indicating prevented effect hemolytic
tocopherol acetate indicating prevented effect hemolytic
acetate indicating prevented effect hemolytic
alpha tocopherol acetate indicating related TAM hemolysis
tocopherol acetate indicating related TAM hemolysis
acetate indicating related TAM hemolysis
alpha acetate indicating prevented effect hemolytic
TAc alpha acetate indicating prevented effect hemolytic
alpha acetate indicating related TAM hemolysis
TAc alpha acetate indicating related TAM hemolysis
hydroxyl acetate indicating prevented effect hemolytic
hydroxyl acetate indicating related TAM hemolysis
oxygen consumption hemolysis
K leakage preceded Hemolysis
K leakage preceded excluding colloid mechanism hemolysis
tocopherols hemolysis
cyclophosphamide therapy complication cystitis Hemorrhagic
cyclophosphamide therapy complication cystitis
mesna neutralizes metabolite causes cystitis hemorrhagic
mesna neutralizes metabolite causes cystitis
cyclophosphamide metabolite causes cystitis hemorrhagic
cyclophosphamide metabolite causes cystitis
mesna uroprophylaxis received patients two had cystitis hemorrhagic
mesna uroprophylaxis received patients two had cystitis
vitamin C increase women diabetes
C increase women diabetes
vitamin C persons diabetic
C persons diabetic
vitamin C intake promote atherosclerosis
C intake promote atherosclerosis
vitamin intake relation studied women reported diabetic
C intake relation studied women reported diabetic
vitamin intake relation stroke
C intake relation stroke
vitamin intake relation artery coronary
vitamin intake relation artery
vitamin intake relation artery disease
C intake relation artery coronary
C intake relation artery
C intake relation artery disease
vitamin E folate intakes medication type 1 adjustment factors cardiovascular
vitamin E folate intakes medication type 1 adjustment factors disease
E folate intakes medication type 1 adjustment factors cardiovascular
E folate intakes medication type 1 adjustment factors disease
vitamin E folate intakes carotene mortality adjusted risks disease cardiovascular
vitamin E folate intakes carotene mortality adjusted risks disease
E folate intakes carotene mortality adjusted risks disease cardiovascular
E folate intakes carotene mortality adjusted risks disease
beta folate intakes medication type 1 adjustment factors cardiovascular
beta folate intakes medication type 1 adjustment factors disease
carotene intakes medication type 1 adjustment factors cardiovascular
carotene intakes medication type 1 adjustment factors disease
beta folate intakes carotene mortality adjusted risks disease cardiovascular
beta folate intakes carotene mortality adjusted risks disease
carotene mortality adjusted risks disease cardiovascular
carotene mortality adjusted risks disease
vitamin intake quintiles 0 < trend P 1 type medication diabetes
C intake quintiles 0 < trend P 1 type medication diabetes
vitamin intake quintiles 0 < trend P 1 type medication duration diabetes
C intake quintiles 0 < trend P 1 type medication duration diabetes
vitamin E folate intakes medication diabetes
E folate intakes medication diabetes
vitamin E folate intakes medication duration diabetes
E folate intakes medication duration diabetes
folate intakes medication diabetes
folate intakes medication duration diabetes
beta folate intakes medication diabetes
carotene intakes medication diabetes
beta folate intakes medication duration diabetes
carotene intakes medication duration diabetes
folate intakes medication type 1 adjustment factors cardiovascular
folate intakes medication type 1 adjustment factors disease
folate intakes carotene mortality adjusted risks disease cardiovascular
folate intakes carotene mortality adjusted risks disease
vitamin intake associated risk mortality women diabetes
C intake associated risk mortality women diabetes
trihexyphenidyl hydrochloride drug treated patient schizophrenic
hydrochloride drug treated patient schizophrenic
disulfiram developed syndrome tachycardia hypotension arterial
disulfiram developed syndrome tachycardia hypotension
disulfiram developed syndrome tachycardia flushing
disulfiram developed syndrome tachycardia
clozapine treated inpatients psychiatric
flumazenil group nausea pain
azathioprine therapy initiation developed patient polymyositis
azathioprine therapy initiation developed patient patient evidence disease liver
azathioprine therapy initiation developed patient patient evidence disease
cephalosporins associated anemia hemolytic
cephalosporins associated anemia
acetaminophen produce toxicities cardiovascular
acetaminophen produce toxicities
acetaminophen demonstrated produce symptoms anaphylaxis
acetaminophen administration developed patients ill critically
acetaminophen administration developed patients ill
METH secondary induced hyperactivity
8 administration monkeys rhesus Toxicity
aminoquinoline 8 administration monkeys rhesus Toxicity
8 aminoquinoline 8 administration monkeys rhesus Toxicity
-LSB- 8 administration monkeys rhesus Toxicity
4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
amino l 4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
l 4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
methylbutyl l 4 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
amino -RSB- -LSB- 8 administration monkeys rhesus Toxicity
-RSB- -LSB- 8 administration monkeys rhesus Toxicity
5 -RSB- -LSB- 8 administration monkeys rhesus Toxicity
l -RSB- -LSB- 8 administration monkeys rhesus Toxicity
hexyloxy l -RSB- -LSB- 8 administration monkeys rhesus Toxicity
6 8 administration monkeys rhesus Toxicity
methoxy 8 administration monkeys rhesus Toxicity
4 8 administration monkeys rhesus Toxicity
methylquinoline 8 administration monkeys rhesus Toxicity
WR methylquinoline 8 administration monkeys rhesus Toxicity
242511 WR methylquinoline 8 administration monkeys rhesus Toxicity
WR doses RESULTS produced methemoglobinemia
242511 WR doses RESULTS produced methemoglobinemia
WR 242511 pursued pretreatment poisoning
242511 pursued pretreatment poisoning
WR 242511 pursued concluded dissociated toxicity
242511 pursued concluded dissociated toxicity
iohexol iopromide incidence determined compared type presence cyanosis
contrast media CIN incidence determined compared type presence cyanosis
media CIN incidence determined compared type presence cyanosis
CM media CIN incidence determined compared type presence cyanosis
CM type presence cyanosis
iopromide incidence determined compared type presence cyanosis
CM type depends depends presence cyanosis
thallium dipyridamole hyperemia
Pentoxifylline inhibit dipyridamole hyperemia
Trental Pentoxifylline inhibit dipyridamole hyperemia
Dipyridamole performed patients unable exercise disease peripheral
Dipyridamole performed patients unable exercise disease vascular
Dipyridamole performed patients unable exercise disease
thallium Dipyridamole performed patients unable exercise disease peripheral
thallium Dipyridamole performed patients unable exercise disease vascular
thallium Dipyridamole performed patients unable exercise disease
methylxanthine derivative improve claudication intermittent
methylxanthine derivative improve claudication
thallium induced hyperemia
theophylline methylxanthines induced hyperemia
methylxanthines induced hyperemia
pentoxifylline inhibits thallium induced hyperemia
theophylline lower decreased hyperemia
pentoxifylline dose decreased hyperemia
pentoxyifylline inhibit dipyridamole induced hyperemia
Doxorubicin anti agent tumor
Disulfiram induced optic
Disulfiram induced optic and
Disulfiram induced optic neuropathy peripheral
Disulfiram induced optic neuropathy
disulfiram use report management alcohol
disulfiram use report management dependence
disulfiram use report case neuropathy optic
disulfiram use report case neuropathy optic and
disulfiram use report case neuropathy optic peripheral
disulfiram use report case neuropathy
disulfiram taking dependence alcohol
disulfiram taking dependence
LSD abuse history patients schizophrenic
LSD abuse history patients disturbances visual
LSD abuse history patients disturbances
Risperidone disturbances patients schizophrenic
risperidone treated patients had developed EPS
LSD abuse history had patients schizophrenic
LSD abuse history had developed EPS
risperidone treated patients schizophrenic
LSD consumption related flashbacks experienced disturbances visual
LSD consumption related flashbacks experienced disturbances
Acetazolamide induced nephrolithiasis
Acetazolamide induced nephrolithiasis implications treatment disorders neuromuscular
Acetazolamide induced nephrolithiasis implications treatment disorders
acetazolamide complication Nephrolithiasis
propafenone overdose induced Ebstein
propafenone overdose induced Ebstein '
propafenone overdose induced syndrome platypnea anomaly s
propafenone overdose induced syndrome platypnea anomaly
propafenone overdose
propafenone overdose induced syndrome platypnea
propafenone overdose induced syndrome platypnea orthodeoxia
propafenone overdose induced syndrome like
propafenone overdose induced syndrome
propafenone overdose precipitated occurred shunt blood ovale patent
propafenone overdose precipitated occurred shunt blood ovale foramen
propafenone overdose precipitated occurred shunt blood ovale
propafenone overdose
corticosteroids exchange treatment discontinuation led resolution MAHA
dipyridamole exchange treatment discontinuation led resolution MAHA
aspirin exchange treatment discontinuation led resolution MAHA
cyclosporin react A immuno drug known induce MAHA
A immuno drug known induce MAHA
CyA A immuno drug known induce MAHA
oxcarbazepine switched treat haloperidol patients schizophrenic
Carbamazepine switched treat haloperidol patients schizophrenic organic
Carbamazepine switched treat haloperidol patients psychotic
oxcarbazepine switched treat haloperidol patients schizophrenic organic
oxcarbazepine switched treat haloperidol patients psychotic
chlorpromazine haloperidol patients schizophrenic
haloperidol patients schizophrenic
haloperidol patients schizophrenic organic
haloperidol patients psychotic
clozapine haloperidol patients schizophrenic
clozapine haloperidol patients schizophrenic organic
clozapine haloperidol patients psychotic
Carbamazepine switched treat haloperidol patients schizophrenic
chlorpromazine haloperidol patients schizophrenic organic
chlorpromazine haloperidol patients psychotic
calcium Effects blockers induced toxicity
bupivacaine blockers induced toxicity
calcium blockers influence investigate bupivacaine induced toxicity
bupivacaine induced toxicity
bepridil pronounced modified decreased time convulsions
calcium blockers decreased time convulsions
calcium resuscitation arrest asystolic
calcium resuscitation arrest cardiac
calcium resuscitation arrest
calcium resuscitation arrest overdose
aspirin nitrate g 8 overdose
paracetamol nitrate g 8 overdose
nitrate g 8 overdose
isosorbide nitrate g 8 overdose
alcohol overdose
calcium therapy overdose onset asystole
calcium therapy overdose
ephedrine doses adding propofol obtund response hypotensive
ephedrine addition appears method obtunding response hypotensive
ephedrine any patients use recommend risk tachycardia inducing ischemia myocardial
ephedrine any patients use recommend risk tachycardia inducing ischemia
propofol use recommend risk tachycardia inducing ischemia myocardial
propofol use recommend risk tachycardia inducing ischemia
fangchinoline tetrandrine Effects thrombosis
tetrandrine Effects mice aggregation platelet
tetrandrine Effects mice aggregation
tetrandrine Effects thrombosis
fangchinoline tetrandrine Effects mice aggregation platelet
fangchinoline tetrandrine Effects mice aggregation
TET effects investigate thrombosis induced epinephrine aggregation coagulation blood
TET effects investigate thrombosis induced epinephrine aggregation coagulation
FAN TET effects investigate thrombosis
TET effects investigate thrombosis induced epinephrine aggregation platelet
TET effects investigate thrombosis induced epinephrine aggregation
epinephrine aggregation platelet
epinephrine aggregation
EP epinephrine aggregation platelet
EP epinephrine aggregation
FAN TET effects investigate thrombosis induced epinephrine aggregation coagulation blood
FAN TET effects investigate thrombosis induced epinephrine aggregation coagulation
epinephrine aggregation coagulation blood
epinephrine aggregation coagulation
EP epinephrine aggregation coagulation blood
EP epinephrine aggregation coagulation
TET effects investigate thrombosis
FAN TET effects investigate thrombosis induced epinephrine aggregation platelet
FAN TET effects investigate thrombosis induced epinephrine aggregation
acetylsalicylic acid showed showed inhibition thrombosis
acid showed showed inhibition thrombosis
ASA mg acid showed showed inhibition thrombosis
FAN TET administration showed inhibition thrombosis
TET administration showed inhibition thrombosis
TET showed aggregations platelet
TET showed aggregations
FAN TET showed aggregations platelet
FAN TET showed aggregations
UMB pretreatment - SM convulsions
24 UMB pretreatment - SM convulsions
SM convulsions
21 SM convulsions
lindane treatment consider initiated Treatment scabies
gamma hexachloride lindane treatment consider initiated Treatment scabies
benzene hexachloride lindane treatment consider initiated Treatment scabies
hexachloride lindane treatment consider initiated Treatment scabies
mitomycin treatment associated failure anemia hemolytic
mitomycin treatment associated failure anemia
C treatment associated failure anemia hemolytic
C treatment associated failure anemia
mitomycin treatment associated failure anemia thrombocytopenia
C treatment associated failure anemia thrombocytopenia
mitomycin treatment start mth 8 develops % failure edema pulmonary
mitomycin treatment start mth 8 develops % failure edema
C treatment start mth 8 develops % failure edema pulmonary
C treatment start mth 8 develops % failure edema
mitomycin C developed died edema pulmonary
mitomycin C developed died edema
C developed died edema pulmonary
C developed died edema
mitomycin C developed failure while thrombocytopenia
C developed failure while thrombocytopenia
mitomycin C developed man adenocarcinoma gastric
mitomycin C developed man adenocarcinoma
C developed man adenocarcinoma gastric
C developed man adenocarcinoma
divalproex reduced deficits cognitive
divalproex reduced deficits cognitive and
divalproex reduced deficits cognitive functional
divalproex reduced deficits
sodium divalproex reduced deficits cognitive
sodium divalproex reduced deficits cognitive and
sodium divalproex reduced deficits cognitive functional
sodium divalproex reduced deficits
Lithium remains treatment disorder bipolar
Lithium remains treatment disorder
lithium effects management polyuria
lithium effects remain written management polyuria
lithium effects management polyuria tremor
lithium effects remain written management polyuria tremor
divalproex alleviate impairments cognitive
divalproex alleviate impairments cognitive and
divalproex alleviate impairments cognitive functional
divalproex alleviate impairments
sodium divalproex alleviate impairments cognitive
sodium divalproex alleviate impairments cognitive and
sodium divalproex alleviate impairments cognitive functional
sodium divalproex alleviate impairments
lithium switching patients bipolar
divalproex switching patients bipolar
sodium divalproex switching patients bipolar
divalproex sodium lithium substitution helpful reducing cognitive
divalproex sodium lithium substitution helpful reducing cognitive motivational
divalproex sodium lithium substitution helpful reducing cognitive or
divalproex sodium lithium substitution helpful reducing cognitive deficits creative
divalproex sodium lithium substitution helpful reducing cognitive deficits
sodium lithium substitution helpful reducing cognitive
sodium lithium substitution helpful reducing cognitive motivational
sodium lithium substitution helpful reducing cognitive or
sodium lithium substitution helpful reducing cognitive deficits creative
sodium lithium substitution helpful reducing cognitive deficits
lithium substitution helpful reducing cognitive deficits attributed lithium patients bipolar
lithium patients bipolar
divalproex sodium lithium substitution helpful reducing cognitive deficits attributed lithium patients bipolar
sodium lithium substitution helpful reducing cognitive deficits attributed lithium patients bipolar
divalproex sodium alternative lithium patients experiencing deficits cognitive
divalproex sodium alternative lithium patients experiencing deficits
sodium alternative lithium patients experiencing deficits cognitive
sodium alternative lithium patients experiencing deficits
divalproex sodium alternative lithium patients experiencing deficits loss
divalproex sodium alternative lithium patients experiencing deficits loss creativity of
divalproex sodium alternative lithium patients experiencing deficits loss creativity
sodium alternative lithium patients experiencing deficits loss
sodium alternative lithium patients experiencing deficits loss creativity of
sodium alternative lithium patients experiencing deficits loss creativity
divalproex sodium alternative lithium patients experiencing deficits impairments functional
divalproex sodium alternative lithium patients experiencing deficits impairments
sodium alternative lithium patients experiencing deficits impairments functional
sodium alternative lithium patients experiencing deficits impairments
lithium patients bipolar
divalproex sodium alternative lithium patients bipolar
sodium alternative lithium patients bipolar
doxorubicin function indicator echocardiography survivors cancer
Dobutamine echocardiography survivors cancer
dobutamine infusion using performed develop due test damage cardiac
dobutamine infusion using performed develop due test damage
doxorubicin due develop performed using differentiate long survivors cancer
doxorubicin treated cancer
dobutamine infusion using differentiate long survivors cancer
doxorubicin due test damage cardiac
doxorubicin due test damage
doxorubicin treated cancer survivors long differentiate using performed develop due test damage cardiac
doxorubicin treated cancer survivors long differentiate using performed develop due test damage
prazosin enalapril safety phase patients failure congestive
prazosin enalapril safety phase patients failure heart
prazosin enalapril safety phase patients failure
enalapril safety phase patients failure congestive
enalapril safety phase patients failure heart
enalapril safety phase patients failure
angiotensin introduction converting treatment patients failure congestive
angiotensin introduction converting treatment patients failure heart
angiotensin introduction converting treatment patients failure
converting treatment patients failure congestive
converting treatment patients failure heart
converting treatment patients failure
enzyme inhibitors converting treatment patients failure congestive
enzyme inhibitors converting treatment patients failure heart
enzyme inhibitors converting treatment patients failure
ACE inhibitors converting treatment patients failure congestive
ACE inhibitors converting treatment patients failure heart
ACE inhibitors converting treatment patients failure
inhibitors converting treatment patients failure congestive
inhibitors converting treatment patients failure heart
inhibitors converting treatment patients failure
enalapril safety assess designed compared incidence hypotension
enalapril hypotension
danazol treatment hamartoma Bile
danazol treatment hamartoma duct
danazol treatment hamartoma
danazol treatment patient developed hamartoma bile
danazol treatment patient developed hamartoma duct
danazol treatment patient developed hamartoma
Ciprofloxacin induced patients cancer
Ciprofloxacin induced nephrotoxicity
ciprofloxacin associated Nephrotoxicity
ciprofloxacin treatment described followed failure developed cancer
MPEP action associated neurotoxicity
dopamine outflow decrease associated neurotoxicity
dopamine outflow decrease hyperthermia
methamphetamine antagonist action associated neurotoxicity
MPEP action associated decrease hyperthermia
methamphetamine neurones toxicity
MPEP mGluR blockade protect neurones toxicity
dopamine efflux induced induced decrease hyperthermia
MPEP rendered Neuroprotection associated induced induced decrease hyperthermia
chloride channels blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
chloride macromolecular benzodiazepine associated sites binding complex blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
benzodiazepine associated sites binding complex blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
GABA benzodiazepine associated sites binding complex blocks rats pretreatment antagonized enhancement adrenaline induced bradycardia
picrotoxin dose rats pretreatment antagonized enhancement adrenaline induced bradycardia
chloride complex acts facilitate bradycardia
benzodiazepine chloride complex acts facilitate bradycardia
GABA chloride complex acts facilitate bradycardia
methimazole had jaundice
propranolol methimazole had treatment hyperthyroidism
propranolol methimazole had jaundice
methimazole had treatment hyperthyroidism
propranolol methimazole had jaundice itching
Methimazole diagnosed cholestasis
propranolol therapy resumed diagnosed cholestasis
diethylstilbestrol exposed adenocarcinoma clear
diethylstilbestrol exposed adenocarcinoma cell
diethylstilbestrol exposed adenocarcinoma
diethylstilbestrol exposed adenocarcinoma vagina of
diethylstilbestrol exposed adenocarcinoma vagina the
diethylstilbestrol exposed adenocarcinoma vagina
Thiazide diuretics hypokalemia arrhythmias cardiac
Thiazide diuretics hypokalemia arrhythmias
Thiazide diuretics hypokalemia
thiazide therapy consequence Hypokalemia
hydrochlorothiazide treated patients hypertension diastolic
hydrochlorothiazide treated patients hypertension
HCTC hydrochlorothiazide treated patients hypertension diastolic
HCTC hydrochlorothiazide treated patients hypertension
thiazide diuretics cause hypokalemia
potassium hypokalemia
Levodopa alleviated dyskinesia choreic dystonic
Levodopa alleviated dyskinesia limbs cases Parkinsonism
levodopa induced lesions course treatment Parkinsonism
levodopa induced lesions thalamic
levodopa induced lesions
ephedrine reduces induced hypotension
ephedrine reduces
ephedrine reduces oxygenation frontal
ephedrine reduces oxygenation lobe
ephedrine reduces oxygenation
Phenylephrine reduces induced hypotension
ephedrine phenylephrine effect describe induced hypotension
phenylephrine effect describe induced hypotension
ephedrine maintains has CONCLUSIONS utilization hypotension
phenylephrine correct hypotension
bupivacaine antagonist effect impairments cardiovascular
bupivacaine antagonist effect impairments
BN antagonist effect impairments cardiovascular
BN antagonist effect impairments
52021 BN antagonist effect impairments cardiovascular
52021 BN antagonist effect impairments
bupivacaine Administration elicited decrease
bupivacaine Administration elicited decrease pressure of
bupivacaine Administration elicited decrease pressure mean
bupivacaine Administration elicited decrease pressure arterial
bupivacaine Administration elicited decrease pressure blood
bupivacaine Administration elicited decrease pressure
bupivacaine Administration elicited decrease pressure MBP
bupivacaine Administration elicited decrease pressure and
bupivacaine Administration elicited decrease pressure rate heart
bupivacaine Administration elicited decrease pressure rate
bupivacaine Administration elicited decrease pressure HR
bupivacaine administration min suppressed decrease
bupivacaine administration min suppressed decrease MBP of
bupivacaine administration min suppressed decrease MBP
bupivacaine administration min suppressed decrease MBP and
bupivacaine administration min suppressed decrease MBP HR
BN 52021 activating suppressed decrease
BN 52021 activating suppressed decrease MBP of
BN 52021 activating suppressed decrease MBP
BN 52021 activating suppressed decrease MBP and
BN 52021 activating suppressed decrease MBP HR
52021 activating suppressed decrease
52021 activating suppressed decrease MBP of
52021 activating suppressed decrease MBP
52021 activating suppressed decrease MBP and
52021 activating suppressed decrease MBP HR
bupivacaine injected observed reversion decrease
bupivacaine injected observed reversion decrease MBP of
bupivacaine injected observed reversion decrease MBP
bupivacaine injected observed reversion decrease MBP and
bupivacaine injected observed reversion decrease MBP HR
BN injected observed reversion decrease
BN injected observed reversion decrease MBP of
BN injected observed reversion decrease MBP
BN injected observed reversion decrease MBP and
BN injected observed reversion decrease MBP HR
52021 BN injected observed reversion decrease
52021 BN injected observed reversion decrease MBP of
52021 BN injected observed reversion decrease MBP
52021 BN injected observed reversion decrease MBP and
52021 BN injected observed reversion decrease MBP HR
bupivacaine induced toxicity cardiovascular
bupivacaine induced toxicity
BN administration alter demonstrate action bupivacaine induced toxicity cardiovascular
BN administration alter demonstrate action bupivacaine induced toxicity
52021 BN administration alter demonstrate action bupivacaine induced toxicity cardiovascular
52021 BN administration alter demonstrate action bupivacaine induced toxicity
BN action bupivacaine induced toxicity cardiovascular
BN action bupivacaine induced toxicity
52021 BN action bupivacaine induced toxicity cardiovascular
52021 BN action bupivacaine induced toxicity
bupivacaine implicated appears induced alterations cardiovascular
bupivacaine implicated appears induced alterations
IH induced cardiotoxicity
636 proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
grape proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
seed proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
proanthocyanidin extract protection damage associated amiodarone induced cardiotoxicity
extract protection damage associated amiodarone induced cardiotoxicity
acetaminophen associated amiodarone toxicity lung
acetaminophen associated amiodarone toxicity
doxorubicin toxicity amiodarone associated induced nephrotoxicity
IH induced amiodarone associated deaths apoptotic necrotic
636 proanthocyanidin extract protection damage associated deaths apoptotic necrotic
grape proanthocyanidin extract protection damage associated deaths apoptotic necrotic
seed proanthocyanidin extract protection damage associated deaths apoptotic necrotic
proanthocyanidin extract protection damage associated deaths apoptotic necrotic
extract protection damage associated deaths apoptotic necrotic
doxorubicin toxicity lung
doxorubicin toxicity
IH induced amiodarone associated induced nephrotoxicity
636 proanthocyanidin extract protection damage associated induced nephrotoxicity
grape proanthocyanidin extract protection damage associated induced nephrotoxicity
seed proanthocyanidin extract protection damage associated induced nephrotoxicity
proanthocyanidin extract protection damage associated induced nephrotoxicity
extract protection damage associated induced nephrotoxicity
IH induced amiodarone toxicity lung
IH induced amiodarone toxicity
636 proanthocyanidin extract protection damage associated amiodarone toxicity lung
636 proanthocyanidin extract protection damage associated amiodarone toxicity
grape proanthocyanidin extract protection damage associated amiodarone toxicity lung
grape proanthocyanidin extract protection damage associated amiodarone toxicity
seed proanthocyanidin extract protection damage associated amiodarone toxicity lung
seed proanthocyanidin extract protection damage associated amiodarone toxicity
proanthocyanidin extract protection damage associated amiodarone toxicity lung
proanthocyanidin extract protection damage associated amiodarone toxicity
extract protection damage associated amiodarone toxicity lung
extract protection damage associated amiodarone toxicity
acetaminophen associated amiodarone induced cardiotoxicity
amiodarone associated induced nephrotoxicity
amiodarone induced cardiotoxicity
IH ability assessed seed proanthocyanidin induced cardiotoxicity
636 IH ability assessed seed proanthocyanidin induced cardiotoxicity
grape seed proanthocyanidin induced cardiotoxicity
seed proanthocyanidin induced cardiotoxicity
proanthocyanidin induced cardiotoxicity
extract proanthocyanidin induced cardiotoxicity
GSPE extract proanthocyanidin induced cardiotoxicity
acetaminophen prevent extract proanthocyanidin induced toxicity lung
acetaminophen prevent extract proanthocyanidin induced toxicity
AAP acetaminophen prevent extract proanthocyanidin induced toxicity lung
AAP acetaminophen prevent extract proanthocyanidin induced toxicity
doxorubicin toxicity induced proanthocyanidin induced nephrotoxicity
DOX doxorubicin toxicity induced proanthocyanidin induced nephrotoxicity
doxorubicin toxicity lung
doxorubicin toxicity
DOX doxorubicin toxicity lung
DOX doxorubicin toxicity
IH ability assessed seed proanthocyanidin induced nephrotoxicity
636 IH ability assessed seed proanthocyanidin induced nephrotoxicity
grape seed proanthocyanidin induced nephrotoxicity
seed proanthocyanidin induced nephrotoxicity
proanthocyanidin induced nephrotoxicity
extract proanthocyanidin induced nephrotoxicity
GSPE extract proanthocyanidin induced nephrotoxicity
IH ability assessed seed proanthocyanidin induced toxicity lung
IH ability assessed seed proanthocyanidin induced toxicity
636 IH ability assessed seed proanthocyanidin induced toxicity lung
636 IH ability assessed seed proanthocyanidin induced toxicity
grape seed proanthocyanidin induced toxicity lung
grape seed proanthocyanidin induced toxicity
seed proanthocyanidin induced toxicity lung
seed proanthocyanidin induced toxicity
proanthocyanidin induced toxicity lung
proanthocyanidin induced toxicity
extract proanthocyanidin induced toxicity lung
extract proanthocyanidin induced toxicity
GSPE extract proanthocyanidin induced toxicity lung
GSPE extract proanthocyanidin induced toxicity
acetaminophen prevent extract proanthocyanidin induced cardiotoxicity
AAP acetaminophen prevent extract proanthocyanidin induced cardiotoxicity
amiodarone nephrotoxicity
AMI nephrotoxicity
amiodarone nephrotoxicity induced proanthocyanidin induced cardiotoxicity
AMI nephrotoxicity induced proanthocyanidin induced cardiotoxicity
GSPE preexposure absence revealed moderate damage tissue
GSPE preexposure absence revealed moderate damage
GSPE blocked organs necrosis
levodopa improving seems improves bradykinesia rigidity
levodopa improving seems improves bradykinesia
propofol sedation underwent dementia
propofol sedation underwent repair hip
propofol sedation underwent repair fracture
propofol sedation use decreased prevalence delirium postoperative
propofol sedation use decreased prevalence delirium
aminoglycoside commonly used provide gram treatment neutropenia febrile
aminoglycoside commonly used provide gram treatment neutropenia
Amikacin used provide gram treatment neutropenia febrile
Amikacin used provide gram treatment neutropenia
aminoglycoside commonly used provide gram treatment neutropenia infections
Amikacin used provide gram treatment neutropenia infections
amikacin conventional randomized patients diagnosis consistent disorder hematologic
amikacin conventional randomized patients diagnosis consistent disorder /
amikacin conventional randomized patients diagnosis consistent disorder oncologic
amikacin conventional randomized patients diagnosis consistent disorder
aminoglycoside required disorder hematologic
aminoglycoside required disorder /
aminoglycoside required disorder oncologic
aminoglycoside required disorder
creatinine increase means nephrotoxicity
ipratropium effects bromide disease chronic
ipratropium effects bromide disease obstructive
ipratropium effects bromide disease pulmonary
ipratropium effects bromide disease
bromide disease chronic
bromide disease obstructive
bromide disease pulmonary
bromide disease
theophylline bromide disease chronic
theophylline bromide disease obstructive
theophylline bromide disease pulmonary
theophylline bromide disease
ipratropium aerosol dose effects tablets compared double controlled disease chronic
ipratropium aerosol dose effects tablets compared double controlled disease obstructive
ipratropium aerosol dose effects tablets compared double controlled disease pulmonary
ipratropium aerosol dose effects tablets compared double controlled disease
bromide aerosol dose effects tablets compared double controlled disease chronic
bromide aerosol dose effects tablets compared double controlled disease obstructive
bromide aerosol dose effects tablets compared double controlled disease pulmonary
bromide aerosol dose effects tablets compared double controlled disease
theophylline tablets compared double controlled disease chronic
theophylline tablets compared double controlled disease obstructive
theophylline tablets compared double controlled disease pulmonary
theophylline tablets compared double controlled disease
theophylline use involve systems cardiovascular
theophylline use involve systems cardiovascular and
theophylline use involve systems cardiovascular gastrointestinal
theophylline use involve systems
ipratropium bronchodilator theophylline patients obstruction chronic
ipratropium bronchodilator theophylline patients obstruction airflow
ipratropium bronchodilator theophylline patients obstruction
theophylline patients obstruction chronic
theophylline patients obstruction airflow
theophylline patients obstruction
catecholamines severity hyperkinesia
catecholamines severity relationship levels psychosis
amphetamine diagnosis service psychiatric
catecholamines relationship patients service psychiatric
catecholamine levels drug assays collected examine relationship patients service psychiatric
cocaine relationship patients service psychiatric
catecholamines symptoms psychotic
catecholamines symptoms
catecholamines relationship examine interviewed psychosis
catecholamine levels drug assays collected examine relationship catecholamines symptoms psychotic
catecholamine levels drug assays collected examine relationship catecholamines symptoms
catecholamine levels drug assays collected examine interviewed psychosis
MFL leucovorin FU mitoxantrone toxicity
mitoxantrone toxicity
leucovorin FU mitoxantrone treated cancer breast
leucovorin FU mitoxantrone treated cancer
leucovorin FU mitoxantrone toxicity
5 dose mitoxantrone treated cancer breast
5 dose mitoxantrone treated cancer
FU mitoxantrone treated cancer breast
FU mitoxantrone treated cancer
MFL leucovorin FU mitoxantrone treated cancer breast
MFL leucovorin FU mitoxantrone treated cancer
mitoxantrone treated cancer breast
mitoxantrone treated cancer
5 dose mitoxantrone toxicity
FU mitoxantrone toxicity
leucovorin treated cancer breast
leucovorin treated cancer
5 infusion day m mitoxantrone treated cancer breast
5 infusion day m mitoxantrone treated cancer
FU infusion day m mitoxantrone treated cancer breast
FU infusion day m mitoxantrone treated cancer
mitoxantrone treated cancer breast
mitoxantrone treated cancer
MFL regimen achieves induces toxicity
regimen achieves induces toxicity
Thalidomide limited single activity non
Thalidomide limited single lymphomas Hodgkin
Thalidomide limited single lymphomas
Thalidomide limited single B Leukemia
Thalidomide limited single trial Cancer
Thalidomide agent activity myeloma lymphoma lymphoplasmacytic
Thalidomide agent activity myeloma lymphoma
Thalidomide agent activity myeloma lymphoma mantle
Thalidomide agent activity myeloma lymphoma cell
Thalidomide agent activity myeloma lymphoma
Thalidomide agent activity myeloma multiple
Thalidomide agent activity myeloma
thalidomide mg received lymphomas
thalidomide lymphomas
lenalidomide agent reported level demonstrate thalidomide lymphomas
VPA signs consciousness marked hyperammonemia
VPA signs consciousness marked slowing frequency seizure
ranitidine replaced disappeared developed impotence
cimetidine doses Treatment associated toxicity hepatic
cimetidine doses Treatment associated toxicity hepatic or
cimetidine doses Treatment associated toxicity hepatic hematologic
cimetidine doses Treatment associated toxicity
cimetidine therapy seen level associated associated toxicity hepatic
cimetidine therapy seen level associated associated toxicity hepatic or
cimetidine therapy seen level associated associated toxicity hepatic hematologic
cimetidine therapy seen level associated associated toxicity
creatinine level associated associated toxicity hepatic
creatinine level associated associated toxicity hepatic or
creatinine level associated associated toxicity hepatic hematologic
creatinine level associated associated toxicity
ranitidine cimetidine doses Treatment associated toxicity hepatic
ranitidine cimetidine doses Treatment associated toxicity hepatic or
ranitidine cimetidine doses Treatment associated toxicity hepatic hematologic
ranitidine cimetidine doses Treatment associated toxicity
ranitidine therapy associated associated toxicity hepatic
ranitidine therapy associated associated toxicity hepatic or
ranitidine therapy associated associated toxicity hepatic hematologic
ranitidine therapy associated associated toxicity
corticosteroids respond % cases uveitis
chloroquine used found case drugs attributable chorioretinopathy
corticosteroids used found number cataracts
DA receptors density increases due concentration nicotine develop hyperactivity locomotor
DA receptors density increases due concentration nicotine develop hyperactivity
DA receptor inducing followed nicotine treated develop hyperactivity locomotor
DA receptor inducing followed nicotine treated develop hyperactivity
prostaglandins responses pain
acetic tests plate using evaluated effects administration prostaglandins responses pain
acid tests plate using evaluated effects administration prostaglandins responses pain
pg doses showed effect hyperalgesic
AH blocked blocked effect hyperalgesic
6809 AH blocked blocked effect hyperalgesic
AH blocked hyperalgesia
6809 AH blocked hyperalgesia
Prostaglandin F had effect responses pain
F had effect responses pain
2 alpha F had effect responses pain
alpha F had effect responses pain
glutathione S alpha transferase levels evaluated toxicity Liver
glutathione S alpha transferase levels evaluated toxicity
15 levels measured results steatosis
F levels measured results steatosis
2 t F levels measured results steatosis
t F levels measured results steatosis
IsoP measured results steatosis
15 levels measured IsoP precedes onset necrosis
F levels measured IsoP precedes onset necrosis
2 t F levels measured IsoP precedes onset necrosis
t F levels measured IsoP precedes onset necrosis
IsoP precedes onset necrosis
allopurinol other given described case anemia aplastic
allopurinol other given described case anemia
midazolam arrest death
midazolam administration associated arrest death
Hibiscus sinensis extract Effect studied reserpine induced dyskinesia
rosa sinensis extract Effect studied reserpine induced dyskinesia
sinensis extract Effect studied reserpine induced dyskinesia
Hibiscus sinensis had role dyskinesia
rosa sinensis had role dyskinesia
sinensis had role dyskinesia
Ketanserin alfentanil induced rigidity muscle
Ketanserin alfentanil induced rigidity
serotonin antagonist type attenuated produced rigidity muscle
serotonin antagonist type attenuated produced rigidity
ketanserin pretreatment attenuated produced rigidity muscle
ketanserin pretreatment attenuated produced rigidity
Chlordiazepoxide failed influence rigidity
ketanserin received animals motionless absence rigidity
serotonin antagonists useful Pretreatment induced rigidity
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS cardiovascular
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS and
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS depression respiratory
serotonin antagonists useful Pretreatment induced necessary assess interaction CNS depression
epinephrine induced ischemia Mechanisms induced ischemia
epinephrine role examined patients disease coronary
epinephrine role examined patients disease artery
epinephrine role examined patients disease
epinephrine infusion compared signs ischemia
oxygen consumption increasing signs ischemia
epinephrine produced depression angina
epinephrine produced depression
epinephrine volume product rate induced characterized ischemia
epinephrine produced ischemia
nimodipine Effect stroke acute
nimodipine Effect stroke
Nimodipine Trial Stroke
Nimodipine Trial BACKGROUND reduction pressure outcome stroke acute
Nimodipine Trial BACKGROUND reduction pressure outcome stroke
nimodipine correlation found Trial Stroke
nimodipine correlation found Trial BACKGROUND reduction pressure outcome stroke acute
nimodipine correlation found Trial BACKGROUND reduction pressure outcome stroke
nimodipine mg METHODS allocated Patients diagnosis stroke ischemic
nimodipine mg METHODS allocated Patients diagnosis stroke
nimodipine mg mg METHODS allocated Patients diagnosis stroke ischemic
nimodipine mg mg METHODS allocated Patients diagnosis stroke
nimodipine stroke acute
nimodipine stroke
caffeine lead stroke
combination due hepatitis Granulomatous
combination due hepatitis
of amoxicillin combination due hepatitis Granulomatous
of amoxicillin combination due hepatitis
amoxicillin combination due hepatitis Granulomatous
amoxicillin combination due hepatitis
and amoxicillin combination due hepatitis Granulomatous
and amoxicillin combination due hepatitis
clavulanic acid amoxicillin combination due hepatitis Granulomatous
clavulanic acid amoxicillin combination due hepatitis
acid amoxicillin combination due hepatitis Granulomatous
acid amoxicillin combination due hepatitis
cimetidine trough 0 less ml renal
cimetidine trough 0 less ml renal and
cimetidine trough 0 less ml liver
cimetidine trough 0 less ml dysfunction
N safety butyl deoxynojirimycin zidovudine patients HIV
N safety butyl deoxynojirimycin infection 1
N safety butyl deoxynojirimycin infection
butyl deoxynojirimycin zidovudine patients HIV
butyl deoxynojirimycin infection 1
butyl deoxynojirimycin infection
deoxynojirimycin zidovudine patients HIV
deoxynojirimycin infection 1
deoxynojirimycin infection
SC deoxynojirimycin zidovudine patients HIV
SC deoxynojirimycin infection 1
SC deoxynojirimycin infection
48334 SC deoxynojirimycin zidovudine patients HIV
48334 SC deoxynojirimycin infection 1
48334 SC deoxynojirimycin infection
zidovudine patients HIV
zidovudine deoxynojirimycin infection 1
zidovudine deoxynojirimycin infection
SC level concentration virus immunodeficiency
48334 steady SC level concentration virus immunodeficiency
anthracycline induced cardiotoxicity
Anthracyclines drugs cause dose related cardiotoxicity
anthracycline therapy cardiotoxicity highlights need search methods sensitive predicting dysfunction cardiac
anthracycline therapy cardiotoxicity highlights need search methods sensitive predicting dysfunction
anthracycline therapy cardiotoxicity
daunorubicin treated leukemia acute
daunorubicin treated leukemia
DNR daunorubicin treated leukemia acute
DNR daunorubicin treated leukemia
daunorubicin treated leukemia induced cardiotoxicity
DNR daunorubicin treated leukemia induced cardiotoxicity
anthracycline induced leukemia acute
anthracycline induced leukemia
anthracycline induced cardiotoxicity
DNR treated patients leukemia acute
DNR treated patients leukemia
anthracycline indicator useful cardiotoxicity
etoposide cisplatinum acid adenocarcinoma gastric
etoposide cisplatinum acid adenocarcinoma
folinic acid adenocarcinoma gastric
folinic acid adenocarcinoma
acid adenocarcinoma gastric
acid adenocarcinoma
5 dose fluorouracil cisplatinum acid adenocarcinoma gastric
5 dose fluorouracil cisplatinum acid adenocarcinoma
fluorouracil cisplatinum acid adenocarcinoma gastric
fluorouracil cisplatinum acid adenocarcinoma
cisplatinum acid adenocarcinoma gastric
cisplatinum acid adenocarcinoma
folinic fluorouracil infusion lasting coma lapsed developed symptoms confusion irritability
acid infusion lasting coma lapsed developed symptoms confusion irritability
5 lasting coma lapsed developed symptoms confusion irritability
fluorouracil infusion lasting coma lapsed developed symptoms confusion irritability
5 dose due neurotoxicity
fluorouracil due neurotoxicity
folinic acid unlikely suspected fluorouracil due neurotoxicity
acid unlikely suspected fluorouracil due neurotoxicity
fluorocitrate fluoroacetate due neurotoxicity
thiamine deficiency fluoroacetate due neurotoxicity
fluoroacetate due neurotoxicity
dihydrouracil deficiency fluoroacetate due neurotoxicity
5 pathogenesis due neurotoxicity
fluorouracil neurotoxicity
folinic therapy become regimen cancers
acid therapy become regimen cancers
5 dose High become regimen cancers
fluorouracil High become regimen cancers
creatine levels lupus systemic
creatine levels lupus
creatine levels diagnosis erythematosus
chloroquine woman year induced myopathy
cyclophosphamide azathioprine undergone suffering erythematosus involvement renal
cyclophosphamide azathioprine undergone suffering erythematosus involvement
azathioprine undergone suffering erythematosus systemic
azathioprine undergone suffering erythematosus lupus
azathioprine undergone suffering erythematosus
azathioprine undergone suffering erythematosus SLE
azathioprine undergone suffering erythematosus involvement renal
azathioprine undergone suffering erythematosus involvement
cyclophosphamide azathioprine undergone suffering erythematosus systemic
cyclophosphamide azathioprine undergone suffering erythematosus lupus
cyclophosphamide azathioprine undergone suffering erythematosus
cyclophosphamide azathioprine undergone suffering erythematosus SLE
chloroquine therapy started arthralgia
CQ therapy started arthralgia
steroids treated suspected Myositis
chloroquine induced myopathy
aniracetam learning impaired
aniracetam learning
aniracetam learning and
aniracetam learning memory
Ro aniracetam learning impaired
Ro aniracetam learning
Ro aniracetam learning and
Ro aniracetam learning memory
13 Ro aniracetam learning impaired
13 Ro aniracetam learning
13 Ro aniracetam learning and
13 Ro aniracetam learning memory
5057 Ro aniracetam learning impaired
5057 Ro aniracetam learning
5057 Ro aniracetam learning and
5057 Ro aniracetam learning memory
aniracetam effect studied forms functions impaired
aniracetam effect studied forms functions cognitive
aniracetam effect studied forms functions
Ro effect studied forms functions impaired
Ro effect studied forms functions cognitive
Ro effect studied forms functions
13 Ro effect studied forms functions impaired
13 Ro effect studied forms functions cognitive
13 Ro effect studied forms functions
5057 Ro effect studied forms functions impaired
5057 Ro effect studied forms functions cognitive
5057 Ro effect studied forms functions
1 5057 Ro effect studied forms functions impaired
1 5057 Ro effect studied forms functions cognitive
1 5057 Ro effect studied forms functions
anisoyl pyrrolidinone 1 5057 Ro effect studied forms functions impaired
anisoyl pyrrolidinone 1 5057 Ro effect studied forms functions cognitive
anisoyl pyrrolidinone 1 5057 Ro effect studied forms functions
2 pyrrolidinone 1 5057 Ro effect studied forms functions impaired
2 pyrrolidinone 1 5057 Ro effect studied forms functions cognitive
2 pyrrolidinone 1 5057 Ro effect studied forms functions
pyrrolidinone 1 5057 Ro effect studied forms functions impaired
pyrrolidinone 1 5057 Ro effect studied forms functions cognitive
pyrrolidinone 1 5057 Ro effect studied forms functions
chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions impaired
chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions cognitive
chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions
cycloheximide chloramphenicol induced task deficit retrieval response rats exposed sublethal short amnesia
cycloheximide chloramphenicol induced task deficit retrieval response protection amnesia
cycloheximide induced task deficit h late administered prevention applied reversal incapacity learn response rats exposed sublethal short amnesia
cycloheximide induced task deficit h late administered prevention applied reversal incapacity learn response protection amnesia
chloramphenicol induced task deficit retrieval response rats exposed sublethal hypercapnia
chloramphenicol induced task deficit retrieval response learn incapacity reversal applied prevention induced electroshock hypercapnia
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal prevention effects produced studied forms functions impaired
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal prevention effects produced studied forms functions cognitive
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal prevention effects produced studied forms functions
aniracetam effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
aniracetam effect studied produced effects prevention reversal incapacity learn response protection amnesia
Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
13 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
13 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal short amnesia
1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response protection amnesia
aniracetam effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
aniracetam effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
13 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
13 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal incapacity learn response rats exposed sublethal hypercapnia
1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
anisoyl pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
2 pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
pyrrolidinone 1 5057 Ro effect studied produced effects prevention reversal applied prevention induced electroshock hypercapnia
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions impaired
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions cognitive
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal prevention effects produced studied forms functions
cycloheximide induced task deficit h late administered prevention applied reversal prevention effects produced studied forms functions impaired
cycloheximide induced task deficit h late administered prevention applied reversal prevention effects produced studied forms functions cognitive
cycloheximide induced task deficit h late administered prevention applied reversal prevention effects produced studied forms functions
cycloheximide chloramphenicol induced task deficit retrieval response rats exposed sublethal hypercapnia
cycloheximide chloramphenicol induced task deficit retrieval response learn incapacity reversal applied prevention induced electroshock hypercapnia
cycloheximide induced task deficit h late administered prevention applied reversal incapacity learn response rats exposed sublethal hypercapnia
cycloheximide induced task deficit h late administered prevention induced electroshock hypercapnia
scopolamine prevention rats sublethal hypercapnia
scopolamine prevention rats sublethal exposed rats response learn incapacity reversal applied prevention induced electroshock hypercapnia
chloramphenicol induced task deficit retrieval response rats exposed sublethal short amnesia
chloramphenicol induced task deficit retrieval response protection amnesia
aniracetam doses seen improvements functions impaired
aniracetam doses seen improvements functions cognitive
aniracetam doses seen improvements functions
fluconazole had cardiomyopathy
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had cardiomyopathy
fluconazole had disease coronary
fluconazole had disease artery
fluconazole had disease
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had disease coronary
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had disease artery
fluconazole initiation association was abnormalities woman glabrata isolated abscess developed days commencing fluconazole had disease
fluconazole commencing days developed abscess isolated glabrata woman failure congestive
fluconazole commencing days developed abscess isolated glabrata woman failure heart
fluconazole commencing days developed abscess isolated glabrata woman failure
fluconazole initiation association was abnormalities woman failure congestive
fluconazole initiation association was abnormalities woman failure heart
fluconazole initiation association was abnormalities woman failure
fluconazole discontinued resolved continued nonsustained tachycardia ventricular
fluconazole discontinued resolved continued nonsustained tachycardia
fluconazole discontinued resolved continued nonsustained tachycardia NSVT
fluconazole use relationship indicates resolved continued nonsustained tachycardia ventricular
fluconazole use relationship indicates resolved continued nonsustained tachycardia
fluconazole use relationship indicates resolved continued nonsustained tachycardia NSVT
fluconazole discontinued resolved continued have contractions premature
fluconazole discontinued resolved continued have contractions ventricular
fluconazole discontinued resolved continued have contractions
fluconazole use relationship indicates resolved continued have contractions premature
fluconazole use relationship indicates resolved continued have contractions ventricular
fluconazole use relationship indicates resolved continued have contractions
potassium currents activating depression
fluconazole suggests was etiology explain TDP disappearance NSVT
fluconazole suggests contractions premature
fluconazole suggests contractions ventricular
fluconazole suggests contractions
fluconazole suggests was etiology explain prolongation QT
fluconazole suggests was etiology explain prolongation
fluconazole cause prolongation
fluconazole cause prolongation interval of
fluconazole cause prolongation interval the
fluconazole cause prolongation interval QT
fluconazole cause prolongation interval
fluconazole administered patients risk arrhythmias ventricular
fluconazole administered patients risk arrhythmias
olanzapine treatment introduction developed disorder psychotic
olanzapine treatment introduction developed disorder
lindane Effect s influence lindane induced neurotoxicity
lindane induced neurotoxicity
phenobarbital increased pretreatment produce incidence convulsions
phenobarbital increased incidence convulsions
3 methylcholanthrene pretreatment produce incidence convulsions
methylcholanthrene pretreatment produce incidence convulsions
3 methylcholanthrene pretreatment produce pretreatment increased incidence convulsions
methylcholanthrene pretreatment produce pretreatment increased incidence convulsions
MC methylcholanthrene pretreatment produce incidence convulsions
MC methylcholanthrene pretreatment produce pretreatment increased incidence convulsions
ethanol B P inducer phenobarbital increased pretreatment produce incidence convulsions
ethanol B P inducer phenobarbital increased incidence convulsions
cobalt incidence convulsions
chloride incidence convulsions
cobalt incidence blocked lindane metabolism P increased involved toxicity
chloride incidence blocked lindane metabolism P increased involved toxicity
lindane metabolism P increased involved toxicity
lindane treated animals increased involved toxicity
lindane se indicating lindane treated animals increased involved toxicity
ethanol PB P formed metabolites lindane treated animals increased P metabolism lindane blocked incidence convulsions
ethanol PB P formed metabolites lindane treated animals increased involved toxicity
PTU associated Syndrome Turner
PTU associated Syndrome
PTU associated Syndrome disease Graves
PTU associated Syndrome disease Graves '
PTU associated Syndrome disease
carbamazepine inhibits development seizures
carbamazepine treatment seizures
CBZ treatment seizures
CBZ administration methods evaluated evaluated effects treatment seizures
CBZ inhibited development seizures
CBZ inhibited had effect seizures
CBZ decreased injected incidence seizure
CBZ had effect lidocaine induced seizures
CBZ injection i effect development seizures
CBZ effects suggest stage development seizure
CBZ effects suggest underlie development seizures
captopril Reversibility induced insufficiency renal
captopril Reversibility induced insufficiency
captopril Reversibility induced case hypertension renovascular
captopril Reversibility induced case hypertension
captopril treatment function deterioration developed kidney artery report case hypertension
captopril induced failure renal
captopril induced failure
lamivudine ve virus infected co HIV
lamivudine ve virus infected co
lamivudine associated infection
na ve virus hepatitis
na ve virus B
na ve virus
na ve virus HBV
na ve virus infected
na ve lamivudine associated infection implications co HBV
na ve lamivudine associated infection implications co HBV and
na ve lamivudine associated infection implications co HBV HIV
na ve lamivudine associated infection implications co
na ve lamivudine associated infection infected
lamivudine associated infection implications co HBV
lamivudine associated infection implications co HBV and
lamivudine associated infection implications co HBV HIV
lamivudine associated infection implications co
lamivudine associated infection infected
lamivudine ve virus hepatitis
lamivudine ve virus B
lamivudine ve virus
lamivudine ve virus HBV
lamivudine ve virus infected
na ve virus infected co HIV
na ve virus infected co
na ve lamivudine associated infection
lamivudine investigate study infection ve co immunodeficiency human
lamivudine investigate study infection ve co immunodeficiency
lamivudine investigate study infection ve co virus
lamivudine investigate study infection ve co HIV
lamivudine investigate study infection ve co
lamivudine investigate study infection
lamivudine strains lamivudine investigate study infection ve co immunodeficiency human
lamivudine strains lamivudine investigate study infection ve co immunodeficiency
lamivudine strains lamivudine investigate study infection ve co virus
lamivudine strains lamivudine investigate study infection ve co HIV
lamivudine strains lamivudine investigate study infection ve co
lamivudine strains lamivudine investigate study infection
na ve infection study investigate lamivudine strains hepatitis
na ve infection study investigate lamivudine strains B
lamivudine strains hepatitis
lamivudine strains B
lamivudine strains hepatitis
lamivudine strains B
na ve co immunodeficiency human
na ve co immunodeficiency
na ve co virus
na ve co HIV
na ve co
na ve infection
lamivudine ve co HIV
lamivudine ve co
lamivudine ve studied infection
na ve patients HBV
na ve patients infected
na ve mono HBV
na ve mono
na ve lamivudine Thirty patients infected
na ve lamivudine Thirty patients HBV
na ve lamivudine Thirty co HIV
na ve lamivudine Thirty co
na ve lamivudine Thirty co patients infected
lamivudine Thirty patients HBV
lamivudine Thirty co HIV
lamivudine Thirty co
lamivudine Thirty co patients infected
lamivudine ve patients HBV
lamivudine ve patients infected
lamivudine ve mono HBV
lamivudine ve mono
lamivudine Thirty patients infected
na ve co HIV
na ve co
na ve studied infection
lamivudine detected 3 mono patients 10 HBV
lamivudine detected 3 mono co HIV
lamivudine detected 3 mono co
lamivudine detected 3 mono patients infected
lamivudine detected 3 mono patients hepatitis
lamivudine detected 3 mono patients B
na HBV
na HBV lamivudine co HIV
na HBV lamivudine co
na HBV lamivudine patients infected
lamivudine HBV
lamivudine co HIV
lamivudine co
lamivudine patients infected
lamivudine result remains applied Africa likely have implications management HBV
lamivudine result remains co HIV
lamivudine result remains co
lamivudine result remains co patients infected
Levodopa induced disease Parkinson
Levodopa induced disease Parkinson '
Levodopa induced disease s
Levodopa induced disease
Levodopa drug treatment disease Parkinson
Levodopa drug treatment disease Parkinson '
Levodopa drug treatment disease s
Levodopa drug treatment disease
dopamine use long precursor complicated fluctuations dyskinesias
dopamine subtypes mechanisms presynaptic role focus lines preclinical induced dyskinesias
glutamate receptors mechanisms presynaptic role focus lines preclinical induced dyskinesias
heparan sulphate Reduction induced nephropathy diabetic
heparan sulphate Reduction induced nephropathy
sulphate Reduction induced nephropathy diabetic
sulphate Reduction induced nephropathy
streptozotocin studied induction diabetes
Heparan sulphate associated glomerular studied induction diabetes
sulphate associated glomerular studied induction diabetes
cuprolinic blue employing associated glomerular studied induction diabetes
blue employing associated glomerular studied induction diabetes
streptozotocin rats diabetic
heparan barrier excretion rats diabetic
sulphate barrier excretion rats diabetic
bupropion use associated failure liver
bupropion use associated failure
carbimazole bupropion use associated failure liver
carbimazole bupropion use associated failure
propranolol carbimazole treated man history hyperthyroidism
carbimazole treated man history hyperthyroidism
chlorpheniramine azelastine treatment rhinitis spring
chlorpheniramine azelastine treatment rhinitis allergic
chlorpheniramine azelastine treatment rhinitis
azelastine treatment rhinitis spring
azelastine treatment rhinitis allergic
azelastine treatment rhinitis
chlorpheniramine maleate compared study efficacy safety treatment rhinitis spring
chlorpheniramine maleate compared study efficacy safety treatment rhinitis allergic
chlorpheniramine maleate compared study efficacy safety treatment rhinitis
maleate compared study efficacy safety treatment rhinitis spring
maleate compared study efficacy safety treatment rhinitis allergic
maleate compared study efficacy safety treatment rhinitis
Azelastine compared study efficacy safety treatment rhinitis spring
Azelastine compared study efficacy safety treatment rhinitis allergic
Azelastine compared study efficacy safety treatment rhinitis
Azelastine appears medication rhinitis seasonal
Azelastine appears medication rhinitis allergic
Azelastine appears medication rhinitis
cyclophosphamide granulomatosis cancer Wegener
cyclophosphamide granulomatosis cancer Wegener '
cyclophosphamide granulomatosis s
cyclophosphamide granulomatosis
cyclophosphamide relation cancer risk assess patients granulomatosis Wegener
cyclophosphamide relation cancer risk assess patients granulomatosis Wegener '
cyclophosphamide relation cancer risk assess patients granulomatosis s
cyclophosphamide relation cancer risk assess patients granulomatosis
cyclophosphamide relationship dose indicate operating granulomatosis Wegener
cyclophosphamide relationship dose indicate operating granulomatosis Wegener '
cyclophosphamide relationship dose indicate operating granulomatosis s
cyclophosphamide relationship dose indicate operating granulomatosis
morphine treated Hyperalgesia patients cancer
morphine doses treated disease stages patients cancer
potassium loss administration patients hypertension
potassium loss hypokalaemia
sodium restriction influence loss administration patients hypertension
sodium restriction influence loss hypokalaemia
chlorthalidone administration patients hypertension
potassium loss investigate performed hypertension
potassium loss hypokalaemia
potassium loss investigate performed hypertension shown hypokalaemia
corticosteroids reactions allergic
corticosteroids reactions
paramethasone different Corticosteroids produced reactions hypersensitivity
paramethasone caused allergy
N effects synthase investigated lidocaine convulsions
nitro effects synthase investigated lidocaine convulsions
L nitro effects synthase investigated lidocaine convulsions
arginine nitro effects synthase investigated lidocaine convulsions
methyl ester effects synthase investigated lidocaine convulsions
ester effects synthase investigated lidocaine convulsions
L ester effects synthase investigated lidocaine convulsions
NAME L ester effects synthase investigated lidocaine convulsions
nitric oxide ester effects synthase investigated lidocaine convulsions
oxide ester effects synthase investigated lidocaine convulsions
NO effects synthase investigated lidocaine convulsions
NO precursor arginine investigated lidocaine convulsions
L inhibitor synthase investigated lidocaine convulsions
arginine investigated lidocaine convulsions
L decreased incidence lidocaine convulsions
NAME decreased incidence lidocaine convulsions
diazepam NAME decreased incidence lidocaine convulsions
L induced convulsions
arginine treatment L induced convulsions
NO mediator convulsions
tamoxifen cancer breast
tamoxifen cancer
Tamoxifen agent cancer breast
Tamoxifen agent cancer
Tamoxifen agent associated development cancer endometrial
Tamoxifen agent associated development cancer
tamoxifen trial randomised have cancer breast
tamoxifen trial randomised have cancer
tamoxifen placebo frequency breast
tamoxifen placebo frequency cancer
tamoxifen receiving women cancer breast
tamoxifen receiving women cancer
tamoxifen receiving women cancer reduction is found cases cancer breast
tamoxifen receiving women cancer reduction is found cases cancer
tamoxifen allocated women case found is reduction cancer breast
tamoxifen allocated women case found is reduction cancer
tamoxifen allocated women case found cases cancer breast
tamoxifen allocated women case found cases cancer
tamoxifen effects apparent has cohort women risk cancer breast
tamoxifen effects apparent has cohort women risk cancer
L patients parkinsonian
dopa overactivation patients parkinsonian
L patients parkinsonian
dopa medication execution task supplementary groups patients parkinsonian
L one medication execution task supplementary groups patients parkinsonian
dopa execution task supplementary groups patients parkinsonian
L movement hyperkinetic
dopa L movement hyperkinetic
Organophosphate induced convulsions damages neuropathological
Organophosphate induced convulsions damages
Organophosphate induced convulsions
acetylcholine levels elevates system irreversible result toxicity
ACh levels elevates system irreversible result toxicity
OPs toxicity
DFP treated showed OP induced signs toxicity
OP induced signs toxicity
atropine showed OP induced signs toxicity
DFP given prevented shortened occurrence signs poisoning
2 PAM CPA given prevented shortened occurrence signs poisoning
PAM CPA given prevented shortened occurrence signs poisoning
atropine DFP given prevented shortened occurrence signs poisoning
diazepam CPA given prevented shortened occurrence signs poisoning
CPA given prevented shortened occurrence signs poisoning
MK 801 offer protection toxicity
801 offer protection toxicity
DFP toxicity
Atropine offer protection toxicity
CPA prevented reduced toxicity
diazepam CPA prevented reduced toxicity
2 PAM CPA prevented reduced toxicity
PAM CPA prevented reduced toxicity
DFP toxicity reduced prevented occurrence signs poisoning
2 PAM CPA prevented occurrence signs poisoning
PAM CPA prevented occurrence signs poisoning
DFP toxicity
atropine combination PAM CPA prevented occurrence signs poisoning
atropine combination PAM CPA prevented reduced toxicity
diazepam CPA prevented occurrence signs poisoning
CPA prevented occurrence signs poisoning
Coenzyme treatment ameliorates nephrotoxicity
Q treatment ameliorates nephrotoxicity
10 treatment ameliorates nephrotoxicity
cisplatin nephrotoxicity
coenzyme Q effect investigated injury acute
coenzyme Q effect investigated injury renal
coenzyme Q effect investigated injury
Q effect investigated injury acute
Q effect investigated injury renal
Q effect investigated injury
10 Q effect investigated injury acute
10 Q effect investigated injury renal
10 Q effect investigated injury
nitric oxide alpha elevations factor necrosis
oxide alpha elevations factor necrosis
superoxide activity level mechanisms deficits decreased elevations factor tumor
Coenzyme deficits decreased elevations factor necrosis
Q deficits decreased elevations factor necrosis
10 deficits decreased elevations factor necrosis
cisplatin administration resulted tissue attenuated alpha elevations factor necrosis
reduced level mechanisms deficits decreased elevations factor tumor
glutathione level mechanisms deficits decreased elevations factor tumor
platinum concentration oxide alpha elevations factor necrosis
selenium ions reductions attenuated alpha elevations factor necrosis
zinc selenium ions reductions attenuated alpha elevations factor necrosis
nitric oxide alpha elevations factor tumor
oxide alpha elevations factor tumor
superoxide activity level mechanisms deficits decreased elevations factor necrosis
Coenzyme deficits decreased elevations factor tumor
Q deficits decreased elevations factor tumor
10 deficits decreased elevations factor tumor
cisplatin administration resulted tissue attenuated alpha elevations factor tumor
reduced level mechanisms deficits decreased elevations factor necrosis
glutathione level mechanisms deficits decreased elevations factor necrosis
platinum concentration oxide alpha elevations factor tumor
selenium ions reductions attenuated alpha elevations factor tumor
zinc selenium ions reductions attenuated alpha elevations factor tumor
coenzyme treatment ameliorated damage renal
coenzyme treatment ameliorated damage tissue
coenzyme treatment ameliorated damage
Q treatment ameliorated damage renal
Q treatment ameliorated damage tissue
Q treatment ameliorated damage
10 treatment ameliorated damage renal
10 treatment ameliorated damage tissue
10 treatment ameliorated damage
cisplatin mediated damage renal
cisplatin mediated damage tissue
cisplatin mediated damage
coenzyme Q represents protect nephrotoxicity
Q represents protect nephrotoxicity
10 Q represents protect nephrotoxicity
cisplatin nephrotoxicity
5 induced exencephaly
azacytidine 13 let induced exencephaly
paracetamol Induction tumours bladder
paracetamol Induction tumours bladder and
paracetamol Induction tumours bladder liver
paracetamol Induction tumours
paracetamol developed bladder epithelium Papillomas
paracetamol % treated developed hyperplasia epithelium coincident presence calculi bladder
paracetamol % treated developed hyperplasia epithelium coincident presence calculi
paracetamol feeding arose yield tumours
carboplatin paclitaxel chemotherapy glioblastoma
paclitaxel chemotherapy glioblastoma
carboplatin paclitaxel application effects feasibility examined recurrences glioblastoma
paclitaxel application effects feasibility examined recurrences glioblastoma
carboplatin paclitaxel phases application resection re underwent total patients recurrence multiforme glioblastoma
paclitaxel phases application resection re underwent total patients recurrence multiforme glioblastoma
tolterodine treatment changes women bladder overactive
tolterodine treatment changes women bladder
tolterodine treatment study bladder overactive
tolterodine treatment study bladder
tolterodine treatment study bladder OAB
Tolterodine tolerated improved OAB
NMDA enhancement antihyperalgesia model pain
NMDA enhancement differences comparisons models pain acute
NMDA enhancement differences comparisons models pain
morphine antihyperalgesia model pain
capsaicin model pain
morphine antihyperalgesia enhancement differences comparisons models pain acute
morphine antihyperalgesia enhancement differences comparisons models pain
capsaicin model antihyperalgesia enhancement differences comparisons models pain acute
capsaicin model antihyperalgesia enhancement differences comparisons models pain
N aspartate models acute
N aspartate models pain
methyl N aspartate models acute
methyl N aspartate models pain
D methyl N aspartate models acute
D methyl N aspartate models pain
aspartate models acute
aspartate models pain
NMDA antagonists aspartate models acute
NMDA antagonists aspartate models pain
morphine effects enhance aspartate models acute
morphine effects enhance aspartate models pain
dextromethorphan antinociception Enhancement seen males models acute
dextromethorphan antinociception Enhancement seen males models pain
morphine antinociception Enhancement seen males models acute
morphine antinociception Enhancement seen males models pain
NMDA antagonists interaction sexually demonstrate model pain
NMDA antagonists interaction sexually demonstrate model distinguished those observed models acute
NMDA antagonists interaction sexually demonstrate model distinguished those observed models pain
morphine antagonists interaction sexually demonstrate model pain
morphine antagonists interaction sexually demonstrate model distinguished those observed models acute
morphine antagonists interaction sexually demonstrate model distinguished those observed models pain
serotonin stimulation HT 1 causes syndrome consists shivering muscle
serotonin stimulation HT 1 causes syndrome consists shivering rigidity
serotonin excess syndrome consists shivering muscle
serotonin excess syndrome consists shivering rigidity
serotonin stimulation HT 1 causes syndrome consists shivering rigidity confusion
serotonin excess syndrome consists shivering rigidity confusion
serotonin stimulation HT 1 causes syndrome consists shivering rigidity salivation
serotonin excess syndrome consists shivering rigidity salivation
serotonin stimulation HT 1 causes syndrome consists shivering rigidity hyperthermia
serotonin excess syndrome consists shivering rigidity hyperthermia
serotonin stimulation HT 1 causes syndrome consists shivering rigidity agitation
serotonin excess syndrome consists shivering rigidity agitation
tranylcypromine depression
venlafaxine y male taking tranylcypromine depression
diazepam i mg F 120 pressure v were remained rigidity muscle
diazepam i mg F 120 pressure v were remained rigidity
Ciprofloxacin induced nephritis anemia autoimmune
Ciprofloxacin induced nephritis anemia hemolytic
Ciprofloxacin induced nephritis anemia
ciprofloxacin case nephritis anemia autoimmune
ciprofloxacin case nephritis anemia hemolytic
ciprofloxacin case nephritis anemia
steroid therapy drug stopping improved anemia Hemolytic
steroid therapy drug stopping improved anemia
cholesteryl esters that remained decreased pre stage nephrotic
esters that remained decreased pre stage nephrotic
fatty acids level stage nephrotic
acids level stage nephrotic
triacylglycerol decreased pre stage nephrotic
oral therapy complications Thromboembolic
contraceptive therapy complications Thromboembolic
Cisapride prescribed treatment disorders gastrointestinal
Cisapride prescribed treatment disorders motility
Cisapride prescribed treatment disorders
diltiazem agent has hypertension
cisapride taking woman year diltiazem agent has hypertension
diltiazem year woman taking cisapride disorder gastroesophageal
diltiazem year woman taking cisapride disorder reflux
diltiazem year woman taking cisapride disorder
cisapride disorder gastroesophageal
cisapride disorder reflux
cisapride disorder
mitomycin C induced study dependency cardiotoxicity
C induced study dependency cardiotoxicity
mitomycin suggested cardiotoxic
C suggested cardiotoxic
MMC C suggested cardiotoxic
doxorubicin given combined cardiotoxic
MMC dose cardiotoxicity
doxorubicin treated patients 2 dose cardiotoxicity
lithium treatment hypothyroidism important development insipidus nephrogenic
lithium treatment hypothyroidism important development insipidus diabetes
lithium treatment hypothyroidism important development insipidus
gentamicin nephrotoxicity prevent glycosuria
Phlorizin prevent glycosuria
Phlorizin prevent nephrotoxicity
gentamicin nephrotoxicity
streptozotocin rats have diuresis glycosuria
gentamicin resistance responsible suggested have diuresis glycosuria
gentamicin resistance responsible suggested have rats streptozotocin mellitus diabetes
gentamicin resistance responsible suggested have rats streptozotocin mellitus
gentamicin resistance responsible suggested have rats streptozotocin DM
streptozotocin rats have suggested failure acute
streptozotocin rats have suggested failure renal
streptozotocin rats have suggested failure
streptozotocin rats have suggested failure ARF
glucose reabsorption blockage induced studied protection nephrotoxicity
glucose reabsorption blockage induced rats diabetic
phlorizin reabsorption blockage induced studied protection nephrotoxicity
P phlorizin reabsorption blockage induced studied protection nephrotoxicity
phlorizin reabsorption blockage induced rats diabetic
P phlorizin reabsorption blockage induced rats diabetic
gentamicin nephrotoxicity
gentamicin nephrotoxicity protection studied induced rats diabetic
P animals that similar rats glycosuria
P animals that similar rats DM
P alone Group received P IV gentamicin DM
P IV gentamicin DM
P + P IV gentamicin DM
gentamicin + P IV gentamicin DM
gentamicin III P IV gentamicin DM
gentamicin DM
gentamicin doses Nephrotoxic
P induced glycosuria evidence dysfunction -RSB- tubular
P induced glycosuria evidence dysfunction -RSB- necrosis
P induced glycosuria
P induced glycosuria evidence dysfunction renal
P induced glycosuria evidence dysfunction
P prevent gentamicin ARF 1 0 001 necrosis tubular
P prevent gentamicin ARF 1 0 001 necrosis
P less 9 001 necrosis tubular
P less 9 001 necrosis
P prevent gentamicin ARF
P less 9 001 0 1 ARF
gentamicin ARF 1 0 001 necrosis tubular
gentamicin ARF 1 0 001 necrosis
P % decrease those different ABSTRACT + 701 day necrosis tubular
P % decrease those different ABSTRACT + 701 day necrosis
ethambutol toxicity
sodium channel induced leads nephropathy
Doxorubicin induced leads nephropathy
sodium channel retention volume
sodium channel retention
sodium channel retention fibrosis
Doxorubicin induced channel retention volume
Doxorubicin induced channel retention
Doxorubicin induced channel retention fibrosis
aldosterone kinase shown participate mediate fibrosis
aldosterone levels increased mice nephrotic
sodium excretion reached associated gain weight
sodium excretion reached associated gain
urea concentrations increased course syndrome nephrotic
urea concentrations increased course syndrome
urea concentrations increased mice uremia
Simvastatin medications human
Simvastatin medications immunodeficiency
Simvastatin medications virus
amiodarone Simvastatin medications human
amiodarone Simvastatin medications immunodeficiency
amiodarone Simvastatin medications virus
sulphasalazine received disease inflammatory
sulphasalazine received disease bowel
sulphasalazine received disease
sulphasalazine received disease born infants found have anomalies congenital
sulphasalazine received disease born infants found have anomalies
coniine sulfate caused deformations
coniine sulfate caused deformations flexion excessive
coniine sulfate caused deformations flexion
coniine sulfate caused deformations flexion or
coniine sulfate caused deformations flexion extension
coniine sulfate caused deformations flexion toes of
coniine sulfate caused deformations flexion toes one
coniine sulfate caused deformations flexion toes one or
coniine sulfate caused deformations flexion toes one more
coniine sulfate caused deformations flexion toes
nicotine coniine sulfate caused deformations
nicotine coniine sulfate caused deformations flexion excessive
nicotine coniine sulfate caused deformations flexion
nicotine coniine sulfate caused deformations flexion or
nicotine coniine sulfate caused deformations flexion extension
nicotine coniine sulfate caused deformations flexion toes of
nicotine coniine sulfate caused deformations flexion toes one
nicotine coniine sulfate caused deformations flexion toes one or
nicotine coniine sulfate caused deformations flexion toes one more
nicotine coniine sulfate caused deformations flexion toes
aspirin administration co carcinomas bladder
aspirin administration co carcinomas
aspirin administration co carcinomas induction tumors forestomach
aspirin administration co carcinomas induction tumors
aspirin effect due consistent experiment suggesting involved carcinogenesis
FANFT carcinogenesis
FANFT effect due consistent experiment suggesting involved carcinogenesis
Sodium status influences nephrotoxicity
sulphasalazine treatment restarting glomerulonephritis
sulphasalazine treatment restarting developed eyes abnormalities urinary
sulphasalazine treatment restarting developed eyes abnormalities
sulphasalazine treatment restarting developed woman colitis ulcerative
sulphasalazine treatment restarting developed woman colitis
sulphasalazine treatment restarting developed eyes eosinophilia
sulphasalazine treatment restarting developed eyes red
sulphasalazine treatment restarting developed eyes
steroid therapy rose increased initiated resulted fever pain chest
steroid therapy rose increased initiated resulted fever pain
steroid therapy rose increased initiated resulted fever
steroid therapy rose increased initiated resulted fever eyes red
steroid therapy rose increased initiated resulted fever eyes
steroid therapy rose increased initiated resulted fever effusions pleural
steroid therapy rose increased initiated resulted fever effusions
steroid therapy rose increased initiated remained effusion pleural
steroid therapy rose increased initiated remained effusion
sulphasalazine treatment cessation resulted fever pain chest
sulphasalazine treatment cessation resulted fever pain
sulphasalazine treatment cessation resulted fever eyes red
sulphasalazine treatment cessation resulted fever eyes
steroid therapy disappeared effusion pleural
steroid therapy disappeared effusion
sulphasalazine induce PR ANCA glomerulonephritis
oxycodone effects adults suffering chronic pain
oxycodone similar aged suggests that suffering changes chronic
oxycodone similar aged suggests that suffering changes neurocognitive pain
methylphenidate started depression year man treatment
methylphenidate started depression year resistant
methylphenidate started depression
methylphenidate started depression disease Alzheimer
methylphenidate started depression disease Alzheimer '
methylphenidate started depression disease s
methylphenidate started depression disease
fluvoxamine replaced diminished ensued obsessive
fluvoxamine replaced diminished ensued behavior compulsive
fluvoxamine replaced diminished ensued behavior
nicotine mg caused locomotor
nicotine mg caused hypoactivity
nicotine enhanced operated lesions significantly locomotor
nicotine enhanced operated lesions significantly locomotor caused hypoactivity
Metamizol potentiates morphine antinociception constipation
metamizol effects constipating
charcoal test used assessed using model nociception pain
metamizol potentiate suggesting produced constipation
metamizol morphine interaction show suggesting useful treatment pain chronic
metamizol morphine interaction show suggesting useful treatment pain
morphine interaction show suggesting useful treatment pain chronic
morphine interaction show suggesting useful treatment pain
adriamycin induced damage renal
adriamycin induced damage
adriamycin injection induced damage renal
adriamycin injection induced damage
adriamycin elicited proteinuria glomerulosclerosis focal
adriamycin elicited proteinuria glomerulosclerosis
adriamycin elicited proteinuria nephrotic
adriamycin elicited proteinuria damage renal
adriamycin elicited proteinuria damage interstitial
adriamycin elicited proteinuria damage
adriamycin severity damage renal
adriamycin severity damage
lithium resistant polyuria
lithium development required Cyclooxygenase induced polyuria
lithium induced polyuria
prostaglandin synthase induced polyuria
E synthase induced polyuria
lithium resistant / induced concentrating polyuria
PGE mPGES 1 / induced concentrating polyuria
2 PGE mPGES 1 / induced concentrating polyuria
lithium PGE 1 mPGES induced expression polyuria
PGE 1 mPGES induced expression polyuria
2 PGE 1 mPGES induced expression polyuria
Pravastatin associated myopathy
pravastatin hypercholesterolemia
pravastatin discontinuation resolved myopathy
simvastatin lovastatin associated myopathy
simvastatin lovastatin associated represent pravastatin myopathy
lovastatin associated myopathy
lovastatin associated represent pravastatin myopathy
pravastatin represent associated myopathy
pravastatin myopathy
chlorofluorocarbons substitutes Epidemic disease liver
chlorofluorocarbons substitutes Epidemic disease
ozone used hydrochlorofluorocarbons caused disease liver
ozone used hydrochlorofluorocarbons caused disease
hydrochlorofluorocarbons caused disease liver
hydrochlorofluorocarbons caused disease
trifluoroacetyl intermediates implicated hepatotoxicity
1 way metabolised bromo trifluoroethane form intermediates implicated hepatotoxicity
bromo trifluoroethane form intermediates implicated hepatotoxicity
1 bromo trifluoroethane form intermediates implicated hepatotoxicity
chloro - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
- 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
2 - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
2 - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
2 - 1 bromo trifluoroethane form intermediates implicated hepatotoxicity
trifluoroethane form intermediates implicated hepatotoxicity
halothane trifluoroethane form intermediates implicated hepatotoxicity
halothane hepatotoxicity
HCFCs 123 result disease liver
HCFCs 123 result disease
123 result disease liver
123 result disease
and 123 result disease liver
and 123 result disease
124 123 result disease liver
124 123 result disease
HCFCs beings exposure result injury liver
HCFCs beings exposure result injury
123 HCFCs beings exposure result injury liver
123 HCFCs beings exposure result injury
and HCFCs beings exposure result injury liver
and HCFCs beings exposure result injury
124 HCFCs beings exposure result injury liver
124 HCFCs beings exposure result injury
trifluoroacetyl suggest known mechanism hepatotoxicity
NIK 247 drug treatment disease Alzheimer
NIK 247 drug treatment disease Alzheimer '
NIK 247 drug treatment disease s
NIK 247 drug treatment disease
- 247 drug treatment disease Alzheimer
- 247 drug treatment disease Alzheimer '
- 247 drug treatment disease s
- 247 drug treatment disease
247 drug treatment disease Alzheimer
247 drug treatment disease Alzheimer '
247 drug treatment disease s
247 drug treatment disease
carbidopa preparation receiving presented had onset hallucinosis
/ preparation receiving presented had onset hallucinosis
levodopa preparation receiving presented had onset hallucinosis
carbidopa preparation receiving presented had failure chronic
carbidopa preparation receiving presented had failure renal
carbidopa preparation receiving presented had failure
/ preparation receiving presented had failure chronic
/ preparation receiving presented had failure renal
/ preparation receiving presented had failure
levodopa preparation receiving presented had failure chronic
levodopa preparation receiving presented had failure renal
levodopa preparation receiving presented had failure
carbidopa preparation receiving presented had onset hallucinosis seizures
/ preparation receiving presented had onset hallucinosis seizures
levodopa preparation receiving presented had onset hallucinosis seizures
citrate toxicity
citrate toxicity
calcium gluconate treatment initiated subsided contractions muscle
calcium gluconate treatment initiated subsided contractions
gluconate treatment initiated subsided contractions muscle
gluconate treatment initiated subsided contractions
calcium chelation reaction consistent anticoagulant resulting hypocalcemia
bumetanide diuretic cause hypocalcemia
loop diuretic cause hypocalcemia
diuretic cause hypocalcemia
citrate toxicity
bupivacaine received None limb paralysis
methotrexate accident cerebrovascular
methotrexate accident
methotrexate accident leukaemia
pilocarpine tropicamide administration points size MEASURES impairment
pilocarpine tropicamide administration points size MEASURES impairment recall in
pilocarpine tropicamide administration points size MEASURES impairment recall word
pilocarpine tropicamide administration points size MEASURES impairment recall
tropicamide administration points size MEASURES impairment
tropicamide administration points size MEASURES impairment recall in
tropicamide administration points size MEASURES impairment recall word
tropicamide administration points size MEASURES impairment recall
amiodarone treatment tachycardia atrial
amiodarone treatment tachycardia
amiodarone treatment occurring abnormalities intraventricular
amiodarone treatment occurring abnormalities conduction
amiodarone treatment occurring abnormalities
amiodarone discontinuation days showed flutter atrial
amiodarone discontinuation days showed flutter
modafinil effect sleepiness daytime
modafinil effect sleepiness
Modafinil associated latency decrease sleepiness daytime
Modafinil associated latency decrease sleepiness
modafinil promotes decreases sleepiness daytime
modafinil promotes decreases sleepiness
cocaine use associated Stroke
cocaine use related stroke
cocaine use followed Stroke
cocaine use related incidence stroke
cocaine use related incidence increasing indicate - occurs stroke
cocaine use related incidence increasing indicate follow stroke
cocaine use related incidence increasing indicate associated stroke
cocaine use related incidence increasing indicate exceeds stroke
cocaine - indicate increasing incidence stroke
cocaine - occurs stroke
cocaine - indicate follow stroke
cocaine - indicate associated stroke
cocaine - indicate exceeds stroke
cocaine administration route follow indicate increasing incidence stroke
cocaine administration route follow indicate - occurs stroke
cocaine administration route follow stroke
cocaine administration route follow indicate associated stroke
cocaine administration route follow indicate exceeds stroke
cocaine use associated indicate increasing incidence stroke
cocaine use associated indicate - occurs stroke
cocaine use associated indicate follow stroke
cocaine use associated stroke
cocaine use associated indicate exceeds stroke
cocaine 5 stroke exceeds indicate increasing incidence stroke
cocaine 5 stroke exceeds indicate - occurs stroke
cocaine 5 stroke exceeds indicate follow stroke
cocaine 5 stroke exceeds indicate associated stroke
cocaine 5 stroke
cocaine use related incidence increasing indicate exceeds stroke frequency hemorrhage intracranial
cocaine use related incidence increasing indicate exceeds stroke frequency hemorrhage
cocaine - indicate exceeds stroke frequency hemorrhage intracranial
cocaine - indicate exceeds stroke frequency hemorrhage
cocaine administration route follow indicate exceeds stroke frequency hemorrhage intracranial
cocaine administration route follow indicate exceeds stroke frequency hemorrhage
cocaine use associated indicate exceeds stroke frequency hemorrhage intracranial
cocaine use associated indicate exceeds stroke frequency hemorrhage
cocaine 5 stroke frequency hemorrhage intracranial
cocaine 5 stroke frequency hemorrhage
cocaine use related incidence increasing indicate associated aneurysms intracranial
cocaine use related incidence increasing indicate associated aneurysms
cocaine - indicate associated aneurysms intracranial
cocaine - indicate associated aneurysms
cocaine administration route follow indicate associated aneurysms intracranial
cocaine administration route follow indicate associated aneurysms
cocaine use associated aneurysms intracranial
cocaine use associated aneurysms
cocaine 5 stroke exceeds indicate associated aneurysms intracranial
cocaine 5 stroke exceeds indicate associated aneurysms
cocaine use related incidence increasing indicate associated arteriovenous
cocaine use related incidence increasing indicate associated arteriovenous malformations
cocaine - indicate associated arteriovenous
cocaine - indicate associated arteriovenous malformations
cocaine administration route follow indicate associated arteriovenous
cocaine administration route follow indicate associated arteriovenous malformations
cocaine use associated arteriovenous
cocaine use associated arteriovenous malformations
cocaine 5 stroke exceeds indicate associated arteriovenous
cocaine 5 stroke exceeds indicate associated arteriovenous malformations
99 mTc induced infarction myocardial
99 mTc induced infarction
mTc induced infarction myocardial
mTc induced infarction
glucarate detection mTc induced infarction myocardial
glucarate detection mTc induced infarction
isoproterenol obtained implies model used produce infarction
glucaric acid based radiopharmaceutical infarct
acid based radiopharmaceutical infarct
99 mTc induced infarction myocardial
99 mTc induced infarction
mTc induced infarction myocardial
mTc induced infarction
glucarate easy mTc induced infarction myocardial
glucarate easy mTc induced infarction
isoproterenol administration developed h infarct
bromocriptine treatment prolactinomas
bromocriptine effects clarify cells prolactinoma
bromocriptine effects clarify applied induced h cells prolactinoma
bromocriptine injection applied clarify cells prolactinoma
bromocriptine injection applied induced h cells prolactinoma
bromocriptine treatment cells adenoma
Calcium toxicity
carbonate toxicity
calcium corrected hypercalcemia
calcium corrected hypercalcemia presented patients report review literature milk
calcium corrected hypercalcemia presented patients report review literature syndrome alkali
calcium corrected hypercalcemia presented patients report review literature syndrome
1 peptide RESULTS patients had insufficiency alkalosis metabolic
1 peptide RESULTS patients had insufficiency alkalosis
25 RESULTS patients had insufficiency alkalosis metabolic
25 RESULTS patients had insufficiency alkalosis
dihydroxyvitamin D RESULTS patients had insufficiency alkalosis metabolic
dihydroxyvitamin D RESULTS patients had insufficiency alkalosis
D RESULTS patients had insufficiency alkalosis metabolic
D RESULTS patients had insufficiency alkalosis
1 peptide RESULTS patients had insufficiency acute
1 peptide RESULTS patients had insufficiency renal
1 peptide RESULTS patients had insufficiency
25 RESULTS patients had insufficiency acute
25 RESULTS patients had insufficiency renal
25 RESULTS patients had insufficiency
dihydroxyvitamin D RESULTS patients had insufficiency acute
dihydroxyvitamin D RESULTS patients had insufficiency renal
dihydroxyvitamin D RESULTS patients had insufficiency
D RESULTS patients had insufficiency acute
D RESULTS patients had insufficiency renal
D RESULTS patients had insufficiency
calcium concentrations patients received intravenously caused hypocalcemia
Pamidronate treatment associated cases hypercalcemia
sirolimus administration psoriasis
rapamycin sirolimus administration psoriasis
sirolimus administration toxicity
rapamycin sirolimus administration toxicity
sirolimus treatment syndrome developed psoriasis
sirolimus specimen OBSERVATIONS induced leak syndrome 3 fold sirolimus treated psoriasis
sirolimus treated psoriasis
dexamethasone spontaneous exhibit tended psoriasis
sirolimus presence apoptosis Activated patients psoriasis
sirolimus effects include fever
sirolimus effects include fever anemia
midazolam group % occurred Pain
diazepam group patients % occurred Pain
alcohol use needle time Smoking had effect incidence complications venous
alcohol use needle time Smoking had effect incidence complications
alcohol use needle time Smoking pain
oxygen species production accompanied failure renal
oxygen species production accompanied failure
oxygen species production accompanied failure causes one Diabetic
oxygen species production accompanied failure causes one nephropathy
streptozotocin induced damage renal
streptozotocin induced damage
crocin L constituents Effects model disease Alzheimer
crocin L constituents Effects model disease Alzheimer '
crocin L constituents Effects model disease s
crocin L constituents Effects model disease
crocins disease Alzheimer
crocins disease Alzheimer '
crocins disease s
crocins disease
crocin attenuated impairment learning
crocin attenuated impairment learning and
crocin attenuated impairment learning memory
crocin attenuated impairment
STZ attenuated impairment learning
STZ attenuated impairment learning and
STZ attenuated impairment learning memory
STZ attenuated impairment
crocin effectiveness demonstrate antagonizing deficits cognitive
crocin effectiveness demonstrate antagonizing deficits
crocin effectiveness demonstrate disease potential treatment diseases neurodegenerative
crocin effectiveness demonstrate disease potential treatment diseases
STZ caused deficits antagonizing demonstrate disease potential treatment diseases neurodegenerative
STZ caused deficits antagonizing demonstrate disease potential treatment diseases
crocin effectiveness demonstrate disease potential treatment diseases Alzheimer
crocin effectiveness demonstrate disease potential treatment diseases Alzheimer '
crocin effectiveness demonstrate disease s
crocin effectiveness demonstrate disease
aminophylline threshold initiating failure respiratory
aminophylline threshold initiating failure
aminophylline threshold threshold failure respiratory
aminophylline threshold threshold failure
PO oxygen pressures kept reduced threshold ventricular
PO oxygen pressures kept reduced threshold fibrillation
2 PO oxygen pressures kept reduced threshold ventricular
2 PO oxygen pressures kept reduced threshold fibrillation
carbon dioxide oxygen pressures kept reduced threshold ventricular
carbon dioxide oxygen pressures kept reduced threshold fibrillation
dioxide oxygen pressures kept reduced threshold ventricular
dioxide oxygen pressures kept reduced threshold fibrillation
CO 2 oxygen pressures kept reduced threshold ventricular
CO 2 oxygen pressures kept reduced threshold fibrillation
2 oxygen pressures kept reduced threshold ventricular
2 oxygen pressures kept reduced threshold fibrillation
oxygen pressures kept reduced threshold ventricular
oxygen pressures kept reduced threshold fibrillation
aminophylline infusion resulted produced failure respiratory
aminophylline infusion resulted produced failure
aminophylline infusion resulted produced hypoventilation
aminophylline agents play contribute incidence arrhythmias failure respiratory
aminophylline agents play contribute incidence arrhythmias failure
aminophylline agents play contribute incidence arrhythmias ventricular
aminophylline agents play contribute incidence arrhythmias
epsilon associated thrombosis sinus sagittal
epsilon associated thrombosis sinus sagittal and
epsilon associated thrombosis sinus sagittal left
epsilon associated thrombosis sinus transverse
epsilon associated thrombosis sinus
epsilon associated thrombosis
aminocaproic therapy year woman developed thrombosis sinus sagittal
aminocaproic therapy year woman developed thrombosis sinus sagittal and
aminocaproic therapy year woman developed thrombosis sinus sagittal left
aminocaproic therapy year woman developed thrombosis sinus transverse
aminocaproic therapy year woman developed thrombosis sinus
aminocaproic therapy year woman developed thrombosis
acid therapy year woman developed thrombosis sinus sagittal
acid therapy year woman developed thrombosis sinus sagittal and
acid therapy year woman developed thrombosis sinus sagittal left
acid therapy year woman developed thrombosis sinus transverse
acid therapy year woman developed thrombosis sinus
acid therapy year woman developed thrombosis
epsilon associated thrombosis developed woman year therapy menorrhagia
aminocaproic therapy menorrhagia
acid therapy menorrhagia
epsilon treatment reported described thrombosis cerebral
epsilon treatment reported described thrombosis sinus
epsilon treatment reported described thrombosis
aminocaproic acid treatment reported described thrombosis cerebral
aminocaproic acid treatment reported described thrombosis sinus
aminocaproic acid treatment reported described thrombosis
acid treatment reported described thrombosis cerebral
acid treatment reported described thrombosis sinus
acid treatment reported described thrombosis
epsilon treatment reported risk disease thromboembolic
epsilon treatment reported risk disease
aminocaproic acid treatment reported risk disease thromboembolic
aminocaproic acid treatment reported risk disease
acid treatment reported risk disease thromboembolic
acid treatment reported risk disease
octreotide analog function patients acromegalic
octreotide day 2 13 somatostatin injection treated acromegaly
octreotide therapy cholecystitis
octreotide therapy patients acromegalic
octreotide therapy patients acromegalic
timolol 0 treated glaucomatous
betaxolol less depression
ACTH N stimulated axons cause long depression
ACTH N stimulated axons cause long depression synapses resulted duration disorder movement
ACTH N stimulated axons cause long depression synapses resulted duration disorder
atropine glycopyrrolate i Comparison bradycardia
suxamethonium doses Comparison bradycardia arrhythmias
glycopyrrolate i Comparison bradycardia arrhythmias
atropine glycopyrrolate i Comparison bradycardia arrhythmias
glycopyrrolate i Comparison bradycardia
atropine 1 administration effectiveness micrograms studied prevent arrhythmia bradycardia
suxamethonium doses arrhythmia
glycopyrrolate kg administration effectiveness micrograms studied prevent arrhythmia
atropine 1 administration effectiveness micrograms studied prevent arrhythmia
glycopyrrolate kg administration effectiveness micrograms studied prevent arrhythmia bradycardia
steroid developed discontinued induced pressure elevated
steroid developed discontinued induced pressure intraocular
steroid developed discontinued induced pressure
steroid induced seem rise IOP
steroid induced seem rise
chloroacetaldehyde metabolite indicating carried elucidate development cystitis hemorrhagic
chloroacetaldehyde metabolite indicating carried elucidate development cystitis
CAA chloroacetaldehyde metabolite indicating carried elucidate development cystitis hemorrhagic
CAA chloroacetaldehyde metabolite indicating carried elucidate development cystitis
CAA role elucidate development cystitis hemorrhagic
CAA role elucidate development cystitis
CAA contribute damage bladder
CAA contribute damage
amphotericin B coccidioidomycosis
B coccidioidomycosis
AmB B coccidioidomycosis
posaconazole resolved abnormalities failure heart
posaconazole resolved abnormalities failure
AmB toxicity
ribavirin disease adenovirus
ribavirin disease
Ribavirin licensed form treatment infection syncytial respiratory
Ribavirin licensed form treatment infection syncytial
Ribavirin licensed form treatment infection virus
Ribavirin licensed form treatment infection
Ribavirin licensed treat C hepatitis
Ribavirin licensed treat C
ribavirin treatment choice infection
ribavirin treatment choice infection viruses with
ribavirin treatment choice infection viruses hemorrhagic
ribavirin treatment choice infection viruses fever
ribavirin treatment choice infection viruses
ribavirin effect anemia
cidofovir use limited effects nephrotoxicity
cidofovir infection adenovirus
cidofovir infection
ribavirin therapy disease adenovirus
ribavirin therapy disease
ribavirin disease adenovirus
ribavirin disease
ribavirin effective unlikely benefit begun course infection
ribavirin effective disease adenovirus
ribavirin effective disease
ribavirin treated disease adenovirus
ribavirin treated disease
ribavirin trial children required seriousness prevalence disease adenovirus
ribavirin trial children required seriousness prevalence disease
oxygen increase result infarction acute
oxygen increase result infarction myocardial
oxygen increase result infarction
cocaine locus remains circumstantial regard spasm
cocaine effect thrombotic
calcium blocker discontinuation showed patients signs neurotoxicity
methylphenidate intake reported stroke ischaemic
methylphenidate intake reported stroke
methylphenidate intake reported documented vasculitis associated abuse amphetamine
methylphenidate intake reported documented vasculitis associated abuse
methylphenidate treated suffered strokes ischaemic
methylphenidate treated suffered strokes
methylphenidate hyperactivity
methylphenidate vasculitis
methylphenidate therapy history patients considered vasculitis
sulphasalazine arthritis rheumatoid
sulphasalazine arthritis
Apomorphine therapy disease Parkinson
Apomorphine therapy disease Parkinson '
Apomorphine therapy disease s
Apomorphine therapy disease
Apomorphine used treat symptoms disease Parkinson
Apomorphine used treat symptoms disease Parkinson '
Apomorphine used treat symptoms disease s
Apomorphine used treat symptoms disease
apomorphine administration fluctuating disease Parkinson
apomorphine administration fluctuating disease Parkinson '
apomorphine administration fluctuating disease s
apomorphine administration fluctuating disease
apomorphine infusions associated reductions preexisting levodopa dyskinesias
apomorphine treatment effects related play complications sedation psychiatric
apomorphine treatment fluctuating disease Parkinson
apomorphine treatment fluctuating disease Parkinson '
apomorphine treatment fluctuating disease s
apomorphine treatment fluctuating disease
sodium nitroprusside cent 8 flow increased fenoldopam induced + hypotension
sodium nitroprusside cent 8 flow hypotension
dopamine agonist causes preserves kidney hypotension
riboflavin thiamine deficiency nutritional
riboflavin thiamine deficiency
thiamine deficiency nutritional
thiamine deficiency
Isoniazid agent neuropathy
Vitamin D toxicity
D toxicity
3 toxicity
vitamin D treated cows None showed signs fever milk
vitamin D treated cows None showed signs fever
D treated cows None showed signs fever milk
D treated cows None showed signs fever
3 D treated cows None showed signs fever milk
3 D treated cows None showed signs fever
vitamin D treated cows None showed developed signs fever milk
vitamin D treated cows None showed developed signs fever
D treated cows None showed developed signs fever milk
D treated cows None showed developed signs fever
3 D treated cows None showed developed signs fever milk
3 D treated cows None showed developed signs fever
vitamin toxicity
D toxicity
3 toxicity
vitamin toxicity Signs observed developed died signs D toxicity
D toxicity Signs observed developed died signs D toxicity
3 toxicity Signs observed developed died signs D toxicity
vitamin D signs died developed observed Signs toxicity
D signs died developed observed Signs toxicity
3 toxicity D signs died developed observed Signs toxicity
vitamin D toxicity
D toxicity
3 toxicity
vitamin toxicity
D toxicity
3 D toxicity
vitamin D doses safety margin cows D toxicity
D doses safety margin cows D toxicity
3 D doses safety margin cows D toxicity
vitamin cannot used concluded D toxicity
D cannot used concluded D toxicity
3 cannot used concluded D toxicity
vitamin toxicity D cows margin prevent fever milk
vitamin toxicity D cows margin prevent fever
D cows margin prevent fever milk
D cows margin prevent fever
3 D cows margin prevent fever milk
3 D cows margin prevent fever
vitamin toxicity D doses induce fever milk
vitamin toxicity D doses induce fever
D doses induce fever milk
D doses induce fever
3 D doses induce fever milk
3 D doses induce fever
vitamin toxicity D concluded used prevent fever milk
vitamin toxicity D concluded used prevent fever
D concluded used prevent fever milk
D concluded used prevent fever
3 D concluded used prevent fever milk
3 D concluded used prevent fever
vitamin D doses safety margin prevent fever milk
vitamin D doses safety margin prevent fever
D doses safety margin prevent fever milk
D doses safety margin prevent fever
3 D doses safety margin prevent fever milk
3 D doses safety margin prevent fever
vitamin D doses safety margin cows D doses induce fever milk
vitamin D doses safety margin cows D doses induce fever
D doses safety margin cows D doses induce fever milk
D doses safety margin cows D doses induce fever
3 D doses safety margin cows D doses induce fever milk
3 D doses safety margin cows D doses induce fever
vitamin D doses safety margin cows D concluded used prevent fever milk
vitamin D doses safety margin cows D concluded used prevent fever
D doses safety margin cows D concluded used prevent fever milk
D doses safety margin cows D concluded used prevent fever
3 D doses safety margin cows D concluded used prevent fever milk
3 D doses safety margin cows D concluded used prevent fever
vitamin cannot used concluded D cows margin prevent fever milk
vitamin cannot used concluded D cows margin prevent fever
D cannot used concluded D cows margin prevent fever milk
D cannot used concluded D cows margin prevent fever
3 cannot used concluded D cows margin prevent fever milk
3 cannot used concluded D cows margin prevent fever
vitamin cannot used concluded D doses induce fever milk
vitamin cannot used concluded D doses induce fever
D cannot used concluded D doses induce fever milk
D cannot used concluded D doses induce fever
3 cannot used concluded D doses induce fever milk
3 cannot used concluded D doses induce fever
vitamin cannot used prevent fever milk
vitamin cannot used prevent fever
D cannot used prevent fever milk
D cannot used prevent fever
3 cannot used prevent fever milk
3 cannot used prevent fever
N C markers toxicity cardiovascular
N C markers toxicity
terminal brain sensitive C markers toxicity cardiovascular
terminal brain sensitive C markers toxicity
pro brain sensitive C markers toxicity cardiovascular
pro brain sensitive C markers toxicity
brain sensitive C markers toxicity cardiovascular
brain sensitive C markers toxicity
natriuretic peptide brain sensitive C markers toxicity cardiovascular
natriuretic peptide brain sensitive C markers toxicity
peptide brain sensitive C markers toxicity cardiovascular
peptide brain sensitive C markers toxicity
NT peptide brain sensitive C markers toxicity cardiovascular
NT peptide brain sensitive C markers toxicity
proBNP NT peptide brain sensitive C markers toxicity cardiovascular
proBNP NT peptide brain sensitive C markers toxicity
glutamate mRNA Loss containing induced seizures
glutamic mRNA determine used vulnerable seizure
acid mRNA determine used vulnerable seizure
glutamic mRNA determine used vulnerable seizure induced model seizures
acid mRNA determine used vulnerable seizure induced model seizures
cresyl staining methods neuronal
cresyl staining methods degeneration
violet staining methods neuronal
violet staining methods degeneration
cresyl staining studies suggested related loss neuronal
cresyl staining studies suggested related loss
violet staining studies suggested related loss neuronal
violet staining studies suggested related loss
bradykinin receptors activation Role barrier hypertension
bradykinin release role barrier hypertension
Hoe vehicle treated rats induced hypertension
140 microM vehicle treated rats induced hypertension
dextran labeled quantitated induced hypertension
bradykinin release related barrier hypertension
phenylephrine Reversal patients infarction acute
phenylephrine Reversal patients infarction myocardial
phenylephrine Reversal patients infarction
nitroglycerin effects phenylephrine Reversal patients infarction acute
nitroglycerin effects phenylephrine Reversal patients infarction myocardial
nitroglycerin effects phenylephrine Reversal patients infarction
Nitroglycerin shown reduce ST elevation infarction acute
Nitroglycerin shown reduce ST elevation infarction myocardial
Nitroglycerin shown reduce ST elevation infarction
nitroglycerin reverse agents potentiated elevation infarction acute
nitroglycerin reverse agents potentiated elevation infarction myocardial
nitroglycerin reverse agents potentiated elevation infarction
nitroglycerin received patients infarctions myocardial
nitroglycerin received patients infarctions
phenylephrine addition beneficial treatment patients infarction acute
phenylephrine addition beneficial treatment patients infarction myocardial
phenylephrine addition beneficial treatment patients infarction
nitroglycerin phenylephrine addition beneficial treatment patients infarction acute
nitroglycerin phenylephrine addition beneficial treatment patients infarction myocardial
nitroglycerin phenylephrine addition beneficial treatment patients infarction
levodopa disability reduces stage disease Parkinson
levodopa disability reduces stage disease Parkinson '
levodopa disability reduces stage disease s
levodopa disability reduces stage disease
mannitol gliomas
mannitol lower elevated ICP tumor brain
mannitol lower elevated ICP tumor
mannitol reduce edema brain
mannitol reduce edema
mannitol passage research patients brain
mannitol passage research patients tumor
Mannitol administered had glioma malignant
Mannitol administered had glioma
Mannitol administered had glioma metastases
Mannitol administered had glioma meningioma
mannitol concentrations higher patients glioma
mannitol concentrations higher patients meningioma metastases
mannitol concentrations higher patients meningioma
mannitol leak BBB gliomas
mannitol leak reversing edema
zidovudine toxicity
vitamin B role supplementation preventing toxicity
B role supplementation preventing toxicity
12 B role supplementation preventing toxicity
folinic supplementation preventing toxicity
acid supplementation preventing toxicity
folinic supplementation preventing zidovudine suppression bone
folinic supplementation preventing zidovudine suppression marrow
folinic supplementation preventing zidovudine suppression
acid supplementation preventing zidovudine suppression bone
acid supplementation preventing zidovudine suppression marrow
acid supplementation preventing zidovudine suppression
vitamin B role supplementation preventing zidovudine suppression bone
vitamin B role supplementation preventing zidovudine suppression marrow
vitamin B role supplementation preventing zidovudine suppression
B role supplementation preventing zidovudine suppression bone
B role supplementation preventing zidovudine suppression marrow
B role supplementation preventing zidovudine suppression
12 B role supplementation preventing zidovudine suppression bone
12 B role supplementation preventing zidovudine suppression marrow
12 B role supplementation preventing zidovudine suppression
folinic acid combination randomized 500 counts virus human
folinic acid combination randomized 500 counts virus immunodeficiency
folinic acid combination randomized 500 counts virus
folinic acid combination randomized 500 counts virus HIV
folinic acid combination randomized 500 counts patients infected
acid combination randomized 500 counts virus human
acid combination randomized 500 counts virus immunodeficiency
acid combination randomized 500 counts virus
acid combination randomized 500 counts virus HIV
acid combination randomized 500 counts patients infected
ZDV receive randomized 500 counts virus human
ZDV receive randomized 500 counts virus immunodeficiency
ZDV receive randomized 500 counts virus
ZDV receive randomized 500 counts virus HIV
ZDV receive randomized 500 counts patients infected
vitamin acid combination randomized 500 counts virus human
vitamin acid combination randomized 500 counts virus immunodeficiency
vitamin acid combination randomized 500 counts virus
vitamin acid combination randomized 500 counts virus HIV
vitamin acid combination randomized 500 counts patients infected
B counts virus human
B counts virus immunodeficiency
B counts virus
B counts virus HIV
B counts patients infected
12 B counts virus human
12 B counts virus immunodeficiency
12 B counts virus
12 B counts virus HIV
12 B counts patients infected
folate levels myelosuppression
vitamin B correlation levels myelosuppression
B correlation levels myelosuppression
12 B correlation levels myelosuppression
folinic supplementation 12 seem B induced myelotoxicity
acid supplementation 12 seem B induced myelotoxicity
Vitamin B induced myelotoxicity
B induced myelotoxicity
12 seem B induced myelotoxicity
phenytoin patients epileptic
phenytoin medication atrophy cerebellar
phenytoin medication atrophy
phenytoin levels elevation duration seizure
phenytoin overdosage result atrophy cerebellar
phenytoin overdosage result atrophy
phenytoin overdosage result conclude unlikely cause atrophy cerebellar
phenytoin overdosage result conclude unlikely cause atrophy
phenytoin medication cause unlikely conclude result atrophy cerebellar
phenytoin medication cause unlikely conclude result atrophy
phenytoin medication cause atrophy cerebellar
phenytoin medication cause atrophy
sirolmus lacks effects nephrotoxic
Srl sirolmus lacks effects nephrotoxic
Srl associated proteinuria reported lacks effects nephrotoxic
angiotensin inhibitor blocker reduced development proteinuria
releasing blocker reduced development proteinuria
blocker reduced development proteinuria
ARB blocker reduced development proteinuria
ACE inhibitor blocker reduced development proteinuria
inhibitor blocker reduced development proteinuria
Srl used monitored proteinuria dysfunction renal
Srl used monitored proteinuria dysfunction
ARB therapy used monitored proteinuria
ARB therapy used monitored proteinuria dysfunction renal
ARB therapy used monitored proteinuria dysfunction
ACEi therapy used monitored proteinuria
ACEi therapy used monitored proteinuria dysfunction renal
ACEi therapy used monitored proteinuria dysfunction
NMDA receptors mediated neurotransmission modulate haloperidol induced catalepsy
amino acid influence mechanisms IC catalepsy
acid influence mechanisms IC catalepsy
dopamine haloperidol induced catalepsy
glutamate antagonists microinjections challenged catalepsy
MK antagonists microinjections challenged catalepsy
801 MK antagonists microinjections challenged catalepsy
NMDA antagonists microinjections challenged catalepsy
NMDA N 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
N 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
methyl 0 15 801 MK antagonists microinjections challenged catalepsy
d 0 15 801 MK antagonists microinjections challenged catalepsy
aspartate NMDA d 0 15 801 MK antagonists microinjections challenged catalepsy
NMDA d 0 15 801 MK antagonists microinjections challenged catalepsy
AP 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
7 AP 0 mmol 0 15 801 MK antagonists microinjections challenged catalepsy
MK microinjection showed attenuated catalepsy
801 previous attenuated catalepsy
AP 7 801 previous attenuated catalepsy
7 801 previous attenuated catalepsy
glutamate induced catalepsy
acetazolamide induced confusion reaction patients impairment renal
acetazolamide induced confusion reaction patients impairment
acetazolamide induced confusion
co treatment pneumonia Pneumocystis
co treatment pneumonia
trimoxazole treatment pneumonia Pneumocystis
trimoxazole treatment pneumonia
co lasting cholestasis
trimoxazole treatment co lasting cholestasis
co treatment pneumonia HIV
co patients infected
trimoxazole treatment pneumonia HIV
trimoxazole treatment co patients infected
co doses treated pneumonia Pneumocystis
co doses treated pneumonia
trimoxazole doses treated pneumonia Pneumocystis
trimoxazole doses treated pneumonia
co doses treated pneumonia PCP
trimoxazole doses treated pneumonia PCP
co doses treated pneumonia infection opportunistic
co doses treated pneumonia infection
trimoxazole doses treated pneumonia infection opportunistic
trimoxazole doses treated pneumonia infection
co doses treated pneumonia infection HIV
co doses treated pneumonia infection individuals infected
trimoxazole doses treated pneumonia infection HIV
trimoxazole doses treated pneumonia infection individuals infected
co exams formation treatment PCP
trimoxazole treatment PCP
co exams formation liver
co exams formation abscess
trimoxazole treatment formation liver
trimoxazole treatment formation abscess
co exams formation cases HIV
co exams formation cases patients infected
trimoxazole treatment formation cases HIV
trimoxazole treatment formation cases patients infected
glycine antagonist 7 5 decreased haloperidol rigidity muscle
glycine antagonist 7 5 decreased haloperidol rigidity
5 decreased haloperidol rigidity muscle
5 decreased haloperidol rigidity
7 5 decreased haloperidol rigidity muscle
7 5 decreased haloperidol rigidity
dichlorokynurenic acid 7 5 decreased haloperidol rigidity muscle
dichlorokynurenic acid 7 5 decreased haloperidol rigidity
acid 7 5 decreased haloperidol rigidity muscle
acid 7 5 decreased haloperidol rigidity
5 acid 7 5 decreased haloperidol rigidity muscle
5 acid 7 5 decreased haloperidol rigidity
7 5 acid 7 5 decreased haloperidol rigidity muscle
7 5 acid 7 5 decreased haloperidol rigidity
DCKA 5 acid 7 5 decreased haloperidol rigidity muscle
DCKA 5 acid 7 5 decreased haloperidol rigidity
vinorelbine Gemcitabine patients nonsmall
vinorelbine Gemcitabine patients cell
vinorelbine Gemcitabine patients lung
vinorelbine Gemcitabine patients carcinoma
Gemcitabine patients nonsmall
Gemcitabine patients cell
Gemcitabine patients lung
Gemcitabine patients carcinoma
cisplatin receive cannot patients years age Gemcitabine patients nonsmall
cisplatin receive cannot patients years age Gemcitabine patients cell
cisplatin receive cannot patients years age Gemcitabine patients lung
cisplatin receive cannot patients years age Gemcitabine patients carcinoma
gemcitabine vinorelbine therapy obtain rate toxicity
GEM vinorelbine therapy obtain rate toxicity
vinorelbine therapy obtain rate toxicity
VNB vinorelbine therapy obtain rate toxicity
GEM combination efficacy toxicity
VNB GEM combination efficacy toxicity
VNB GEM combination patients NSCLC
GEM combination patients NSCLC
cisplatin contraindication those combination efficacy toxicity
cisplatin contraindication those combination patients NSCLC
cisplatin receiving contraindication had age included patients NSCLC
levofloxacin treatment sinusitis
levofloxacin efficacy evaluate treating sinusitis
levofloxacin mg treatment sinusitis
cAMP aggregation platelet
cAMP aggregation
ribavirin effect patients fever Argentine
ribavirin effect patients fever hemorrhagic
ribavirin effect patients fever
ribavirin effect studied patients fever Argentine
ribavirin effect studied patients fever hemorrhagic
ribavirin effect studied patients fever
ribavirin effect studied patients fever AHF
ribavirin Administration resulted neutralization viremia
ribavirin has effect cases AHF
ribavirin days AHF
iodixanol osmolar study comparing effects nephrotoxic
creatinine concentrations involved diabetes
iodixanol used patients high develop likely CONCLUSIONS Nephropathy
acetylcholine release seizure
acetylcholine release relationship seizure
alcohol examined sensitivity METHODS Prone ve Seizure
carbachol nicotine administered recorded latencies onset tremor
neostigmine nicotine administered recorded latencies onset tremor
nicotine administered recorded latencies onset tremor
ACh measured testing handling convulsions
ACh measured testing handling convulsions
ACh elevated measured testing handling convulsions
ethanol severity associated differences activity convulsants
alcohol withdrawal implicate associated differences activity convulsants
vincristine treated Lymphoma patients Non
vincristine treated Lymphoma Hodgkin
vincristine treated Lymphoma Hodgkin '
vincristine treated Lymphoma s
vincristine treated Lymphoma
vincristine effects evaluate investigated patients Non
vincristine effects evaluate investigated patients Lymphoma Hodgkin
vincristine effects evaluate investigated patients Lymphoma Hodgkin '
vincristine effects evaluate investigated patients Lymphoma s
vincristine effects evaluate investigated patients Lymphoma
vincristine dose reversible signs neuropathy
vincristine neuropathy
fluocinolone implants treated pressure patients uveitis
acetonide implants treated pressure patients uveitis
fluocinolone implant treated uveitis
acetonide implant treated uveitis
FA implant treated uveitis
carteolol hydrochloride effect induced catalepsy
hydrochloride effect induced catalepsy
propranolol those studied effects carteolol beta induced catalepsy
biperiden propranolol those studied effects carteolol beta induced catalepsy
carteolol beta induced catalepsy
propranolol Carteolol inhibited haloperidol induced catalepsy
biperiden propranolol Carteolol inhibited haloperidol induced catalepsy
Carteolol inhibited haloperidol induced catalepsy
dopamine receptor evoke stimulating signs stereotypy hyperlocomotion
Carteolol evoke stimulating signs stereotypy hyperlocomotion
haloperidol induced adrenoceptor expected effective treatment akathisia
dopamine activity due induced induced adrenoceptor expected effective treatment akathisia
carteolol improves haloperidol induced catalepsy
carteolol improves haloperidol induced adrenoceptor expected effective treatment akathisia
dopamine activity due induced induced catalepsy
corticosterone effects related Dose induced neuropathy
organophosphorus related Dose induced neuropathy
corticosterone concentrations induced neuropathy
TOTP % hr 24 Neurotoxic
organophosphorous compounds chickens measured values % hr 24 Neurotoxic
DFP TOTP % hr 24 Neurotoxic
tris administration shown protect effects hepatotoxic
salt administration shown protect effects hepatotoxic
CS administration shown protect effects hepatotoxic
cholesteryl administration shown protect effects hepatotoxic
hemisuccinate administration shown protect effects hepatotoxic
carbon tetrachloride adriamycin non toxicity
tetrachloride adriamycin non toxicity
gamma form non toxicity
cholesteryloxybutyric acid gamma form non toxicity
acid gamma form non toxicity
adriamycin non toxicity
CS cytoprotection mechanism understanding further examined abilities non toxicity
CS abilities non toxicity
CS form non toxicity
tris salt form non toxicity
salt form non toxicity
CSE salt form non toxicity
galactosamine chloroform toxicity
chloroform toxicity
acetaminophen salt form non toxicity
CS dose resulted protection effects hepatotoxic
adriamycin administration effect pretreatment pretreatment dose resulted protection effects hepatotoxic
CHCl CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
3 CHCl CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
acetaminophen CHCl CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
4 CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
galactosamine CCl effects protection resulted dose pretreatment pretreatment effect cardiotoxic
CS dose pretreatment pretreatment effect cardiotoxic
CS protection mechanism appear dependent reactive intermediate light protection observed hepatotoxicity
edaravone effect vestibulotoxicity
edaravone induced vestibulotoxicity
Edaravone has used treat infarction cerebral
Edaravone has used treat infarction
edaravone suppresses streptomycin induced vestibulotoxicity
misoprostol effect induced dysfunction renal
misoprostol effect induced dysfunction
misoprostol Addition minimize affecting control pain
misoprostol Addition minimize impairment renal
misoprostol Addition minimize impairment
glutamate supplementation failed protect neurotoxicity peripheral
glutamate supplementation failed protect neurotoxicity
glutamate claimed ameliorate neurotoxicity
glutamine glutamate claimed ameliorate neurotoxicity
amino glutamine glutamate claimed ameliorate neurotoxicity
acid glutamine glutamate claimed ameliorate neurotoxicity
glutamate claimed factor neuropathy peripheral
glutamate claimed factor neuropathy
glutamine glutamate claimed factor neuropathy peripheral
glutamine glutamate claimed factor neuropathy
paclitaxel chemotherapy factor claimed ameliorate neurotoxicity
PAC paclitaxel chemotherapy factor claimed ameliorate neurotoxicity
PAC ameliorate neurotoxicity
amino glutamine glutamate claimed factor neuropathy peripheral
amino glutamine glutamate claimed factor neuropathy
acid glutamine glutamate claimed factor neuropathy peripheral
acid glutamine glutamate claimed factor neuropathy
glutamate supplementation role evaluate aimed induced neuropathy peripheral
glutamate supplementation role evaluate aimed induced neuropathy
glutamate mg supplemented 23 regimen available patients ovarian
glutamate mg supplemented 23 regimen available patients cancer
PAC cycles regimen available patients ovarian
PAC cycles regimen available patients cancer
glutamate supplementation fails protect neurotoxicity peripheral
glutamate supplementation fails protect neurotoxicity
ketoconazole gentamicin administration aggravate toxicity
gentamicin administration aggravate toxicity
amphothericin B gentamicin administration potential nephrotoxic
B gentamicin administration potential nephrotoxic
amphothericin B gentamicin administration aggravate toxicity
B gentamicin administration aggravate toxicity
CSA administration aggravate toxicity
CSA toxicity
ketoconazole gentamicin administration potential nephrotoxic
gentamicin administration potential nephrotoxic
Gentamicin increased nephrotoxicity
benzodiazepine lorazepam controlled Akathisia
lorazepam controlled Akathisia
calcium chloride injury arterial
calcium chloride injury
chloride injury arterial
chloride injury
CaCl chloride injury arterial
CaCl chloride injury
2 NNS chloride injury arterial
2 NNS chloride injury
alcohol use interval men interval suffer fever hay
alcohol use interval men interval suffer fever
alcohol use interval men interval suffer fever asthma
ibuprofen agents use age history gout
ibuprofen agents use age preexisting disease renal
ibuprofen agents use age preexisting disease
ibuprofen agents use age history stones kidney
ibuprofen agents use age history stones
KF administration ameliorated responses cataleptic
17837 KF administration ameliorated responses cataleptic
adenosine administration agonist manner induced responses cataleptic
KF 17837 reduced catalepsy
17837 reduced catalepsy
KF 17837 drug treatment parkinsonism
17837 drug treatment parkinsonism
timolol treatment infarction myocardial
timolol treatment infarction
timolol treatment evaluated infarction myocardial
timolol treatment evaluated infarction
timolol placebo study effect treatment evaluated infarction myocardial
timolol placebo study effect treatment evaluated infarction
timolol bradycardia
timolol group remained increased re infarction
BCNU chemotherapy treatment gliomas malignant
BCNU chemotherapy treatment gliomas
BCNU clearance 1 provide treatment gliomas malignant
BCNU clearance 1 provide treatment gliomas
1 BCNU clearance 1 provide treatment gliomas malignant
1 BCNU clearance 1 provide treatment gliomas
3 BCNU clearance 1 provide treatment gliomas malignant
3 BCNU clearance 1 provide treatment gliomas
bis 3 BCNU clearance 1 provide treatment gliomas malignant
bis 3 BCNU clearance 1 provide treatment gliomas
2 BCNU clearance 1 provide treatment gliomas malignant
2 BCNU clearance 1 provide treatment gliomas
chloroethyl 2 BCNU clearance 1 provide treatment gliomas malignant
chloroethyl 2 BCNU clearance 1 provide treatment gliomas
1 provide treatment gliomas malignant
1 provide treatment gliomas
nitrosourea 1 provide treatment gliomas malignant
nitrosourea 1 provide treatment gliomas
BCNU therapy courses received Twenty patients recurrent Grade astrocytomas
ethanol diluent concentration lowered decreased frequency loss visual
ethanol diluent concentration lowered decreased frequency loss
penicillamine therapy caused arthritis rheumatoid
penicillamine therapy caused arthritis
chloroquine penicillamine therapy caused arthritis rheumatoid
chloroquine penicillamine therapy caused arthritis
penicillamine therapy arthritis rheumatoid
penicillamine therapy arthritis
chloroquine penicillamine therapy arthritis rheumatoid
chloroquine penicillamine therapy arthritis
ketamine Injections produced depression
dopamine receptors induce catalepsy
dopamine antagonists induced catalepsy
dopamine antagonists induced catalepsy tested determined subtypes involved catalepsy
dopamine subtypes determined tested catalepsy
dopamine subtypes involved catalepsy
Dopamine fluphenazine sulpiride induced catalepsy
SKF 38393 D decreased catalepsy
38393 D decreased catalepsy
quinpirole decreased catalepsy
SKF Combination cause catalepsy
38393 SKF Combination cause catalepsy
quinpirole Combination cause catalepsy
dopamine antagonists induced catalepsy
metoprolol Effect glucagon induced ischemia myocardial
metoprolol Effect glucagon induced ischemia
metoprolol metoprolol Effect glucagon induced ischemia myocardial
metoprolol metoprolol Effect glucagon induced ischemia
metoprolol attenuates evidence ischemia myocardial
metoprolol attenuates evidence ischemia
epinephrine mepivacaine seen addition damage muscle
epinephrine mepivacaine seen addition damage
Ketamine sedation fractures
ketamine safety examine treatment fractures
ketamine manipulation fracture dislocation
ketamine manipulation fracture
Ketamine provided sedation facilitate reduction fractures
dopamine neurons induced neurotoxicity
LY induced neurotoxicity
274614 LY induced neurotoxicity
amino antagonist Protection induced neurotoxicity
acid antagonist Protection induced neurotoxicity
dopamine neurons compounds effect neurotoxic
LY 274614 antagonist involves effect neurotoxic
274614 antagonist involves effect neurotoxic
NMDA receptors involves effect neurotoxic
NMDA antagonist involves effect neurotoxic
valdecoxib placebo events patients arthritis
valdecoxib placebo events thrombotic
valdecoxib data arthritis rheumatoid
valdecoxib data arthritis
valdecoxib data inhibitor patients osteoarthritis
diclofenac bid NSAID valdecoxib data osteoarthritis
naproxen bid bid NSAID valdecoxib trials rheumatoid
naproxen bid bid NSAID valdecoxib trials arthritis
valdecoxib trials rheumatoid
valdecoxib trials arthritis
ibuprofen tid bid NSAID valdecoxib analyzing determined incidence events thrombotic
ibuprofen tid bid NSAID valdecoxib analyzing determined incidence cardiac thrombotic
ibuprofen tid bid NSAID valdecoxib trials rheumatoid
ibuprofen tid bid NSAID valdecoxib trials arthritis
diclofenac bid NSAID valdecoxib trials rheumatoid
diclofenac bid NSAID valdecoxib trials arthritis
valdecoxib data osteoarthritis
ibuprofen tid bid NSAID valdecoxib data osteoarthritis
naproxen bid bid NSAID valdecoxib data osteoarthritis
valdecoxib analyzing determined incidence events thrombotic
valdecoxib analyzing determined incidence cardiac thrombotic
naproxen bid bid NSAID valdecoxib analyzing determined incidence events thrombotic
naproxen bid bid NSAID valdecoxib analyzing determined incidence cardiac thrombotic
diclofenac bid NSAID valdecoxib analyzing determined incidence events thrombotic
diclofenac bid NSAID valdecoxib analyzing determined incidence cardiac thrombotic
valdecoxib similar Crude incidences events thrombotic
valdecoxib dose similar risk events thrombotic
valdecoxib aspirin nonusers higher risk Thrombotic
valdecoxib doses therapeutic treatment associated incidence events patients rheumatoid
valdecoxib doses therapeutic treatment associated incidence events patients arthritis
valdecoxib doses therapeutic treatment associated incidence events osteoarthritis
valdecoxib doses therapeutic treatment associated incidence events thrombotic
Capsaicin induced alters muscle
Capsaicin induced alters pain
nitric oxide levels gene headache patients tension
nitric oxide levels gene type
nitric oxide levels gene type headache
oxide levels gene headache patients tension
oxide levels gene type
oxide levels gene type headache
nitric oxide induced headache headaches primary
nitric oxide induced headache headaches
oxide induced headache headaches primary
oxide induced headache headaches
NO oxide induced headache headaches primary
NO oxide induced headache headaches
NO donor glyceryl trinitrate induced patients tension
NO donor glyceryl trinitrate induced headache headache type
NO donor glyceryl trinitrate induced headache headache
glyceryl trinitrate induced patients tension
glyceryl trinitrate induced headache headache type
glyceryl trinitrate induced headache headache
trinitrate induced patients tension
trinitrate induced headache headache type
trinitrate induced headache headache
GTN trinitrate induced patients tension
GTN trinitrate induced headache headache type
GTN trinitrate induced headache headache
Levodopa induced dystonia palsy progressive
Levodopa induced dystonia palsy supranuclear
Levodopa induced dystonia palsy
Levodopa induced reported disease atrophy multiple
Levodopa induced reported disease atrophy system
Levodopa induced reported disease atrophy
Levodopa induced reported disease Parkinson
Levodopa induced reported disease Parkinson '
Levodopa induced reported disease s
Levodopa induced reported disease
Levodopa induced reported dyskinesias
levodopa case describe dystonia patient PSP
levodopa case describe highlight importance recognizing complication management PSP
levodopa case describe dystonia Oromandibular
levodopa case describe dystonia
levodopa case describe dystonia OMD
VPA treatment tonic
VPA convulsions clonic
VPA convulsions
VPA administration consider result combination factors weakness
VPA administration consider result combination factors weakness system of
VPA administration consider result combination factors weakness system the
VPA administration consider result combination factors weakness system central
VPA administration consider result combination factors weakness system nervous
VPA administration consider result combination factors weakness system
furosemide effect nephropathy
furosemide efficacy determine fluids prevention nephropathy
creatinine rise pretreated function Renal
creatinine rise pretreated function
creatinine rise pretreated function deteriorated significantly
creatinine rise pretreated function deteriorated
furosemide associated failure Renal
furosemide associated failure
furosemide associated loss weight
furosemide associated loss
Furosemide deleterious prevention nephropathy
sodium application valproate revealed disorders neurological
sodium application valproate revealed disorders
valproate revealed disorders neurological
valproate revealed disorders
valproate revealed disorders neurological
valproate revealed disorders
sodium application valproate revealed indicating damage cerebellum
sodium application valproate revealed indicating damage
valproate revealed indicating damage cerebellum
valproate revealed indicating damage
valproate revealed indicating damage cerebellum
valproate revealed indicating damage
valproate encephalopathy development damage hepatic
valproate encephalopathy development damage
valproate encephalopathy development damage hyperammonemia
dopamine agonist use 86929 study levodopa parkinsonian
A agonist use 86929 study levodopa parkinsonian
86929 study levodopa parkinsonian
levodopa parkinsonian
dopamine agonists utility treatment disease Parkinson
dopamine agonists utility treatment disease Parkinson '
dopamine agonists utility treatment disease s
dopamine agonists utility treatment disease
dopamine agonists utility treatment disease PD
DA agonists utility treatment disease Parkinson
DA agonists utility treatment disease Parkinson '
DA agonists utility treatment disease s
DA agonists utility treatment disease
DA agonists utility treatment disease PD
A 0 doses evaluate induced dyskinesias
86929 -LSB- A 0 doses evaluate induced dyskinesias
A 0 doses evaluate locomotor effects dyskinetic
86929 -LSB- A 0 doses evaluate locomotor effects dyskinetic
-LSB- A 0 doses evaluate induced dyskinesias
-RSB- A 0 doses evaluate induced dyskinesias
-LSB- 5 aR A 0 doses evaluate induced dyskinesias
5 aR A 0 doses evaluate induced dyskinesias
aR A 0 doses evaluate induced dyskinesias
11 -RSB- aR A 0 doses evaluate induced dyskinesias
bS -RSB- aR A 0 doses evaluate induced dyskinesias
-RSB- aR A 0 doses evaluate induced dyskinesias
4 b A 0 doses evaluate induced dyskinesias
5 b A 0 doses evaluate induced dyskinesias
5 b A 0 doses evaluate induced dyskinesias
a b A 0 doses evaluate induced dyskinesias
6 b A 0 doses evaluate induced dyskinesias
7 b A 0 doses evaluate induced dyskinesias
11 b A 0 doses evaluate induced dyskinesias
b A 0 doses evaluate induced dyskinesias
hexahydro A 0 doses evaluate induced dyskinesias
2 A 0 doses evaluate induced dyskinesias
propyl A 0 doses evaluate induced dyskinesias
3 A 0 doses evaluate induced dyskinesias
thia A 0 doses evaluate induced dyskinesias
5 A 0 doses evaluate induced dyskinesias
+ azacyclopent A 0 doses evaluate induced dyskinesias
++ azacyclopent A 0 doses evaluate induced dyskinesias
azacyclopent A 0 doses evaluate induced dyskinesias
1 A 0 doses evaluate induced dyskinesias
ena -LSB- 1 A 0 doses evaluate induced dyskinesias
-LSB- 1 A 0 doses evaluate induced dyskinesias
c 1 A 0 doses evaluate induced dyskinesias
-RSB- phenathrene 1 A 0 doses evaluate induced dyskinesias
phenathrene 1 A 0 doses evaluate induced dyskinesias
9 A 0 doses evaluate induced dyskinesias
10 A 0 doses evaluate induced dyskinesias
diol A 0 doses evaluate induced dyskinesias
-LSB- A 0 doses evaluate locomotor effects dyskinetic
-RSB- A 0 doses evaluate locomotor effects dyskinetic
-LSB- 5 aR A 0 doses evaluate locomotor effects dyskinetic
5 aR A 0 doses evaluate locomotor effects dyskinetic
aR A 0 doses evaluate locomotor effects dyskinetic
11 -RSB- aR A 0 doses evaluate locomotor effects dyskinetic
bS -RSB- aR A 0 doses evaluate locomotor effects dyskinetic
-RSB- aR A 0 doses evaluate locomotor effects dyskinetic
4 b A 0 doses evaluate locomotor effects dyskinetic
5 b A 0 doses evaluate locomotor effects dyskinetic
5 b A 0 doses evaluate locomotor effects dyskinetic
a b A 0 doses evaluate locomotor effects dyskinetic
6 b A 0 doses evaluate locomotor effects dyskinetic
7 b A 0 doses evaluate locomotor effects dyskinetic
11 b A 0 doses evaluate locomotor effects dyskinetic
b A 0 doses evaluate locomotor effects dyskinetic
hexahydro A 0 doses evaluate locomotor effects dyskinetic
2 A 0 doses evaluate locomotor effects dyskinetic
propyl A 0 doses evaluate locomotor effects dyskinetic
3 A 0 doses evaluate locomotor effects dyskinetic
thia A 0 doses evaluate locomotor effects dyskinetic
5 A 0 doses evaluate locomotor effects dyskinetic
+ azacyclopent A 0 doses evaluate locomotor effects dyskinetic
++ azacyclopent A 0 doses evaluate locomotor effects dyskinetic
azacyclopent A 0 doses evaluate locomotor effects dyskinetic
1 A 0 doses evaluate locomotor effects dyskinetic
ena -LSB- 1 A 0 doses evaluate locomotor effects dyskinetic
-LSB- 1 A 0 doses evaluate locomotor effects dyskinetic
c 1 A 0 doses evaluate locomotor effects dyskinetic
-RSB- phenathrene 1 A 0 doses evaluate locomotor effects dyskinetic
phenathrene 1 A 0 doses evaluate locomotor effects dyskinetic
9 A 0 doses evaluate locomotor effects dyskinetic
10 A 0 doses evaluate locomotor effects dyskinetic
diol A 0 doses evaluate locomotor effects dyskinetic
1 study dose conducted methyl exposed monkeys primed induced dyskinesias
methyl exposed monkeys primed induced dyskinesias
4 methyl exposed monkeys primed induced dyskinesias
phenyl - 4 methyl exposed monkeys primed induced dyskinesias
- 4 methyl exposed monkeys primed induced dyskinesias
1 - 4 methyl exposed monkeys primed induced dyskinesias
2 - 4 methyl exposed monkeys primed induced dyskinesias
3 - 4 methyl exposed monkeys primed induced dyskinesias
6 - 4 methyl exposed monkeys primed induced dyskinesias
tetrahydropyridine - 4 methyl exposed monkeys primed induced dyskinesias
1 study dose conducted methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
phenyl - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
- 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
1 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
2 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
3 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
6 - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
tetrahydropyridine - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
MPTP tetrahydropyridine - 4 methyl exposed monkeys primed induced dyskinesias
MPTP tetrahydropyridine - 4 methyl exposed monkeys primed induced evaluate locomotor effects dyskinetic
DA D doses evaluate induced dyskinesias
DA D doses evaluate locomotor effects dyskinetic
LY levodopa induced parkinsonism
171555 efficacious alleviating MPTP induced parkinsonism
LY with efficacious alleviating MPTP induced parkinsonism
171555 86929 efficacious alleviating MPTP induced parkinsonism
A administration 86929 efficacious induced dyskinesias
86929 efficacious induced dyskinesias
MPTP alleviating efficacious induced dyskinesias
A administration 86929 efficacious alleviating MPTP induced parkinsonism
86929 efficacious alleviating MPTP induced parkinsonism
LY levodopa induced MPTP alleviating efficacious induced dyskinesias
171555 efficacious induced dyskinesias
LY with efficacious induced dyskinesias
171555 86929 efficacious induced dyskinesias
levodopa induced parkinsonism
levodopa reproduce likely efficacious alleviating MPTP induced parkinsonism
levodopa challenge 171555 86929 efficacious alleviating MPTP induced parkinsonism
A efficacy duration 86929 agents tools PD
86929 agents tools PD
DA agents tools PD
vincristin administration due myeloencephalopathy
vincristine instillation girl leucemia acute
vincristine instillation girl leucemia lymphoblastic
vincristine instillation girl leucemia
vincristine instillation 57 man lymphoma lymphoblastic
vincristine instillation 57 man lymphoma
vincristine transformation pseudocystic
vincristine transformation
vincristine transformation degeneration
vincristine transformation degeneration myelin of
vincristine transformation degeneration myelin
vincristine transformation degeneration myelin and
vincristine transformation degeneration myelin axons
fluoxetine exposure induces hypertension fetal
fluoxetine exposure induces hypertension pulmonary
fluoxetine exposure induces hypertension
fluoxetine exposure resulted hypertension fetal
fluoxetine exposure resulted hypertension pulmonary
fluoxetine exposure resulted hypertension
estradiol dependent levels inhibition hyperprolactinemic
ribonucleic levels inhibition hyperprolactinemic
acid levels inhibition hyperprolactinemic
estrogen secretion fertility necessary induced inhibited hyperprolactinemia
estradiol levels presence frequency frequency caused hyperprolactinemia
dopamine sulpiride induced hyperprolactinemia
steroid manner hyperprolactinemia
molindone administration failure rhabdomyolysis illustrate reported case patient schizophrenic
epinephrine overdose accidental due systolic left
epinephrine overdose accidental due systolic ventricular
epinephrine overdose accidental due systolic
epinephrine overdose accidental due systolic and
epinephrine overdose accidental due systolic dysfunction diastolic
epinephrine overdose accidental due systolic dysfunction
epinephrine overdose
Catecholamine induced recognized catecholamines due cardiomyopathy
catecholamines due cardiomyopathy
epinephrine mg injected woman year left elevated markers necrosis myocardial
epinephrine mg injected woman year left elevated markers necrosis
epinephrine mg injected woman year left
epinephrine mg injected woman year left dysfunction ventricular
epinephrine mg injected woman year left dysfunction systolic
epinephrine mg injected woman year left dysfunction systolic and
epinephrine mg injected woman year left dysfunction systolic diastolic
epinephrine mg injected woman year left dysfunction
sevoflurane effects convulsions
sevoflurane influence studied convulsions
sevoflurane concentration 0 end lidocaine / was threshold convulsive
sevoflurane threshold convulsive
enflurane sevoflurane threshold convulsive
sevoflurane concentrations administered decreased pressure convulsions
sevoflurane enflurane marked administered decreased pressure convulsions
enflurane sevoflurane concentrations administered decreased pressure convulsions
enflurane marked administered decreased pressure convulsions
Apamin had decrease threshold convulsive
lidocaine toxicity
sevoflurane reduces effect toxicity
sevoflurane reduces effect convulsive
sevoflurane reduces carries due depression
lidocaine toxicity effect reduces carries due depression
atenolol resolved arrhythmia
atenolol week stopping disappeared arrhythmia
salbutamol agonist beta known induce tachycardia
atenolol blocker beta relieve swallowing originating reflexes trigger beta known induce tachycardia
imipenem therapy activity Seizure
imipenem cilastatin doses receiving developed patients history accident cerebral
imipenem cilastatin doses receiving developed patients history accident vascular
imipenem cilastatin doses receiving developed patients history accident
/ cilastatin doses receiving developed patients history accident cerebral
/ cilastatin doses receiving developed patients history accident vascular
/ cilastatin doses receiving developed patients history accident
cilastatin doses receiving developed patients history accident cerebral
cilastatin doses receiving developed patients history accident vascular
cilastatin doses receiving developed patients history accident
imipenem cilastatin doses receiving developed patients history accident CVA
/ cilastatin doses receiving developed patients history accident CVA
cilastatin doses receiving developed patients history accident CVA
imipenem cilastatin doses receiving developed patients history trauma head
imipenem cilastatin doses receiving developed patients history trauma
/ cilastatin doses receiving developed patients history trauma head
/ cilastatin doses receiving developed patients history trauma
cilastatin doses receiving developed patients history trauma head
cilastatin doses receiving developed patients history trauma
imipenem cilastatin doses receiving developed patients history trauma evidence disease renal
imipenem cilastatin doses receiving developed patients history trauma evidence disease
/ cilastatin doses receiving developed patients history trauma evidence disease renal
/ cilastatin doses receiving developed patients history trauma evidence disease
cilastatin doses receiving developed patients history trauma evidence disease renal
cilastatin doses receiving developed patients history trauma evidence disease
phenytoin doses controlled seizures
beta doses received antibiotics evidence activity seizure
lactam antibiotics evidence activity seizure
steroids using seen tumors liver
steroids using seen tumors
digoxin group patients capacity selected patients rheumatic
digoxin group patients capacity selected patients heart
digoxin group patients capacity selected patients disease
lithium therapy secondary developed attacks syncopal
lithium therapy secondary developed attacks
lithium levels remained attacks syncopal
lithium levels remained attacks
propranolol diazepam effects patients disorder panic
propranolol diazepam effects patients disorder
diazepam effects patients disorder panic
diazepam effects patients disorder
propranolol diazepam effects patients disorder agoraphobia
diazepam effects patients disorder agoraphobia
propranolol diazepam doses performance patients disorders panic
propranolol diazepam doses performance patients disorders
diazepam doses performance patients disorders panic
diazepam doses performance patients disorders
propranolol diazepam doses performance patients disorders agoraphobia
diazepam doses performance patients disorders agoraphobia
6 man leukemia acute
6 man leukemia lymphocytic
6 man leukemia
thioguanine year man leukemia acute
thioguanine year man leukemia lymphocytic
thioguanine year man leukemia
Unfractionated sodium BACKGROUND used prevent thrombosis
heparin sodium BACKGROUND used prevent thrombosis
sodium BACKGROUND used prevent thrombosis
UFH sodium BACKGROUND used prevent thrombosis
low sodium BACKGROUND used prevent thrombosis
molecular heparin used prevent thrombosis
weight heparin used prevent thrombosis
heparin used prevent thrombosis
heparin induced negative test platelet
heparin induced negative test aggregation
clonidine produced pressure decrease rats hypertensive
nalozone inhibited micrograms rats hypertensive
naloxone reversed effect hypotensive
clonidine influence membranes rats hypertensive
clonidine dihydroergocryptine influence influence membranes rats hypertensive
-LSB- -RSB- stereoselective influence membranes rats hypertensive
3 -RSB- stereoselective influence membranes rats hypertensive
H -RSB- stereoselective influence membranes rats hypertensive
-RSB- stereoselective influence membranes rats hypertensive
naloxone -RSB- stereoselective influence membranes rats hypertensive
-LSB- binding -RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
3 -LSB- binding -RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
H -RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
-RSB- clonidine dihydroergocryptine influence influence membranes rats hypertensive
dihydroergocryptine influence influence membranes rats hypertensive
naloxone influence influence membranes rats hypertensive
Lamivudine antigen seropositive undergoing patients cancer
Lamivudine prevention reactivation hepatitis
Lamivudine prevention reactivation B
hepatitis reactivation prevention Lamivudine antigen seropositive undergoing patients cancer
B antigen seropositive undergoing patients cancer
surface antigen seropositive undergoing patients cancer
antigen seropositive undergoing patients cancer
HBSAG antigen seropositive undergoing patients cancer
lamivudine received patients cancer
lamivudine receive group received patients cancer
lamivudine received patients have malignancies solid hematological
lamivudine received patients have malignancies
lamivudine receive group received patients have malignancies solid hematological
lamivudine receive group received patients have malignancies
lamivudine received patients have malignancies infection HBV
lamivudine received patients have malignancies infection
lamivudine receive group received patients have malignancies infection HBV
lamivudine receive group received patients have malignancies infection
lamivudine group observed hepatitis
lamivudine decreases incidence morbidity patients cancer
etoposide A effect observed patient T acute
etoposide A effect observed patient T
etoposide A effect observed patient leukemia lymphocytic
etoposide A effect observed patient leukemia
cyclosporin etoposide A effect observed patient T acute
cyclosporin etoposide A effect observed patient T
cyclosporin etoposide A effect observed patient leukemia lymphocytic
cyclosporin etoposide A effect observed patient leukemia
A effect observed patient T acute
A effect observed patient T
A effect observed patient leukemia lymphocytic
A effect observed patient leukemia
cyclosporin etoposide A administration resulted eradication infiltration leukemic
cyclosporin etoposide A administration resulted eradication infiltration
A administration resulted eradication infiltration leukemic
A administration resulted eradication infiltration
etoposide A administration resulted eradication infiltration leukemic
etoposide A administration resulted eradication infiltration
butylated hydroxyanisole induced rats carcinogenesis acetate effect carcinogenic
hydroxyanisole induced rats carcinogenesis acetate effect carcinogenic
retinyl acetate carcinogenesis forestomach
retinyl acetate carcinogenesis
acetate carcinogenesis forestomach
acetate carcinogenesis
retinyl acetate effect carcinogenic
acetate effect carcinogenic
retinyl acetate effect hydroxyanisole tumorigenesis forestomach
retinyl acetate effect hydroxyanisole tumorigenesis
acetate effect hydroxyanisole tumorigenesis forestomach
acetate effect hydroxyanisole tumorigenesis
RA effect hydroxyanisole tumorigenesis forestomach
RA effect hydroxyanisole tumorigenesis
RA % animals observed BHA given groups increased incidence papilloma squamous
RA % animals observed BHA given groups increased incidence papilloma cell
RA % animals observed BHA given groups increased incidence papilloma
RA given group increased incidence papilloma squamous
RA given group increased incidence papilloma cell
RA given group increased incidence papilloma
BHA given groups increased incidence papilloma squamous
BHA given groups increased incidence papilloma cell
BHA given groups increased incidence papilloma
BHA given groups increased incidence papilloma carcinoma
BHA given groups increased % 9 rats carcinoma
BHA given groups increased % 3 20 rat carcinoma
RA % animals observed BHA given groups increased incidence tumors forestomach
RA % animals observed BHA given groups increased incidence tumors
RA given group increased incidence tumors forestomach
RA given group increased incidence tumors
RA % animals observed BHA given groups increased incidence papilloma carcinoma
RA % animals observed BHA given groups increased % 9 rats carcinoma
RA % animals observed BHA given groups increased % 3 20 rat carcinoma
RA given group increased incidence papilloma carcinoma
RA given group increased % 9 rats carcinoma
RA given group increased % 3 20 rat carcinoma
BHA given rats showed dose induced hyperplasia epithelial
BHA given rats showed dose induced hyperplasia
BHA development enhancing dependent dose induced hyperplasia epithelial
BHA development enhancing dependent dose induced hyperplasia
RA co showed dose induced hyperplasia epithelial
RA co showed dose induced hyperplasia
RA 0 rats rat % administration induced Tumors papillomas
RA co % administration induced Tumors papillomas
RA 0 rats rat % administration induced Tumors
RA co % administration induced Tumors
RA acted indicate forestomach
RA acted indicate forestomach carcinogenesis
crack abusers endorsing CIP
cocaine abusers endorsing CIP
crack abusers endorsing CIP group denied CIP
cocaine abusers endorsing CIP group denied CIP
crack addicts group CIP
crack addicts group denied CIP
crack abusers group distinguish able Measures oscillation pupillary
crack abusers group distinguish able Measures oscillation
cocaine abusers group distinguish able Measures oscillation pupillary
cocaine abusers group distinguish able Measures oscillation
crack addicts group CIP endorsing abusers group distinguish able Measures oscillation pupillary
crack addicts group CIP endorsing abusers group distinguish able Measures oscillation
Propylthiouracil induced staining autoantibody vasculitis
propylthiouracil case describe induced vasculitis
propylthiouracil treated hyperthyroidism
propylthio associated vasculitis
uracil pANCA vasculitis
propylthio attributable vasculitis
uracil therapy manifestation induced attributable vasculitis
Adriamycin induced plays death
3 methyladenine used model heart
3 methyladenine used model failure
methyladenine used model heart
methyladenine used model failure
3 MA methyladenine used model heart
3 MA methyladenine used model failure
MA methyladenine used model heart
MA methyladenine used model failure
adriamycin induced rats plays death
adriamycin toxicity
polyethylene Effect glycol toxicity
glycol toxicity
400 glycol toxicity
ADR activity tumor L
ADR activity tumor leukemia 1210
ADR activity tumor leukemia
ADR activity tumor leukemia ascites Ehrlich
ADR activity tumor leukemia ascites
ADR activity tumor
salicylates association lack disappearing syndrome Reye
salicylates association lack disappearing syndrome
pergolide treated disease disease patients Parkinson
pergolide treated disease disease patients Parkinson '
pergolide treated disease s
pergolide treated disease
pergolide treated disease disease Valvular
pergolide treated disease disease heart
pergolide treated disease disease
pergolide treated patients disease Parkinson
pergolide treated patients disease Parkinson '
pergolide treated patients disease s
pergolide treated patients disease
pergolide treated patients disease PD
pergolide treated patients reported abnormalities Valvular
pergolide treated patients reported abnormalities heart
pergolide treated patients reported abnormalities
pergolide treated area patients PD
pergolide role suggestive pattern observed patients two failure heart
pergolide role suggestive pattern observed patients two failure
pergolide role suggestive pattern regurgitation valvular
pergolide role suggestive pattern regurgitation
Pergolide discontinued resulting failure heart
Pergolide discontinued resulting failure
Pergolide discontinued disease valvular
Pergolide discontinued disease heart
Pergolide discontinued disease
dopamine agonists non converted usual reveals supports frequency regurgitation valve
dopamine agonists non converted usual reveals supports frequency regurgitation
dopamine agonists non converted usual reveals supports frequency regurgitation patients PD
pergolide treated patients PD
pergolide treated patients regurgitation valve
pergolide treated patients regurgitation
Nimodipine prevents impairment hypotension
Nimodipine prevents impairment memory
Nimodipine prevents impairment
nimodipine administered tested preserve hypotension
NIMO nimodipine administered tested preserve hypotension
NIMO saline injected those showed Mice subjected hypotensive
NIMO attenuated caused improve absence hypotension
NIMO effect attributable hypotension
calcium homeostasis preservation attributable hypotension
Valproic acid given patients epileptic
acid given patients epileptic
VPA acid given patients epileptic
tobramicyn regimen effect evaluate concentrations toxicity
creatinine observed evidence nephrotoxicity
lithium sex duration respect had relative disease thyroid
lithium sex duration respect had relative disease
lithium therapy receiving disorder bipolar
lithium therapy receiving disorder
lithium therapy years hypothyroidism onset accelerated patients having first relatives affected illness thyroid
lithium therapy years hypothyroidism onset accelerated patients having first relatives affected illness
lithium therapy onset years hypothyroidism onset accelerated patients having first relatives affected illness thyroid
lithium therapy onset years hypothyroidism onset accelerated patients having first relatives affected illness
lithium therapy factor illness thyroid
lithium therapy factor illness
lithium therapy factor hypothyroidism hypercalcemia
Doxorubicin cardiomyopathy induced attenuated inflammation
doxorubicin use limited effects cardiotoxic
DOX doxorubicin use limited effects cardiotoxic
anthracycline doxorubicin use limited effects cardiotoxic
DOX cardiomyopathy development elucidate studied B mice investigating inflammation
DOX induction investigating inflammation
DOX mice showed dysfunction cardiac
DOX mice showed dysfunction
DOX mice improved dysfunction cardiac
DOX mice improved dysfunction
DOX mice improved dysfunction cardiac
DOX mice improved dysfunction
DCE reversed amnesia
DCE prove remedy management dysfunctions cognitive
DCE prove remedy management dysfunctions
cholesterol property improving remedy management dysfunctions cognitive
cholesterol property improving remedy management dysfunctions
Indomethacin induced insufficiency renal
Indomethacin induced insufficiency
indomethacin therapy pulmonale reported case failure renal
indomethacin therapy pulmonale reported case failure
bicuculline containing medium Mg resulted pilocarpine treated mice experience SE
Mg resulted pilocarpine treated mice experience SE
glutamate antagonists blocked duration afterdischarges shifts followed spike resulted survivors SE
glutamate photostimulation distant duration slices survivors SE
carbidopa levodopa point normality lead toxicity
levodopa therapy starting is started carbidopa levodopa point normality lead toxicity
levodopa point normality lead toxicity
levodopa psychosis
levodopa psychosis disturbances sleep
levodopa psychosis disturbances
Pilocarpine age seizures
Pilocarpine induced resulted loss seizures
Pilocarpine induced resulted had loss seizures
baclofen muscimol drugs jerks myoclonic
baclofen muscimol drugs jerks
benzodiazepines drugs jerks myoclonic
benzodiazepines drugs jerks
clonazepam found blocking jerks myoclonic
clonazepam found blocking jerks
diazepam potent found blocking jerks myoclonic
diazepam potent found blocking jerks
benzodiazepines found blocking jerks myoclonic
benzodiazepines found blocking jerks
5 fact found beneficial management myoclonus
HTP found beneficial management myoclonus
5 fact found seems myoclonus
HTP found seems myoclonus
benzodiazepines HTP found beneficial management myoclonus
benzodiazepines HTP found seems myoclonus
MK value myoclonus
212 value myoclonus
baclofen value myoclonus
nitroglycerin Provocation neuropathy diabetic
nitroglycerin Provocation neuropathy autonomic
nitroglycerin Provocation neuropathy
nitroglycerin effect compared subjects subjects neuropathy autonomic
nitroglycerin effect compared subjects subjects neuropathy
nitroglycerin effect compared neuropathy autonomic
nitroglycerin effect compared neuropathy
nitroglycerin effect compared subjects subjects diabetic
nitroglycerin effect compared subjects subjects diabetic
nitroglycerin pressure decrease increase course similar neuropathy autonomic
nitroglycerin pressure decrease increase course similar neuropathy
nitroglycerin pressure decrease increase course similar occurred neuropathy autonomic
nitroglycerin pressure decrease increase course similar occurred neuropathy
nitroglycerin pressure decrease increase course similar subjects normal diabetic
nitroglycerin pressure decrease increase course similar occurred subjects diabetic
phenytoin administration safe child hypothermic
phenytoin administered part surgery prophylaxis seizure
atropine refractory developed bradycardia
adrenaline atropine refractory developed bradycardia
phenytoin hypothermia
phenytoin presence hypothermia
haloperidol potentiation induced hyperactivity
apomorphine prevention catalepsy
steroids protect acid seizures epilepticus status
steroids protect acid seizures epilepticus
steroids protect acid seizures
deoxycorticosterone progesterone metabolites seizures
3 alpha progesterone metabolites seizures
alpha progesterone metabolites seizures
hydroxy pregnane alpha progesterone metabolites seizures
pregnane alpha progesterone metabolites seizures
21 pregnane alpha progesterone metabolites seizures
diol 21 pregnane alpha progesterone metabolites seizures
20 diol 21 pregnane alpha progesterone metabolites seizures
ones 21 pregnane alpha progesterone metabolites seizures
progesterone metabolites seizures
3 alpha progesterone metabolites seizures
alpha progesterone metabolites seizures
hydroxy pregnane alpha progesterone metabolites seizures
pregnane alpha progesterone metabolites seizures
20 pregnane alpha progesterone metabolites seizures
ones 20 pregnane alpha progesterone metabolites seizures
N metabolites seizures
methyl metabolites seizures
D methyl metabolites seizures
aspartate metabolites seizures
NMDA aspartate metabolites seizures
Steroids induced seizures epilepticus status
Steroids induced seizures epilepticus
Steroids induced seizures
benzodiazepine clonazepam potent protecting seizures
benzodiazepine clonazepam potent had values TD divided protection seizure
clonazepam potent had values indicating have toxicity
clonazepam values indicating have toxicity
benzodiazepine clonazepam potent had values indicating have toxicity
steroids potent had values indicating have toxicity
steroids had values indicating have toxicity
steroids have toxicity
steroids potent protecting seizures
steroids potent had values TD divided protection seizure
steroids had potent protecting seizures
steroids had values TD divided protection seizure
steroids have indicating values had potent protecting seizures
steroids have indicating values TD divided protection seizure
clonazepam potent protecting seizures
clonazepam potent had values TD divided protection seizure
clonazepam values had potent protecting seizures
clonazepam values TD divided protection seizure
pilocarpine seizures protecting potent had values indicating have toxicity
Steroids produced onset seizures
Steroids produced protect seizures
steroid dose administered However obtained seizures epilepticus status
steroid dose administered However obtained seizures epilepticus
steroid dose administered However obtained seizures
steroids caused protect seizures
NMDA delay dose induced caused protect seizures
NMDA seizures
steroids effective protecting acid seizures epilepticus status
steroids effective protecting acid seizures epilepticus
steroids effective utility treatment forms epilepticus status
steroids effective utility treatment forms epilepticus
steroids effective protecting acid seizures
naloxazone Pretreatment blocked morphine analgesia catalepsy
naloxazone Pretreatment blocked morphine analgesia
morphine analgesia
naloxazone Pretreatment blocked morphine analgesia hypothermia
naloxazone attenuated bradycardia
morphine bradycardia induced hypotension depression respiratory
morphine bradycardia induced hypotension depression
morphine induced hypotension depression respiratory
morphine induced hypotension depression
naloxazone attenuated bradycardia induced hypotension
naloxazone attenuated bradycardia induced hypotension depression respiratory
naloxazone attenuated bradycardia induced hypotension depression
methylprednisolone dose reviews mechanisms death sudden
methylprednisolone dose reviews mechanisms death
IVMP methylprednisolone dose reviews mechanisms death sudden
IVMP methylprednisolone dose reviews mechanisms death
mipafox inhibition correlation damage neuropathic
mipafox inhibition correlation damage
mipafox inhibition esterase neurotoxic
organophosphate Mipafox exposed rats examined correlation esterase neurotoxic
organophosphate neurotoxic
Mipafox exposed rats examined correlation damage neuropathic
Mipafox exposed rats examined correlation damage
Mipafox exposed rats examined correlation esterase enzyme neuropathy
N Mipafox exposed rats examined correlation damage neuropathic
N Mipafox exposed rats examined correlation damage
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage neuropathic
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation damage
N Mipafox exposed rats examined correlation esterase enzyme neuropathy
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase enzyme neuropathy
Mipafox exposed rats examined correlation esterase neurotoxic
Mipafox organophosphate neurotoxic
N Mipafox exposed rats examined correlation esterase neurotoxic
N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
' N diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
- diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
diisopropylphosphorodiamidofluoridate N Mipafox exposed rats examined correlation esterase neurotoxic
N Mipafox organophosphate neurotoxic
N diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
' N diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
- diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
diisopropylphosphorodiamidofluoridate N Mipafox organophosphate neurotoxic
organophosphate Mipafox exposed rats examined correlation damage neuropathic
organophosphate Mipafox exposed rats examined correlation damage
organophosphate Mipafox exposed rats examined correlation esterase enzyme neuropathy
Mipafox exposure sampled cord inhibition percentage predict damage neuropathic
Mipafox exposure sampled cord inhibition percentage predict damage
Amiodarone proved treatment tachyarrhythmias
amiodarone treatment due hepatitis patient cholestatic
amiodarone treatment due hepatitis
amiodarone hepatotoxicity review given presented hepatitis patient cholestatic
amiodarone hepatotoxicity review given presented hepatitis
amiodarone treatment due injury exists concluded alterations hepatitis alcoholic
amiodarone treatment due injury exists concluded alterations hepatitis
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis cholestatic
amiodarone treatment due injury exists concluded alterations hepatitis hepatitis
isoflurane metabolism flow aneurysms cerebral
isoflurane metabolism flow aneurysms
oxygen flow measured isoflurane hypotension
isoflurane hypotension patients subjected craniotomy clipping aneurysm cerebral
isoflurane hypotension patients subjected craniotomy clipping aneurysm
oxygen flow measured isoflurane hypotension patients subjected craniotomy clipping aneurysm cerebral
oxygen flow measured isoflurane hypotension patients subjected craniotomy clipping aneurysm
xenon Schmidt 5 days haemorrhage subarachnoid
xenon Schmidt 5 days haemorrhage
Hg induced MAP hypotension
isoflurane concentration reduced clipping aneurysm
Spironolactone induced patients failure heart
Spironolactone induced patients failure
spironolactone use evaluating patients heart
spironolactone use evaluating patients failure
spironolactone benefits reported changed treatments failure heart
spironolactone benefits reported changed treatments failure
spironolactone treated patients heart
spironolactone treated patients failure
spironolactone treated patients heart
spironolactone treated patients failure
K > mg dL developed hyperkalemia
K > insufficiency renal
K > insufficiency
Cr > insufficiency renal
Cr > insufficiency
Cr > insufficiency > mg dL developed hyperkalemia
potassium levels had Patients developed older hyperkalemia
potassium doses levels had Patients developed older hyperkalemia
potassium levels had Patients developed older likely have diabetes
potassium doses levels had Patients developed older likely have diabetes
thiazide diuretics treated likely had Patients developed insufficiency renal
thiazide diuretics treated likely had Patients developed insufficiency
creatinine weight had Patients developed insufficiency renal
creatinine weight had Patients developed insufficiency
MDMA users reported deficits memory
MDMA users reported deficits
3 MDMA users reported deficits memory
3 MDMA users reported deficits
4 3 MDMA users reported deficits memory
4 3 MDMA users reported deficits
methylenedioxymethamphetamine 3 MDMA users reported deficits memory
methylenedioxymethamphetamine 3 MDMA users reported deficits
ecstasy methylenedioxymethamphetamine 3 MDMA users reported deficits memory
ecstasy methylenedioxymethamphetamine 3 MDMA users reported deficits
barbiturate melatonin effects narcosis
barbiturate narcosis
barbiturate narcosis
barbiturate mechanism specific seems action melatonin narcosis
diclofenac therapy associated hepatitis Chronic
diclofenac therapy associated hepatitis active
diclofenac therapy associated hepatitis
sodium therapy associated hepatitis Chronic
sodium therapy associated hepatitis active
sodium therapy associated hepatitis
diclofenac sodium therapy developed hepatitis chronic
diclofenac sodium therapy developed hepatitis active
diclofenac sodium therapy developed hepatitis
sodium therapy developed hepatitis chronic
sodium therapy developed hepatitis active
sodium therapy developed hepatitis
3 shown known lesions neurotoxic
3 shown known lesions
4 3 shown known lesions neurotoxic
4 3 shown known lesions
methylenedioxymethamphetamine 4 3 shown known lesions neurotoxic
methylenedioxymethamphetamine 4 3 shown known lesions
MDMA methylenedioxymethamphetamine 4 3 shown known lesions neurotoxic
MDMA methylenedioxymethamphetamine 4 3 shown known lesions
ecstasy MDMA methylenedioxymethamphetamine 4 3 shown known lesions neurotoxic
ecstasy MDMA methylenedioxymethamphetamine 4 3 shown known lesions
MDMA HT consequences long lesions neurotoxic
MDMA HT consequences long lesions
serotonin neurons damage shown known lesions neurotoxic
serotonin neurons damage shown known lesions
5 neurons damage shown known lesions neurotoxic
5 neurons damage shown known lesions
HT 5 neurons damage shown known lesions neurotoxic
HT 5 neurons damage shown known lesions
5 HT consequences long lesions neurotoxic
5 HT consequences long lesions
HT consequences long lesions neurotoxic
HT consequences long lesions
5 functions known lesions neurotoxic
5 functions known lesions
HT involved 5 functions known lesions neurotoxic
HT involved 5 functions known lesions
neurotensin Effects catalepsy parkinsonian
neurotensin Effects catalepsy
haloperidol induced symptoms parkinsonian
haloperidol induced symptoms
neurotensin effects investigate haloperidol induced symptoms parkinsonian
neurotensin effects investigate haloperidol induced symptoms
neurotensin pallidus infusions RESULTS catalepsy parkinsonian
neurotensin pallidus infusions RESULTS catalepsy
testosterone fat effects carcinogenesis
testosterone implanted rats developed interval % developed tumors
testosterone implanted rats developed interval % included tumors
citalopram adolescent depressed
citalopram boy treatment report depression major
citalopram boy treatment report depression
naloxone administered animals facilitated reversed Amnesia
morphine min reversed Amnesia
morphine facilitated reversed Amnesia
penicillamine therapy effects patient arthritis rheumatoid
penicillamine therapy effects patient arthritis
penicillamine therapy complications recorded patients arthritis rheumatoid
penicillamine therapy complications recorded patients arthritis
penicillamine treated arthritis reported serpiginosa perforans resembled lesion skin
penicillamine treated arthritis reported serpiginosa perforans resembled lesion
penicillamine treated arthritis rheumatoid
penicillamine treated arthritis
penicillamine treated arthritis reported serpiginosa perforans elastosis
penicillamine treated arthritis reported serpiginosa perforans
penicillamine treated arthritis reported serpiginosa
penicillamine treated arthritis reported effect patients disease Wilson
penicillamine treated arthritis reported effect patients disease Wilson '
penicillamine treated arthritis reported effect patients disease s
penicillamine treated arthritis reported effect patients disease
morphine infusion patients compared incidence apnoea
bupivacaine patients patients compared incidence apnoea
morphine infusion had patients occurred obstructive
morphine infusion had patients occurred obstructive 05 less P
morphine infusion had patients occurred obstructive 05 less
morphine infusion had patients occurred obstructive 05 than
morphine infusion had patients occurred obstructive 05 0
morphine infusion had patients occurred obstructive 05
morphine infusion had patients occurred obstructive and
morphine infusion had patients occurred obstructive apnoea central
morphine infusion had patients occurred obstructive apnoea
morphine group incidence tachyarrhythmias
lamivudine use therapy disorders rheumatologic
lamivudine use therapy disorders
lamivudine patients disease rheumatologic
lamivudine patients disease
hepatitis antigen lamivudine patients disease rheumatologic
hepatitis antigen lamivudine patients disease
B antigen lamivudine patients disease rheumatologic
B antigen lamivudine patients disease
virus antigen lamivudine patients disease rheumatologic
virus antigen lamivudine patients disease
surface antigen lamivudine patients disease rheumatologic
surface antigen lamivudine patients disease
antigen lamivudine patients disease rheumatologic
antigen lamivudine patients disease
HBs Ag antigen lamivudine patients disease rheumatologic
HBs Ag antigen lamivudine patients disease
Ag antigen lamivudine patients disease rheumatologic
Ag antigen lamivudine patients disease
lamivudine therapies patients diseases rheumatologic
lamivudine therapies patients diseases
HBs patients diseases rheumatologic
HBs patients diseases
Ag patients diseases rheumatologic
Ag patients diseases
CCNU toxicity
lomustine toxicity
1 receiving dogs tumour toxicities haematological
1 receiving dogs tumour toxicities haematological renal
1 receiving dogs tumour toxicities haematological hepatic
1 receiving dogs tumour toxicities haematological and
1 receiving dogs tumour toxicities haematological gastrointestinal
1 receiving dogs tumour toxicities
2 toxicities haematological
2 toxicities haematological renal
2 toxicities haematological hepatic
2 toxicities haematological and
2 toxicities haematological gastrointestinal
2 toxicities
chloroethyl 2 toxicities haematological
chloroethyl 2 toxicities haematological renal
chloroethyl 2 toxicities haematological hepatic
chloroethyl 2 toxicities haematological and
chloroethyl 2 toxicities haematological gastrointestinal
chloroethyl 2 toxicities
3 describe incidence toxicities haematological
3 describe incidence toxicities haematological renal
3 describe incidence toxicities haematological hepatic
3 describe incidence toxicities haematological and
3 describe incidence toxicities haematological gastrointestinal
3 describe incidence toxicities
cyclohexyl nitrosourea 3 describe incidence toxicities haematological
cyclohexyl nitrosourea 3 describe incidence toxicities haematological renal
cyclohexyl nitrosourea 3 describe incidence toxicities haematological hepatic
cyclohexyl nitrosourea 3 describe incidence toxicities haematological and
cyclohexyl nitrosourea 3 describe incidence toxicities haematological gastrointestinal
cyclohexyl nitrosourea 3 describe incidence toxicities
1 nitrosourea 3 describe incidence toxicities haematological
1 nitrosourea 3 describe incidence toxicities haematological renal
1 nitrosourea 3 describe incidence toxicities haematological hepatic
1 nitrosourea 3 describe incidence toxicities haematological and
1 nitrosourea 3 describe incidence toxicities haematological gastrointestinal
1 nitrosourea 3 describe incidence toxicities
nitrosourea 3 describe incidence toxicities haematological
nitrosourea 3 describe incidence toxicities haematological renal
nitrosourea 3 describe incidence toxicities haematological hepatic
nitrosourea 3 describe incidence toxicities haematological and
nitrosourea 3 describe incidence toxicities haematological gastrointestinal
nitrosourea 3 describe incidence toxicities
CCNU nitrosourea 3 describe incidence toxicities haematological
CCNU nitrosourea 3 describe incidence toxicities haematological renal
CCNU nitrosourea 3 describe incidence toxicities haematological hepatic
CCNU nitrosourea 3 describe incidence toxicities haematological and
CCNU nitrosourea 3 describe incidence toxicities haematological gastrointestinal
CCNU nitrosourea 3 describe incidence toxicities
CCNU treated dogs met class toxicity
CCNU used treatment lymphoma
CCNU used treatment lymphoma lymphoma epitheliotropic
CCNU used treatment lymphoma lymphoma
CCNU used treatment lymphoma tumour mast
CCNU used treatment lymphoma tumour cell
CCNU used treatment lymphoma tumour
CCNU used treatment lymphoma tumour brain
CCNU used treatment lymphoma tumour
CCNU used treatment lymphoma tumours histiocytic
CCNU used treatment lymphoma tumours
alanine transaminase toxicity
CCNU CONCLUSIONS common toxicity
phenobarbital containing diet fed rats developed fed rats developed nodules carcinomas hepatocellular
phenobarbital containing diet fed rats developed fed rats developed nodules carcinomas
phenobarbital containing diet fed rats developed nodule carcinoma hepatocellular
phenobarbital containing diet fed rats developed nodule carcinoma
phenobarbital diet fed rats fed rats % carcinomas incidence hepatocellular
phenobarbital diet fed rats fed rats % carcinomas
amine Effects pretreatment catatonia
catecholamines role idolamines catatonia
norepinephrine pretreatment did increased duration catatonia
gamma transmitted part neurophysiology epilepsy absence
gamma transmitted part neurophysiology epilepsy
aminobutyric acid gamma transmitted part neurophysiology epilepsy absence
aminobutyric acid gamma transmitted part neurophysiology epilepsy
acid gamma transmitted part neurophysiology epilepsy absence
acid gamma transmitted part neurophysiology epilepsy
saralasin prevented hypertensive
sodium nitroprusside prevented hypertensive
nitroprusside prevented hypertensive
angiotensin system hypotension
saralasin treated demonstrated increase
saralasin treated demonstrated pressure in
saralasin treated demonstrated pressure blood
saralasin treated demonstrated pressure
SNP infusion demonstrated increase
SNP infusion demonstrated pressure in
SNP infusion demonstrated pressure blood
SNP infusion demonstrated pressure
angiotensin system antagonizing effects hypotensive
iopamidol patients disease chronic
iopamidol patients disease kidney
iopamidol patients disease
iodixanol iopamidol patients disease chronic
iodixanol iopamidol patients disease kidney
iodixanol iopamidol patients disease
N use mellitus diabetes
N use mellitus
acetylcysteine use mellitus diabetes
acetylcysteine use mellitus
iopamidol % mg increases patients diabetes
iodixanol % mg increases patients diabetes
iopamidol less all 0 patients diabetes
iopamidol patients administration different mellitus diabetes
iopamidol patients administration different mellitus
iodixanol high iopamidol patients administration different mellitus diabetes
iodixanol high iopamidol patients administration different mellitus
cyclophosphamide associated cancer urothelial
cyclophosphamide associated cancer
Amisulpride symptoms schizophrenic
risperidone antipsychotics treated disorders Tic
risperidone antipsychotics treated disorders
ziprasidone risperidone antipsychotics treated disorders Tic
ziprasidone risperidone antipsychotics treated disorders
olanzapine risperidone antipsychotics treated disorders Tic
olanzapine risperidone antipsychotics treated disorders
quetiapine occurring show tic
quetiapine occurring like
quetiapine occurring symptoms
clozapine quetiapine occurring show tic
clozapine quetiapine occurring like
clozapine quetiapine occurring symptoms
amisulpride treatment months movements year schizophrenic
amisulpride treatment months movements year schizophrenic developed eye involuntary
amisulpride treatment months movements year schizophrenic developed eye
amisulpride treatment months movements blinking
amisulpride treatment months movements
quetiapine occur suggests tic
quetiapine occur symptoms like
quetiapine occur symptoms
clozapine quetiapine occur suggests tic
clozapine quetiapine occur symptoms like
clozapine quetiapine occur symptoms
5 reaction Allergic
5 reaction
fluorouracil infusion reaction Allergic
fluorouracil infusion reaction
cisplatin occurred patient carcinoma cavity cirrhosis
5 infusion occurred induced impaired
5 infusion occurred function renal
5 infusion occurred function
fluorouracil occurred induced impaired
fluorouracil occurred function renal
fluorouracil occurred function
5 infusion occurred reaction allergic
5 infusion occurred reaction
fluorouracil occurred reaction allergic
fluorouracil occurred reaction
cisplatin occurred induced impaired
cisplatin occurred function renal
cisplatin occurred function
cisplatin occurred patient carcinoma
cisplatin occurred patient carcinoma cavity of
cisplatin occurred patient carcinoma cavity the
cisplatin occurred patient carcinoma cavity oral
cisplatin occurred patient carcinoma cavity
cisplatin occurred reaction allergic
cisplatin occurred reaction
5 infusion occurred patient carcinoma
5 infusion occurred patient carcinoma cavity of
5 infusion occurred patient carcinoma cavity the
5 infusion occurred patient carcinoma cavity oral
5 infusion occurred patient carcinoma cavity
fluorouracil occurred patient carcinoma
fluorouracil occurred patient carcinoma cavity of
fluorouracil occurred patient carcinoma cavity the
fluorouracil occurred patient carcinoma cavity oral
fluorouracil occurred patient carcinoma cavity
5 infusion occurred patient carcinoma cavity cirrhosis
fluorouracil occurred patient carcinoma cavity cirrhosis
cisplatin occurred reaction consisting edema angioneurotic
cisplatin occurred reaction consisting edema
diphenhydramine Oral ineffective preventing recurrence reaction allergic
diphenhydramine Oral ineffective preventing recurrence reaction
prednisone diphenhydramine Oral ineffective preventing recurrence reaction allergic
prednisone diphenhydramine Oral ineffective preventing recurrence reaction
cisapride motor Effects function patients syndrome irritable
cisapride motor Effects function patients syndrome bowel
cisapride motor Effects function patients syndrome
cisapride agent treatment symptoms bowel irritable
cisapride agent treatment symptoms bowel
cisapride agent treatment long syndrome
cisapride agent treatment long syndrome IBS
cisapride h underwent patients IBS constipation n diarrhoea
cisapride h underwent patients IBS
cisapride h underwent patients IBS constipation
cisapride groups observed patients RESULTS diarrhoea
cisapride / treated diarrhoea
cisapride / treated diarrhoea
cisapride sec 2 3 longer duration 6 cisapride / treated diarrhoea
cisapride 001 0 + + 2 lower frequency 6 cisapride / treated diarrhoea
cisapride constipation patients IBS
cisapride mm 14 patients IBS
cisapride lower scores relating severity constipation
cisapride constipation
cisapride mm 14 patients constipation cisapride lower scores relating severity constipation
cisapride mm 14 patients constipation
cisapride score had Diarrhoea
cisapride mm Diarrhoea
cisapride score had patients IBS
cisapride mm Diarrhoea had patients IBS
cisapride score had score pain
cisapride mm Diarrhoea had score pain
Cisapride affects characteristics symptoms IBS
pilocarpine effects evaluate designed models arrhythmia
pilocarpine delayed decreased course tachycardia ventricular
pilocarpine delayed decreased course tachycardia
pilocarpine delayed decreased course tachycardia and
pilocarpine delayed decreased course tachycardia fibrillation
pilocarpine delayed onset arrhythmias
pilocarpine delayed reduced score arrhythmia
pilocarpine delayed increased time rats arrhythmic
pilocarpine produced rat arrhythmic
prazosin taking change resolve incontinence
warfarin model hemorrhage
Warfarin associated type stroke
PCC suggesting treatment ICH
caffeine migraine
ergotamine mg comparison caffeine migraine
rizatriptan mg comparison caffeine migraine
5 selective agonist onset action treatment migraine
- agonist onset action treatment migraine
HT agonist onset action treatment migraine
Rizatriptan agonist onset action treatment migraine
caffeine tablets patients treating attack migraine
ergotamine assessed caffeine tablets patients treating attack migraine
rizatriptan tablet assessed caffeine tablets patients treating attack migraine
rizatriptan % Faster reason relief headache
caffeine ergotamine preferred % Faster reason relief headache
ergotamine preferred % Faster reason relief headache
rizatriptan favor co endpoint free pain
ergotamine caffeine treated % Forty pain
caffeine treated % Forty pain
rizatriptan pain
rizatriptan caffeine treated % Forty pain
rizatriptan % relief Headache
rizatriptan caffeine superior relief Headache
caffeine superior relief Headache
caffeine relief Headache
ergotamine % relief Headache
ergotamine superior relief Headache
ergotamine caffeine patients % free pain
caffeine patients % free pain
rizatriptan taking patients % free pain
Rizatriptan superior ergotamine proportions patients nausea phonophobia
caffeine ergotamine proportions patients nausea phonophobia
ergotamine proportions patients nausea phonophobia
Rizatriptan superior ergotamine proportions patients nausea vomiting
caffeine ergotamine proportions patients nausea
ergotamine proportions patients nausea photophobia
ergotamine proportions patients nausea vomiting
Rizatriptan superior ergotamine proportions patients nausea photophobia
caffeine ergotamine proportions patients nausea vomiting
caffeine ergotamine proportions patients nausea photophobia
ergotamine proportions patients nausea
caffeine events dizziness 6 nausea
caffeine events dizziness 6 somnolence
caffeine events dizziness
ergotamine rizatriptan caffeine events dizziness
ergotamine rizatriptan caffeine events dizziness 6 somnolence
rizatriptan caffeine events dizziness 6 somnolence
ergotamine rizatriptan caffeine events dizziness 6 nausea
rifampin therapy tuberculosis pulmonary
rifampin therapy tuberculosis
isoniazid rifampin regimen 10 underwent discovered developed signs failure renal
isoniazid rifampin regimen 10 underwent discovered developed signs failure
rifampin regimen 10 underwent tuberculosis pulmonary
rifampin regimen 10 underwent tuberculosis
isoniazid rifampin regimen 10 underwent tuberculosis pulmonary
isoniazid rifampin regimen 10 underwent tuberculosis
glutamate subtype modulates models disease Parkinson
glutamate subtype modulates models disease Parkinson '
glutamate subtype modulates models disease s
glutamate subtype modulates models disease
glutamate receptors modulate represent treatment disease Parkinson
glutamate receptors modulate represent treatment disease Parkinson '
glutamate receptors modulate represent treatment disease s
glutamate receptors modulate represent treatment disease
glutamate receptors modulate represent treatment disease PD
N effects tested models PD
N dihydrochloride effects tested models PD
' N dihydrochloride effects tested models PD
dibenzhydrylethane dihydrochloride effects tested models PD
- dibenzhydrylethane dihydrochloride effects tested models PD
1 - dibenzhydrylethane dihydrochloride effects tested models PD
2 - dibenzhydrylethane dihydrochloride effects tested models PD
diamine dihydrochloride effects tested models PD
dihydrochloride effects tested models PD
AMN dihydrochloride effects tested models PD
082 AMN dihydrochloride effects tested models PD
AMN 0 administration oral reverses haloperidol induced catalepsy
082 AMN 0 administration oral reverses haloperidol induced catalepsy
AMN 082 reverses mg lesioned task used evaluate symptoms akinetic
082 reverses mg lesioned task used evaluate symptoms akinetic
6 cue respond reverses mg lesioned task used evaluate symptoms akinetic
OHDA cue respond reverses mg lesioned task used evaluate symptoms akinetic
AMN 082 reverses mg lesioned task used evaluate symptoms patients PD
082 reverses mg lesioned task used evaluate symptoms patients PD
6 cue respond reverses mg lesioned task used evaluate symptoms patients PD
OHDA cue respond reverses mg lesioned task used evaluate symptoms patients PD
AMN 082 reduces duration induced catalepsy
082 reduces duration induced catalepsy
AMN doses have effect models PD
082 AMN doses have effect models PD
amsacrine CI study 921 non
amsacrine CI study cell small
amsacrine CI study cell
amsacrine CI study cell cancer lung
amsacrine CI study cell cancer
CI study 921 non
CI study cell small
CI study cell
CI study cell cancer lung
CI study cell cancer
921 non
921 study cell small
921 study cell
921 study cell cancer lung
921 study cell cancer
NSC 921 non
NSC 921 study cell small
NSC 921 study cell
NSC 921 study cell cancer lung
NSC 921 study cell cancer
343499 NSC 921 non
343499 NSC 921 study cell small
343499 NSC 921 study cell
343499 NSC 921 study cell cancer lung
343499 NSC 921 study cell cancer
isoflurane anesthesia hypertensive
2 determined extent injury neuronal
2 determined extent injury
3 5 2 determined extent injury neuronal
3 5 2 determined extent injury
5 2 determined extent injury neuronal
5 2 determined extent injury
triphenyltetrazolium 5 2 determined extent injury neuronal
triphenyltetrazolium 5 2 determined extent injury
phenylephrine indicate instituted aggravate edema
phenylephrine indicate instituted aggravate improves edema
phenylephrine indicate instituted aggravate core ischemic
phenylephrine indicate instituted aggravate improves periphery territory ischemic
phenylephrine indicate instituted aggravate reduces area dysfunction neuronal
phenylephrine indicate instituted aggravate reduces area dysfunction
phenylephrine indicate instituted aggravate MCAO
suxamethonium dose spasm threatening developed primigravida year case congenita myotonia
suxamethonium dose spasm threatening developed primigravida year case congenita
DFU Comparison toxicity
piroxicam study DFU Comparison toxicity
DFU COX piroxicam toxicity
5 DFU COX piroxicam toxicity
5 5 DFU COX piroxicam toxicity
dimethyl 5 DFU COX piroxicam toxicity
3 dimethyl 5 DFU COX piroxicam toxicity
3 dimethyl 5 DFU COX piroxicam toxicity
fluorophenyl 3 dimethyl 5 DFU COX piroxicam toxicity
4 5 DFU COX piroxicam toxicity
4 phenyl 4 5 DFU COX piroxicam toxicity
methylsulphonyl 4 phenyl 4 5 DFU COX piroxicam toxicity
phenyl 4 5 DFU COX piroxicam toxicity
2 5 DFU COX piroxicam toxicity
5 H 2 5 DFU COX piroxicam toxicity
H 2 5 DFU COX piroxicam toxicity
furanon 2 5 DFU COX piroxicam toxicity
piroxicam toxicity
piroxicam septal analysis ventricular
piroxicam septal
piroxicam septal VSD
piroxicam septal and
piroxicam septal midline
piroxicam septal MD
piroxicam septal defects
piroxicam dose treated rats found toxicity
DFU toxicity
gentamicin regimen Nephrotoxicity
cephalothin Nephrotoxicity
gentamicin therapy sodium combination receiving necrosis characterized clinically failure oliguric
gentamicin therapy sodium combination receiving necrosis characterized clinically failure renal
gentamicin therapy sodium combination receiving necrosis characterized clinically failure
sulfate therapy sodium combination receiving necrosis characterized clinically failure oliguric
sulfate therapy sodium combination receiving necrosis characterized clinically failure renal
sulfate therapy sodium combination receiving necrosis characterized clinically failure
cephalothin sodium combination receiving necrosis characterized clinically failure oliguric
cephalothin sodium combination receiving necrosis characterized clinically failure renal
cephalothin sodium combination receiving necrosis characterized clinically failure
sodium combination receiving necrosis characterized clinically failure oliguric
sodium combination receiving necrosis characterized clinically failure renal
sodium combination receiving necrosis characterized clinically failure
morphine induced interval ischemia spinal
morphine induced interval ischemia cord
morphine induced interval ischemia
N activation contribute degeneration neurons induced interval ischemia spinal
N activation contribute degeneration neurons induced interval ischemia cord
N activation contribute degeneration neurons induced interval ischemia
methyl N activation contribute degeneration neurons induced interval ischemia spinal
methyl N activation contribute degeneration neurons induced interval ischemia cord
methyl N activation contribute degeneration neurons induced interval ischemia
D N activation contribute degeneration neurons induced interval ischemia spinal
D N activation contribute degeneration neurons induced interval ischemia cord
D N activation contribute degeneration neurons induced interval ischemia
aspartate receptors N activation contribute degeneration neurons induced interval ischemia spinal
aspartate receptors N activation contribute degeneration neurons induced interval ischemia cord
aspartate receptors N activation contribute degeneration neurons induced interval ischemia
morphine interval occlusion aortic
morphine interval occlusion
N receptors activation degeneration relationship investigated morphine interval occlusion aortic
N receptors activation degeneration relationship investigated morphine interval occlusion
methyl receptors activation degeneration relationship investigated morphine interval occlusion aortic
methyl receptors activation degeneration relationship investigated morphine interval occlusion
d methyl receptors activation degeneration relationship investigated morphine interval occlusion aortic
d methyl receptors activation degeneration relationship investigated morphine interval occlusion
aspartate receptors activation degeneration relationship investigated morphine interval occlusion aortic
aspartate receptors activation degeneration relationship investigated morphine interval occlusion
NMDA receptors activation degeneration relationship investigated morphine interval occlusion aortic
NMDA receptors activation degeneration relationship investigated morphine interval occlusion
MK induced paraparesis spastic
MK induced paraparesis
801 MK induced paraparesis spastic
801 MK induced paraparesis
MK reduced paraparesis spastic
MK reduced paraparesis
801 reduced paraparesis spastic
801 reduced paraparesis
NMDA activation involved glutamate increase induces paraparesis spastic
NMDA activation involved glutamate increase induces paraparesis
glutamate increase induces paraparesis spastic
glutamate increase induces paraparesis
NMDA activation ischemia setting neurotoxic
NMDA activation ischemia spinal
NMDA activation ischemia cord
NMDA activation ischemia
Thiopentone pretreatment pain
lidocaine reduces incidence pain
thiopentone reduces reduces incidence pain
amantadine activity depressed
amines results suggest decrease account depression behavioral
amines results suggest decrease account depression
catecholamine rate decrease account depression behavioral
catecholamine rate decrease account depression
norepinephrine methylation rate decrease account depression behavioral
norepinephrine methylation rate decrease account depression
Naloxone reversal hypotension
captopril overdose due reversal hypotension
Naloxone reversal due overdose
captopril overdose
naloxone shown block actions hypotensive
captopril actions hypotensive
naloxone administration resolved overdose manifested hypotension
captopril overdose manifested hypotension
naloxone administration resolved overdose
captopril overdose
naloxone treated hypotension
captopril case hypotension
naloxone reversal hypotension
captopril resulting hypotension
Amphotericin B induced AIDS
B induced AIDS
amphotericin infusion patent AIDS
B infusion patent AIDS
amphotericin B infusion experienced seizures grand
amphotericin B infusion experienced seizures mal
amphotericin B infusion experienced seizures
B infusion experienced seizures grand
B infusion experienced seizures mal
B infusion experienced seizures
lorazepam phenytoin administration persisted seizures
phenytoin administration persisted seizures
alcohol cause seizures
alcohol cause had history abuse alcohol
alcohol cause had history abuse
Didanosine has potential inducing seizures
amphotericin B cause seizures patient AIDS
B cause seizures patient AIDS
ritanserin Microinjection improves scopolamine amnesia
ritanserin effect amnesia
ritanserin microinjection improves amnesia
scopolamine caused amnesia
L glyceryl Effect phosphorylcholine amnesia
alpha glyceryl Effect phosphorylcholine amnesia
glyceryl Effect phosphorylcholine amnesia
phosphorylcholine amnesia
L effects alpha glycerylphosphorylcholine impairment memory
L effects alpha glycerylphosphorylcholine impairment
alpha glycerylphosphorylcholine impairment memory
alpha glycerylphosphorylcholine impairment
glycerylphosphorylcholine impairment memory
glycerylphosphorylcholine impairment
L glycerylphosphorylcholine impairment memory
L glycerylphosphorylcholine impairment
alpha L glycerylphosphorylcholine impairment memory
alpha L glycerylphosphorylcholine impairment
GFC L glycerylphosphorylcholine impairment memory
GFC L glycerylphosphorylcholine impairment
beta reactions allergic
beta reactions
lactam antibiotics evaluated group patients reactions allergic
lactam antibiotics evaluated group patients reactions
penicillin derivatives reacting allergic
penicillin derivatives reacting allergic had responses allergic
beta allergic
lactam antibiotics had allergic
beta allergic had responses allergic
lactam antibiotics had responses allergic
beta diagnosed allergic
lactam antibiotics diagnosed allergic
PG tolerance selected cases allergy
BPO negative test negative MDM
PG negative MDM
PG reported tolerated patients allergic
azathioprine agents associated have risk development leukemia acute
azathioprine agents associated have risk development leukemia nonlymphocytic
azathioprine agents associated have risk development leukemia
Cyclophosphamide therapy increases risk carcinoma
Cyclophosphamide therapy increases risk carcinoma bladder of
Cyclophosphamide therapy increases risk carcinoma bladder the
Cyclophosphamide therapy increases risk carcinoma bladder
cyclophosphamide azathioprine treated arthritis rheumatoid
cyclophosphamide azathioprine treated arthritis
cyclophosphamide azathioprine treated arthritis patients incidence most cancers
azathioprine treated arthritis rheumatoid
azathioprine treated arthritis
azathioprine treated arthritis patients incidence most cancers
alkylating agents drugs use reserved collected Data risk malignancy arthritis rheumatoid
alkylating agents drugs use reserved collected Data risk malignancy arthritis
agents drugs use reserved collected Data risk malignancy arthritis rheumatoid
agents drugs use reserved collected Data risk malignancy arthritis
alkylating agents drugs use treatment arthritis rheumatoid
alkylating agents drugs use treatment arthritis
agents drugs use treatment arthritis rheumatoid
agents drugs use treatment arthritis
alkylating agents drugs use reserved collected Data risk malignancy
agents drugs use reserved collected Data risk malignancy
Ethambutol used treatment tuberculosis
Ifosfamide encephalopathy presenting asterixis
ifosfamide infusion developed plasmacytoma
ifosfamide administration discontinued resolved asterixis
ifosfamide findings infusion asterixis
IFX use associated suggest presence asterixis
Methamphetamine induced neurotoxicity
DA neurons neurodegeneration
DA system models neurotoxicity
DA system selective hypothesized plays role induced neurotoxicity
METH caused damage selective system models neurotoxicity
METH caused damage selective hypothesized plays role induced neurotoxicity
METH role plays hypothesized selective system models neurotoxicity
METH role induced neurotoxicity
MPTP METH caused damage selective system models neurotoxicity
MPTP METH caused damage selective hypothesized plays role induced neurotoxicity
DA system selective damage CNS
DA system selective damage
METH treated examined neurotoxicity
METH activation neurotoxicity
bupivacaine prilocaine incidence symptoms Transient
bupivacaine prilocaine incidence symptoms neurologic
bupivacaine prilocaine incidence symptoms
bupivacaine infrequent follow symptoms transient
bupivacaine infrequent follow symptoms neurologic
bupivacaine infrequent follow symptoms
bupivacaine infrequent follow symptoms TNSs
bupivacaine lidocaine prilocaine compares duration risk TNSs
bupivacaine receiving patients none Nine patients receiving TNSs
bupivacaine receiving patients none Nine RESULTS had TNSs
gemcitabine chemotherapy approach carcinoma nonsmall
gemcitabine chemotherapy approach carcinoma cell
gemcitabine chemotherapy approach carcinoma lung
gemcitabine chemotherapy approach carcinoma
cisplatin Paclitaxel chemotherapy approach carcinoma nonsmall
cisplatin Paclitaxel chemotherapy approach carcinoma cell
cisplatin Paclitaxel chemotherapy approach carcinoma lung
cisplatin Paclitaxel chemotherapy approach carcinoma
Paclitaxel chemotherapy approach carcinoma nonsmall
Paclitaxel chemotherapy approach carcinoma cell
Paclitaxel chemotherapy approach carcinoma lung
Paclitaxel chemotherapy approach carcinoma
Cisplatin BACKGROUND based improve quality life carcinoma nonsmall
Cisplatin BACKGROUND based improve quality life carcinoma cell
Cisplatin BACKGROUND based improve quality life carcinoma lung
Cisplatin BACKGROUND based improve quality life carcinoma
Cisplatin BACKGROUND based improve quality life NSCLC
gemcitabine combination paclitaxel toxicity
gemcitabine combination paclitaxel toxicity feasibility determine treat NSCLC
cisplatin paclitaxel toxicity
cisplatin paclitaxel toxicity feasibility determine treat NSCLC
paclitaxel toxicity feasibility determine treat NSCLC
paclitaxel toxicity
gemcitabine 1 cisplatin Day treated chemotherapy patients NSCLC
cisplatin Day treated chemotherapy patients NSCLC
paclitaxel combination treated chemotherapy patients NSCLC
gemcitabine paclitaxel tolerated shows NSCLC
cisplatin paclitaxel tolerated shows NSCLC
paclitaxel tolerated shows NSCLC
amphetamine reflects rotation lesion substantia
amphetamine reflects rotation lesion nigra
amphetamine reflects rotation lesion
6 reported period rotation contralateral
6 reported period rotation
OHDA SN 6 reported period rotation contralateral
OHDA SN 6 reported period rotation
6 reported precede circling ipsilateral
6 reported precede circling
OHDA SN 6 reported precede circling ipsilateral
OHDA SN 6 reported precede circling
6 SN
6 SN lesion
OHDA SN
OHDA SN lesion
macrolides experience recorded function side established gastroenteritis
erythromycin administration demonstrated Cardiotoxicity
macrolides reported demonstrated Cardiotoxicity
clarithromycin doses occurred case dysrhythmias ventricular
clarithromycin doses occurred case dysrhythmias
Phenobarbital dyskinesia neurologically
Phenobarbital child impaired
phenobarbital therapy starting seizures
phenobarbital therapy starting developed impairment neurologic
phenobarbital therapy starting developed impairment
Phenobarbital added list cause disorders movement
Phenobarbital added list cause disorders
CB synthase mediated cytotoxicity
3717 CB synthase mediated cytotoxicity
N CB synthase mediated cytotoxicity
10 N CB synthase mediated cytotoxicity
propargyl N CB synthase mediated cytotoxicity
- propargyl N CB synthase mediated cytotoxicity
5 - propargyl N CB synthase mediated cytotoxicity
8 - propargyl N CB synthase mediated cytotoxicity
dideazafolic acid N CB synthase mediated cytotoxicity
acid N CB synthase mediated cytotoxicity
CB fold determinant cytotoxicity
3717 CB fold determinant cytotoxicity
CB cytotoxicity
3717 cytotoxicity
CB studies seen cancer cancer ovarian
CB studies seen cancer cancer
3717 CB studies seen cancer cancer ovarian
3717 CB studies seen cancer cancer
CB studies seen cancer mesothelioma
3717 CB studies seen cancer mesothelioma
CB studies seen cancer breast
CB studies seen cancer
3717 CB studies seen cancer breast
3717 CB studies seen cancer
CB studies seen cancer hepatoma
3717 CB studies seen cancer hepatoma
salbutamol doses administration assessed patients disease obstructive
salbutamol doses administration assessed patients disease lung
salbutamol doses administration assessed patients disease
4 bolus done tumors
' 4 bolus done tumors
0 tetrahydropyranyladriamycin done tumors
tetrahydropyranyladriamycin done tumors
Pirarubicin tetrahydropyranyladriamycin done tumors
sodium density subunits dependence inactivation susceptibility seizures
sodium beta lacking mice seizures
carbamazepine presenting reaction eosinophilia
carbamazepine presented erythroderma eosinophilia
dopamine neurotransmission dysfunction associated Schizophrenia
N D antagonists produce schizophrenic
methyl D antagonists produce schizophrenic
D antagonists produce schizophrenic
aspartate receptor D antagonists produce schizophrenic
NMDA receptor D antagonists produce schizophrenic
NMDA receptor system dysfunctioning idea led observation produce schizophrenic
glutamate D antagonists produce schizophrenic
NMDA Nr challenge models hyperactivity
SSR properties investigating focus models hyperactivity
103800 SSR properties investigating focus models hyperactivity
NMDA antagonist hyperactivity
NMDA antagonist hyperactivity 801 hyperactivity
NMDA Nr hyperactivity 801 hyperactivity
NMDA Nr hyperactivity
SSR blocked hyperactivity
103800 SSR blocked hyperactivity
SSR blocked hyperactivity 801 hyperactivity
103800 SSR blocked hyperactivity 801 hyperactivity
dopamine transporter observed induced hyperactivity
SSR 103800 failed affect induced hyperactivity
103800 failed affect induced hyperactivity
aripiprazole clozapine olanzapine atypical antipsychotics classical effective models hyperactivity
haloperidol classical effective models hyperactivity
olanzapine atypical antipsychotics classical effective models hyperactivity
clozapine olanzapine atypical antipsychotics classical effective models hyperactivity
SSR 103800 produce catalepsy
103800 produce catalepsy
Valproate syndrome manifest individuals epileptic
cimetidine mg continuous hour receiving developed year man leukemia
cimetidine mg continuous hour receiving developed year history disease cardiac
cimetidine mg continuous hour receiving developed year history disease
cimetidine related arrhythmias
ranitidine treatment recur related arrhythmias
methyl dopa treated histories psychiatric
dopa treated histories psychiatric
aryl induced catalepsy
piperazine Reversal induced catalepsy
buspirone drug reverses induced catalepsy
buspirone analogues series tested ability reverse catalepsy
aryl series tested ability reverse catalepsy
piperazine analogues series tested ability reverse catalepsy
5 buspirone analogues series tested ability reverse catalepsy
hydroxytryptaminergic agonists tested ability reverse catalepsy
agonists tested ability reverse catalepsy
5 affinity drugs hydroxytryptamine able reverse catalepsy
hydroxytryptamine able reverse catalepsy
5 inhibition receptors reversal catalepsy
HT receptors reversal catalepsy
gemfibrozil cyclosporin treated patients lovastatin reported associated myoglobinuria
lovastatin reported Myopathy
cyclosporin treated patients lovastatin reported associated failure renal
cyclosporin treated patients lovastatin reported associated failure
niacin cyclosporin treated patients lovastatin reported associated myoglobinuria
cyclosporin treated patients lovastatin reported associated myoglobinuria
niacin cyclosporin treated patients lovastatin reported associated failure renal
niacin cyclosporin treated patients lovastatin reported associated failure
gemfibrozil cyclosporin treated patients lovastatin reported associated failure renal
gemfibrozil cyclosporin treated patients lovastatin reported associated failure
iodine induced cardiomyopathy
125 iodine induced cardiomyopathy
metaiodobenzylguanidine Detection induced cardiomyopathy
adriamycin treatment duration analyzed degree degeneration vacuolar
adriamycin treatment duration analyzed degree degeneration
adriamycin treatment duration analyzed degree degeneration cells of
adriamycin treatment duration analyzed degree degeneration cells myocardial
adriamycin treatment duration analyzed degree degeneration cells
adriamycin detection method indicates appearance presence impairment scattered degeneration vacuolar
adriamycin detection method indicates appearance presence impairment scattered degeneration
MIBG method indicates appearance presence impairment myocardial
MIBG method indicates appearance presence impairment
MIBG method detection adriamycin induced cardiomyopathy
MIBG method indicates appearance presence impairment scattered degeneration vacuolar
MIBG method indicates appearance presence impairment scattered degeneration
sodium nitroprusside than greater hemorrhage
nitroprusside than greater hemorrhage
sodium nitroprusside infusion decreased decreased decreased hemorrhage
nitroprusside infusion decreased decreased decreased hemorrhage
sodium nitroprusside infusion decreased decreased decreased hemorrhage HEM
nitroprusside infusion decreased decreased decreased hemorrhage HEM
SNP nitroprusside infusion decreased decreased decreased hemorrhage
SNP nitroprusside infusion decreased decreased decreased hemorrhage HEM
SNP group that lower hypotension HEM
SNP group Hg / Hg group HEM
SNP HEM
propranolol bendrofluazide reactions treatment hypertension
bendrofluazide reactions treatment hypertension
propranolol bendrofluazide one allocated Participants trial hypertension
bendrofluazide one allocated Participants trial hypertension
propranolol taking phenomenon include tolerance gout
bendrofluazide treatment associated men gout tolerance include phenomenon Raynaud
bendrofluazide treatment associated men gout tolerance include phenomenon Raynaud '
bendrofluazide treatment associated men gout tolerance include phenomenon s
bendrofluazide treatment associated men gout tolerance include phenomenon
bendrofluazide treatment associated men gout tolerance include phenomenon dyspnoea
propranolol taking phenomenon include tolerance impaired
propranolol taking phenomenon include tolerance glucose
propranolol taking phenomenon include tolerance
propranolol group occurred known disease corneal
propranolol group occurred known disease
scopolamine induced Components dementia
s effects dementia
limonene anti effects dementia
s limonene anti effects dementia
perillyl alcohol observed limonene anti effects dementia
alcohol observed limonene anti effects dementia
s associative showed improve memory
s associative showed improve memory impaired
perillyl alcohol relieved s associative showed improve memory
perillyl alcohol relieved s associative showed improve memory impaired
alcohol relieved s associative showed improve memory
alcohol relieved s associative showed improve memory impaired
s relieved deficit
s relieved deficit memory of
s relieved deficit memory associative
s relieved deficit memory
perillyl alcohol relieved deficit
perillyl alcohol relieved deficit memory of
perillyl alcohol relieved deficit memory associative
perillyl alcohol relieved deficit memory
alcohol relieved deficit
alcohol relieved deficit memory of
alcohol relieved deficit memory associative
alcohol relieved deficit memory
aminoglycosides dose appeared Ototoxicity
aminoglycosides dose drugs ototoxic
furosemide aminoglycosides dose appeared Ototoxicity
furosemide aminoglycosides dose drugs ototoxic
Dexmedetomidine associated mortality OR infarction myocardial
Dexmedetomidine associated mortality OR infarction
Dexmedetomidine associated mortality OR ischaemia myocardial
Dexmedetomidine associated mortality OR ischaemia
calcium blockers administration levels reduction led relief pain
cyclosporine effect Syndrome CIPS
tacrolimus cyclosporine effect Syndrome CIPS
Warfarin induced vasculitis leukocytoclastic
Warfarin induced vasculitis
warfarin LV
warfarin receiving developed eruptions skin
warfarin receiving developed eruptions
warfarin discontinued available results biopsies skin
warfarin discontinued available results biopsies lesion
warfarin therapy associated reaction late LV
angiotensin inhibitor Effects converting coagulation intravascular
angiotensin inhibitor Effects converting coagulation
Captopril enzyme converting coagulation intravascular
Captopril enzyme converting coagulation
Captopril enzyme insufficiency pulmonary
Captopril enzyme insufficiency pulmonary and
Captopril enzyme insufficiency pulmonary renal
Captopril enzyme insufficiency
angiotensin inhibitor Effects converting enzyme insufficiency pulmonary
angiotensin inhibitor Effects converting enzyme insufficiency pulmonary and
angiotensin inhibitor Effects converting enzyme insufficiency pulmonary renal
angiotensin inhibitor Effects converting enzyme insufficiency
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling pulmonary
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling pulmonary and
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling pulmonary renal
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling insufficiency
acid injection fibrinolysis coagulation Induction gives resembling pulmonary
acid injection fibrinolysis coagulation Induction gives resembling pulmonary and
acid injection fibrinolysis coagulation Induction gives resembling pulmonary renal
acid injection fibrinolysis coagulation Induction gives resembling insufficiency
AMCA acid injection fibrinolysis coagulation Induction gives resembling pulmonary
AMCA acid injection fibrinolysis coagulation Induction gives resembling pulmonary and
AMCA acid injection fibrinolysis coagulation Induction gives resembling pulmonary renal
AMCA acid injection fibrinolysis coagulation Induction gives resembling insufficiency
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling occurring trauma
acid injection fibrinolysis coagulation Induction gives resembling occurring trauma
AMCA acid injection fibrinolysis coagulation Induction gives resembling occurring trauma
tranexamic thrombin acid injection fibrinolysis coagulation Induction gives resembling occurring trauma sepsis
acid injection fibrinolysis coagulation Induction gives resembling occurring trauma sepsis
AMCA acid injection fibrinolysis coagulation Induction gives resembling occurring trauma sepsis
Captopril Injection reduced insufficiency pulmonary
Captopril Injection reduced insufficiency pulmonary and
Captopril Injection reduced insufficiency pulmonary renal
Captopril Injection reduced insufficiency
angiotensin inhibitor converting reduced insufficiency pulmonary
angiotensin inhibitor converting reduced insufficiency pulmonary and
angiotensin inhibitor converting reduced insufficiency pulmonary renal
angiotensin inhibitor converting reduced insufficiency
Captopril prevented damage Renal
Captopril prevented damage
urea increase reflected damage Renal
urea increase reflected damage
Captopril reduce produced damage kidney
Captopril reduce produced damage
cephalosporins associated defects birth
cephalosporins associated defects
erythromycins associated defects birth
erythromycins associated defects
penicillins Reassuringly erythromycins associated defects birth
penicillins Reassuringly erythromycins associated defects
estrogens exogenous had disease Hodgkin
estrogens exogenous had disease
estrogens exogenous had failure ovarian
estrogens exogenous had failure
estrogens failure ovarian
estrogens failure
estrogens failure therapy cancer
apomorphine induced catalepsy
amphetamine behavior climbing induced designed induced catalepsy
histamine H effect study designed induced catalepsy
apomorphine used induced Catalepsy
amphetamine apomorphine used induced Catalepsy
R cause catalepsy
alpha R cause catalepsy
methylhistamine R cause catalepsy
RAMH methylhistamine R cause catalepsy
THP reduced amphetamine induced hyperactivity
THP exhibited antipsychotic like induced hyperactivity
apomorphine reducing induced like induced catalepsy
amphetamine reducing like induced catalepsy
haloperidol potentiating like induced hyperactivity
apomorphine reducing induced hyperactivity
hydrogen production superoxide failure acute
hydrogen production superoxide failure liver
hydrogen production superoxide failure
peroxide production superoxide failure acute
peroxide production superoxide failure liver
peroxide production superoxide failure
superoxide failure acute
superoxide failure liver
superoxide failure
hydrogen superoxide production Defects implicated incidence infections bacterial
hydrogen superoxide production Defects implicated incidence infections
peroxide production Defects implicated incidence infections bacterial
peroxide production Defects implicated incidence infections
hydrogen superoxide production Defects implicated patients failure acute
hydrogen superoxide production Defects implicated patients failure liver
hydrogen superoxide production Defects implicated patients failure
peroxide production Defects implicated patients failure acute
peroxide production Defects implicated patients failure liver
peroxide production Defects implicated patients failure
hydrogen superoxide production Defects implicated patients failure ALF
peroxide production Defects implicated patients failure ALF
superoxide production Defects implicated incidence infections bacterial
superoxide production Defects implicated incidence infections
superoxide production Defects implicated patients failure acute
superoxide production Defects implicated patients failure liver
superoxide production Defects implicated patients failure
superoxide production Defects implicated patients failure ALF
oxygen production patients ALF
oxygen production patients ALF due overdose
paracetamol overdose
hydrogen Superoxide production neutrophils ALF
peroxide production neutrophils ALF
hydrogen Superoxide production neutrophils stimulated zymosan opsonized serum ALF
peroxide production neutrophils stimulated zymosan opsonized serum ALF
Superoxide production neutrophils ALF
Superoxide production neutrophils stimulated zymosan opsonized serum ALF
hydrogen Superoxide production neutrophils stimulated patients ALF
peroxide production neutrophils stimulated patients ALF
formyl phenylalanine stimulated patients ALF
methionyl phenylalanine stimulated patients ALF
leucyl methionyl phenylalanine stimulated patients ALF
phenylalanine stimulated patients ALF
fMLP phenylalanine stimulated patients ALF
Superoxide production neutrophils stimulated patients ALF
paracetamol overdose
tacrine treated showed outcome CNS onset epileptic
tacrine induced processes severity model epilepsy
lithium model epilepsy
oxygen level correlated NIN
hepatitis vaccine injections injections globulin hepatitis
hepatitis vaccine injections injections globulin B
B vaccine injections injections globulin hepatitis
B vaccine injections injections globulin B
vaccine injections injections globulin hepatitis
vaccine injections injections globulin B
folate concentrations efficacy toxicity
carbamazepine treatment efficacy toxicity
propylene glycol vehicle found exhibit seizures
glycol vehicle found exhibit seizures
propylene glycol vehicle found inhibited gain weight
propylene glycol vehicle found inhibited gain
glycol vehicle found inhibited gain weight
glycol vehicle found inhibited gain
CBZ measure found Seizures
CBZ measure found seizures
CBZ administration h dose induced seizures
CBZ administration h toxic measured gain weight
CBZ administration h toxic measured gain
HFDE protective induced dose h toxic measured gain weight
HFDE protective induced dose h toxic measured gain
calcitonin injections induced hyperactivity
Pyrrolidine dithiocarbamate protects cortex model status
Pyrrolidine dithiocarbamate protects cortex model epilepticus
dithiocarbamate protects cortex model status
dithiocarbamate protects cortex model epilepticus
oxygen species production activation implicated damage neuronal
oxygen species production activation implicated damage
PDTC epilepticus status
PDTC epilepticus
PDTC epilepticus status
PDTC epilepticus
PDTC exert development epilepticus status
PDTC exert development epilepticus
PDTC vehicle treated rats epilepticus status
PDTC vehicle treated rats epilepticus
PDTC inhibitor NF protected affect loss neuronal
PDTC inhibitor NF protected affect loss
oxygen species generation plays role seizure
oxygen species generation associated damage neuronal
oxygen species generation associated damage
Amiodarone toxicity pulmonary
Amiodarone toxicity
amiodarone toxicity thought result injury related accumulation pneumonitis hypersensitivity
amiodarone toxicity thought result injury related accumulation pneumonitis
amiodarone toxicity pulmonary
amiodarone toxicity
amiodarone induced toxicity pulmonary
amiodarone induced toxicity
green tea Effect induced infarction myocardial
green tea Effect induced infarction
tea Effect induced infarction myocardial
tea Effect induced infarction
vitamin combination tea Effect induced infarction myocardial
vitamin combination tea Effect induced infarction
E combination tea Effect induced infarction myocardial
E combination tea Effect induced infarction
green tea effects ATPases infarction myocardial
green tea effects ATPases infarction
tea effects ATPases infarction myocardial
tea effects ATPases infarction
vitamin E tea effects ATPases infarction myocardial
vitamin E tea effects ATPases infarction
E tea effects ATPases infarction myocardial
E tea effects ATPases infarction
green tea effect indicate ISO induced infarction myocardial
green tea effect indicate ISO induced infarction
tea effect indicate ISO induced infarction myocardial
tea effect indicate ISO induced infarction
vitamin E tea effect indicate ISO induced infarction myocardial
vitamin E tea effect indicate ISO induced infarction
E tea effect indicate ISO induced infarction myocardial
E tea effect indicate ISO induced infarction
lignocaine instillation tinnitus
lidocaine Treatment tinnitus
lignocaine instillation treating IST
lidocaine lignocaine instillation treating IST
magnesium supplementation importance furosemide Tetany rhabdomyolysis
magnesium supplementation importance furosemide Tetany
calcium potassium supplementation corrected cannot spasms associated hypomagnesemia
potassium supplementation corrected cannot spasms associated hypomagnesemia
calcium potassium supplementation corrected cannot spasms associated cause hypokalemia
calcium potassium supplementation corrected cannot spasms muscle
calcium potassium supplementation corrected cannot spasms
calcium potassium supplementation corrected cannot spasms associated cause weakness muscle
calcium potassium supplementation corrected cannot spasms associated cause weakness
calcium potassium supplementation corrected cannot spasms tetany
potassium supplementation corrected cannot spasms tetany
potassium supplementation corrected cannot spasms associated cause hypokalemia
potassium supplementation corrected cannot spasms muscle
potassium supplementation corrected cannot spasms
potassium supplementation corrected cannot spasms associated cause weakness muscle
potassium supplementation corrected cannot spasms associated cause weakness
magnesium depletion effects noted reported observed hypocalcemia
magnesium depletion effects noted reported hypokalemia
ribavirin strategies anemia treatment C hepatitis
ribavirin strategies anemia treatment C
interferon published OBJECTIVES alpha treatment C chronic
interferon published OBJECTIVES alpha treatment C hepatitis
interferon published OBJECTIVES alpha treatment C
alpha treatment C chronic
alpha treatment C hepatitis
alpha treatment C
interferon published OBJECTIVES alpha treatment C CHC
alpha treatment C CHC
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C chronic
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C hepatitis
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C
ribavirin therapy effectiveness efficacy demonstrated published OBJECTIVES alpha treatment C CHC
cyclophosphamide high based cancer breast
cyclophosphamide high based cancer
cyclophosphamide high observed toxicity Cardiac
cyclophosphamide high observed toxicity
melphalan paclitaxel combined We DESIGN regimen patients cancer breast
melphalan paclitaxel combined We DESIGN regimen patients cancer
carboplatin cyclophosphamide DESIGN regimen patients cancer breast
carboplatin cyclophosphamide DESIGN regimen patients cancer
cyclophosphamide DESIGN regimen patients cancer breast
cyclophosphamide DESIGN regimen patients cancer
paclitaxel combined We DESIGN regimen patients cancer breast
paclitaxel combined We DESIGN regimen patients cancer
thiotepa cyclophosphamide DESIGN regimen patients cancer breast
thiotepa cyclophosphamide DESIGN regimen patients cancer
anthracyclines use age women cancer breast
anthracyclines use age women cancer
anthracyclines use age hypertension
anthracyclines use age mellitus diabetes
anthracyclines use age mellitus
cyclophosphamide women age hypertension
cyclophosphamide women age mellitus diabetes
cyclophosphamide women age mellitus
cyclophosphamide women cancer breast
cyclophosphamide women cancer
anthracyclines use age women cyclophosphamide high regimen failure congestive
anthracyclines use age women cyclophosphamide high regimen failure heart
anthracyclines use age women cyclophosphamide high regimen failure
anthracyclines use age women cyclophosphamide high regimen failure CHF
cyclophosphamide toxicity cardiac
cyclophosphamide toxicity
Octreotide induced hypertension hypoxemia
octreotide developed enhance resolution fistula
phenobarbital action carcinogenic
diethylnitrosamine given phenobarbital action carcinogenic
phenobarbital carcinogenesis
PB phenobarbital carcinogenesis
diethylnitrosamine administered carcinogenesis
DEN phenobarbital carcinogenesis
PB or weeks treated schedule hepatocarcinogenesis
DEN weeks treated schedule hepatocarcinogenesis
DEN PB or weeks treated schedule hepatocarcinogenesis
PB given reduced number size foci preneoplastic
PB given reduced number size foci
DEN PB prolonged decreased incidence tumor
DEN obtained results decreased incidence tumor
PB prolonged decreased incidence tumor
PB promotes carcinogenesis
DEN treatment administered promotes carcinogenesis
DEN given reduces PB promotes carcinogenesis
androgens role favored pathogenesis apnea sleep
androgens role favored pathogenesis apnea
nitroprusside discontinuation observed hypertension
Cyproterone acetate licensed treatment women acne hirsutism
acetate licensed treatment women acne hirsutism
CPA EE acetate licensed treatment women acne hirsutism
Cyproterone acetate licensed treatment women acne
acetate licensed treatment women acne
CPA EE acetate licensed treatment women acne
Cyproterone acetate licensed option syndrome polycystic
Cyproterone acetate licensed option syndrome ovary
Cyproterone acetate licensed option syndrome
acetate licensed option syndrome polycystic
acetate licensed option syndrome ovary
acetate licensed option syndrome
Cyproterone acetate licensed option syndrome PCOS
acetate licensed option syndrome PCOS
CPA EE acetate licensed option syndrome polycystic
CPA EE acetate licensed option syndrome ovary
CPA EE acetate licensed option syndrome
CPA EE acetate licensed option syndrome PCOS
ethinyl estradiol combined acetate licensed treatment women acne hirsutism
estradiol combined acetate licensed treatment women acne hirsutism
EE acetate licensed treatment women acne hirsutism
ethinyl estradiol combined acetate licensed treatment women acne
estradiol combined acetate licensed treatment women acne
EE acetate licensed treatment women acne
ethinyl estradiol combined acetate licensed option syndrome polycystic
ethinyl estradiol combined acetate licensed option syndrome ovary
ethinyl estradiol combined acetate licensed option syndrome
estradiol combined acetate licensed option syndrome polycystic
estradiol combined acetate licensed option syndrome ovary
estradiol combined acetate licensed option syndrome
ethinyl estradiol combined acetate licensed option syndrome PCOS
estradiol combined acetate licensed option syndrome PCOS
EE acetate licensed option syndrome polycystic
EE acetate licensed option syndrome ovary
EE acetate licensed option syndrome
EE acetate licensed option syndrome PCOS
oral contraceptives associated thromboembolism venous
oral contraceptives associated thromboembolism
contraceptives associated thromboembolism venous
contraceptives associated thromboembolism
oral contraceptives associated thromboembolism VTE
contraceptives associated thromboembolism VTE
CPA EE associated VTE risk estimate aged years acne hirsutism
CPA EE associated VTE risk estimate aged years acne
CPA EE associated VTE risk estimate aged years acne PCOS
EE associated VTE risk estimate aged years acne hirsutism
EE associated VTE risk estimate aged years acne
EE associated VTE risk estimate aged years acne PCOS
CPA EE women acne hirsutism
CPA EE women acne
CPA EE women acne PCOS
EE women acne hirsutism
EE women acne
EE women acne PCOS
5 patients supervision discontinued observed pain tachyarrhythmia
FU treatment supervision discontinued observed pain tachyarrhythmia
Valproate mg month improved subthalamotomy developed had hemianopsia homonymous
Valproate mg month improved subthalamotomy developed had hemianopsia
fentanyl administration effects include rigidity chest
fentanyl administration effects include rigidity wall
fentanyl administration effects include rigidity
fentanyl infusion result mimicking hydronephrosis
serotonin blockers induced treatment effects sexual
serotonin blockers induced treatment effects side
serotonin blockers induced treatment effects
Yohimbine treatment effects sexual
Yohimbine treatment effects side
Yohimbine treatment effects
yohimbine facilitates helpful treatment impotence male
yohimbine facilitates helpful treatment impotence
yohimbine used treat effects sexual
yohimbine used treat effects side
yohimbine used treat effects
serotonin blockers caused study evaluated treatment effects sexual
serotonin blockers caused study evaluated treatment effects side
serotonin blockers caused study evaluated treatment effects
yohimbine evaluated treatment effects sexual
yohimbine evaluated treatment effects side
yohimbine evaluated treatment effects
yohimbine given suffered patients disorder obsessive
yohimbine given suffered patients disorder compulsive
yohimbine given suffered patients disorder
yohimbine given suffered patients disorder disorders affective
yohimbine given suffered patients disorder disorders
serotonin blockers treatment given suffered patients disorder obsessive
serotonin blockers treatment given suffered patients disorder compulsive
serotonin blockers treatment given suffered patients disorder
yohimbine given suffered patients disorder anxiety
serotonin blockers treatment given suffered patients disorder anxiety
serotonin blockers treatment given suffered effects sexual
serotonin blockers treatment given suffered effects side
serotonin blockers treatment given suffered effects
yohimbine given suffered patients disorder trichotillomania
serotonin blockers treatment given suffered patients disorder trichotillomania
yohimbine given suffered effects sexual
yohimbine given suffered effects side
yohimbine given suffered effects
serotonin blockers treatment given suffered patients disorder disorders affective
serotonin blockers treatment given suffered patients disorder disorders
yohimbine effects included sweating anxiety
serotonin blockers caused effects sexual
serotonin blockers caused effects side
serotonin blockers caused effects
yohimbine treatment effects sexual
yohimbine treatment effects side
yohimbine treatment effects
ifosfamide toxicity children treated tumors malignant
ifosfamide toxicity children treated tumors mesenchymal
ifosfamide toxicity children treated tumors
ifosfamide protocol received children tumors malignant
ifosfamide protocol received children tumors mesenchymal
ifosfamide protocol received children tumors
ifosfamide protocol Society -RSB- Malignant
ifosfamide protocol Society -RSB- Mesenchymal
ifosfamide protocol Society -RSB- Tumor
creatinine clearance electrolytes proteinuria
phosphate reabsorption electrolytes proteinuria
phosphate reabsorption electrolytes glucosuria
creatinine clearance electrolytes glucosuria
phosphate reabsorption electrolytes aminoaciduria
creatinine clearance electrolytes aminoaciduria
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome Fanconi
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome Fanconi '
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome s
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome
phosphate reabsorption microglobulinuria included identified included patients developed toxicity resulting syndrome TDFS
phosphate reabsorption microglobulinuria included identified included patients developed toxicity
ifosfamide 2 correlated toxicity
ifosfamide predominance involvement tumor
ifosfamide efficacy evaluated treatment tumors mesenchymal
ifosfamide efficacy evaluated treatment tumors
epsilon due treatment necrotizing case patient haemorrhage subarachnoid
epsilon due treatment necrotizing case patient haemorrhage
aminocaproic acid epsilon due treatment necrotizing case patient haemorrhage subarachnoid
aminocaproic acid epsilon due treatment necrotizing case patient haemorrhage
acid epsilon due treatment necrotizing case patient haemorrhage subarachnoid
acid epsilon due treatment necrotizing case patient haemorrhage
epsilon due treatment necrotizing case SAH
aminocaproic acid epsilon due treatment necrotizing case SAH
acid epsilon due treatment necrotizing case SAH
EACA acid epsilon due treatment necrotizing case patient haemorrhage subarachnoid
EACA acid epsilon due treatment necrotizing case patient haemorrhage
EACA acid epsilon due treatment necrotizing case SAH
epsilon due treatment necrotizing
epsilon due myopathy
aminocaproic acid epsilon due treatment necrotizing
aminocaproic acid epsilon due myopathy
acid epsilon due treatment necrotizing
acid epsilon due myopathy
EACA acid epsilon due treatment necrotizing
EACA acid epsilon due myopathy
Valproate induced hyperglycinemia nonketotic
Valproate induced hyperglycinemia
glycine system defect leads disorder
glycine system defect leads disorder metabolism of
glycine system defect leads disorder metabolism amino
glycine system defect leads disorder metabolism acid
glycine system defect leads disorder metabolism
glycine accumulation leads disorder
glycine accumulation leads disorder metabolism of
glycine accumulation leads disorder metabolism amino
glycine accumulation leads disorder metabolism acid
glycine accumulation leads disorder metabolism
glycine system defect leads disorder hyperglycinemia Nonketotic
glycine system defect leads disorder hyperglycinemia
glycine accumulation leads disorder hyperglycinemia Nonketotic
glycine accumulation leads disorder hyperglycinemia
valproate therapy initiation have found delay retardation mental
valproate therapy initiation have found delay retardation
valproate therapy initiation have hyperglycinemia nonketotic
valproate therapy initiation have hyperglycinemia
valproate therapy initiation have found delay language
valproate therapy initiation have found delay
carboplatin rhabdomyosarcoma embryonal
carboplatin rhabdomyosarcoma
Spironolactone it hypokalemia patients cancer
amphotericin B prevention drug it hypokalemia patients cancer
B prevention drug it hypokalemia patients cancer
Spironolactone it hypokalemia
amphotericin B effect Nephrotoxicity
B effect Nephrotoxicity
AmB B effect Nephrotoxicity
potassium wasting responsible seems toxicity
AmB treatment effect wasting responsible seems toxicity
Potassium depletion potentiates toxicity
AmB toxicity
AmB treatment patients neutropenic
spironolactone ability assess reduce prevent patients neutropenic
spironolactone ability assess reduce prevent hypokalemia
potassium requirements reduce prevent hypokalemia
potassium requirements reduce prevent patients neutropenic
AmB receive randomized patients disorders hematological
AmB receive randomized patients disorders
AmB mg randomized patients disorders hematological
AmB mg randomized patients disorders
spironolactone AmB mg daily developing proven infection fungal
spironolactone AmB mg daily developing proven infection
AmB receive randomized mg daily developing proven infection fungal
AmB receive randomized mg daily developing proven infection
AmB mg daily developing proven infection fungal
AmB mg daily developing proven infection
spironolactone AmB mg randomized patients disorders hematological
spironolactone AmB mg randomized patients disorders
AmB treatment patients neutropenic
spironolactone reduce prevent reducing patients neutropenic
spironolactone reduce prevent hypokalemia
potassium requirements reduce prevent hypokalemia
potassium loss reducing prevent hypokalemia
potassium requirements reduce prevent reducing patients neutropenic
potassium loss reducing patients neutropenic
methyldopa related disease liver
methyldopa related disease
methyldopa taking another showed died presented failure hepatic
methyldopa taking another showed died presented failure
methyldopa episode recommenced developed hepatitis fulminant
methyldopa episode recommenced developed hepatitis
methyldopa hepatic
methyldopa dysfunction
sulfasalazine arthritis
caffeine toxicity
acetaminophen Reduction toxicity
caffeine effects augment reported focused reduced toxicity
caffeine toxicity
acetaminophen presence reduced toxicity
acetaminophen increased interval administration onset convulsions
acetaminophen pretreatment pretreatment acetaminophen reduced incidence seizures
acetaminophen pretreatment pretreatment acetaminophen increased interval administration onset convulsions
acetaminophen reduced incidence seizures
acetaminophen reduced caffeine 5 seizures
acetaminophen modify seizures
Bupropion toxicity
Zyban Bupropion toxicity
diazepam treated treated tachycardia
adenosine treated tachycardia
adenosine treated treated seizures
diazepam treated seizures
Zyban caused overdose
Zyban caused neurological
Zyban caused neurological and
Zyban caused neurological toxicity cardiovascular
Zyban caused neurological toxicity
deferoxamine therapy receiving studies neurotoxicity auditory
deferoxamine therapy receiving studies neurotoxicity
iron therapy receiving anemia
deferoxamine documented Visual
deferoxamine documented Visual and
deferoxamine documented Visual auditory
deferoxamine documented neurotoxicity
deferoxamine anemia
iron therapy receiving anemia deferoxamine documented Visual
iron therapy receiving anemia deferoxamine documented Visual and
iron therapy receiving anemia deferoxamine documented Visual auditory
iron therapy receiving anemia deferoxamine documented neurotoxicity
deferoxamine doses receiving recommended mg kg degree abnormality auditory
deferoxamine doses receiving recommended mg kg degree abnormality
deferoxamine doses receiving recommended demonstrated toxicity
deferoxamine receiving receiving demonstrated deterioration provided convincing cause administration ototoxicity
deferoxamine relation cause administration ototoxicity
oxprenolol mediated hypokalemia
oxprenolol efficacy investigated antagonizing hypokalemia
oxprenolol pretreatment concentrations spite antagonized hypokalemia
thalidomide study carcinoma renal
thalidomide study carcinoma cell
thalidomide study carcinoma
thalidomide toxicity
thalidomide toxicity evaluate patients cancer renal
thalidomide toxicity evaluate patients cancer cell
thalidomide toxicity evaluate patients cancer
thalidomide carcinoma renal
thalidomide carcinoma cell
thalidomide carcinoma
thalidomide carcinoma renal
thalidomide carcinoma cell
thalidomide carcinoma
amlodipine telmisartan combination hypertension
amlodipine hypertension
telmisartan combination hypertension
amlodipine mg monotherapy patients hypertension
amlodipine 5 mg monotherapy patients hypertension
telmisartan + efficacy amlodipine mg monotherapy patients hypertension
pyridoxine responsive convulsions
isoniazid mg infant day 17 kg admitted tuberculosis
pyridoxine hours ceased fits
pyridoxine deficiency aetiology suggesting ceased fits
warfarin juice haemopericardium
warfarin dosage maintaining consumed man report case haemorrhage
vancomycin course osteomyelitis
tenofovir AIDS patients failure Acute
tenofovir AIDS patients failure renal
tenofovir AIDS patients failure
tenofovir AIDS
vancomycin course receiving Acute failure patients AIDS
tenofovir AIDS patients failure Acute receiving course osteomyelitis
tenofovir fumarate receiving patients developed failure Renal
tenofovir fumarate receiving patients developed failure
disoproxil fumarate receiving patients developed failure Renal
disoproxil fumarate receiving patients developed failure
fumarate receiving patients developed failure Renal
fumarate receiving patients developed failure
vancomycin therapy course developed failure Renal
vancomycin therapy course developed failure
Tenofovir implicated development insufficiency renal
Tenofovir implicated development insufficiency
Tenofovir implicated development syndrome Fanconi
Tenofovir implicated development syndrome
Vancomycin infrequent nephrotoxicity
Vancomycin infrequent result agent nephrotoxic
vancomycin administration raise risk failure renal
vancomycin administration raise risk failure
tenofovir raise risk failure renal
tenofovir raise risk failure
CC received presented pain chest
CC received presented pain
CC complication Thrombosis
Thorazine receiving developed tachycardia Supraventricular
Thorazine receiving developed tachycardia
chlorpromazine Thorazine receiving developed tachycardia Supraventricular
chlorpromazine Thorazine receiving developed tachycardia
lidocaine administration responded arrhythmias ventricular
lidocaine administration responded arrhythmias
propranolol instances required responded arrhythmias ventricular
propranolol instances required responded arrhythmias
phenothiazines drugs receiving patients quantify risk complications cardiac
phenothiazines drugs receiving patients quantify risk complications
cocaine abusers hospitalized evidence injury myocardial
cocaine abusers hospitalized evidence injury
cocaine electrocardiograms compared ECGs controls schizophrenic
cocaine abusers Eleven had evidence injury defined infarction ischemia
cocaine abusers Eleven had evidence injury myocardial
cocaine abusers Eleven had evidence injury
anthracycline derivative induced cardiomyopathy
SM derivative induced cardiomyopathy
5887 SM derivative induced cardiomyopathy
SM potential cardiotoxic
5887 potential cardiotoxic
SM potential pre cardiotoxicity
5887 potential pre cardiotoxicity
SM effect 5887 potential cardiotoxic
5887 potential cardiotoxic
SM effect 5887 potential pre cardiotoxicity
5887 potential pre cardiotoxicity
doxorubicin induced potential cardiotoxic
doxorubicin induced potential pre cardiotoxicity
SM sacrificed animals cardiomyopathy
5887 administration show demonstrated changes decrease cardiomyopathy
SM effect cardiotoxic
5887 effect cardiotoxic
SM effect examine cardiomyopathy
5887 effect examine cardiomyopathy
doxorubicin cardiomyopathy examine effect cardiotoxic
doxorubicin treatment enhanced changes cardiotoxic
SM progress grade cardiomyopathy
5887 treatment SM progress grade cardiomyopathy
SM have potential cardiotoxicity
5887 have potential cardiotoxicity
SM induced cardiotoxicity
5887 have SM induced cardiotoxicity
doxorubicin effect potential cardiotoxicity
doxorubicin effect potential have SM induced cardiotoxicity
metoprolol antagonism hypokalemia
diphenylhydantoin toxicity
DPH toxicity
DPH toxicity manifest liable patients damage cerebral
DPH toxicity manifest liable patients damage
dexamethasone given rats had glomeruli glomerulosclerosis
dexamethasone shows results reduction number glomerulosclerosis
Heparin induced thrombocytopenia thrombosis
heparin resistance count a
heparin resistance count falling
heparin resistance count platelet
heparin resistance count
heparin added plasma revealed count a
heparin added plasma revealed count falling
heparin added plasma revealed count platelet
heparin added plasma revealed count
heparin receiving indicated testing platelet
heparin receiving indicated testing aggregation
Curcumin ameliorates dysfunction cognitive
Curcumin ameliorates dysfunction
curcumin administration effect investigate impairment cognitive
curcumin administration effect investigate impairment
curcumin administration prevented impairment cognitive
curcumin administration prevented impairment
curcumin has effect mitigating deterioration
curcumin has effect mitigating deterioration functions of
curcumin has effect mitigating deterioration functions cognitive
curcumin has effect mitigating deterioration functions
curcumin considered phenobarbitone preventing impairment cognitive
curcumin considered phenobarbitone preventing impairment
calcium chloride injected mydriasis tremor
chloride injected mydriasis tremor
calcium chloride injected mydriasis clonic
calcium chloride injected mydriasis produced convulsions tonic
calcium chloride injected mydriasis produced convulsions
chloride injected mydriasis clonic
chloride injected mydriasis produced convulsions tonic
chloride injected mydriasis produced convulsions
calcium chloride injected mydriasis
chloride injected mydriasis
calcium chloride changed hand tremor
chloride changed hand tremor
calcium chloride changed hand clonic
calcium chloride changed convulsions tonic
calcium chloride changed convulsions
chloride changed hand clonic
chloride changed convulsions tonic
chloride changed convulsions
calcium chloride changed hand mydriasis
chloride changed hand mydriasis
calcium chloride dissociate phenomena mydriasis tremor
chloride dissociate phenomena mydriasis tremor
calcium chloride dissociate phenomena mydriasis clonic
calcium chloride dissociate phenomena convulsions tonic
calcium chloride dissociate phenomena convulsions
chloride dissociate phenomena mydriasis clonic
chloride dissociate phenomena convulsions tonic
chloride dissociate phenomena convulsions
calcium chloride dissociate phenomena mydriasis
chloride dissociate phenomena mydriasis
ritodrine labor preterm
ritodrine labor
ritodrine effects interactions risk patients receiving ritodrine labor preterm
ritodrine effects interactions risk patients receiving ritodrine labor
ritodrine infusion cessation result complications cardiovascular
ritodrine infusion cessation result complications
phenylephrine treat tachycardia
phenylephrine treat patients hypotensive
Ro 4368554 restores models deficiency memory
Ro 4368554 restores models deficiency
4368554 restores models deficiency memory
4368554 restores models deficiency
metrifonate i kg reversed induced deficits memory
metrifonate i kg reversed induced deficits
TRP scopolamine depletion induced deficits memory
TRP scopolamine depletion induced deficits
Ro reversed induced deficits memory
Ro reversed induced deficits
4368554 Ro reversed induced deficits memory
4368554 Ro reversed induced deficits
Ro 4368554 improve reversed cholinergic deficit memory
Ro 4368554 improve reversed cholinergic deficit
4368554 improve reversed cholinergic deficit memory
4368554 improve reversed cholinergic deficit
Ro memory facilitation involved suggesting reversed cholinergic deficit memory
Ro memory facilitation involved suggesting reversed cholinergic deficit
4368554 Ro memory facilitation involved suggesting reversed cholinergic deficit memory
4368554 Ro memory facilitation involved suggesting reversed cholinergic deficit
5 involved suggesting reversed cholinergic deficit memory
5 involved suggesting reversed cholinergic deficit
HT 5 involved suggesting reversed cholinergic deficit memory
HT 5 involved suggesting reversed cholinergic deficit
Estradiol reduces seizure
Estradiol reduces seizure induced injury hippocampal
Estradiol reduces seizure induced injury
kainic acid induced injury hippocampal
kainic acid induced injury
acid induced injury hippocampal
acid induced injury
kainic acid induced injury epilepticus status
kainic acid induced injury epilepticus
acid induced injury epilepticus status
acid induced injury epilepticus
kainic acid induced injury epilepticus SE
acid induced injury epilepticus SE
17 beta effects pilocarpine SE
beta effects pilocarpine SE
estradiol effects pilocarpine SE
17 beta alter extent CA evaluated SE
beta alter extent CA evaluated SE
Estradiol alter extent CA evaluated SE
silver extent CA evaluated SE
estradiol threshold seizure
timolol Comparison response patients treatment glaucoma
timolol trial DESIGN rate patients treated glaucoma
timolol solution timolol trial DESIGN rate patients treated glaucoma
timolol suspension trial DESIGN rate patients treated glaucoma
timolol gellan conjunctiva forms suspension trial DESIGN rate patients treated glaucoma
timolol solution placebo masked Forty randomized patients years open
timolol solution placebo masked Forty randomized patients years open glaucoma angle
timolol solution placebo masked Forty randomized patients years open glaucoma
timolol gellan placebo masked Forty randomized patients years open
timolol gellan placebo masked Forty randomized patients years open glaucoma angle
timolol gellan placebo masked Forty randomized patients years open glaucoma
timolol solution placebo masked Forty randomized patients years open glaucoma hypertension ocular
timolol solution placebo masked Forty randomized patients years open glaucoma hypertension
timolol gellan placebo masked Forty randomized patients years open glaucoma hypertension ocular
timolol gellan placebo masked Forty randomized patients years open glaucoma hypertension
tobramycin nephrotoxicity
gentamicin tobramycin nephrotoxicity
tobramycin sulfate sulfate continue demonstrate ototoxicity nephrotoxicity
sulfate sulfate continue demonstrate ototoxicity nephrotoxicity
Gentamicin sulfate continue demonstrate ototoxicity
sulfate continue demonstrate ototoxicity
Gentamicin sulfate continue demonstrate ototoxicity nephrotoxicity
sulfate continue demonstrate ototoxicity nephrotoxicity
tobramycin sulfate sulfate continue demonstrate ototoxicity
sulfate sulfate continue demonstrate ototoxicity
aminoglycoside development followed failure renal
aminoglycoside development followed failure
gamma effects induced seizures
hexachlorocyclohexane effects induced seizures
lindane hexachlorocyclohexane effects induced seizures
Gamma shown decrease threshold seizure
hexachlorocyclohexane shown decrease threshold seizure
Gamma shown decrease pentylenetrazol h seizures
hexachlorocyclohexane shown decrease pentylenetrazol h seizures
gamma hexachlorocyclohexane shown decrease threshold seizure
HCH gamma hexachlorocyclohexane shown decrease threshold seizure
gamma hexachlorocyclohexane shown decrease pentylenetrazol h seizures
HCH gamma hexachlorocyclohexane shown decrease pentylenetrazol h seizures
lindane ingredient hexachlorocyclohexane shown decrease threshold seizure
lindane ingredient hexachlorocyclohexane shown decrease pentylenetrazol h seizures
gamma exposure h pentylenetrazol decrease threshold seizure
HCH threshold h pentylenetrazol decrease threshold seizure
gamma exposure h seizures
HCH threshold h seizures
gamma exposure h seizures h pentylenetrazol decrease threshold seizure
HCH h pentylenetrazol decrease threshold seizure
gamma exposure h seizures
HCH h seizures
gamma kg severity response seizure
HCH gamma kg severity response seizure
gamma administration activity seizure
HCH administration activity seizure
gamma h observed increased hour inducing administration activity seizure
HCH gamma h observed increased hour inducing administration activity seizure
gamma PTX occur activity seizure
HCH decreased suggest occur activity seizure
gamma PTX occur suggest decreased HCH response seizure
HCH response seizure
gamma linked h site responsible decrease activity seizure
HCH GABA gamma linked h site responsible decrease activity seizure
GABA gamma linked h site responsible decrease activity seizure
Metformin prevents pathway induced nephropathy
gentamicin pathway induced nephropathy
metformin diminish prevent dysfunction vascular
metformin diminish prevent dysfunction
gentamicin toxicity
Metformin treatment blocked gentamicin failure acute
Metformin treatment blocked gentamicin failure renal
Metformin treatment blocked gentamicin failure
metformin correction markers dysfunction kidney
metformin correction markers dysfunction
metformin effects lessen nephrotoxicity
gentamicin lessen nephrotoxicity
sodium administration toxicity Treatment sulphonate patients cancer lung
sodium administration toxicity Treatment sulphonate patients cancer
2 sodium administration toxicity Treatment sulphonate patients cancer lung
2 sodium administration toxicity Treatment sulphonate patients cancer
mercaptoethane sulphonate patients cancer lung
mercaptoethane sulphonate patients cancer
sulphonate patients cancer lung
sulphonate patients cancer
MESNA sulphonate patients cancer lung
MESNA sulphonate patients cancer
sodium administration toxicity urothelial
sodium administration toxicity
2 sodium administration toxicity urothelial
2 sodium administration toxicity
mercaptoethane sulphonate Treatment toxicity urothelial
mercaptoethane sulphonate Treatment toxicity
sulphonate Treatment toxicity urothelial
sulphonate Treatment toxicity
MESNA sulphonate Treatment toxicity urothelial
MESNA sulphonate Treatment toxicity
ifosfamide Treatment sulphonate patients cancer lung
ifosfamide Treatment sulphonate patients cancer
sodium effect tested group patients cancer lung
sodium effect tested group patients cancer
2 sodium effect tested group patients cancer lung
2 sodium effect tested group patients cancer
mercaptoethane sulphonate sodium effect tested group patients cancer lung
mercaptoethane sulphonate sodium effect tested group patients cancer
sulphonate sodium effect tested group patients cancer lung
sulphonate sodium effect tested group patients cancer
MESNA sulphonate sodium effect tested group patients cancer lung
MESNA sulphonate sodium effect tested group patients cancer
thiol compound administration effect tested group patients cancer lung
thiol compound administration effect tested group patients cancer
sodium sulphonate toxicity urothelial
sodium sulphonate toxicity
2 sodium sulphonate toxicity urothelial
2 sodium sulphonate toxicity
mercaptoethane sulphonate toxicity urothelial
mercaptoethane sulphonate toxicity
sulphonate toxicity urothelial
sulphonate toxicity
MESNA sulphonate toxicity urothelial
MESNA sulphonate toxicity
ifosfamide induced toxicity sulphonate sodium effect tested group patients cancer lung
ifosfamide induced toxicity sulphonate sodium effect tested group patients cancer
IF effect tested group patients cancer lung
IF effect tested group patients cancer
IF treatment tested group patients cancer lung
IF treatment tested group patients cancer
thiol compound administration effect sodium sulphonate toxicity urothelial
thiol compound administration effect sodium sulphonate toxicity
MESNA series differences were toxicity
Alpha prevents damage mitochondrial
Alpha prevents damage
lipoic acid prevents damage mitochondrial
lipoic acid prevents damage
acid prevents damage mitochondrial
acid prevents damage
Alpha prevents damage neurotoxicity
lipoic acid prevents damage neurotoxicity
acid prevents damage neurotoxicity
Alpha prevents neuropathy
lipoic acid prevents neuropathy
acid prevents neuropathy
alpha neuroprotective chemotherapy induced plays damage mitochondrial
alpha neuroprotective chemotherapy induced plays damage
lipoic acid neuroprotective chemotherapy induced plays damage mitochondrial
lipoic acid neuroprotective chemotherapy induced plays damage
acid neuroprotective chemotherapy induced plays damage mitochondrial
acid neuroprotective chemotherapy induced plays damage
alpha effects neuroprotective plays damage mitochondrial
alpha effects neuroprotective plays damage
lipoic acid alpha neuroprotective chemotherapy induced plays damage mitochondrial
lipoic acid alpha neuroprotective chemotherapy induced plays damage
acid alpha neuroprotective chemotherapy induced plays damage mitochondrial
acid alpha neuroprotective chemotherapy induced plays damage
alpha neuroprotective chemotherapy induced neurotoxicity
lipoic acid neuroprotective chemotherapy induced neurotoxicity
acid neuroprotective chemotherapy induced neurotoxicity
alpha effects neuroprotective plays induced neurotoxicity
lipoic acid alpha neuroprotective chemotherapy induced neurotoxicity
acid alpha neuroprotective chemotherapy induced neurotoxicity
alpha neuroprotective chemotherapy induced plays role cascade toxic
alpha neuroprotective chemotherapy induced plays role cascade neurodegenerative
alpha neuroprotective chemotherapy induced plays role cascade
lipoic acid neuroprotective chemotherapy induced plays role cascade toxic
lipoic acid neuroprotective chemotherapy induced plays role cascade neurodegenerative
lipoic acid neuroprotective chemotherapy induced plays role cascade
acid neuroprotective chemotherapy induced plays role cascade toxic
acid neuroprotective chemotherapy induced plays role cascade neurodegenerative
acid neuroprotective chemotherapy induced plays role cascade
alpha effects neuroprotective plays role cascade toxic
alpha effects neuroprotective plays role cascade neurodegenerative
alpha effects neuroprotective plays role cascade
lipoic acid alpha neuroprotective chemotherapy induced plays role cascade toxic
lipoic acid alpha neuroprotective chemotherapy induced plays role cascade neurodegenerative
lipoic acid alpha neuroprotective chemotherapy induced plays role cascade
acid alpha neuroprotective chemotherapy induced plays role cascade toxic
acid alpha neuroprotective chemotherapy induced plays role cascade neurodegenerative
acid alpha neuroprotective chemotherapy induced plays role cascade
alpha acid preventing damage axonal
alpha acid preventing damage
lipoic acid preventing damage axonal
lipoic acid preventing damage
acid preventing damage axonal
acid preventing damage
alpha preventing damage axonal
alpha preventing damage
lipoic acid alpha acid preventing damage axonal
lipoic acid alpha acid preventing damage
acid alpha acid preventing damage axonal
acid alpha acid preventing damage
paclitaxel cisplatin cause impairment mitochondrial
paclitaxel cisplatin cause impairment
cisplatin cause impairment mitochondrial
cisplatin cause impairment
Alpha exerts rescues toxicity mitochondrial
Alpha exerts rescues toxicity
lipoic acid exerts rescues toxicity mitochondrial
lipoic acid exerts rescues toxicity
acid exerts rescues toxicity mitochondrial
acid exerts rescues toxicity
Alpha exerts chemotherapy induced neurotoxicity
lipoic acid exerts chemotherapy induced neurotoxicity
acid exerts chemotherapy induced neurotoxicity
paclitaxel event toxicity mitochondrial
paclitaxel event toxicity
paclitaxel induced neurotoxicity
cisplatin paclitaxel event toxicity mitochondrial
cisplatin paclitaxel event toxicity
cisplatin paclitaxel induced neurotoxicity
alpha suggest reduce risk developing toxicity peripheral
alpha suggest reduce risk developing toxicity nerve
alpha suggest reduce risk developing toxicity
lipoic acid reduce risk developing toxicity peripheral
lipoic acid reduce risk developing toxicity nerve
lipoic acid reduce risk developing toxicity
acid reduce risk developing toxicity peripheral
acid reduce risk developing toxicity nerve
acid reduce risk developing toxicity
prostaglandin E effects hypotension haemodilution
E effects hypotension haemodilution
1 E effects hypotension haemodilution
prostaglandin E hypotension haemodilution
E hypotension haemodilution
1 E hypotension haemodilution
PGE 1 E hypotension haemodilution
1 PGE 1 E hypotension haemodilution
dextran solution amount replacing withdrawing produced Haemodilution
bilirubin SGOT showed showed decrease decrease min start hypotension
PGE min hypotension haemodilution
1 PGE min hypotension haemodilution
tamoxifen use tumors
tamoxifen treated year 52 CASE breast
tamoxifen treated year 52 CASE breast carcinoma
estrogen receptor tamoxifen treated year 52 CASE breast
estrogen receptor tamoxifen treated year 52 CASE breast carcinoma
tamoxifen Patients CONCLUSION induced risk tumors granulosa
tamoxifen Patients CONCLUSION induced risk tumors cell
tamoxifen Patients CONCLUSION induced risk tumors
tamoxifen metabolism alterations tumors granulosa
tamoxifen metabolism alterations tumors cell
tamoxifen metabolism alterations tumors
quetiapine symptoms extrapyramidal
quetiapine symptoms
quetiapine symptoms EPS
quetiapine studies patients mania bipolar
quetiapine studies patients mania
quetiapine evaluate symptoms akathisia
quetiapine evaluate symptoms extrapyramidal
quetiapine evaluate symptoms
quetiapine evaluate symptoms EPS
quetiapine patients mania bipolar
quetiapine patients mania
quetiapine different monotherapy events akathisia
quetiapine different monotherapy related RESULTS incidence EPS
QTP Li events DVP EPS
DVP EPS
DVP different DVP EPS
DVP low low incidence akathisia
DVP DVP low low incidence akathisia
quetiapine monotherapy low incidence akathisia
QTP DVP low low incidence akathisia
Li DVP low low incidence akathisia
Li DVP DVP low low incidence akathisia
quetiapine associated incidence tremor
quetiapine associated contributed tremor
quetiapine associated contributed rate tremor
quetiapine induced incidence akathisia
quetiapine induced incidence akathisia syndrome extrapyramidal
quetiapine induced incidence akathisia syndrome
quetiapine induced incidence akathisia tremor
quetiapine therapy incidence EPS akathisia
quetiapine therapy incidence EPS
quetiapine therapy incidence similar mania bipolar
quetiapine therapy incidence similar mania
haloperidol behaviors disease Alzheimer
haloperidol behaviors disease Alzheimer '
haloperidol behaviors disease s
haloperidol behaviors disease
haloperidol behaviors psychosis disruptive
haloperidol behaviors
haloperidol behaviors psychosis
haloperidol doses effects compare patients disease Alzheimer
haloperidol doses effects compare patients disease Alzheimer '
haloperidol doses effects compare patients disease s
haloperidol doses effects compare patients disease
haloperidol doses effects compare treatment behaviors psychosis disruptive
haloperidol doses effects compare treatment behaviors
haloperidol doses effects compare treatment behaviors psychosis
haloperidol 2 trial 6 / compared outpatients disease Alzheimer
haloperidol 2 trial 6 / compared outpatients disease Alzheimer '
haloperidol 2 trial 6 / compared outpatients disease s
haloperidol 2 trial 6 / compared outpatients disease
haloperidol 6 / compared outpatients disease Alzheimer
haloperidol 6 / compared outpatients disease Alzheimer '
haloperidol 6 / compared outpatients disease s
haloperidol 6 / compared outpatients disease
haloperidol efficacious efficacious agitation psychomotor
haloperidol efficacious efficacious agitation
haloperidol low factor efficacious efficacious agitation psychomotor
haloperidol low factor efficacious efficacious agitation
haloperidol efficacious factor psychosis
haloperidol low factor psychosis
haloperidol observed window apply neuroleptics used patients Alzheimer
haloperidol observed window apply neuroleptics used patients Alzheimer '
haloperidol observed window apply neuroleptics used patients s
haloperidol observed window apply neuroleptics used patients disease
haloperidol observed window apply neuroleptics used behaviors psychosis disruptive
haloperidol observed window apply neuroleptics used behaviors
haloperidol observed window apply neuroleptics used behaviors psychosis
nitric production Association model nephropathy
oxide production Association model nephropathy
NO association role studied apoptosis model syndrome nephrotic
NO association role studied apoptosis model syndrome
ADR groups groups nephropathy
ADR revealed areas proliferation mesangial
ADR revealed areas proliferation
ADR revealed areas proliferation inflammation tubulointerstitial
ADR revealed areas proliferation inflammation
ADR increased group nephropathy
nitrite levels increased group nephropathy
acetylcholine phenylephrine responses impaired group nephropathy
phenylephrine responses impaired group nephropathy
ADR group nephropathy
ADR group nephropathy
ADR pathogenesis important nephrosis
NO interactions important nephrosis
PPA abuse linked involved overdose
PPA abuse linked injury myocardial
PPA abuse linked injury
Dexatrim case injury myocardial
Dexatrim case injury
PPA Dexatrim case injury myocardial
PPA Dexatrim case injury
PPA injury myocardial
PPA injury
PG test passive prevented amnesia
9 prevented amnesia
PG induced amnesia
9 able PG induced amnesia
mexiletine I Report findings arrhythmia
mexiletine form effects evaluated infarction myocardial
mexiletine form effects evaluated infarction
Mexitil effects evaluated infarction myocardial
Mexitil effects evaluated infarction
Perlongets Mexitil effects evaluated infarction myocardial
Perlongets Mexitil effects evaluated infarction
mexiletine group deaths
E terfenadine compounds known increase cause investigated TDP
4031 terfenadine compounds known increase cause investigated TDP
poly polymerase Activation contributes development failure heart
poly polymerase Activation contributes development failure
ADP polymerase Activation contributes development failure heart
ADP polymerase Activation contributes development failure
ribose ADP polymerase Activation contributes development failure heart
ribose ADP polymerase Activation contributes development failure
anthracycline antibiotic factor implicated cardiotoxicity
doxorubicin cardiotoxicity
DOX doxorubicin cardiotoxicity
DOX induced cardiotoxicity
DOX induced dysfunction cardiac
DOX induced dysfunction
PJ deletion Using demonstrate development dysfunction cardiac
PJ deletion Using demonstrate development dysfunction
34 PJ deletion Using demonstrate development dysfunction cardiac
34 PJ deletion Using demonstrate development dysfunction
PJ Treatment improved dysfunction cardiac
PJ Treatment improved dysfunction
34 PJ Treatment improved dysfunction cardiac
34 PJ Treatment improved dysfunction
DOX cardiotoxicity
DOX treatment associated complications cardiac
DOX treatment associated complications
cefazedone cefonicid effects model hematotoxicity
cefonicid effects model hematotoxicity
cephalosporin hematotoxicity
Cephalosporin antibiotics cause variety disturbances hematologic
Cephalosporin antibiotics cause variety disturbances
cefazedone beagle cefonicid dogs administration caused studies toxicity
cefonicid dogs administration caused studies toxicity
cefazedone kg mg receiving dogs % occurred compromising cytopenias
cefonicid mg receiving dogs % occurred compromising cytopenias
cefazedone cefonicid tested dogs reproduced syndrome hematologic
cefazedone cefonicid tested dogs reproduced syndrome
cefonicid tested dogs reproduced syndrome hematologic
cefonicid tested dogs reproduced syndrome
cephalosporin rechallenge reproduced syndrome hematologic
cephalosporin rechallenge reproduced syndrome
cefazedone cefonicid doses administration induce similar hematotoxicity
cefazedone cefonicid doses administration induce conclude described dyscrasias blood
cefazedone cefonicid doses administration induce conclude described dyscrasias
cefonicid doses administration induce similar hematotoxicity
cefonicid doses administration induce conclude described dyscrasias blood
cefonicid doses administration induce conclude described dyscrasias
cephalosporin similar hematotoxicity
cephalosporin similar induce conclude described dyscrasias blood
cephalosporin similar induce conclude described dyscrasias
tincture effect infarction myocardial
tincture effect infarction
of Crataegus tincture effect infarction myocardial
of Crataegus tincture effect infarction
Crataegus tincture effect infarction myocardial
Crataegus tincture effect infarction
TCR effect investigate induced infarction myocardial
TCR effect investigate induced infarction
ethinyl treatment cholestasis extrahepatic
ethinyl treatment cholestasis
estradiol treatment cholestasis extrahepatic
estradiol treatment cholestasis
EE treatment cholestasis extrahepatic
EE treatment cholestasis
pyridoxine disorder behavioral
pyridoxine disorder
isoniazid administration difficulties hyperkinesis irritability
isoniazid administration difficulties sleeping
isoniazid administration difficulties
pyridoxine withdrawal associated return hyperkinesis
fentanyl dose received period case rigidity leading respiratory
fentanyl dose received period case rigidity leading respiratory described failure
oxytocin administration associated intoxication abortion
oxytocin administration intoxication described abortions
Oxytocin administration advocated carried report asthenia
Oxytocin administration advocated carried report asthenia irritability
Oxytocin administration advocated abortions
Oxytocin administration advocated carried report asthenia headaches
halogenated hydroxyquinolines Neurotoxicity
hydroxyquinolines Neurotoxicity
halogenated hydroxyquinolines presented cases reactions neurotoxic
hydroxyquinolines presented cases reactions neurotoxic
clioquinol dose ingestion related encephalopathy consisted disturbance neurological
clioquinol dose ingestion related encephalopathy consisted disturbance
clioquinol received enteropathica acrodermatitis
clioquinol received enteropathica
ursodeoxycholic acid response Composition stones gall
ursodeoxycholic acid response Composition stones bladder
ursodeoxycholic acid response Composition stones
acid response Composition stones gall
acid response Composition stones bladder
acid response Composition stones
Octreotide treatment acromegaly
octreotide treated patients acromegalic
cholesterol contained showed analysis stones gall
cholesterol contained showed analysis stones
cholesterol rich suggesting partial dissolution gall
cholesterol rich suggesting partial dissolution stone
cholesterol rich small stones gall
cholesterol rich small stones
cholesterol rich small have common disease gall
cholesterol rich small have common disease stone
cholesterol rich small have common disease
cholesterol rich small have duct stones gall
cholesterol rich small have duct stones
calcium containing stones duct have small stones gall
calcium containing stones duct have small stones
calcium containing stones duct have common disease gall
calcium containing stones duct have common disease stone
calcium containing stones duct have common disease
calcium containing stones gall
calcium containing stones
metoclopramide took disorder gastrointestinal
metoclopramide took disorder
morphine doubled increased incoordination
NH 4 Ac blocked reversed depression
4 Ac blocked reversed depression
Ac blocked reversed depression
catecholamine release blocked reversed depression
acetaldehyde release blocked reversed depression
calcium Addition reversed depression
calcium reversed depression
NH 4 activity analgesia
4 activity analgesia
Ac activity analgesia
NH verapamil mg activity analgesia
4 Ac verapamil mg activity analgesia
Ac verapamil mg activity analgesia
verapamil mg activity analgesia diazepam incoordination
verapamil mg activity analgesia diazepam incoordination
diazepam analgesia
amphetamine analgesia diazepam incoordination
verapamil mg activity analgesia
verapamil mg activity analgesia
morphine analgesia diazepam incoordination
amphetamine analgesia
metrazol action affected verapamil mg activity analgesia diazepam incoordination
metrazol action affected verapamil mg activity analgesia
morphine analgesia
calcium channel exerts hyperammonemia
hydrocortisone rise associated output increased
hydrocortisone rise associated output cardiac
hydrocortisone rise associated output
Nitric expression hypertension
oxide expression hypertension
oxygen species reduced hypertension
nitrotyrosine sequestration increased reduced hypertension
NO metabolites excretion reduced hypertension
NO sequestration increased reduced hypertension
NO expression depressed due reduction NOx hypertension
MDA concentration lowered ameliorated hypertension
Vitamin supplementation ameliorated hypertension
E supplementation ameliorated hypertension
NO inactivation actions stress associated hypertension
procainamide administered treatment contractions flutter atrial
procainamide administered treatment contractions flutter
procainamide administered treatment contractions premature
procainamide administered treatment contractions ventricular
procainamide administered treatment contractions
procainamide produce Q prolonged
procainamide produce Q
procainamide produce Q syndrome T
procainamide produce Q syndrome
dopamine produce induce hypothermia
dopamine agonist Apomorphine selected effects ability induce hypothermia
agonist Apomorphine selected effects ability induce hypothermia
Atorvastatin prevented dexamethasone induced hypertension
atorvastatin effects assess hypertension
atorva atorvastatin effects assess hypertension
atorva kg treated day hypertension
Atorva reversed dex hypertension
atorva 441 < 0001 392 + superoxide hypertension
superoxide hypertension
atorvastatin prevented dexamethasone induced hypertension
Glyceryl trinitrate induces aura sufferers migraine
Glyceryl trinitrate induces aura sufferers migraine aura with
Glyceryl trinitrate induces aura sufferers migraine aura
trinitrate induces aura sufferers migraine
trinitrate induces aura sufferers migraine aura with
trinitrate induces aura sufferers migraine aura
nitric oxide involved mechanisms pain
oxide involved mechanisms pain
NO oxide involved mechanisms pain
glyceryl trinitrate infusion examined response headache
trinitrate infusion examined response headache
GTN trinitrate infusion examined response headache
glyceryl trinitrate infusion examined clarify true migraine
glyceryl trinitrate infusion examined clarify true migraine aura with
glyceryl trinitrate infusion examined clarify true migraine aura
trinitrate infusion examined clarify true migraine
trinitrate infusion examined clarify true migraine aura with
trinitrate infusion examined clarify true migraine aura
glyceryl trinitrate infusion examined sufferers migraine
glyceryl trinitrate infusion examined sufferers migraine aura with
glyceryl trinitrate infusion examined sufferers migraine aura
trinitrate infusion examined sufferers migraine
trinitrate infusion examined sufferers migraine aura with
trinitrate infusion examined sufferers migraine aura
GTN trinitrate infusion examined clarify true migraine
GTN trinitrate infusion examined clarify true migraine aura with
GTN trinitrate infusion examined clarify true migraine aura
GTN trinitrate infusion examined sufferers migraine
GTN trinitrate infusion examined sufferers migraine aura with
GTN trinitrate infusion examined sufferers migraine aura
GTN infusion during controls severe migraineurs
GTN infusion during controls severe Headache
GTN induced headache disappeared occurred migraineurs
GTN induced headache
GTN induced headache disappeared occurred intensity headache
NO involved mechanisms migraine
NO involved aura with
NO involved aura
NO involved mechanisms pain
NO liberate shown help spreading migraine
NO liberate shown help spreading migraine aura with
NO liberate shown help spreading migraine aura
NO liberate shown cortical spreading depression
NO liberate shown help spreading depression
NO liberate shown help spreading depression headache
timolol hypokalemia
timolol drug tended correct hypokalemia
alpha induced Peroxisomes lesions liver
alpha induced Peroxisomes lesions
benzene hexachloride examined induced Peroxisomes lesions liver
benzene hexachloride examined induced Peroxisomes lesions
hexachloride examined induced Peroxisomes lesions liver
hexachloride examined induced Peroxisomes lesions
ethyl p respond were most hepatomas
alpha p respond were most hepatomas
p respond were most hepatomas
chlorophenoxyisobutyrate p respond were most hepatomas
ethyl p respond were differentiated tumors
alpha p respond were differentiated tumors
p respond were differentiated tumors
chlorophenoxyisobutyrate p respond were differentiated tumors
ethyl p respond cells tumor
alpha p respond cells tumor
p respond cells tumor
chlorophenoxyisobutyrate p respond cells tumor
Morphine alter hyperalgesia
sertraline effect Absence sensitization impairment cognitive
sertraline effect Absence sensitization impairment
sertraline administration worsened profile impairment cognitive
sertraline administration worsened profile impairment
estradiol progesterone use left forty year woman developed headache vomiting
estradiol progesterone use left forty year woman developed headache nausea
progesterone use left hemiparesis seizure
estradiol progesterone use left forty year woman developed headache
progesterone use left hemiparesis
progesterone use left forty year woman developed headache
estradiol progesterone use left hemiparesis
estradiol progesterone use left hemiparesis seizure
progesterone use left forty year woman developed headache vomiting
progesterone use left forty year woman developed headache nausea
estradiol use increased thrombogenicity provided thrombosis
estradiol use increased thrombogenicity provided thrombosis ICA of
estradiol use increased thrombogenicity provided thrombosis ICA both
estradiol use increased thrombogenicity provided thrombosis ICA the
estradiol use increased thrombogenicity provided thrombosis ICA
estradiol use increased thrombogenicity provided thrombosis ICA and
estradiol use increased thrombogenicity provided thrombosis ICA sinus the
estradiol use increased thrombogenicity provided thrombosis ICA sinus venous
estradiol use increased thrombogenicity provided thrombosis ICA sinus
progesterone estradiol DM
estradiol DM
progesterone estradiol use increased thrombogenicity provided thrombosis
progesterone estradiol use increased thrombogenicity provided thrombosis ICA of
progesterone estradiol use increased thrombogenicity provided thrombosis ICA both
progesterone estradiol use increased thrombogenicity provided thrombosis ICA the
progesterone estradiol use increased thrombogenicity provided thrombosis ICA
progesterone estradiol use increased thrombogenicity provided thrombosis ICA and
progesterone estradiol use increased thrombogenicity provided thrombosis ICA sinus the
progesterone estradiol use increased thrombogenicity provided thrombosis ICA sinus venous
progesterone estradiol use increased thrombogenicity provided thrombosis ICA sinus
cocaine intoxications abnormalities movement
cocaine intoxications abnormalities
cocaine intoxications abnormalities known hyperkinesias Choreatiform
cocaine intoxications abnormalities known hyperkinesias
heroine abusing methadone report movements euphoria choreoathetoid
heroine abusing methadone report movements
tamoxifen trial participating Patients group women cancer breast
tamoxifen trial participating Patients group women cancer
anastrozole trial participating Patients group women cancer breast
anastrozole trial participating Patients group women cancer
metoclopramide induced preexisting block left
metoclopramide induced preexisting block bundle
metoclopramide induced preexisting block branch
metoclopramide induced preexisting block
metoclopramide administration developed block left
metoclopramide administration developed block bundle
metoclopramide administration developed block branch
metoclopramide administration developed block
cocaine life short occur some seizures strokes
cocaine characterized resulted death
cocaine characterized prolonged resulted death
BE induced those prolonged characterized resulted death
BE induced those prolonged resulted death
mazindol dystrophy Duchenne
mazindol dystrophy
mazindol trial controlled boys dystrophy Duchenne
mazindol trial controlled boys dystrophy
Mazindol doses slow progression weakness
Mazindol doses slow dystrophy Duchenne
Mazindol doses slow dystrophy
ifosfamide patient breast
ifosfamide patient cancer
ifosfamide sixty developed cancer breast
ifosfamide sixty developed cancer
cisplatin treated cancer developed anuria
ifosfamide sixty developed failure renal
ifosfamide sixty developed failure
cisplatin treated cancer developed failure renal
cisplatin treated cancer developed failure
cisplatin treated cancer breast
cisplatin treated cancer
cisplatin received perfusion occurring due anuria
ifosfamide due occurring perfusion due hypotension
cisplatin received perfusion due hypotension
amiloride syndrome Attenuation diabetes
amiloride syndrome Attenuation diabetes insipidus
amiloride syndrome like
amiloride syndrome
lithium effect polydipsia polyuria
lithium concentration polydipsia polyuria
LiCl treated chronically rats investigated effect polydipsia
LiCl treated chronically rats investigated effect polydipsia polyuria
lithium effect polydipsia
lithium concentration polydipsia
amiloride effect polydipsia polyuria
amiloride effect polydipsia
amiloride attenuation diabetes
amiloride attenuation insipidus
amiloride attenuation syndrome like
amiloride attenuation syndrome
potassium level elevation ratio reduction accompanied attenuation diabetes
potassium level elevation ratio reduction accompanied attenuation insipidus
potassium level elevation ratio reduction accompanied attenuation syndrome like
potassium level elevation ratio reduction accompanied attenuation syndrome
lithium concluded relieve patients suffering polydipsia polyuria
lithium levels result relieve patients suffering polydipsia polyuria
lithium concluded relieve patients suffering polydipsia
lithium levels result relieve patients suffering polydipsia
amiloride administration concluded relieve patients suffering polydipsia polyuria
amiloride supplementation result relieve patients suffering polydipsia polyuria
amiloride administration concluded relieve patients suffering polydipsia
amiloride supplementation result relieve patients suffering polydipsia
glycopyrronium Use kg induced bradycardias
N effects seizure
2 urea effects seizure
propylpentanoyl 2 urea effects seizure
urea effects seizure
amino neurotransmitters urea effects seizure
acid neurotransmitters urea effects seizure
VPU exhibiting kg protecting rats seizure
VPA exhibiting kg protecting rats seizure
VPA value mg seizure
glutamate reduction offset suggested finding seizure
VPU protect finding seizure
aspartate glutamate reduction offset suggested finding seizure
VPA VPU protect finding seizure
amino neurotransmitters reduction minor suggested finding seizure
acid neurotransmitters reduction minor suggested finding seizure
glutamate increases account induced finding induced seizure
VPU reduce finding induced seizure
aspartate glutamate increases account induced finding induced seizure
VPA induced seizure
antidepressant use syndrome Rabbit
antidepressant use syndrome
desipramine toxicity
desipramine toxicity
quinine available banned cramps nocturnal
quinine available banned cramps leg
quinine available banned cramps
quinine containing products produce complications neurological
quinine containing products produce complications
4 chloride Effect therapy toxicity
aminopyridine therapy toxicity
desipramine toxicity
calcium chloride Effect therapy toxicity
chloride Effect therapy toxicity
calcium blockade role hypotension
calcium overdose
NaHCO RESULTS reversed prolongation hypotension
3 NaHCO RESULTS reversed prolongation hypotension
CaCl group incidence arrhythmias seizures
2 group incidence arrhythmias seizures
4 CaCl administration CONCLUSION reverse antidepressant hypotension
aminopyridine reverse antidepressant hypotension
CaCl administration CONCLUSION reverse antidepressant hypotension
2 CaCl administration CONCLUSION reverse antidepressant hypotension
CaCl therapy worsen cardiovascular
CaCl therapy worsen cardiovascular and
CaCl therapy worsen cardiovascular toxicity central
CaCl therapy worsen cardiovascular toxicity nervous
CaCl therapy worsen cardiovascular toxicity system
CaCl therapy worsen cardiovascular toxicity
2 therapy worsen cardiovascular
2 therapy worsen cardiovascular and
2 therapy worsen cardiovascular toxicity central
2 therapy worsen cardiovascular toxicity nervous
2 therapy worsen cardiovascular toxicity system
2 therapy worsen cardiovascular toxicity
calcium inhibition role hypotension
ouabain Effects supply patients disease coronary
ouabain Effects supply patients disease artery
ouabain Effects supply patients disease
oxygen ouabain Effects supply patients disease coronary
oxygen ouabain Effects supply patients disease artery
oxygen ouabain Effects supply patients disease
digitalis glycosides effects interest presence disease coronary
digitalis glycosides effects interest presence disease artery
digitalis glycosides effects interest presence disease
glycosides effects interest presence disease coronary
glycosides effects interest presence disease artery
glycosides effects interest presence disease
oxygen supply glycosides effects interest presence disease coronary
oxygen supply glycosides effects interest presence disease artery
oxygen supply glycosides effects interest presence disease
ouabain effects assessed patients disease coronary
ouabain effects assessed patients disease artery
ouabain effects assessed patients disease
ouabain effects assessed failure congestive
ouabain effects assessed failure heart
ouabain effects assessed failure
ouabain administration falls conclude disease coronary
ouabain administration falls conclude disease artery
ouabain administration falls conclude disease
ouabain administration falls conclude disease failure congestive
ouabain administration falls conclude disease failure heart
ouabain administration falls conclude disease failure
Statins cause myopathy hyperCKaemia
diethylstilbestrol associated Angiosarcoma
diethylstilbestrol associated Angiosarcoma liver of
diethylstilbestrol associated Angiosarcoma liver the
diethylstilbestrol associated Angiosarcoma liver
diethylstilbestrol differentiated adenocarcinoma
diethylstilbestrol differentiated adenocarcinoma liver of
diethylstilbestrol differentiated adenocarcinoma liver the
diethylstilbestrol differentiated adenocarcinoma liver
diethylstilbestrol differentiated occurred Angiosarcoma
diethylstilbestrol differentiated occurred Angiosarcoma liver of
diethylstilbestrol differentiated occurred Angiosarcoma liver the
diethylstilbestrol differentiated occurred Angiosarcoma liver
remifentanil propofol controlled Reduction pain
remifentanil infusing prevented pain
remifentanil prevent pain
Remifentanil assessed evaluated pain
remifentanil infusion assessed evaluated pain
remifentanil propofol TCI anaesthesia induction achieved reduction pain
remifentanil ml administration achieved reduction pain
anthracyclines cyclophosphamide used example patients systemic
anthracyclines cyclophosphamide used example patients sclerosis
cyclophosphamide used example patients systemic
cyclophosphamide used example patients sclerosis
mitoxantrone cyclophosphamide used example patients systemic
mitoxantrone cyclophosphamide used example patients sclerosis
anthracyclines cyclophosphamide used damage heart
anthracyclines cyclophosphamide used damage
warfarin contributed haemorrhage
warfarin contributed considered complication bleeding
warfarin patients 24 haemorrhage
warfarin patients 24 haemorrhage contributed considered complication bleeding
choline acetyltransferase activates MC induced amnesia
Daidzein activates MC induced amnesia
acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer
acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer '
acetylcholine production augmentation transmission enhances activator factor treatment disease s
acetylcholine production augmentation transmission enhances activator factor treatment disease
acetylcholine production augmentation transmission enhances activator factor treatment disease AD
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease Alzheimer '
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease s
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease
ACh acetylcholine production augmentation transmission enhances activator factor treatment disease AD
choline acetyltransferase activator factor treatment disease Alzheimer
choline acetyltransferase activator factor treatment disease Alzheimer '
choline acetyltransferase activator factor treatment disease s
choline acetyltransferase activator factor treatment disease
choline acetyltransferase activator factor treatment disease AD
scopolamine thunbergiana impairments
scopolamine thunbergiana impairments learning of
scopolamine thunbergiana impairments learning
scopolamine thunbergiana impairments learning and
scopolamine thunbergiana impairments learning memory
daidzein effects investigate thunbergiana impairments
daidzein effects investigate thunbergiana impairments learning of
daidzein effects investigate thunbergiana impairments learning
daidzein effects investigate thunbergiana impairments learning and
daidzein effects investigate thunbergiana impairments learning memory
daidzein Administration shown reverse test scopolamine induced amnesia
acetylcholine biosynthesis role play ameliorates scopolamine amnesia
daidzein play ameliorates scopolamine amnesia
GR accumbens shell induced hyperactivity locomotor
GR accumbens shell induced hyperactivity
55562 GR accumbens shell induced hyperactivity locomotor
55562 GR accumbens shell induced hyperactivity
GR antagonist effects consisting modification core shell microinjected indicate modified hyperlocomotion
55562 GR antagonist effects consisting modification core shell microinjected indicate modified hyperlocomotion
ampicillin treated septicemia
gentamicin ampicillin treated septicemia
penicillins allergy
penicillins allergy manifestation myocarditis Hypersensitivity
penicillins allergy manifestation myocarditis
caffeine administration developed patient history disease arrhythmia
caffeine administration developed patient history disease cardiac
caffeine administration developed patient history disease
caffeine tolerated aware potential arrhythmias ventricular
caffeine tolerated aware potential arrhythmias
heparin therapy receiving patients thromboembolism
heparin associated complication thromboembolism
heparin therapy complication thromboembolism
heparin therapy initiation days occurring ischemia
heparin therapy initiation days occurring ischemia thrombi
heparin induced aggregation platelet
heparin induced aggregation
heparin factor relating thromboembolism
doxorubicin cardiotoxicity
adriamycin use limits complication toxicity Cardiac
adriamycin use limits complication toxicity
tachykinins involvement E hyperactivity bladder
tachykinins involvement E hyperactivity
tachykinins release contribute hyperactivity urge bladder
tachykinins release contribute hyperactivity
Prostanoids contribute hyperactivity urge bladder
Prostanoids contribute hyperactivity
L complications arise patients Parkinson
L complications arise patients Parkinson '
L complications arise patients s
L complications arise patients disease
DOPA L complications arise patients Parkinson
DOPA L complications arise patients Parkinson '
DOPA L complications arise patients s
DOPA L complications arise patients disease
L complications arise patients PD
DOPA L complications arise patients PD
L treatment arise patients Parkinson
L treatment arise patients Parkinson '
L treatment arise patients s
L treatment arise patients disease
DOPA arise patients Parkinson
DOPA arise patients Parkinson '
DOPA arise patients s
DOPA arise patients disease
L treatment arise patients PD
DOPA arise patients PD
bromocriptine DOPA changes model PD
L saline treated PD
DOPA changes model PD
6 obtained samples level occurring changes model PD
hydroxydopamine occurring changes model PD
clozapine threshold lowered have risk EPS
clozapine agranulocytosis threshold lowered have risk EPS
clozapine threshold lowered have associated degrees sedation dysfunction sexual
clozapine threshold lowered have associated degrees sedation dysfunction
clozapine agranulocytosis threshold lowered have associated degrees sedation dysfunction sexual
clozapine agranulocytosis threshold lowered have associated degrees sedation dysfunction
clozapine threshold seizure
clozapine agranulocytosis threshold seizure
clozapine threshold lowered have associated degrees sedation gain weight
clozapine threshold lowered have associated degrees sedation gain
clozapine agranulocytosis threshold lowered have associated degrees sedation gain weight
clozapine agranulocytosis threshold lowered have associated degrees sedation gain
deferoxamine tocopherol Effect induced neurotoxicity
methamphetamine tocopherol Effect induced neurotoxicity
alpha Effect induced neurotoxicity
tocopherol Effect induced neurotoxicity
Methamphetamine neurotoxicity
MA Methamphetamine neurotoxicity
iron chelator scavenger tocopherol induced neurotoxicity
oxygen species scavenger tocopherol induced neurotoxicity
deferoxamine species scavenger tocopherol induced neurotoxicity
DFO species scavenger tocopherol induced neurotoxicity
MA scavenger tocopherol induced neurotoxicity
alpha effect examined induced neurotoxicity
tocopherol induced neurotoxicity
alpha tocopherol induced neurotoxicity
TC alpha tocopherol induced neurotoxicity
alpha TC attenuated induced hyperthermia
TC attenuated induced hyperthermia
DFO TC attenuated induced hyperthermia
DFO TC ameliorate induced damage neuronal
DFO TC ameliorate induced damage
alpha induced damage neuronal
alpha induced damage
TC ameliorate induced damage neuronal
TC ameliorate induced damage
MK catalepsy
801 haloperidol catalepsy
serotonin release correlation concentration related attack migraine
NO attack migraine
calcitonin gene increase attack migraine
gene increase attack migraine
related attack migraine
peptide concentration related attack migraine
CGRP concentration related attack migraine
serotonin concentration content headache attack migraine
5 concentration content headache attack migraine
hydroxytriptamine 5 concentration content headache attack migraine
5 5 concentration content headache attack migraine
HT 5 5 concentration content headache attack migraine
nitroglycerin provoked concentration content headache attack migraine
serotonin concentration content headache
5 concentration content headache
hydroxytriptamine 5 concentration content headache
5 5 concentration content headache
HT 5 5 concentration content headache
nitroglycerin provoked concentration content headache
calcitonin gene investigate was provoked concentration content headache
gene investigate was provoked concentration content headache
related concentration content headache
peptide concentration content headache
CGRP concentration content headache
calcitonin gene investigate was provoked concentration content headache attack migraine
gene investigate was provoked concentration content headache attack migraine
related concentration content headache attack migraine
peptide concentration content headache attack migraine
CGRP concentration content headache attack migraine
nitroglycerin application collected collected min beginning attack migraine
CGRP concentration increased attack migraine
CGRP concentration increased returned cessation migraine
CGRP concentrations failed change headache
CGRP concentrations failed change change subjects attack migraine
5 higher tended lower subjects experienced attack migraine
HT content tended lower subjects experienced attack migraine
CGRP concentration higher tended lower subjects experienced attack migraine
serotonin content decreased significantly observed nitroglycerin subjects attack migraine
serotonin content decreased significantly observed patients attack migraine
nitroglycerin subjects attack migraine
nitroglycerin observed patients attack migraine
CGRP timing headache
CGRP relationship suggests fact CGRP timing headache
CGRP timing headache migraine
CGRP fact suggests relationship CGRP migraine
CGRP relationship suggests fact CGRP timing headache migraine
CGRP migraine
serotonin release provoke migraine
serotonin release provoke counteract headache
CGRP release headache
CGRP release headache counteract provoke migraine
Clonidine attention
Clonidine deficit
Clonidine deficit analysis changes II disorder hyperactivity
Clonidine deficit analysis changes II disorder
methylphenidate children attention
methylphenidate children attention deficit
methylphenidate disorder hyperactivity
methylphenidate disorder
methylphenidate disorder ADHD
clonidine used or disorder methylphenidate children attention
clonidine used or disorder methylphenidate children attention deficit
clonidine used or disorder hyperactivity
clonidine used or disorder
clonidine used or disorder ADHD
methylphenidate assigned children ADHD
methylphenidate clonidine assigned children ADHD
clonidine assigned children ADHD
clonidine assigned children ADHD
clonidine common Drowsiness
methylphenidate or used Clonidine appears safe tolerated ADHD
Clonidine appears safe tolerated ADHD
clonidine monitor advise likelihood drowsiness
Chloroquine block heart
Chloroquine block
chloroquine ingestion presented deterioration
chloroquine ingestion presented deterioration vision of
chloroquine ingestion presented deterioration vision
chloroquine retinopathy features revealed revealed features failure block heart
chloroquine retinopathy features revealed revealed features failure block
chloroquine discontinuation resolved failure insertion treated block heart
chloroquine discontinuation resolved failure insertion treated block
levonorgestrel dose presence identified years had infarction myocardial
levonorgestrel dose presence identified years had infarction
levonorgestrel 925 women had infarction myocardial
levonorgestrel 925 women had infarction
estrogen dose presence identified years had infarction myocardial
estrogen dose presence identified years had infarction
estrogen dose levonorgestrel 925 women had infarction myocardial
estrogen dose levonorgestrel 925 women had infarction
hepatitis antigen born infants done following screening B rubella
B antigen born infants done following screening B rubella
surface antigen born infants done following screening B rubella
antigen born infants done following screening B rubella
hepatitis antigen immunity rubella
B antigen immunity rubella
surface antigen immunity rubella
antigen immunity rubella
hepatitis antigen administration vaccine rubella
B antigen administration vaccine rubella
surface antigen administration vaccine rubella
antigen administration vaccine rubella
hepatitis antigen born women rubella
B antigen born women rubella
surface antigen born women rubella
antigen born women rubella
benzylisoquinolinium NMBA short besylate associated paralysis
trifluoroacetyl adduct protein response detected patients hepatitis
enflurane reactivity cross determine hypersensitivity
halothane induced hypersensitivity
isoflurane enflurane reactivity cross determine hypersensitivity
enflurane produce condition hypersensitivity
halothane hepatitis that similar produce condition hypersensitivity
halothane administration subsequent produce condition hypersensitivity
isoflurane / enflurane produce condition hypersensitivity
cyclophosphamide doxorubicin encapsulated efficacy preserved cardiotoxicity
cyclophosphamide encapsulated efficacy preserved cardiotoxicity
doxorubicin encapsulated efficacy preserved cardiotoxicity
doxorubicin encapsulated efficacy preserved cardiotoxicity
cyclophosphamide doxorubicin encapsulated cyclophosphamide trial cancer breast
cyclophosphamide doxorubicin encapsulated cyclophosphamide trial cancer
cyclophosphamide trial cancer breast
cyclophosphamide trial cancer
doxorubicin encapsulated cyclophosphamide trial cancer breast
doxorubicin encapsulated cyclophosphamide trial cancer
doxorubicin encapsulated cyclophosphamide trial cancer breast
doxorubicin encapsulated cyclophosphamide trial cancer
cyclophosphamide combination Myocet reduces cardiotoxicity
Myocet reduces cardiotoxicity
doxorubicin Myocet reduces cardiotoxicity
doxorubicin cardiotoxicity
cyclophosphamide combination Myocet reduces determine treatment cancer breast
cyclophosphamide combination Myocet reduces determine treatment cancer
cyclophosphamide combination Myocet reduces determine treatment cancer MBC
Myocet reduces determine treatment cancer breast
Myocet reduces determine treatment cancer
Myocet reduces determine treatment cancer MBC
doxorubicin Myocet reduces determine treatment cancer breast
doxorubicin Myocet reduces determine treatment cancer
doxorubicin Myocet reduces determine treatment cancer MBC
doxorubicin cardiotoxicity reduces determine treatment cancer breast
doxorubicin cardiotoxicity reduces determine treatment cancer
doxorubicin cardiotoxicity reduces determine treatment cancer MBC
Myocet m mg m cyclophosphamide toxicity
doxorubicin Myocet m mg m cyclophosphamide toxicity
cyclophosphamide toxicity
cyclophosphamide m receive randomized Two patients MBC
Myocet m mg m receive randomized Two patients MBC
doxorubicin Myocet m mg m receive randomized Two patients MBC
cyclophosphamide used provides improves index doxorubicin reducing neutropenia cardiotoxicity
Myocet improves index doxorubicin reducing neutropenia cardiotoxicity
doxorubicin reducing neutropenia cardiotoxicity
cyclophosphamide used first therapy MBC
Myocet improves provides used first therapy MBC
doxorubicin index improves provides used first therapy MBC
puromycin aminonucleoside rats nephrosis model syndrome nephrotic
puromycin aminonucleoside rats nephrosis model syndrome
aminonucleoside rats nephrosis model syndrome nephrotic
aminonucleoside rats nephrosis model syndrome
puromycin aminonucleoside induced abnormalities hematological
puromycin aminonucleoside induced abnormalities
aminonucleoside induced abnormalities hematological
aminonucleoside induced abnormalities
Puromycin aminonucleoside induced dysfunction hyperlipidemia
aminonucleoside induced dysfunction hyperlipidemia
Puromycin aminonucleoside induced dysfunction renal
Puromycin aminonucleoside induced dysfunction
aminonucleoside induced dysfunction renal
aminonucleoside induced dysfunction
puromycin aminonucleoside induced syndrome nephrotic
puromycin aminonucleoside induced syndrome
aminonucleoside induced syndrome nephrotic
aminonucleoside induced syndrome
U injection causes hypertension
II causes hypertension
U injection causes hypertension bradycardia
II causes hypertension bradycardia
corticosterone level had induced erection penile
corticosterone level had induced erection
U administration II had induced erection penile
U administration II had induced erection
II had induced erection penile
II had induced erection
U II involved aspects disorders psychiatric
U II involved aspects disorders
- II involved aspects disorders psychiatric
- II involved aspects disorders
II involved aspects disorders psychiatric
II involved aspects disorders
lometrexol has activity tumours
methotrexate drugs refractory tumours
lometrexol development curtailed toxicities
folic administration prevented toxicity
acid administration prevented toxicity
lometrexol toxicity
folic supplementation confirmed reduced toxicity
acid supplementation confirmed reduced toxicity
folic supplementation reduced toxicity
acid supplementation reduced toxicity
lometrexol study prompted supplementation confirmed reduced toxicity
lometrexol toxicity
folate elevation extent relationship toxicity
folic administration altered indicating unlikely reduce toxicity
acid administration altered indicating unlikely reduce toxicity
lometrexol pharmacokinetics altered indicating unlikely reduce toxicity
lometrexol clearance enhancing reduce toxicity
lactate elevates mice AIDS
lactate elevates causes cardiomyopathy
lactate AIDS
LA lactate AIDS
lactate implicated implicated mechanisms dysfunction mitochondrial
lactate implicated implicated mechanisms dysfunction
LA lactate implicated implicated mechanisms dysfunction mitochondrial
LA lactate implicated implicated mechanisms dysfunction
lactate implicated implicated cardiomyopathy
lactate implicated implicated cardiomyopathy CM
LA lactate implicated implicated cardiomyopathy
LA lactate implicated implicated cardiomyopathy CM
zidovudine combination treated n week hemizygous mice AIDS
lamivudine zidovudine combination treated n week hemizygous mice AIDS
indinavir zidovudine combination treated n week hemizygous mice AIDS
calcium SERCA mRNA echocardiography quantitation abundance markers CM
LA determination echocardiography quantitation abundance markers CM
LA caused mice AIDS
LA caused CM
epinephrine administer scene paramedics led onset distress respiratory
epinephrine administer scene paramedics led onset distress
epinephrine administer scene paramedics led onset distress rash
Epinephrine has viewed use paramedics patients reaction hypertension
Epinephrine has viewed use paramedics patients reaction allergic
Epinephrine has viewed use paramedics patients reaction
heparin treated stopped months onset anuria
dipyridamole heparin treated stopped months onset anuria
Ca L decreases promotes occurrence fibrillation atrial
Ca L decreases promotes occurrence fibrillation
Ca L decreases promotes occurrence fibrillation AF
Ca L decreases promotes BACKGROUND tachycardia Atrial
Ca L decreases promotes BACKGROUND tachycardia
Ca channel promote AF
Ca channel promote AF consistent AF
Ca inhibition effect promoting AF
Ca inhibition effect promoting AF consistent AF
chloralose dogs morphine verapamil administered evaluate mechanisms promotion AF
Ca blockers evaluate mechanisms promotion AF
morphine verapamil administered evaluate mechanisms promotion AF
Diltiazem affect ERP length AF
Diltiazem affect ERP duration AF
diltiazem shared promoting dogs AF
amphotericin B administration developed patient cirrhosis
B administration developed patient cirrhosis
amphotericin B administration developed patient cirrhosis sporotrichosis
B administration developed patient cirrhosis sporotrichosis
pilocarpine reported seizures
pilocarpine reported used localize genes seizure
pilocarpine seizures
pilocarpine tested A induced seizures
13 trial cis acid children neuroblastoma
cis acid children neuroblastoma
retinoic acid children neuroblastoma
acid children neuroblastoma
13 lines neuroblastoma
cis PURPOSE Treatment lines neuroblastoma
retinoic acid cause PURPOSE Treatment lines neuroblastoma
acid cause PURPOSE Treatment lines neuroblastoma
cis acid cause PURPOSE Treatment lines neuroblastoma
RA cis acid cause PURPOSE Treatment lines neuroblastoma
cis effective demonstrated patients neuroblastoma
RA demonstrated patients neuroblastoma
cis pharmacokinetics maximal toxicities
RA pharmacokinetics maximal toxicities
cis pharmacokinetics RA administered neuroblastoma
RA administered neuroblastoma
cis resolved toxicities
RA discontinued resolved toxicities
lithium exposed screening Cross induced malformations cardiac
lithium exposed screening Cross induced malformations
lithium presence assessment provide gestation exposed screening Cross induced malformations cardiac
lithium presence assessment provide gestation exposed screening Cross induced malformations
cocaine nephritis Henoch cases hypertension microangiopathy nephritis lupus
cocaine nephritis Henoch cases hypertension microangiopathy nephritis
cocaine nephritis Henoch cases hypertension microangiopathy thrombotic
cocaine nephritis Henoch cases hypertension microangiopathy
cocaine nephritis glomerulonephritis
cocaine nephritis Henoch
cocaine nephritis Schonlein
cocaine nephritis
cocaine nephritis Henoch cases hypertension malignant
cocaine nephritis Henoch cases hypertension
Norepinephrine signaling critical induced anxiety
dopamine beta performance induced anxiety
norepinephrine lack mice performance induced anxiety
NE norepinephrine lack mice performance induced anxiety
disulfiram administration mice Cocaine induced attenuated anxiety
dopamine beta disulfiram administration mice Cocaine induced attenuated anxiety
prazosin had C type pretreatment antagonist anxiety
yohimbine prazosin had C type pretreatment antagonist anxiety
propranolol cocaine antagonist anxiety
echothiophate eye instillation resulting toxicity
iodide eye instillation resulting toxicity
echothiophate drops use developed given diagnosis gravis myasthenia
echothiophate drops use developed given diagnosis gravis
iodide drops use developed given diagnosis gravis myasthenia
iodide drops use developed given diagnosis gravis
lidocaine hyperalgesia
ketamine lidocaine hyperalgesia
lidocaine ketamine hyperalgesia
lidocaine brush pain
ketamine hyperalgesia
ketamine lidocaine brush pain
Ketamine reduced evoked hyperalgesia
Ketamine reduced evoked tended reduce brush pain
Lidocaine reduced area hyperalgesia
lidocaine ketamine hyperalgesia
lidocaine ketamine effects suggest mediated types hyperalgesia
ketamine hyperalgesia
ketamine effects suggest mediated types hyperalgesia
levodopa pallidotomy signs parkinsonian
levodopa responsiveness outcome signs parkinsonian
levodopa responsiveness outcome correlations volume dyskinesias signs parkinsonian
levodopa responsiveness value indicate responsible generation signs parkinsonian
ifosfamide prevention mesna dexamethasone Use cystitis hemorrhagic
ifosfamide prevention mesna dexamethasone Use cystitis
dexamethasone Use cystitis hemorrhagic
dexamethasone Use cystitis
mesna dexamethasone Use cystitis hemorrhagic
mesna dexamethasone Use cystitis
ifosfamide chemotherapy effect AIM cystitis Hemorrhagic
ifosfamide chemotherapy effect AIM cystitis
ifosfamide chemotherapy effect AIM cystitis HC
IFS ifosfamide chemotherapy effect AIM cystitis Hemorrhagic
IFS ifosfamide chemotherapy effect AIM cystitis
IFS ifosfamide chemotherapy effect AIM cystitis HC
IFS prevention HC
dexamethasone use investigated mesna prevention HC
mesna prevention HC
IFS HC
Dexamethasone efficient blocking IFS HC
mesna combination Dexamethasone efficient blocking IFS HC
dexamethasone doses all mesna replacement prevent HC
mesna replacement prevent HC
mesna doses all mesna replacement prevent HC
D penicillamine treatment scleroderma localized
D penicillamine treatment scleroderma
penicillamine treatment scleroderma localized
penicillamine treatment scleroderma
D treated reports patients scleroderma localized
D treated reports patients scleroderma
penicillamine summarized reports patients scleroderma localized
penicillamine summarized reports patients scleroderma
D caused developed insufficiency renal
D caused developed insufficiency
Penicillamine caused developed insufficiency renal
Penicillamine caused developed insufficiency
D effective cases scleroderma localized
D effective cases scleroderma
penicillamine D effective cases scleroderma localized
penicillamine D effective cases scleroderma
serotonin inhibitor hydrochloride induced hyperprolactinemia effects model adenomyosis
serotonin inhibitor hydrochloride induced induction adenomyosis
serotonin inhibitor hydrochloride induced hyperprolactinemia
serotonin inhibitor Fluoxetine given produce hyperprolactinemia
dipivalyl epinephrine glaucoma
epinephrine glaucoma
azathioprine Treatment psoriasis
Azathioprine treatment benefited 19 patients suffering psoriasis
azathioprine therapy continued detected damage liver
azathioprine therapy continued detected damage
amphetamine cocaine screening prevalence determine patients seizure
cocaine screening prevalence determine patients seizure
alcohol drug underlying history time seizure
alcohol drug underlying history time seizure
alcohol drug underlying history history abuse cocaine
alcohol drug underlying history history abuse cocaine or
alcohol drug underlying history history abuse cocaine amphetamine
alcohol drug underlying history history abuse
amphetamines cocaine screening patients seizure
cocaine screening patients seizure
verapamil therapy hypotension adrenergic failure developed patients disease ischaemic
verapamil therapy hypotension adrenergic failure developed patients disease heart
verapamil therapy hypotension adrenergic failure developed patients disease
beta verapamil therapy hypotension adrenergic failure developed patients disease ischaemic
beta verapamil therapy hypotension adrenergic failure developed patients disease heart
beta verapamil therapy hypotension adrenergic failure developed patients disease
adrenergic failure developed patients disease ischaemic
adrenergic failure developed patients disease heart
adrenergic failure developed patients disease
blocking developed patients disease ischaemic
blocking developed patients disease heart
blocking developed patients disease
drugs blocking developed patients disease ischaemic
drugs blocking developed patients disease heart
drugs blocking developed patients disease
prazosin blockade 2 rats hypertensive
prazosin treatment alters function control pressure rats hypertensive
rauwolscine treated SHR treated treated hypotension orthostatic
rauwolscine treated SHR treated treated hypotension
prazosin pretreatment determined responses bradycardia
prazosin abolished pressor effects bradycardia
prazosin treatment greater bradycardia
prazosin treatment similar bradycardia
methylprednisolone Value syndrome myalgia
iron dextran infusion associated syndrome myalgia
dextran infusion associated syndrome myalgia
methylprednisolone prevention arthralgia
MP administration demonstrate reduces frequency syndrome myalgia
MP administration demonstrate reduces frequency syndrome arthralgia
benzodiazepine antagonist used reverse depression sedation respiratory
benzodiazepine antagonist used reverse depression
benzodiazepines induced depression sedation respiratory
benzodiazepines induced depression
Flumazenil antagonist used reverse depression sedation respiratory
Flumazenil antagonist used reverse depression
nitrendipine nephrosclerosis rats hypertension renovascular
nitrendipine nephrosclerosis rats hypertension
calcium blocker effect nitrendipine nephrosclerosis
calcium blocker effect nitrendipine nephrosclerosis rats hypertension renovascular
calcium blocker effect nitrendipine nephrosclerosis rats hypertension
nitrendipine treatment effect studied rats kidney hypertension renovascular
nitrendipine treatment effect studied rats kidney hypertension
angiotensin converting pressure albuminuria
enalapril converting angiotensin effect studied rats kidney hypertension renovascular
enalapril converting angiotensin effect studied rats kidney hypertension
enalapril converting pressure albuminuria
angiotensin effect studied rats kidney hypertension renovascular
angiotensin effect studied rats kidney hypertension
calcium nitrendipine treatment effect angiotensin converting pressure albuminuria
calcium nitrendipine treatment effect studied rats kidney hypertension renovascular
calcium nitrendipine treatment effect studied rats kidney hypertension
nitrendipine assigned rats hypertensive
nitrendipine assigned groups controls hypertensive
enalapril controls groups assigned rats hypertensive
enalapril controls hypertensive
enalapril treatment change excretion glomerulosclerosis
nitrendipine contrast controls hr hypertensive
nitrendipine treated controls hypertensive
nitrendipine increased index glomerulosclerosis
nitrendipine group higher in treated controls hypertensive
enalapril treated controls hypertensive
nitrazepam + morphine premedicated patients kg found lasted occurred apnoea
morphine premedicated patients kg found lasted occurred apnoea
scopolamine morphine premedicated patients kg found lasted occurred apnoea
perhexiline maleate noted used treatment pectoris angina
perhexiline maleate noted used treatment pectoris
maleate noted used treatment pectoris angina
maleate noted used treatment pectoris
oxypurines nucleosides ischemia cerebral
oxypurines nucleosides ischemia
nucleosides ischemia cerebral
nucleosides ischemia
oxypurines time observed ischemia
nucleosides oxypurines time observed ischemia
malondialdehyde increased min ischemia
nitroprusside mg w ischemia
nitroprusside mg receiving one model subjected animals groups recorded min ischemia
acetylsalicylate intravenously w mg nitroprusside hypotensive
malondialdehyde recorded groups animals subjected model one receiving mg nitroprusside hypotensive
malondialdehyde higher ischemia min recorded groups animals subjected model one receiving mg nitroprusside hypotensive
acetylsalicylate intravenously w ischemia
acetylsalicylate intravenously w mg receiving one model subjected animals groups recorded min ischemia
malondialdehyde recorded groups animals subjected model one receiving mg w ischemia
malondialdehyde recorded min ischemia
malondialdehyde higher ischemia min recorded groups animals subjected model one receiving mg w ischemia
malondialdehyde higher ischemia
nitroprusside hypotensive
oxypurines malondialdehyde determination used monitor alterations tissues occurring phenomena ischemic
malondialdehyde determination used monitor alterations tissues occurring phenomena ischemic
nucleosides malondialdehyde determination used monitor alterations tissues occurring phenomena ischemic
propranolol disease Parkinson
propranolol disease Parkinson '
propranolol disease s
propranolol disease
propranolol dyskinesia
levodopa Improvement dyskinesia propranolol disease Parkinson
levodopa Improvement dyskinesia propranolol disease Parkinson '
levodopa Improvement dyskinesia propranolol disease s
levodopa Improvement dyskinesia propranolol disease
propranolol low received patients suffering disease Parkinson
propranolol low received patients suffering disease Parkinson '
propranolol low received patients suffering disease s
propranolol low received patients suffering disease
propranolol low received patients suffering disease PD
propranolol low received patients suffering dyskinesia
levodopa improve induced dyskinesia PD
corticosteroids agents blocking neuromuscular paralysis
nondepolarizing paralysis
neuromuscular paralysis
blocking neuromuscular paralysis
agents blocking neuromuscular paralysis
ND discontinuation weakness developed insufficiency respiratory
ND discontinuation weakness developed insufficiency
NMBAs patients insufficiency respiratory
NMBAs patients insufficiency
corticosteroids due junction pathology due weakness
corticosteroids due junction pathology
corticosteroids due junction at
corticosteroids due junction both
corticosteroids due junction the
corticosteroids due junction neuromuscular
corticosteroids due junction
doxorubicin cycle fibrillation association form dystrophy muscular
doxorubicin cycle fibrillation association form dystrophy
doxorubicin cycle fibrillation association lymphoma gastric
doxorubicin cycle fibrillation association lymphoma
doxorubicin cycle fibrillation association lymphoma dystrophy myotonic
doxorubicin cycle fibrillation association lymphoma dystrophy
maltolyl p compound attenuates deficits cognitive
maltolyl p compound attenuates deficits
p compound attenuates deficits cognitive
p compound attenuates deficits
coumarate p compound attenuates deficits cognitive
coumarate p compound attenuates deficits
maltolyl p compound attenuates shows models vitro dementia
p compound attenuates shows models vitro dementia
coumarate p compound attenuates shows models vitro dementia
maltolyl p improve decline cognitive
maltolyl p improve decline
p improve decline cognitive
p improve decline
coumarate improve decline cognitive
coumarate improve decline
amyloid peptide injected p improve decline cognitive
amyloid peptide injected p improve decline
beta peptide injected p improve decline cognitive
beta peptide injected p improve decline
peptide injected p improve decline cognitive
peptide injected p improve decline
1 peptide injected p improve decline cognitive
1 peptide injected p improve decline
42 1 peptide injected p improve decline cognitive
42 1 peptide injected p improve decline
Maltolyl p found attenuate deficits cognitive
Maltolyl p found attenuate deficits
p found attenuate deficits cognitive
p found attenuate deficits
coumarate found attenuate deficits cognitive
coumarate found attenuate deficits
amyloid peptide hippocampus observed death reduce attenuate deficits cognitive
amyloid peptide hippocampus observed death reduce attenuate deficits
beta peptide hippocampus observed death reduce attenuate deficits cognitive
beta peptide hippocampus observed death reduce attenuate deficits
peptide hippocampus observed death reduce attenuate deficits cognitive
peptide hippocampus observed death reduce attenuate deficits
1 peptide hippocampus observed death reduce attenuate deficits cognitive
1 peptide hippocampus observed death reduce attenuate deficits
42 1 peptide hippocampus observed death reduce attenuate deficits cognitive
42 1 peptide hippocampus observed death reduce attenuate deficits
maltolyl p suggests candidate characterized death decline
maltolyl p suggests candidate characterized death function of
maltolyl p suggests candidate characterized death function cognitive
maltolyl p suggests candidate characterized death function
p suggests candidate characterized death decline
p suggests candidate characterized death function of
p suggests candidate characterized death function cognitive
p suggests candidate characterized death function
coumarate candidate characterized death decline
coumarate candidate characterized death function of
coumarate candidate characterized death function cognitive
coumarate candidate characterized death function
maltolyl p suggests candidate disease Alzheimer
maltolyl p suggests candidate disease Alzheimer '
maltolyl p suggests candidate disease s
maltolyl p suggests candidate disease
p suggests candidate disease Alzheimer
p suggests candidate disease Alzheimer '
p suggests candidate disease s
p suggests candidate disease
coumarate candidate disease Alzheimer
coumarate candidate disease Alzheimer '
coumarate candidate disease s
coumarate candidate disease
maltolyl p suggests candidate characterized death neuronal
maltolyl p suggests candidate characterized death
p suggests candidate characterized death neuronal
p suggests candidate characterized death
coumarate candidate characterized death neuronal
coumarate candidate characterized death
Galanthamine hydrobromide used patient demonstrating effects overdosage
hydrobromide used patient demonstrating effects overdosage
cibenzoline effects arrhythmias ventricular
cibenzoline effects arrhythmias
cibenzoline + effects examined using models ventricular
cibenzoline + effects examined using models arrhythmia
cibenzoline examined using models ventricular
cibenzoline examined using models arrhythmia
pentobarbital ouabain injection intermittent induced arrhythmia
Na blockers suppressed arrhythmia
Digitalis arrhythmia
Ca blockers suppressed arrhythmia Adrenaline
Ca blockers suppressed arrhythmia
halothane infusion induced arrhythmia Adrenaline
halothane infusion induced arrhythmia
cibenzoline arrhythmias
digitalis cibenzoline arrhythmias
cibenzoline 1 arrhythmias
digitalis arrhythmias
cibenzoline suppressed induced v arrhythmia
cibenzoline - dose needed suppress adrenaline arrhythmias
digitalis induced v arrhythmia
digitalis induced suppressed cibenzoline - dose needed suppress adrenaline arrhythmias
cibenzoline 0 arrhythmia
digitalis arrhythmia
naloxone reversal paralysis respiratory
naloxone reversal paralysis
GABA involvement reversal paralysis respiratory
GABA involvement reversal paralysis
naloxone reversed paralysis respiratory
naloxone reversed paralysis
amino acids any affecting stem produced arrest respiratory
amino acids any affecting stem produced arrest
acids any affecting stem produced arrest respiratory
acids any affecting stem produced arrest
glutamate decrease stem produced arrest respiratory
glutamate decrease stem produced arrest
thiopental produced arrest respiratory
thiopental produced arrest
GABA produced arrest respiratory
GABA produced arrest
Naloxone reversed levels respiratory
Naloxone reversed levels paralysis
GABA paralysis levels respiratory
GABA paralysis
glutamate paralysis levels respiratory
glutamate paralysis
naloxone reverses paralysis respiratory
naloxone reverses paralysis
GABA involves reverses paralysis respiratory
GABA involves reverses paralysis
nitrazepam overdose took received symptoms withdrawal
nitrazepam overdose took received symptoms
chlormethiazole doses received symptoms withdrawal
chlormethiazole doses received symptoms
alcohol symptoms withdrawal
alcohol symptoms
chlormethiazole doses received took overdose
alcohol symptoms received took overdose
chlormethiazole intoxication those two patient overdose
physostigmine attenuated potentiated hyperactivity
methscopolamine had effect hyperactivity
neostigmine methscopolamine had effect hyperactivity
serotonin depletor chlorophenylalamine pretreatment caused hyperactivity
p pretreatment caused hyperactivity
chlorophenylalamine pretreatment caused hyperactivity
heparin products lots number found contaminated derivative elicit response hypotensive
heparin products Using showed produces dose hypotension
Zonisamide broad drug used treat types seizures
Topiramate medication becoming more prescribed efficacy treating seizures refractory
Topiramate medication becoming more prescribed efficacy treating seizures
calcium nephrolithiasis
phosphate nephrolithiasis
Loreclezole exerted reducing durations seizure
carbon tetrachloride relationship Phenobarbitone enlargement
carbon tetrachloride relationship Phenobarbitone enlargement liver of
carbon tetrachloride relationship Phenobarbitone enlargement liver the
carbon tetrachloride relationship Phenobarbitone enlargement liver
tetrachloride relationship Phenobarbitone enlargement
tetrachloride relationship Phenobarbitone enlargement liver of
tetrachloride relationship Phenobarbitone enlargement liver the
tetrachloride relationship Phenobarbitone enlargement liver
carbon tetrachloride relationship Phenobarbitone induced cirrhosis
tetrachloride relationship Phenobarbitone induced cirrhosis
Phenobarbitone induced cirrhosis
carbon tetrachloride yield given induced enlargement
carbon tetrachloride yield given induced enlargement liver of
carbon tetrachloride yield given induced enlargement liver the
carbon tetrachloride yield given induced enlargement liver
tetrachloride yield given induced enlargement
tetrachloride yield given induced enlargement liver of
tetrachloride yield given induced enlargement liver the
tetrachloride yield given induced enlargement liver
carbon tetrachloride dose giving increased primed given induced enlargement
carbon tetrachloride dose giving increased primed given induced enlargement liver of
carbon tetrachloride dose giving increased primed given induced enlargement liver the
carbon tetrachloride dose giving increased primed given induced enlargement liver
tetrachloride dose giving increased primed given induced enlargement
tetrachloride dose giving increased primed given induced enlargement liver of
tetrachloride dose giving increased primed given induced enlargement liver the
tetrachloride dose giving increased primed given induced enlargement liver
carbon tetrachloride yield cirrhosis defined nodular normal g dl splenomegaly
tetrachloride yield cirrhosis defined nodular normal g dl splenomegaly
carbon tetrachloride dose giving increased primed given yield cirrhosis defined nodular normal g dl splenomegaly
tetrachloride dose giving increased primed given yield cirrhosis defined nodular normal g dl splenomegaly
carbon tetrachloride yield cirrhosis defined nodular testicular atrophy
tetrachloride yield cirrhosis defined nodular testicular atrophy
carbon tetrachloride dose giving increased primed given yield cirrhosis defined nodular testicular atrophy
tetrachloride dose giving increased primed given yield cirrhosis defined nodular testicular atrophy
phenobarbitone given yield cirrhosis defined nodular testicular atrophy
phenobarbitone peak giving increased primed given yield cirrhosis defined nodular testicular atrophy
phenobarbitone given yield cirrhosis defined nodular normal g dl splenomegaly
phenobarbitone peak giving increased primed given yield cirrhosis defined nodular normal g dl splenomegaly
carbon tetrachloride yield cirrhosis defined nodular ascites
tetrachloride yield cirrhosis defined nodular ascites
carbon tetrachloride dose giving increased primed given yield cirrhosis defined nodular ascites
tetrachloride dose giving increased primed given yield cirrhosis defined nodular ascites
phenobarbitone given yield cirrhosis defined nodular ascites
phenobarbitone peak giving increased primed given yield cirrhosis defined nodular ascites
ceftriaxone induced hepatitis erythroblastocytopenia
beta antibiotic withholding returned was increase decrease concentration caused anemia erythroblastocytopenia
lactam antibiotic withholding returned was increase decrease concentration caused anemia erythroblastocytopenia
bilirubin increase decrease concentration caused anemia autoimmune
bilirubin increase decrease concentration caused anemia hemolytic
bilirubin increase decrease concentration caused anemia
beta antibiotic withholding returned was increase decrease concentration caused anemia autoimmune
beta antibiotic withholding returned was increase decrease concentration caused anemia hemolytic
beta antibiotic withholding returned was increase decrease concentration caused anemia
lactam antibiotic withholding returned was increase decrease concentration caused anemia autoimmune
lactam antibiotic withholding returned was increase decrease concentration caused anemia hemolytic
lactam antibiotic withholding returned was increase decrease concentration caused anemia
bilirubin increase decrease concentration caused anemia erythroblastocytopenia
pindolol propranolol inhibiting arrhythmia
propranolol inhibiting arrhythmia
deoxycholic acid hydroxylation sulfation cholestasis
acid hydroxylation sulfation cholestasis
potassium Diuretics disease hypertensive
potassium Diuretics arrhythmias
potassium Diuretics disease coronary
potassium Diuretics disease
potassium changes alter tendency arrhythmias cardiac
potassium changes alter tendency arrhythmias
potassium known hypertension
potassium conserving known hypertension
amiloride conserving known hypertension
potassium known disease coronary
potassium known disease artery
potassium known disease
potassium conserving known disease coronary
potassium conserving known disease artery
potassium conserving known disease
chlorthalidone losing known disease coronary
chlorthalidone losing known disease artery
chlorthalidone losing known disease
amiloride conserving known disease coronary
amiloride conserving known disease artery
amiloride conserving known disease
chlorthalidone losing known hypertension
amiloride treatment associated frequency beats ventricular
amiloride treatment associated frequency beats ectopic
amiloride treatment associated frequency beats
potassium increase patients disease ischaemic
potassium increase patients disease heart
potassium increase patients disease
potassium concentrations avoided falls increase patients disease ischaemic
potassium concentrations avoided falls increase patients disease heart
potassium concentrations avoided falls increase patients disease
amiodarone therapy Pneumonitis effusion neuropathy
amiodarone therapy Pneumonitis effusion pleural
amiodarone therapy Pneumonitis effusion pleural and
amiodarone therapy Pneumonitis effusion pleural pericardial
amiodarone therapy Pneumonitis effusion
amiodarone treated patient disease sinuatrial
amiodarone treated patient disease
amiodarone treated control tachyarrhythmias supraventricular
amiodarone treated control tachyarrhythmias
steroid therapy need diagnosis pneumonitis
fusidic acid disease Crohn
fusidic acid disease Crohn '
fusidic acid disease s
fusidic acid disease
acid disease Crohn
acid disease Crohn '
acid disease s
acid disease
cyclosporin similar properties antibiotic Treatment disease Crohn
cyclosporin similar properties antibiotic Treatment disease Crohn '
cyclosporin similar properties antibiotic Treatment disease s
cyclosporin similar properties antibiotic Treatment disease
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn '
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease s
fusidic treatment pharmacodynamics active estimate undertaken need development treatments disease
acid treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn
acid treatment pharmacodynamics active estimate undertaken need development treatments disease Crohn '
acid treatment pharmacodynamics active estimate undertaken need development treatments disease s
acid treatment pharmacodynamics active estimate undertaken need development treatments disease
fusidic acid benefit patients Crohn
fusidic acid benefit patients '
fusidic acid benefit patients s
fusidic acid benefit patients disease
acid benefit patients Crohn
acid benefit patients '
acid benefit patients s
acid benefit patients disease
fusidic acid use rationale exist level disease inflammatory
fusidic acid use rationale exist level disease bowel
fusidic acid use rationale exist level disease
acid use rationale exist level disease inflammatory
acid use rationale exist level disease bowel
acid use rationale exist level disease
risperidone profile produce efficacy symptoms psychotic
risperidone profile produce efficacy symptoms
creatinine > Controls CRF
creatinine > Controls ESRD
creatinine > n 748 CRF
creatinine > Controls ESRD
creatinine levels percentage patients syndrome hepatorenal
creatinine levels percentage patients syndrome
creatinine higher levels percentage patients syndrome hepatorenal
creatinine higher levels percentage patients syndrome
creatinine levels had patients CRF
creatinine levels had patients CRF ESRD
creatinine higher levels had patients CRF
creatinine higher levels had patients CRF ESRD
creatinine increase factors development CRF
creatinine increase factors ESRD
creatinine preoperative have likely have syndrome hepatorenal
creatinine preoperative have likely have syndrome
creatinine preoperative have Patients develop ESRD
creatinine increase predictive development CRF
creatinine increase predictive development CRF ESRD
pilocarpine induced Investigation involvement model epilepsy
pilocarpine model phase oxidase expression provoke provoke sufficient generation FR epilepticus status
pilocarpine model phase oxidase expression provoke provoke sufficient generation FR epilepticus
acetaminophen factor failure chronic
acetaminophen factor failure renal
acetaminophen factor failure
acetaminophen use associated failure chronic
acetaminophen use associated failure renal
acetaminophen use associated failure
acetaminophen use associated failure ESRD
acetaminophen phenacetin contribute burden ESRD
acetaminophen use increases risk ESRD
terbutaline treatment abnormalities Neuroinflammation
terbutaline treatment abnormalities Neuroinflammation behavioral
terbutaline treatment abnormalities
Terbutaline associated 2 agonist used arrest labor preterm
Terbutaline associated 2 agonist used arrest labor
ketoconazole treated syndrome Cushing
ketoconazole treated syndrome Cushing '
ketoconazole treated syndrome s
ketoconazole treated syndrome
cortisol levels plasma achieved demonstrated hypertension
pegylated interferon C chronic
pegylated interferon C hepatitis
pegylated interferon C
interferon C chronic
interferon C hepatitis
interferon C
ribavirin treatment interferon C chronic
ribavirin treatment interferon C hepatitis
ribavirin treatment interferon C
pegylated interferon administration alpha 2 ribavirin hepatitis chronic
pegylated interferon administration alpha 2 ribavirin hepatitis
pegylated interferon administration weeks experienced C
interferon administration alpha 2 ribavirin hepatitis chronic
interferon administration alpha 2 ribavirin hepatitis
interferon administration weeks experienced C
IFN interferon administration alpha 2 ribavirin hepatitis chronic
IFN interferon administration alpha 2 ribavirin hepatitis
IFN interferon administration weeks experienced C
alpha 2 ribavirin hepatitis chronic
alpha 2 ribavirin hepatitis
alpha administration weeks experienced C
2 ribavirin hepatitis chronic
2 ribavirin hepatitis
2 alpha administration weeks experienced C
b 2 ribavirin hepatitis chronic
b 2 ribavirin hepatitis
b 2 alpha administration weeks experienced C
pegylated interferon administration weeks experienced C CHC
interferon administration weeks experienced C CHC
IFN interferon administration weeks experienced C CHC
alpha administration weeks experienced C CHC
2 alpha administration weeks experienced C CHC
b 2 alpha administration weeks experienced C CHC
ribavirin hepatitis chronic
ribavirin hepatitis
ribavirin 2 alpha administration weeks experienced C
ribavirin 2 alpha administration weeks experienced C CHC
pegylated interferon administration weeks experienced diplopia
interferon administration weeks experienced diplopia
IFN interferon administration weeks experienced diplopia
alpha administration weeks experienced diplopia
2 alpha administration weeks experienced diplopia
b 2 alpha administration weeks experienced diplopia
ribavirin 2 alpha administration weeks experienced diplopia
pegylated alpha ribavirin CHC
IFN alpha ribavirin CHC
alpha ribavirin CHC
2 alpha ribavirin CHC
b alpha ribavirin CHC
IFN therapy complications review present reported myasthenia associated therapy alpha ribavirin CHC
ribavirin CHC
asenapine trial Efficacy schizophrenia
haloperidol asenapine trial Efficacy schizophrenia
Asenapine approved adults treatment schizophrenia
Asenapine approved approved episodes manic
Asenapine approved approved episodes associated disorder bipolar
Asenapine approved approved episodes associated disorder I
Asenapine approved approved episodes associated disorder
Asenapine approved approved episodes associated features psychotic
asenapine treatment patients schizophrenia
asenapine mg trial patients schizophrenia
haloperidol BID mg trial patients schizophrenia
bupivacaine injection deficit neurological
bupivacaine injection deficit
bupivacaine mg occurred case deficit neurological
bupivacaine mg occurred case deficit
sevoflurane induction undergoing arrest child palsy cerebral
sevoflurane induction undergoing arrest child palsy
clonidine undergoing arrest child palsy cerebral
clonidine undergoing arrest child palsy
sevoflurane induction undergoing arrest Cardiac
sevoflurane induction undergoing arrest
baclofen pump placement presented restlessness receiving present case 5 child palsy disorder seizure
baclofen pump placement presented restlessness receiving present case 5 child palsy disorder
baclofen pump placement presented restlessness
baclofen pump placement presented restlessness receiving present case 5 child palsy cerebral
baclofen pump placement presented restlessness receiving present case 5 child palsy
clonidine receiving restlessness
clonidine receiving present case 5 child palsy cerebral
clonidine receiving present case 5 child palsy
clonidine receiving present case 5 child palsy disorder seizure
clonidine receiving present case 5 child palsy disorder
clonidine doses administered reduce anxiety
Heparin BACKGROUND presents thromboemboli arterial
Heparin BACKGROUND presents thromboemboli arterial or
Heparin BACKGROUND presents thromboemboli arterial venous
Heparin BACKGROUND presents thromboemboli
heparin exposure presents thromboemboli arterial
heparin exposure presents thromboemboli arterial or
heparin exposure presents thromboemboli arterial venous
heparin exposure presents thromboemboli
heparin became complications thromboembolic
heparin results Platelet onset thromboembolism
heparin exposure included return complications thromboembolic
heparin thrombocytopenia initiated returns thromboembolism
heparin returns thromboembolism
amlodipine pill started report female hypertension
benazapril report female hypertension
angiotensin converting enzyme angioedema intestinal
angiotensin converting enzyme angioedema
angiotensin blocker enzyme angioedema intestinal
angiotensin blocker enzyme angioedema
Verapamil withdrawal woman hypertensive
captopril introduction coincided woman hypertension
verapamil withdrawal introduction coincided woman hypertension
captopril introduction coincided infarction myocardial
captopril introduction coincided infarction
prednisone exposure developed lethargy
prednisone exposure developed lethargy polydipsia
prednisone exposure developed lethargy somnolence
prednisone exposure developed lethargy polyuria
prednisone exposure developed lethargy polyphagia
lactate level ketosis
lactate level ketosis present present acidosis lactic
lactate level ketosis present present acidosis
corticosterone level occurs observed hypotension
Dopamine plays role control seizures epileptic
Dopamine plays role control seizures
DA Dopamine plays role control seizures epileptic
DA Dopamine plays role control seizures
DA receptors role known occurrence epilepsy
pilocarpine treated analyze occurrence seizures neurotoxicity
acetylcholine glutamate induced seizures
glutamate induced seizures
bisphosphonate proteinuria failure acute
bisphosphonate proteinuria failure renal
bisphosphonate proteinuria failure
bisphosphonate proteinuria alendronate administration patient glomerulosclerosis focal
bisphosphonate proteinuria alendronate administration patient glomerulosclerosis segmental
bisphosphonate proteinuria alendronate administration patient glomerulosclerosis
bisphosphonate proteinuria
alendronate administration patient glomerulosclerosis focal
alendronate administration patient glomerulosclerosis segmental
alendronate administration patient glomerulosclerosis
steroid therapy responding man syndrome nephrotic
steroid therapy responding man syndrome
steroid therapy responding man syndrome due glomerulosclerosis focal
steroid therapy responding man syndrome due glomerulosclerosis segmental
steroid therapy responding man syndrome due glomerulosclerosis
bisphosphonate administration days increased g failure acute
bisphosphonate administration days increased g failure renal
bisphosphonate administration days increased g failure
bisphosphonates intravenous aggravate failure proteinuria acute
bisphosphonates intravenous aggravate failure renal
bisphosphonates intravenous aggravate failure
bisphosphonates intravenous aggravate failure proteinuria
dobutamine detecting ECG lead assess using m Sestamibi single emission computed assess presence ischemia
Tc m Sestamibi single emission computed assess presence ischemia
99 m Sestamibi single emission computed assess presence ischemia
m Sestamibi single emission computed assess presence ischemia
Sestamibi single emission computed assess presence ischemia
Tc m using assess induced ischemia myocardial
Tc m using assess induced ischemia
99 m using assess induced ischemia myocardial
99 m using assess induced ischemia
m using assess induced ischemia myocardial
m using assess induced ischemia
Sestamibi m using assess induced ischemia myocardial
Sestamibi m using assess induced ischemia
D Tiopronin due nephritis
Penicillamine D Tiopronin due nephritis
D Tiopronin due nephritis dermatitis
Penicillamine D Tiopronin due nephritis dermatitis
D Tiopronin due due dermatitis
Penicillamine D Tiopronin due due dermatitis
gold thiosulphate due dermatitis due due nephritis
thiosulphate due dermatitis due due nephritis
thiosulphate due dermatitis due due nephritis dermatitis
thiosulphate due dermatitis
Tiopronin group observed patients RA
thiamine transketolase studied fibroblasts patient developed encephalopathy Wernicke
thiamine transketolase studied fibroblasts patient developed encephalopathy Wernicke '
thiamine transketolase studied fibroblasts patient developed encephalopathy s
thiamine transketolase studied fibroblasts patient developed encephalopathy
tolazamide treated encephalopathy developed patient fibroblasts studied delineate transketolase syndrome Km reported Wernicke
tolazamide treated encephalopathy developed patient fibroblasts studied delineate transketolase syndrome Korsakoff
tolazamide treated encephalopathy developed patient fibroblasts studied delineate transketolase syndrome
thiamine transketolase studied fibroblasts patient diabetic
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient diabetic
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient diabetic
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient diabetic
tolazamide treated encephalopathy developed patient diabetic
thiamine transketolase studied delineate transketolase syndrome Km reported Wernicke
thiamine transketolase studied delineate transketolase syndrome Korsakoff
thiamine transketolase studied delineate transketolase syndrome
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke '
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy s
thiamine pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke '
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy s
pyrophosphate -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy Wernicke '
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy s
TPP -RSB- Km syndrome transketolase delineate studied fibroblasts patient developed encephalopathy
thiamine pyrophosphate -RSB- Km reported Wernicke
thiamine pyrophosphate -RSB- Km syndrome Korsakoff
thiamine pyrophosphate -RSB- Km syndrome
pyrophosphate -RSB- Km reported Wernicke
pyrophosphate -RSB- Km syndrome Korsakoff
pyrophosphate -RSB- Km syndrome
TPP -RSB- Km reported Wernicke
TPP -RSB- Km syndrome Korsakoff
TPP -RSB- Km syndrome
TPP Km determined mentioned patient kindreds diabetic
TPP Km determined mentioned history encephalopathy Wernicke
TPP Km determined mentioned history encephalopathy Wernicke '
TPP Km determined mentioned history encephalopathy s
TPP Km determined mentioned history encephalopathy
tolazamide patient syndrome similarity Wernicke
tolazamide patient syndrome Korsakoff
tolazamide patient syndrome
cocaine exposed prenatally dysgenesis Brainstem
cocaine exposed prenatally dysgenesis
serotonin nerves involved effect hypotensive
serotonin cells methyldopa neurons microinjection elicits response hypotensive
methyldopa microinjection caused hypertensive
serotonin group area caused hypotension
serotonin abolished caused hypotension
5 neurotoxin serotonin abolished caused hypotension
7 neurotoxin serotonin abolished caused hypotension
dihydroxytryptamine injected caused hypotension
5 dihydroxytryptamine injected caused hypotension
7 5 dihydroxytryptamine injected caused hypotension
DHT 5 dihydroxytryptamine injected caused hypotension
5 neurotoxin serotonin abolished caused hypertensive stroke
7 neurotoxin serotonin abolished caused hypertensive stroke
dihydroxytryptamine injected caused hypertensive stroke
5 dihydroxytryptamine injected caused hypertensive stroke
7 5 dihydroxytryptamine injected caused hypertensive stroke
DHT 5 dihydroxytryptamine injected caused hypertensive stroke
serotonin group area caused hypertensive
serotonin abolished caused hypertensive
5 neurotoxin serotonin abolished caused hypertensive
7 neurotoxin serotonin abolished caused hypertensive
dihydroxytryptamine injected caused hypertensive
5 dihydroxytryptamine injected caused hypertensive
7 5 dihydroxytryptamine injected caused hypertensive
DHT 5 dihydroxytryptamine injected caused hypertensive
serotonin group area caused hypertensive stroke
serotonin abolished caused hypertensive stroke
methyldopa microinjection caused hypertensive stroke
serotonin projections lesion produce 5 injection affect hypotension
5 injection affect hypotension
7 5 injection affect hypotension
DHT produce 5 injection affect hypotension
serotonin contribute cells mediate hypotension
serotonin contribute action hypotensive
aspirin reduces reduces risk stroke
warfarin reduces risk stroke
aspirin preventing strokes
warfarin superior aspirin preventing strokes
Ximelagatran found efficient antagonist prevention events embolic
Ximelagatran found efficient antagonist prevention events
vitamin K antagonist prevention events embolic
vitamin K antagonist prevention events
K antagonist prevention events embolic
K antagonist prevention events
vitamin K antagonist withdrawn tests abnormal
vitamin K antagonist withdrawn tests liver
vitamin K antagonist withdrawn tests function
K antagonist withdrawn tests abnormal
K antagonist withdrawn tests liver
K antagonist withdrawn tests function
warfarin superior platelet therapy events embolic
warfarin superior platelet therapy events
Clopidogrel Trial W demonstrated superior platelet therapy events embolic
Clopidogrel Trial W demonstrated superior platelet therapy events
clopidogrel aspirin therapy events embolic
clopidogrel aspirin therapy events
Irbesartan Trial W demonstrated superior platelet therapy events embolic
Irbesartan Trial W demonstrated superior platelet therapy events
Clopidogrel Trial Atrial
Clopidogrel Trial Fibrillation
clopidogrel aspirin therapy platelet superior demonstrated W Trial Atrial
clopidogrel aspirin therapy platelet superior demonstrated W Trial Fibrillation
aspirin therapy events embolic
aspirin therapy events
warfarin superior demonstrated W Trial Atrial
warfarin superior demonstrated W Trial Fibrillation
Irbesartan Trial Atrial
Irbesartan Trial Fibrillation
aspirin therapy platelet superior demonstrated W Trial Atrial
aspirin therapy platelet superior demonstrated W Trial Fibrillation
Idraparinux evaluated patients fibrillation atrial
Idraparinux evaluated patients fibrillation
angiotensin receptor inhibitors converting blocking hold remodelling cardiac
angiotensin receptor inhibitors converting blocking hold remodelling
II receptor inhibitors converting blocking hold remodelling cardiac
II receptor inhibitors converting blocking hold remodelling
angiotensin receptor inhibitors converting blocking hold promise fibrillation atrial
angiotensin receptor inhibitors converting blocking hold promise fibrillation
II receptor inhibitors converting blocking hold promise fibrillation atrial
II receptor inhibitors converting blocking hold promise fibrillation
Angiotensin converting blocking hold remodelling cardiac
Angiotensin converting blocking hold remodelling
Angiotensin converting blocking hold promise fibrillation atrial
Angiotensin converting blocking hold promise fibrillation
Lamotrigine associated myoclonus epilepsies idiopathic
Lamotrigine associated myoclonus epilepsies generalized
Lamotrigine associated myoclonus epilepsies
lamotrigine exacerbation treated patients epilepsies idiopathic
lamotrigine exacerbation treated patients epilepsies generalized
lamotrigine exacerbation treated patients epilepsies
lamotrigine exacerbation treated patients IGE
LTG exacerbation treated patients epilepsies idiopathic
LTG exacerbation treated patients epilepsies generalized
LTG exacerbation treated patients epilepsies
LTG exacerbation treated patients IGE
angiotensin converting hypertension
tizanidine initiation Hypotension treated angiotensin converting hypertension
angiotensin treated Hypotension
angiotensin treated Adults have ability respond hypotension
angiotensin converting control hypertension
angiotensin chronically treatment spasticity
lisinopril treated chronically treatment spasticity
tizanidine addition hypotension developed hypertension
tizanidine addition hypotension developed hypertension control converting angiotensin chronically treatment spasticity
angiotensin converting control hypertension developed hypotension
lisinopril treated chronically angiotensin converting control hypertension
tizanidine agents interaction kept treat hypertension
tizanidine agents interaction kept treat hypertension spasticity
FK utility complicated hypertension nephrotoxicity
506 FK utility complicated hypertension nephrotoxicity
nitric activity 1 expression 1 hypertension
oxide activity 1 expression 1 hypertension
FR antagonist studied hypertension
139317 FR antagonist studied hypertension
FR administration prevented FK induced hypertension
139317 FR administration prevented FK induced hypertension
kainate receptor prodrugs antagonists models pain
formalin reversal models pain
formalin reversal models induced hyperalgesia thermal
formalin reversal models induced hyperalgesia
formalin reversal models induced hyperalgesia mechanical
formalin reversal models induced hyperalgesia
carrageenan licking models pain
capsaicin hyperalgesia induced models pain
TRI antagonize hypothermia
5 potentiate antagonize hypothermia
hydroxytryptophan twitches 5 potentiate antagonize hypothermia
dopamine D hydroxy d induced hyperactivity
phenylephrine evoked stimulation aggressiveness
clonidine evoked aggressiveness
heparin collagenase 014 induction ICH fold 4 6 over seen animals bleeding
heparin collagenase 014 induction ICH
heparin collagenase 014 induction ICH fold 4 6 over seen animals ICH
ISO response shows phase hypertrophic
FK nephropathy
506 FK nephropathy
FK nephropathy nephropathy
506 FK nephropathy nephropathy
FK nephropathy nephropathy
506 nephropathy nephropathy
FK nephropathy
506 nephropathy
FK nephropathy nephropathy type rejection nephropathy IgA
FK nephropathy nephropathy type rejection nephropathy
506 FK nephropathy nephropathy type rejection nephropathy IgA
506 FK nephropathy nephropathy type rejection nephropathy
FK nephropathy type rejection nephropathy IgA
FK nephropathy type rejection nephropathy
506 nephropathy type rejection nephropathy IgA
506 nephropathy type rejection nephropathy
FK nephropathy
506 nephropathy
FK 506 consisted nephropathy
506 consisted nephropathy
FK 506 consisted vacuolization form fibrosis interstitial
FK 506 consisted vacuolization form fibrosis
506 consisted vacuolization form fibrosis interstitial
506 consisted vacuolization form fibrosis
FK higher group nephropathy
506 group nephropathy
FK higher those group nephropathy
506 group higher those group nephropathy
FK chronic group those higher group nephropathy
506 FK chronic group those higher group nephropathy
FK chronic group nephropathy
506 FK chronic group nephropathy
creatinine levels FK higher group nephropathy
creatinine levels FK higher those group nephropathy
FK 506 consists nephropathy
506 consists nephropathy
FK 506 consists demonstrates condition nephropathy
506 consists demonstrates condition nephropathy
FK 506 condition demonstrates consists nephropathy
506 condition demonstrates consists nephropathy
FK 506 condition nephropathy
506 condition nephropathy
22 suppresses inducing dogs failure renal
22 suppresses inducing dogs failure
oxacalcitriol suppresses inducing dogs failure renal
oxacalcitriol suppresses inducing dogs failure
22 suppresses inducing turnover low
22 suppresses inducing turnover bone
22 suppresses inducing turnover
oxacalcitriol suppresses inducing turnover low
oxacalcitriol suppresses inducing turnover bone
oxacalcitriol suppresses inducing turnover
22 suppresses hyperparathyroidism secondary
22 suppresses hyperparathyroidism
oxacalcitriol suppresses hyperparathyroidism secondary
oxacalcitriol suppresses hyperparathyroidism
Calcitriol therapy suppresses patients failure renal
Calcitriol therapy suppresses patients failure
OCT effects determine states function normal impaired
OCT effects determine states function renal
OCT effects determine states function
OCT decreased induction insufficiency renal
OCT decreased induction insufficiency
OCT stabilized long standing hyperparathyroidism secondary
OCT stabilized long standing hyperparathyroidism
OCT reversed formation osteoid woven
OCT reversed formation osteoid
OCT reversed formation osteoid fibrosis
OCT prevent insufficiency renal
OCT prevent insufficiency
OCT prevent use induce turnover low
OCT prevent use induce turnover bone
OCT prevent use induce turnover
OCT prevent use induce increase risk disease adynamic
OCT prevent use induce increase risk disease bone
OCT prevent use induce increase risk disease
OCT prevent use management hyperparathyroidism secondary
OCT prevent use management hyperparathyroidism
trihexyphenidyl relationship examine measures reflecting sedation confusion
trihexyphenidyl relationship investigate examine measures reflecting sedation confusion
Flurbiprofen arthritis juvenile
Flurbiprofen arthritis rheumatoid
Flurbiprofen arthritis
flurbiprofen treated patients had baseline indices arthritis
flurbiprofen treated patients arthritis juvenile
flurbiprofen treated patients arthritis rheumatoid
flurbiprofen treated patients arthritis
potassium known medications given suggestive relationship sulindac hyperkalemia
adriamycin carcinoma bladder
adriamycin carcinoma
Adriamycin administered resection T tumors bladder
Adriamycin administered resection T tumors
sulfasalazine therapy colitis ulcerative
sulfasalazine therapy colitis
sulfasalazine lupus manifested serositis
sulfasalazine treat disease inflammatory
sulfasalazine treat disease bowel
sulfasalazine treat disease
sulfasalazine signs aware Physicians use sulfasalazine treat disease inflammatory
sulfasalazine signs aware Physicians use sulfasalazine treat disease bowel
sulfasalazine signs aware Physicians use sulfasalazine treat disease
CC complications thromboembolic
CC intake disturbance uncommon include search literature complications thromboembolic
CC treating patients infertility
Pemoline choreoathetosis
amphetamines different used treatment disorder attention
amphetamines different used treatment disorder deficit
amphetamines different used treatment disorder
oxazolidine derivative different used treatment disorder attention
oxazolidine derivative different used treatment disorder deficit
oxazolidine derivative different used treatment disorder
Pemoline derivative different used treatment disorder attention
Pemoline derivative different used treatment disorder deficit
Pemoline derivative different used treatment disorder
Pemoline associated literature cause disorders movement
Pemoline associated literature cause disorders
pemoline experienced choreoathetosis
methylphenidate treated disorder attention
methylphenidate treated disorder deficit
methylphenidate treated disorder
benzodiazepines decontamination received attempt control movements choreoathetoid
Pemoline associated reported disorder movement
Pemoline associated reported disorder
pemoline overdose presenting patients considered possibility movements choreoathetoid
vasopressin secretion thirst have showed remained thirsty polyuric
vasopressin secretion thirst have showed evidence insipidus nephrogenic
vasopressin secretion thirst have showed evidence insipidus diabetes
vasopressin secretion thirst have showed evidence insipidus
dapsone dose taking developed woman trait leprosy
dapsone dose taking associated hemolysis
haloperidol study found effective treatment syndromes psychotic
haloperidol study found effective treatment syndromes
haloperidol study found effective treatment syndromes belonging
haloperidol study found effective treatment syndromes belonging predominantly
haloperidol study found effective treatment syndromes belonging group to
haloperidol study found effective treatment syndromes belonging group the
haloperidol study found effective treatment syndromes belonging group schizophrenia
haloperidol study found effective treatment syndromes belonging group
rifampin proteinuria treated tuberculosis
rifampin treated patients tuberculosis
sirolimus associated dysfunction proteinuria acute
sirolimus associated dysfunction renal
sirolimus associated dysfunction
sirolimus associated dysfunction acute
sirolimus associated dysfunction renal
sirolimus associated dysfunction
angiotensin use minimised close monitoring function proteinuria
angiotensin use occurs proteinuria
angiotensin blockers inhibitors converting use minimised close monitoring function proteinuria
II blockers inhibitors converting use minimised close monitoring function proteinuria
angiotensin blockers inhibitors converting use occurs proteinuria
II blockers inhibitors converting use occurs proteinuria
Clomipramine exposure include anxiety inflexibility behavioral
Clomipramine exposure include anxiety inflexibility
Clomipramine exposure dysfunction corticostriatal
Clomipramine exposure dysfunction
norepinephrine rate augmentation tachycardia
nitroglycerin hydralazine induced hypotension contrast observed tachycardia
hydralazine induced hypotension contrast observed tachycardia
norepinephrine rate augmentation tachycardia observed contrast hypotension
sulfonylureas reported induced hepatotoxicity
sulfonylurea reports hepatotoxicity
glyburide therapy initiation developed patients mellitus type
glyburide therapy initiation developed patients mellitus II
glyburide therapy initiation developed patients mellitus diabetes
glyburide therapy initiation developed patients mellitus
sodium retention edema
sodium retention accompanied syndrome Nephrotic
sodium retention accompanied syndrome
sodium excretion proteinuria ascites
sodium excretion proteinuria hypoalbuminemia
sodium excretion proteinuria
sodium retention associated syndrome nephrotic
sodium retention associated syndrome
prostaglandins factor urine patients bladder overactive
prostaglandins factor urine patients bladder
PGs NGF investigated women OAB
PG NGF correlations parameters patients OAB
PGI different OAB
2 PGI different OAB
PGI alpha correlate parameters patients OAB
2 PGI alpha correlate parameters patients OAB
PGs NGF have roles development symptoms OAB
cyclophosphamide secondary myocarditis haemorrhagic
cyclophosphamide secondary myocarditis
cyclophosphamide therapy complication myocarditis Haemorrhagic
cyclophosphamide therapy complication myocarditis
Iron accumulation considered involved pathogenesis disease Parkinson
Iron accumulation considered involved pathogenesis disease Parkinson '
Iron accumulation considered involved pathogenesis disease s
Iron accumulation considered involved pathogenesis disease
tyrosine immunohistochemistry used study demonstrate detection study degeneration
tyrosine immunohistochemistry used study demonstrate detection study degeneration neurons of
tyrosine immunohistochemistry used study demonstrate detection study degeneration neurons dopaminergic
tyrosine immunohistochemistry used study demonstrate detection study degeneration neurons
iron overload relationship demonstrate detection study degeneration
iron overload relationship demonstrate detection study degeneration neurons of
iron overload relationship demonstrate detection study degeneration neurons dopaminergic
iron overload relationship demonstrate detection study degeneration neurons
iron staining immunohistochemistry used study demonstrate detection study degeneration
iron staining immunohistochemistry used study demonstrate detection study degeneration neurons of
iron staining immunohistochemistry used study demonstrate detection study degeneration neurons dopaminergic
iron staining immunohistochemistry used study demonstrate detection study degeneration neurons
iron content detection study degeneration
iron content detection study degeneration neurons of
iron content detection study degeneration neurons dopaminergic
iron content detection study degeneration neurons
iron level increase SN causes degeneration
iron level increase SN causes degeneration neurons of
iron level increase SN causes degeneration neurons dopaminergic
iron level increase SN causes degeneration neurons
iron causes degeneration
iron causes degeneration neurons of
iron causes degeneration neurons dopaminergic
iron causes degeneration neurons
benzylthiouracil carbimazole reactivity hepatitis Toxic
benzylthiouracil carbimazole reactivity hepatitis
carbimazole induced hepatitis cholestatic
carbimazole induced hepatitis
N omercazole carbimazole induced hepatitis cholestatic
N omercazole carbimazole induced hepatitis
omercazole carbimazole induced hepatitis cholestatic
omercazole carbimazole induced hepatitis
Benzylthiouracil replaced appeared hepatitis
Basd ne Benzylthiouracil replaced appeared hepatitis
ne Benzylthiouracil replaced appeared hepatitis
alprazolam disorder panic
alprazolam disorder
alprazolam disorder agoraphobia
alprazolam randomised criteria disorder panic
alprazolam randomised criteria disorder
alprazolam randomised criteria disorder agoraphobia
alprazolam patients developed reactions depression aggression
alprazolam patients developed reactions effects irritability
everolimus prophylaxis Graft
everolimus prophylaxis versus
everolimus prophylaxis host
everolimus prophylaxis disease
tacrolimus everolimus prophylaxis Graft
tacrolimus everolimus prophylaxis versus
tacrolimus everolimus prophylaxis host
tacrolimus everolimus prophylaxis disease
methotrexate inhibitor prophylaxis graft
methotrexate inhibitor prophylaxis disease versus
methotrexate inhibitor prophylaxis disease host
methotrexate inhibitor prophylaxis disease
methotrexate inhibitor prophylaxis disease GVHD
everolimus combination report undergoing patients syndrome leukemia acute
everolimus combination report undergoing patients syndrome leukemia myeloid
everolimus combination report undergoing patients syndrome leukemia
everolimus combination report undergoing patients syndrome AML
tacrolimus everolimus combination report undergoing patients syndrome myelodysplastic
tacrolimus everolimus combination report undergoing patients syndrome
tacrolimus everolimus combination report undergoing patients syndrome MDS
tacrolimus everolimus combination report undergoing patients syndrome leukemia acute
tacrolimus everolimus combination report undergoing patients syndrome leukemia myeloid
tacrolimus everolimus combination report undergoing patients syndrome leukemia
tacrolimus everolimus combination report undergoing patients syndrome AML
everolimus combination report undergoing patients syndrome myelodysplastic
everolimus combination report undergoing patients syndrome
everolimus combination report undergoing patients syndrome MDS
adrenaline containing mg observed increase accompanied fibrillation loss
adrenaline containing mg observed increase accompanied fibrillation loss consciousness of
adrenaline containing mg observed increase accompanied fibrillation loss consciousness
mepivacaine 850 block performance mg observed increase accompanied fibrillation agitation
adrenaline containing mg observed increase accompanied fibrillation agitation
mepivacaine 850 block performance mg observed increase accompanied fibrillation shouts incomprehensible
mepivacaine 850 block performance mg observed increase accompanied fibrillation shouts
mepivacaine 850 block performance mg containing adrenaline contracture Dupuytren
mepivacaine 850 block performance mg containing adrenaline contracture Dupuytren '
mepivacaine 850 block performance mg containing adrenaline contracture s
mepivacaine 850 block performance mg containing adrenaline contracture
adrenaline contracture Dupuytren
adrenaline contracture Dupuytren '
adrenaline contracture s
adrenaline contracture
adrenaline containing mg observed increase accompanied fibrillation shouts incomprehensible
adrenaline containing mg observed increase accompanied fibrillation shouts
mepivacaine 850 block performance mg observed increase accompanied fibrillation loss
mepivacaine 850 block performance mg observed increase accompanied fibrillation loss consciousness of
mepivacaine 850 block performance mg observed increase accompanied fibrillation loss consciousness
dipyridamole Effects induced injury myocardial
dipyridamole Effects induced injury
hydrocortisone dipyridamole Effects induced injury myocardial
hydrocortisone dipyridamole Effects induced injury
acetylsalicylic acid Effects induced injury myocardial
acetylsalicylic acid Effects induced injury
acid Effects induced injury myocardial
acid Effects induced injury
epinephrine infusion injury producing model developed study effects alter evolution infarction myocardial
epinephrine infusion injury producing model developed study effects alter evolution infarction
PCPA exposure decreased activity irritability
PCPA exposure decreased had effect behavior aggression
5 central speculated prone exhibit behavior aggressive
5 central speculated prone exhibit behavior
HT prone exhibit behavior aggressive
HT prone exhibit behavior
angiotensin failure heart
angiotensin failure
angiotensin failure patients function decreased
angiotensin failure patients function renal
angiotensin failure patients function
angiotensin failure patients function converting therapy results studies dysfunction left
angiotensin failure patients function converting therapy results studies dysfunction ventricular
angiotensin failure patients function converting therapy results studies dysfunction
angiotensin reduces patients failure congestive
angiotensin reduces patients failure heart
angiotensin reduces patients failure
angiotensin reduces patients failure CHF
angiotensin reduces cause function decreased
angiotensin reduces cause function renal
angiotensin reduces cause function
angiotensin prescribed function patients CHF
angiotensin prescribed function quantify predictors reduction
angiotensin prescribed function in
angiotensin prescribed function renal
angiotensin prescribed function
enalapril trial controlled data Studies Dysfunction Left
enalapril trial controlled data Studies Dysfunction Ventricular
enalapril trial controlled data Studies Dysfunction
enalapril trial controlled treatment CHF
creatinine > rise defined function Decreased
creatinine > rise defined function renal
creatinine > rise defined function
diuretic antiplatelet hypertension diabetes
diuretic antiplatelet hypertension
creatinine age pressure history hypertension diabetes
creatinine age pressure history hypertension
diuretic therapy age diabetes
enalapril groups placebo associated age diabetes
enalapril had placebo patients diabetes
Enalapril use caused risk function patients CHF
enalapril group reduced associated Diabetes
enalapril group reduced associated risk impairment patients CHF
adenosine studies suggest suggests effective states hypersensitivity
adenosine formulation volunteers studies suggests effective states hypersensitivity
adenosine studies suggest effective treatment pain acute
adenosine studies suggest effective treatment pain acute and
adenosine studies suggest effective treatment pain acute chronic
adenosine studies suggest effective treatment pain
adenosine formulation volunteers studies suggests suggest effective treatment pain acute
adenosine formulation volunteers studies suggests suggest effective treatment pain acute and
adenosine formulation volunteers studies suggests suggest effective treatment pain acute chronic
adenosine formulation volunteers studies suggests suggest effective treatment pain
adenosine formulation efficacy screen using stimulation hypersensitivity
capsaicin stimulation hypersensitivity
adenosine trial doses 25 2 mg blind studied obtained analysis ratings pain
adenosine trial placebo blind studied obtained analysis ratings pain
adenosine trial doses 25 2 mg blind studied obtained stimuli hyperalgesia mechanical
adenosine trial doses 25 2 mg blind studied obtained stimuli hyperalgesia
adenosine trial doses 25 2 mg blind studied obtained stimuli hyperalgesia allodynia
adenosine trial placebo blind studied obtained stimuli hyperalgesia mechanical
adenosine trial placebo blind studied obtained stimuli hyperalgesia
adenosine trial placebo blind studied obtained stimuli hyperalgesia allodynia
capsaicin injection determined obtained analysis ratings pain
Adenosine produced report pain
Adenosine produced reduced hyperalgesia mechanical
Adenosine produced reduced hyperalgesia
Adenosine produced reduced hyperalgesia allodynia
capsaicin injection reduced produced report pain
adenosine hypersensitivity
capsaicin injection reflect presumed adenosine hypersensitivity
adenosine residence due observed pain neuropathic
adenosine residence due observed pain
losartan administration developed case 70 man hypertensive
losartan administration developed case 70 man kidney insufficiency chronic
losartan administration developed case 70 man kidney insufficiency renal
losartan administration developed case 70 man kidney insufficiency
losartan prescribed dysfunction systolic
losartan prescribed dysfunction
furosemide high lasted anuria
amine infusion furosemide high lasted anuria
angiotensin system renin activation resulted stenosis failure heart
angiotensin system renin activation resulted stenosis failure
angiotensin system renin activation resulted stenosis renal
angiotensin system renin activation resulted stenosis artery
angiotensin system renin activation resulted stenosis
losartan cause patients disease renovascular
losartan cause patients disease
angiotensin losartan cause patients disease renovascular
angiotensin losartan cause patients disease
II losartan cause patients disease renovascular
II losartan cause patients disease
penicillin discharges epileptic
penicillin discharges stimulation Effects model epilepsy
penicillin activity epileptic
penicillin activity model epilepsy
penicillin suppressed DBS RESULTS induced independent activity epileptic
GABA receptor effects sensitive seizures
benzodiazepine site carboxylate injection resistance seizures
GABA agonist site carboxylate injection resistance seizures
diazepam induced seizures
diazepam test plus induced diazepam induced seizures
doxorubicin both T survivors tumors bone
doxorubicin both T survivors tumors
Rosen treated tumors bone
Rosen treated tumors
' Rosen treated tumors bone
' Rosen treated tumors
s T survivors tumors bone
s T survivors tumors
T survivors tumors bone
T survivors tumors
5 T survivors tumors bone
5 T survivors tumors
or T survivors tumors bone
or T survivors tumors
T protocol T survivors tumors bone
T protocol T survivors tumors
10 protocol T survivors tumors bone
10 protocol T survivors tumors
protocol T survivors tumors bone
protocol T survivors tumors
doxorubicin induced cardiotoxicity
lopinavir related neonates toxicity cardiac
lopinavir related neonates toxicity
/ therapy lopinavir related neonates toxicity cardiac
/ therapy lopinavir related neonates toxicity
ritonavir therapy lopinavir related neonates toxicity cardiac
ritonavir therapy lopinavir related neonates toxicity
argatroban elevation thrombocytopenia thrombosis
argatroban elevation thrombocytopenia
heparin history patient argatroban elevation thrombocytopenia thrombosis
heparin history patient argatroban elevation thrombocytopenia
heparin history patients HIT thrombosis HITT
heparin history patients HIT thrombosis
heparin history patients thrombocytopenia
heparin history patients thrombocytopenia HIT
heparin history patients HIT
argatroban administered year history HITT
argatroban administered year old patient critically
argatroban administered year old patient ill
argatroban concentrations measured RESULTS observed published minutes -RSB- hepatic
argatroban concentrations measured RESULTS observed published minutes -RSB- impairment
argatroban minutes measured RESULTS observed published minutes -RSB- hepatic
argatroban minutes measured RESULTS observed published minutes -RSB- impairment
argatroban concentration Correlation suggest contributed coagulopathy
argatroban levels contributed coagulopathy
argatroban concentration measure report extended coagulopathy
K Na cardiac affinities Changes ATPase hypertension
sodium affinities Changes ATPase hypertension
Na cardiac affinities Changes ATPase hypertension
ATP sodium affinities Changes ATPase hypertension
sodium level elevation documented models hypertension
K Na cardiac response induced hypertension
Na + transport disturbances basis assess studied response induced hypertension
Na cardiac response induced hypertension
N inhibition response induced hypertension
G N inhibition response induced hypertension
nitro response induced hypertension
L nitro response induced hypertension
arginine ester response induced hypertension
methyl ester response induced hypertension
ester response induced hypertension
L ester response induced hypertension
NAME L ester response induced hypertension
K Na ATPase activity increased recovery hypertension
Na ATPase activity increased recovery hypertension
ATP affinity due increased recovery hypertension
ATP value revealed site increased recovery hypertension
NO Inhibition synthase induced hypertension accompanied + depressed
K Na properties hypertension
K Na properties hypertension accompanied + depressed
Na + accompanied hypertension
Na + consequence cells extrusion hypertension
Na properties hypertension
Na + depressed
Na + consequence cells extrusion hypertension accompanied + depressed
Na properties hypertension accompanied + depressed
amiodarone therapy tachycardia fibrillation ventricular
amiodarone therapy tachycardia fibrillation
amiodarone therapy Long efficacy toxicity
amiodarone therapy tachycardia ventricular
amiodarone therapy tachycardia
Amiodarone administered sustained tachycardia ventricular
Amiodarone administered sustained tachycardia
Amiodarone administered sustained tachycardia VT
Amiodarone administered sustained tachycardia arrest cardiac
Amiodarone administered sustained tachycardia arrest
amiodarone continued had recurrence VT fibrillation ventricular
amiodarone continued had recurrence VT fibrillation
amiodarone continued had recurrence VT VF
amiodarone continued had recurrence VT
amiodarone managed had recurrence VT
amiodarone large effective VT VF
amiodarone large effective causes toxicity
amiodarone large effective VT
amiodarone managed % patients VT VF
amiodarone managed % patients VT
venlafaxine overdose took woman depression major
venlafaxine overdose took woman depression
nitric oxide type study 1 arteritis
oxide type study 1 arteritis
theophylline fenoldopam induced arteritis 1 study type oxide factor tumor
nitric oxide factor tumor
oxide factor tumor
fenoldopam induced arteritis 1 study type oxide factor tumor
nitric synthase type expressions examined Arteritis
oxide synthase type expressions examined Arteritis
theophylline vasodilators induced Arteritis examined expressions type synthase factor tumor
nitric synthase factor tumor
oxide synthase factor tumor
fenoldopam vasodilators induced Arteritis examined expressions type synthase factor tumor
bethanechol stimulation prevented rats diabetic
ATP stimulation prevented rats diabetic
bethanechol stimulation reversed rats diabetic
ATP stimulation reversed rats diabetic
Ketoconazole induced sequelae neurologic
Ketoconazole induced sequelae
gum Arabic nephrotoxicity
Arabic nephrotoxicity
gentamicin nephrotoxicity
gum rats treatment effect assessed Arabic failure induced gentamicin nephrotoxicity
Arabic failure induced gentamicin nephrotoxicity
gentamicin nephrotoxicity
GM gentamicin nephrotoxicity
glutathione plasma measuring assessed Nephrotoxicity
GSH glutathione plasma measuring assessed Nephrotoxicity
urea creatinine concentrations measuring assessed Nephrotoxicity
creatinine concentrations measuring assessed Nephrotoxicity
GSH that decreased % GM necrosis tubular
GSH that decreased % GM necrosis
urea creatinine increased gum indicated decreased % GM necrosis tubular
urea creatinine increased gum indicated decreased % GM necrosis
GM Arabic increased gum indicated decreased % GM necrosis tubular
GM Arabic increased gum indicated decreased % GM necrosis
GM cellulose treated rats compared gum indicated decreased % GM necrosis tubular
GM cellulose treated rats compared gum indicated decreased % GM necrosis
GM cellulose group % % GM necrosis tubular
GM cellulose group % % GM necrosis
GM necrosis tubular
GM necrosis
GM given rats severe appeared necrosis tubular
GM given rats severe appeared necrosis
GM than severe appeared necrosis tubular
GM than severe appeared necrosis
creatinine increased gum indicated decreased % GM necrosis tubular
creatinine increased gum indicated decreased % GM necrosis
gum indicated decreased % GM necrosis tubular
gum indicated decreased % GM necrosis
Arabic increased gum indicated decreased % GM necrosis tubular
Arabic increased gum indicated decreased % GM necrosis
gum Arabic given rats severe appeared necrosis tubular
gum Arabic given rats severe appeared necrosis
Arabic given rats severe appeared necrosis tubular
Arabic given rats severe appeared necrosis
gum treatment induced nephrotoxicity
Arabic treatment induced nephrotoxicity
GM indices some amelioration induced nephrotoxicity
everolimus associated neuritis brachial
everolimus associated neuritis
cocaine use Fatal provide mechanisms toxicity
cocaine toxicity
cocaine registry compared victims overdose
cocaine overdose
benzoylecgonine cocaine concentrations had EDDs
cocaine use disrupts precipitate agitation
cocaine use coupled disrupts precipitate agitation
tranexamic acid containing sealants application seizures Epileptic
tranexamic acid containing sealants application seizures
acid containing sealants application seizures Epileptic
acid containing sealants application seizures
tAMCA shown cause seizures epileptic
tAMCA shown cause seizures
desipramine administration induced linking alteration sensitivity convulsions
norepinephrine function induced linking alteration sensitivity convulsions
norepinephrine transporter Alterations function sensitization seizures
desipramine administration increased incidence appearance induced convulsions
desipramine administration increased incidence appearance induced convulsions
desipramine lidocaine administration reversed changes activity convulsive
desipramine administration induced activity convulsive
desipramine administration induced NET regulation relevant sensitization convulsions
desipramine relevant sensitization convulsions
Desipramine have sensitization seizures
Triazolam induced patient depressed
triazolam doses induced woman depressed
lidocaine reduce succinylcholine induced myalgia postoperative
lidocaine reduce succinylcholine induced myalgia
lidocaine pretreatment effect determine undertaken undergoing myalgia
succinylcholine reduction determine undertaken undergoing myalgia
lidocaine proven agent reduction myalgia postoperative
lidocaine proven agent reduction myalgia
phenytoin treatment due psychosis Acute
phenytoin treatment due psychosis
phenytoin treatment neuralgia trigeminal
phenytoin treatment neuralgia
phenytoin treatment psychosis
phenytoin treatment patients epileptic
phenytoin treatment occur symptoms result unrelated seizures
phenytoin treatment occur symptoms psychotic
phenytoin treatment occur symptoms
L rats Reversal coma
dopa Reversal coma
ammonia coma
Ammonia coma
L dopa prevented coma
- dopa prevented coma
dopa prevented coma
ammonium injection prevented coma
salt injection prevented coma
dopamine infusion prevent coma
dopamine raise sufficient dopamine infusion prevent coma
ammonia coma
ammonia concentrations blood affect prevent coma
L effect eliminated prevented dopa ammonia coma
dopa ammonia coma
ammonia coma
ammonia coma
L coma
dopa reduction prevention coma
dopamine effect accounted reduction prevention coma
ammonia reduction prevention coma
ammonia coma
L receiving patients encephalopathic
dopa L receiving patients encephalopathic
lignocaine dose ranged mg caused neurotoxicity
lignocaine neurotoxicity
sulpiride reported dyskinesia parkinsonism
sulpiride reported dyskinesia tardive
sulpiride reported dyskinesia
nitrogranulogen drugs action nephrotoxic
NG nitrogranulogen drugs action nephrotoxic
cyclophosphamide nitrogranulogen drugs action nephrotoxic
CY cyclophosphamide nitrogranulogen drugs action nephrotoxic
CY -RSB- evaluated action nephrotoxic
methotrexate nitrogranulogen drugs action nephrotoxic
MTX methotrexate nitrogranulogen drugs action nephrotoxic
MTX + or administered action nephrotoxic
5 nitrogranulogen drugs action nephrotoxic
fluorouracil 5 nitrogranulogen drugs action nephrotoxic
5 fluorouracil 5 nitrogranulogen drugs action nephrotoxic
FU 5 fluorouracil 5 nitrogranulogen drugs action nephrotoxic
5 + or administered action nephrotoxic
FU -RSB- evaluated action nephrotoxic
5 combined cause caused cystitis hemorrhagic
5 combined cause caused cystitis
FU 5 combined cause caused cystitis hemorrhagic
FU 5 combined cause caused cystitis
MTX FU 5 combined cause caused cystitis hemorrhagic
MTX FU 5 combined cause caused cystitis
CY caused cystitis hemorrhagic
CY caused cystitis
CY monotherapy indicate nephrotoxicity
MTX + nephrotoxicity
5 + nephrotoxicity
FU CY monotherapy indicate nephrotoxicity
cyclophosphamide cytotoxicity restores reduction anemia
cyclophosphamide cytotoxicity
cyclophosphamide cytotoxicity tumors
cyclophosphamide cytotoxicity treatment examine impact prevention anemia
cyclophosphamide cytotoxicity
cyclophosphamide cytotoxicity treatment examine tumors
carboplatin treatment days implanted tumors
carboplatin treatment days implanted tumors DS sarcoma
carboplatin influenced rate tumor
cyclophosphamide dose treated tumors
cyclophosphamide dose treated observed delay regrowth tumors
oxygen supply result increases reduces anemia
oxygen supply result increases correction anemia
cyclophosphamide cytotoxicity reduces anemia
cyclophosphamide cytotoxicity reduces increases correction anemia
cyclophosphamide cytotoxicity
cyclophosphamide tumors
cyclophosphamide cytotoxicity reduces increases result supply tissue tumor
oxygen supply result increases reduces cytotoxicity cyclophosphamide tumors
oxygen supply tissue tumor
oxygen supply result increases reduces cytotoxicity
hexamethonium atropine administration reduced induced catalepsy
atropine administration reduced induced catalepsy
mecamylamine atropine administration reduced induced catalepsy
naloxone atropine administration reduced induced catalepsy
hexamethonium atropine injection induced catalepsy
atropine injection induced catalepsy
naloxone atropine injection induced catalepsy
testosterone rats Production cancer prostate
testosterone rats Production cancer
N treatments most tumor
nitroso treatments most tumor
N treatments most tumor
methylurea treatments most tumor
testosterone methylurea treatments most tumor
propionate CAS testosterone methylurea treatments most tumor
TP CAS testosterone methylurea treatments most tumor
TP acted agent tumor
Dexmedetomidine prevents opiate rigidity muscle
Dexmedetomidine prevents opiate rigidity
dexmedetomidine highly capable inducing flaccidity muscle
dexmedetomidine highly capable inducing flaccidity
D highly capable inducing flaccidity muscle
D highly capable inducing flaccidity
MED D highly capable inducing flaccidity muscle
MED D highly capable inducing flaccidity
D MED treatment prevents rigidity muscle
D MED treatment prevents rigidity
- MED treatment prevents rigidity muscle
- MED treatment prevents rigidity
MED treatment prevents rigidity muscle
MED treatment prevents rigidity
D induced rigidity muscle
D induced rigidity
MED D induced rigidity muscle
MED D induced rigidity
D akinetic
MED animals akinetic
D akinetic lacked response startle
MED animals akinetic lacked response startle
Antithymocyte globulin induced anemia aplastic
Antithymocyte globulin induced anemia
globulin induced anemia aplastic
globulin induced anemia
antithymocyte therapy anemia aplastic
antithymocyte therapy anemia
globulin therapy anemia aplastic
globulin therapy anemia
antithymocyte globulin Use treatment D induced anemia aplastic
antithymocyte globulin Use treatment D induced anemia
globulin Use treatment D induced anemia aplastic
globulin Use treatment D induced anemia
adriamycin Effect induced nephropathy
enalapril effect assessed Munich rats nephrosis
enalapril reduced reducing albuminuria
enalapril effect assess progression injury renal
enalapril effect assess progression injury
enalapril effect assess nephrosis
adriamycin nephrosis assess progression injury renal
adriamycin nephrosis assess progression injury
enalapril treatment reduced reducing albuminuria
levodopa dyskinesias monkeys parkinsonian
Levodopa induced present problem patients long management disease Parkinson
Levodopa induced present problem patients long management disease Parkinson '
Levodopa induced present problem patients long management disease s
Levodopa induced present problem patients long management disease
Levodopa induced present problem patients long management disease PD
MPTP types Using parkinsonism study evaluated degree involved development LIDs
levodopa therapy duration progression rate involved degree evaluated study parkinsonism
MPTP exposure Monkeys developed dyskinesia
MPTP exposure monkeys resistant LIDs
MPTP exposure monkeys resistant LIDs e developed dyskinesia
etoposide containing man factors disease coronary
etoposide containing man factors disease heart
etoposide containing man factors disease
Dipyridamole induced ischemia myocardial
Dipyridamole induced ischemia
dipyridamole therapy effect reported demonstrated occur disease coronary
dipyridamole therapy effect reported demonstrated occur disease artery
dipyridamole therapy effect reported demonstrated occur disease
dipyridamole demonstrated occur disease coronary
dipyridamole demonstrated occur disease artery
dipyridamole demonstrated occur disease
dipyridamole therapy effect reported demonstrated dipyridamole ischemia myocardial
dipyridamole therapy effect reported demonstrated dipyridamole ischemia
dipyridamole ischemia myocardial
dipyridamole ischemia
dipyridamole mechanism demonstrated observed ischemia
levodopa effect reflect incidence haemorrhage cause death
noradrenaline levels reflect incidence haemorrhage cause death patients disease Parkinson
noradrenaline levels reflect incidence haemorrhage cause death patients disease Parkinson '
noradrenaline levels reflect incidence haemorrhage cause death patients disease s
noradrenaline levels reflect incidence haemorrhage cause death patients disease
noradrenaline levels brain parkinsonian
levodopa effect reflect incidence haemorrhage cause death patients disease Parkinson
levodopa effect reflect incidence haemorrhage cause death patients disease Parkinson '
levodopa effect reflect incidence haemorrhage cause death patients disease s
levodopa effect reflect incidence haemorrhage cause death patients disease
levodopa effect reflect levels brain parkinsonian
noradrenaline levels reflect incidence haemorrhage cause death
noradrenaline levels reflect effect hypotensive
noradrenaline levels reflect effect levodopa mechanism hypotensive
levodopa effect reflect incidence haemorrhage cerebral
levodopa effect reflect incidence haemorrhage
noradrenaline levels reflect incidence haemorrhage cerebral
noradrenaline levels reflect incidence haemorrhage
tobramycin netilmicin efficacy toxicity
netilmicin efficacy toxicity
tobramycin sulfate sulfate efficacy compared sodium patients infections
sulfate sulfate efficacy compared sodium patients infections
netilmicin sulfate efficacy compared sodium patients infections
sulfate efficacy compared sodium patients infections
piperacillin sodium patients infections
sodium patients infections
aminoglycoside severe ototoxicity
adriamycin Effect combined tissues tumor
adriamycin Effect combined hyperthermia
Adriamycin enhancement mediated activity toxicities
Adriamycin enhancement mediated hyperthermia
Adriamycin enhanced hyperthermia
Adriamycin enhances increased toxicity
Adriamycin enhances hyperthermia
atropine administration Pro pre abolished increases
atropine administration Pro pre abolished increases flow in
atropine administration Pro pre abolished increases flow dural
atropine administration Pro pre abolished increases flow blood
atropine administration Pro pre abolished increases flow
thyroxine abuse considered reminds illustrates derangements function seen eating
thyroxine abuse considered reminds illustrates derangements function seen eating disorders
ketoconazole treatment associated deaths
cibenzoline concentrations arrhythmias ventricular
cibenzoline concentrations arrhythmias
cibenzoline effects examined Using two induced arrhythmias ventricular
cibenzoline effects examined Using two induced arrhythmias
cibenzoline effects examined determined concentration model arrhythmia
Cibenzoline suppressed arrhythmias
Cibenzoline suppressed arrhythmias concentrations arrhythmias
cibenzoline had found active given dogs arrhythmia
cibenzoline had hypotensive
cibenzoline had hypotensive effects depressive
estrogen development receptor factor induced mediate tumors pituitary
estrogen development receptor factor induced mediate tumors
estrogen mediate tumors pituitary
estrogen mediate tumors
estrogen development receptor factor initiated angiogenesis tumor
estrogen mediate induced factor initiated angiogenesis tumor
Estrogens associated types cancers
Estrogens induce angiogenesis tumor
estrogen carcinogenesis
estrogen carcinogenesis unknown details induction tumor
estrogen role elucidate regulation angiogenesis tumor
E pituitary expression associated potential tumor
2 pituitary expression associated potential tumor
estrogen induced angiogenesis tumor
pregnenolone sulphate effects amnesic
sulphate effects amnesic
Steroid structure determine anti effects amnesic
PREGS able reverse ligands amnesic
GABA NMDAR effects amnesic
PREGS effects enhancing tested task using model amnesia
PREGS ability demonstrated scopolamine amnesia
ketoconazole taking developed disease coronary
ketoconazole taking developed disease artery
ketoconazole taking developed disease
ketoconazole taking treatment infection fungal
ketoconazole taking treatment infection
corticosteroids doses treated patients occur myopathy
steroid showed reduction
steroid showed reduction intake of
steroid showed reduction intake food
steroid showed reduction intake
M longer was similar tensions tetanic
steroid groups prolonged was similar tensions tetanic
steroid groups IIa showed revealed absence necrosis
steroid groups IIa atrophy
steroid groups IIa atrophy
T showed revealed absence necrosis
steroids induced respiratory types steroids induced atrophy
steroids induced atrophy
steroid caused conclude contractile treatment doses steroids induced respiratory types steroids induced atrophy
steroids doses treatment contractile conclude caused necrosis
steroids types respiratory induced steroids doses treatment contractile conclude caused necrosis
steroid caused necrosis
steroids doses treatment contractile conclude caused atrophy
steroids types respiratory induced steroids doses treatment contractile conclude caused atrophy
steroid caused conclude caused atrophy
capsaicin intensity pain
capsaicin attention affected ratings pain
capsaicin treatment interaction suggest showing affect pain
capsaicin suggest showing affect pain
PG 9 able prevent amnesia
9 able prevent amnesia
PG profiles Affinity 2 effect amnesic
9 shown PG profiles Affinity 2 effect amnesic
PG 2 effect amnesic
9 PG 2 effect amnesic
acetylcholine levels increase 9 PG 2 effect amnesic
Sch mg exceeded was stimulation tetanic
sodium channel subunit syndrome nephrotic
sodium channel subunit syndrome
sodium excretion decreased syndrome nephrotic
sodium excretion decreased syndrome
aldosterone concentration excretion proteinuria
sodium excretion proteinuria
sodium excretion appearance proteinuria
aldosterone escape appears increased phase syndrome nephrotic
aldosterone escape appears increased phase syndrome
azithromycin beginning treatment pharyngitis
methylprednisolone dexamethasone Corticosteroids agents mentioned associated development hiccups
dexamethasone Corticosteroids agents mentioned associated development hiccups
midazolam benzodiazepines Corticosteroids agents mentioned associated development hiccups
benzodiazepines Corticosteroids agents mentioned associated development hiccups
macrolide antimicrobials related reported hiccups
macrolides reaction reports possible absence explanation hiccups
macrolide antimicrobials reported associated hiccups
Sirolimus agent used have nephrotoxicity
creatinine ratios samples assessed magnitude proteinuria
creatinine ratios samples estimate grams proteinuria
sirolimus initiation development nephrotic
nifedipine receiving patients hypertensive
nifedipine receiving comprising other patients hypertensive
nifedipine reducing nephrotoxicity
tacrolimus associated nephrotoxicity
nifedipine recipients impact factor selecting agent treat hypertension
S correlates psychosis
ketamine psychosis
N D aspartate implicated pathophysiology schizophrenia
methyl D aspartate implicated pathophysiology schizophrenia
D aspartate implicated pathophysiology schizophrenia
aspartate implicated pathophysiology schizophrenia
NMDA aspartate implicated pathophysiology schizophrenia
NMDA ketamine non dose leads psychopathological similar those observed schizophrenia
ketamine non dose leads psychopathological similar those observed schizophrenia
ketamine exacerbates supporting hypothesis dysfunction glutamatergic
ketamine exacerbates supporting hypothesis dysfunction
ketamine exacerbates patients schizophrenia
Ketamine induces similar those observed patients schizophrenia
NMDA dysfunction pathophysiology schizophrenia
fluoxetine receiving treatment disorder depression major
fluoxetine receiving treatment disorder depression
fluoxetine receiving treatment disorder obsessive
fluoxetine receiving treatment disorder compulsive
fluoxetine receiving treatment disorder
fluoxetine purposeless indistinguishable anxiety
propranolol beta responded appeared Akathisia
antidepressant akathisia jitteriness pathophysiology identical caused fluoxetine akathisia
antidepressant akathisia
verapamil ablation induced syndrome patient White Wolff
verapamil ablation induced syndrome patient White Parkinson
verapamil ablation induced syndrome patient White
verapamil ablation induced syndrome
verapamil ablation induced syndrome cardiomyopathy idiopathic
verapamil ablation induced syndrome cardiomyopathy dilated
verapamil ablation induced syndrome cardiomyopathy
Sodium alleviates penile pain induced injections dysfunction erectile
Sodium alleviates penile pain induced injections dysfunction
bicarbonate alleviates penile pain induced injections dysfunction erectile
bicarbonate alleviates penile pain induced injections dysfunction
Sodium alleviates penile
Sodium alleviates penile pain
bicarbonate alleviates penile
bicarbonate alleviates penile pain
sodium bicarbonate addition performed attempt determine due pain penile
sodium bicarbonate addition performed attempt determine due pain
bicarbonate addition performed attempt determine due pain penile
bicarbonate addition performed attempt determine due pain
sodium bicarbonate addition performed study comparing incidence pain penile
sodium bicarbonate addition performed study comparing incidence pain
bicarbonate addition performed study comparing incidence pain penile
bicarbonate addition performed study comparing incidence pain
papaverine total patients presented received clinic impotence
sodium bicarbonate patients complained pain penile
sodium bicarbonate patients complained pain
bicarbonate patients complained pain penile
bicarbonate patients complained pain
sodium bicarbonate patients complained complained pain penile
sodium bicarbonate patients complained complained pain
bicarbonate patients complained complained pain penile
bicarbonate patients complained complained pain
sodium bicarbonate received men 1 complained complained pain penile
sodium bicarbonate received men 1 complained complained pain
bicarbonate received men 1 complained complained pain penile
bicarbonate received men 1 complained complained pain
sodium bicarbonate received men 1 complained pain penile
sodium bicarbonate received men 1 complained pain
bicarbonate received men 1 complained pain penile
bicarbonate received men 1 complained pain
prochlorperazine headache nausea
prochlorperazine headache
prochlorperazine headache vomiting
prochlorperazine treatment headache nausea
prochlorperazine treatment headache
Valsartan antagonist treatment hypertension
angiotensin antagonist treatment hypertension
II antagonist treatment hypertension
amlodipine efficacy study Valsartan antagonist treatment hypertension
valsartan receive allocated outpatients hypertension
amlodipine valsartan receive allocated outpatients hypertension
valsartan amlodipine treatment hypertension
amlodipine treatment hypertension
ifosfamide induced cystitis hemorrhagic
ifosfamide induced cystitis
mesna administration subcutaneous prevent ifosfamide induced cystitis hemorrhagic
mesna administration subcutaneous prevent ifosfamide induced cystitis
ifosfamide toxicity cystitis Hemorrhagic
ifosfamide toxicity cystitis
mesna administering prevented toxicity
ifosfamide toxicity
mesna administering prevented toxicity cystitis Hemorrhagic
mesna administering prevented toxicity cystitis
mesna concentrations risk emesis
mesna taking patient emesis
ifosfamide experiences mesna taking patient emesis
fluorouracil underwent cancer colorectal
fluorouracil underwent cancer
catecholamines levels contributed development ABS
catecholamines neuropeptides caused diagnosis cancer
H O CPAP produced increased rate output decreased
H O CPAP produced increased rate output cardiac
H O CPAP produced increased rate output
2 O CPAP produced increased rate output decreased
2 O CPAP produced increased rate output cardiac
2 O CPAP produced increased rate output
O CPAP produced increased rate output decreased
O CPAP produced increased rate output cardiac
O CPAP produced increased rate output
nitroprusside infusion produced increased rate output decreased
nitroprusside infusion produced increased rate output cardiac
nitroprusside infusion produced increased rate output
H O CPAP produced decrease
H O CPAP produced pressure in
H O CPAP produced pressure arterial
H O CPAP produced pressure blood
H O CPAP produced pressure
2 O CPAP produced decrease
2 O CPAP produced pressure in
2 O CPAP produced pressure arterial
2 O CPAP produced pressure blood
2 O CPAP produced pressure
O CPAP produced decrease
O CPAP produced pressure in
O CPAP produced pressure arterial
O CPAP produced pressure blood
O CPAP produced pressure
H O 10 levels produce decreases
H O 10 levels produce pressure in
H O 10 levels produce pressure arterial
H O 10 levels produce pressure blood
H O 10 levels produce pressure
H O 10 levels produce pressure and
H O 10 levels produce pressure output cardiac
H O 10 levels produce pressure output
2 O 10 levels produce decreases
2 O 10 levels produce pressure in
2 O 10 levels produce pressure arterial
2 O 10 levels produce pressure blood
2 O 10 levels produce pressure
2 O 10 levels produce pressure and
2 O 10 levels produce pressure output cardiac
2 O 10 levels produce pressure output
O 10 levels produce decreases
O 10 levels produce pressure in
O 10 levels produce pressure arterial
O 10 levels produce pressure blood
O 10 levels produce pressure
O 10 levels produce pressure and
O 10 levels produce pressure output cardiac
O 10 levels produce pressure output
nitroprusside infusion alter produce decreases
nitroprusside infusion alter produce pressure in
nitroprusside infusion alter produce pressure arterial
nitroprusside infusion alter produce pressure blood
nitroprusside infusion alter produce pressure
nitroprusside infusion alter produce pressure and
nitroprusside infusion alter produce pressure output cardiac
nitroprusside infusion alter produce pressure output
bupropion dysfunction sexual
bupropion dysfunction
selective serotonin induced dysfunction sexual
selective serotonin induced dysfunction
serotonin induced dysfunction sexual
serotonin induced dysfunction
reuptake effects bupropion dysfunction sexual
reuptake effects bupropion dysfunction
inhibitor reuptake effects bupropion dysfunction sexual
inhibitor reuptake effects bupropion dysfunction
bupropion release dysfunction sexual
bupropion release dysfunction
bupropion release dysfunction SD
bupropion release dysfunction induced side SD
selective inhibitor induced dysfunction sexual
selective inhibitor induced dysfunction
serotonin inhibitor induced dysfunction sexual
serotonin inhibitor induced dysfunction
reuptake inhibitor induced dysfunction sexual
reuptake inhibitor induced dysfunction
inhibitor induced dysfunction sexual
inhibitor induced dysfunction
selective inhibitor induced dysfunction SD
serotonin inhibitor induced dysfunction SD
reuptake inhibitor induced dysfunction SD
inhibitor induced dysfunction SD
selective inhibitor induced side SD
serotonin inhibitor induced side SD
reuptake inhibitor induced side SD
inhibitor induced side SD
SSRI inhibitor induced dysfunction sexual
SSRI inhibitor induced dysfunction
SSRI inhibitor induced dysfunction SD
SSRI inhibitor induced side SD
SSRIs effect bupropion release dysfunction sexual
SSRIs effect bupropion release dysfunction
SSRIs effect bupropion release dysfunction SD
SSRIs effect bupropion release dysfunction induced side SD
SSRI type used affected duration SD
Bupropion treatment SD
SSRIs induced SD
prazosin antagonized rigidity muscular
prazosin antagonized rigidity
isoproterenol demand hypotension
oxygen supply mismatch vs unknown damage myocardial
oxygen supply mismatch vs unknown damage
oxygen supply mismatch vs unknown demand hypotension hyperactivity myocardial
oxygen supply mismatch vs unknown demand hypotension hyperactivity
oxygen supply mismatch vs unknown demand hypotension
diatrizoate fibrillation Ventricular
diatrizoate fibrillation
Renografin toxicity
76 % Renografin toxicity
% Renografin toxicity
Hypaque that compared toxicity
76 % Hypaque that compared toxicity
% Hypaque that compared toxicity
Renografin occurred suggesting contribute toxicity
Renografin occurred fibrillation Ventricular
Renografin occurred fibrillation
bleomycin cisplatin treatment alkaloid developed microangiopathy thrombotic
bleomycin cisplatin treatment alkaloid developed microangiopathy
vinca cisplatin treatment alkaloid developed characterized insufficiency anemia microangiopathic
vinca cisplatin treatment alkaloid developed characterized insufficiency anemia hemolytic
vinca cisplatin treatment alkaloid developed characterized insufficiency anemia
alkaloid developed characterized insufficiency anemia microangiopathic
alkaloid developed characterized insufficiency anemia hemolytic
alkaloid developed characterized insufficiency anemia
vinca cisplatin treatment alkaloid developed characterized insufficiency thrombocytopenia
alkaloid developed characterized insufficiency thrombocytopenia
bleomycin cisplatin treatment alkaloid developed characterized insufficiency renal
bleomycin cisplatin treatment alkaloid developed characterized insufficiency
vinca cisplatin treatment alkaloid developed microangiopathy thrombotic
vinca cisplatin treatment alkaloid developed microangiopathy
alkaloid developed microangiopathy thrombotic
alkaloid developed microangiopathy
bleomycin cisplatin treatment alkaloid developed characterized insufficiency anemia microangiopathic
bleomycin cisplatin treatment alkaloid developed characterized insufficiency anemia hemolytic
bleomycin cisplatin treatment alkaloid developed characterized insufficiency anemia
bleomycin cisplatin treatment alkaloid developed characterized insufficiency thrombocytopenia
cisplatin treatment alkaloid developed microangiopathy thrombotic
cisplatin treatment alkaloid developed microangiopathy
cisplatin treatment alkaloid developed characterized insufficiency renal
cisplatin treatment alkaloid developed characterized insufficiency
bleomycin cisplatin treatment alkaloid developed patients carcinoma
vinca cisplatin treatment alkaloid developed characterized insufficiency renal
vinca cisplatin treatment alkaloid developed characterized insufficiency
alkaloid developed characterized insufficiency renal
alkaloid developed characterized insufficiency
vinca cisplatin treatment alkaloid developed patients carcinoma
alkaloid developed patients carcinoma
cisplatin treatment alkaloid developed patients carcinoma
cisplatin treatment alkaloid developed characterized insufficiency anemia microangiopathic
cisplatin treatment alkaloid developed characterized insufficiency anemia hemolytic
cisplatin treatment alkaloid developed characterized insufficiency anemia
cisplatin treatment alkaloid developed characterized insufficiency thrombocytopenia
cisplatin nephrotoxicity ascribed examined suppression bone
cisplatin nephrotoxicity ascribed examined suppression marrow
cisplatin nephrotoxicity ascribed examined suppression
cisplatin nephrotoxicity anemia
cisplatin nephrotoxicity ascribed failure renal
cisplatin nephrotoxicity ascribed failure
cisplatin nephrotoxicity anemia thrombocytopenia
lactate infusion produced injury
lactate infusion produced injury cortex in
lactate infusion produced injury cortex the
lactate infusion produced injury cortex
creatine development arrhythmia
Tiapride movements involuntary
Tiapride movements
metoclopramide related derivative Tiapride induced disease Parkinson idiopathic
metoclopramide related derivative Tiapride induced disease Parkinson
metoclopramide related derivative Tiapride induced disease Parkinson '
metoclopramide related derivative Tiapride induced disease s
metoclopramide related derivative Tiapride induced disease
Tiapride induced movements involuntary
Tiapride induced movements
metoclopramide related derivative Tiapride induced movements involuntary
metoclopramide related derivative Tiapride induced movements
levodopa Tiapride induced disease Parkinson idiopathic
levodopa Tiapride induced disease Parkinson
levodopa Tiapride induced disease Parkinson '
levodopa Tiapride induced disease s
levodopa Tiapride induced disease
benzamide derivative Tiapride induced movements involuntary
benzamide derivative Tiapride induced movements
benzamide derivative Tiapride induced disease Parkinson idiopathic
benzamide derivative Tiapride induced disease Parkinson
benzamide derivative Tiapride induced disease Parkinson '
benzamide derivative Tiapride induced disease s
benzamide derivative Tiapride induced disease
Tiapride induced disease Parkinson idiopathic
Tiapride induced disease Parkinson
Tiapride induced disease Parkinson '
Tiapride induced disease s
Tiapride induced disease
Tiapride had effect period dystonia
levodopa effect period dystonia
dopamine receptors group overstimulation caused levodopa dyskinesias
ASA administered strains Dawley Sprague results compare test confounds toxicity gastrointestinal
ASA administered strains Dawley Sprague results compare test confounds toxicity
ASA malformations detection confounds toxicity gastrointestinal
ASA malformations detection confounds toxicity
ASA induces focused suggested induce defects defects midline
ASA induces focused suggested induce defects defects
ASA induces focused suggested induce defects defects MDs
ASA induces focused suggested induce defects defects rats MDs
Suxamethonium induced arrest death
suxamethonium use hyperkalaemia result death
suxamethonium caused death
isoproterenol pretreatment Effects tachycardia
isoproterenol pretreatment reduced ii activation mediated tachycardia
dopamine activation mediated tachycardia
isoproterenol pretreatment abolish bromocriptine tachycardia
isoproterenol pretreatment unaffected reversed tachycardia
Bromocriptine induced unaffected reversed bradycardia
isoproterenol pretreatment unaffected hypotension
domperidone i reduced effect bradycardia reversed unaffected hypotension
domperidone i reduced effect bradycardia reversed tachycardia
isoproterenol pretreatment abolished 15 induced tachycardia
bromocriptine reversed abolished 15 induced bradycardia
dopamine receptors mask bradycardia
bromocriptine tachycardia appears predominate mask bradycardia
dopamine receptors mask predominate appears tachycardia
oxygen saturations range % mean associated incidence bradycardia
sulindac difluoromethylornithine trial audiograms prevention adenomas colorectal
sulindac difluoromethylornithine trial audiograms prevention adenomas
difluoromethylornithine trial audiograms prevention adenomas colorectal
difluoromethylornithine trial audiograms prevention adenomas
difluoromethylornithine months treatment assessed recurrence polyps adenomatous
difluoromethylornithine months treatment assessed recurrence polyps
DFMO difluoromethylornithine months treatment assessed recurrence polyps adenomatous
DFMO difluoromethylornithine months treatment assessed recurrence polyps
sulindac assessed recurrence polyps adenomatous
sulindac assessed recurrence polyps
DFMO treatment toxicity
DFMO treatment toxicity loss hearing
DFMO treatment toxicity loss
DFMO subjects proportion difference group experienced loss hearing
DFMO subjects proportion difference group experienced loss
ribavirin associated anemia hemolytic
ribavirin associated anemia
ribavirin found found cause hemolysis
pegylated interferon treated patients infected chronically
pegylated interferon treated patients infected
pegylated interferon treated patients infected virus with
pegylated interferon treated patients infected virus hepatitis
pegylated interferon treated patients infected virus C
pegylated interferon treated patients infected virus
interferon treated patients infected chronically
interferon treated patients infected
interferon treated patients infected virus with
interferon treated patients infected virus hepatitis
interferon treated patients infected virus C
interferon treated patients infected virus
alpha interferon treated patients infected chronically
alpha interferon treated patients infected
alpha interferon treated patients infected virus with
alpha interferon treated patients infected virus hepatitis
alpha interferon treated patients infected virus C
alpha interferon treated patients infected virus
2 alpha interferon treated patients infected chronically
2 alpha interferon treated patients infected
2 alpha interferon treated patients infected virus with
2 alpha interferon treated patients infected virus hepatitis
2 alpha interferon treated patients infected virus C
2 alpha interferon treated patients infected virus
a interferon treated patients infected chronically
a interferon treated patients infected
a interferon treated patients infected virus with
a interferon treated patients infected virus hepatitis
a interferon treated patients infected virus C
a interferon treated patients infected virus
ribavirin a interferon treated patients infected chronically
ribavirin a interferon treated patients infected
ribavirin a interferon treated patients infected virus with
ribavirin a interferon treated patients infected virus hepatitis
ribavirin a interferon treated patients infected virus C
ribavirin a interferon treated patients infected virus
ribavirin anemia patients C hepatitis
ribavirin anemia patients C
ribavirin anemia
Serotonin gene psychosis
serotonin receptor targeted HT amphetamine induced hyperactivity
5 serotonin receptor targeted HT amphetamine induced hyperactivity
HT 5 serotonin receptor targeted HT amphetamine induced hyperactivity
5 use corrected rats induced hyperactivity
HT amphetamine induced hyperactivity
olanzapine clozapine such targeted HT amphetamine induced hyperactivity
d targeted HT amphetamine induced hyperactivity
amphetamine induced hyperactivity
clozapine such targeted HT amphetamine induced hyperactivity
5 altered suggests considered reflect symptoms schizophrenia
HT receptors involved considered reflect symptoms schizophrenia
5 altered suggests considered involved pathophysiology disorders psychotic
5 altered suggests considered involved pathophysiology disorders
HT receptors involved pathophysiology disorders psychotic
HT receptors involved pathophysiology disorders
methamphetamine symptoms similar those schizophrenia paranoid
methamphetamine symptoms similar those schizophrenia type
methamphetamine symptoms similar those schizophrenia
METH methamphetamine symptoms similar those schizophrenia paranoid
METH methamphetamine symptoms similar those schizophrenia type
METH methamphetamine symptoms similar those schizophrenia
5 induced psychosis
HT gene 5 induced psychosis
isoflurane exposure Acute hepatitis cholestatic
isoflurane exposure Acute hepatitis
isoflurane exposure hepatitis cholestatic
isoflurane exposure hepatitis
dipyrone analgesia
Isoflurane cause hepatitis cholestatic
Isoflurane cause hepatitis
mefloquine prophylaxis malaria
Ticlopidine induced hepatitis cholestatic
Ticlopidine induced hepatitis
ticlopidine cases report induced hepatitis cholestatic
ticlopidine cases report induced hepatitis
ticlopidine percutaneous receiving developed hepatitis cholestatic
ticlopidine percutaneous receiving developed hepatitis
ticlopidine complication hepatitis Cholestatic
ticlopidine complication hepatitis
ticlopidine developed showed characteristics hepatitis cholestatic
ticlopidine developed showed characteristics hepatitis
ticlopidine effect hepatitis Cholestatic
ticlopidine effect hepatitis
methylprednisolone administration assess space end surgery cataract
gentamicin methylprednisolone administration assess space end surgery cataract
gabapentin drug patients neuropathic
gabapentin drug patients pain
gabapentin induced hyperalgesia secondary
gabapentin induced hyperalgesia
lithium toxicity regurgitation Tricuspid
lithium toxicity regurgitation valve
lithium toxicity regurgitation
carbonate toxicity regurgitation Tricuspid
carbonate toxicity regurgitation valve
carbonate toxicity regurgitation
lithium toxicity
carbonate toxicity
lithium level newborn regurgitation failure congestive
lithium level newborn regurgitation failure heart
lithium level newborn regurgitation failure
lithium level newborn regurgitation tricuspid
lithium level newborn regurgitation
lithium level newborn regurgitation flutter atrial
lithium level newborn regurgitation flutter
lithium compounds exposed infants described disease cardiac
lithium compounds exposed infants described disease
lithium compounds exposed infants described patient manifest regurgitation tricuspid
lithium compounds exposed infants described patient manifest regurgitation
lithium compounds exposed infants described patient manifest regurgitation flutter atrial
lithium compounds exposed infants described patient manifest regurgitation flutter
Lithium carbonate factor incidence disease congenital
Lithium carbonate factor incidence disease heart
Lithium carbonate factor incidence disease
carbonate factor incidence disease congenital
carbonate factor incidence disease heart
carbonate factor incidence disease
thallium correlation severity stenosis coronary
thallium correlation severity stenosis
dipyridamole had 12 dogs stenosis coronary
dipyridamole had 12 dogs stenosis
Thallium induced hyperemia
lithium Rats induced nephropathy
lithium Rats induced feeding uninephrectomy combination these attempt induce hyperfiltration failure renal
lithium Rats induced feeding uninephrectomy combination these attempt induce hyperfiltration failure
Lithium caused absence glomerulosclerosis
lithium rats decrease increase tended fact failed failed progression failure renal
lithium rats decrease increase tended fact failed failed progression failure
creatinine levels decrease increase tended fact failed failed progression failure renal
creatinine levels decrease increase tended fact failed failed progression failure
Li nephropathy
bromocriptine received inhibition
bromocriptine received inhibition lactation of
bromocriptine received inhibition lactation
bromocriptine received seen patients history psychiatric
Bromocriptine associated psychosis patients receiving drug disease Parkinson
Bromocriptine associated psychosis patients receiving drug disease Parkinson '
Bromocriptine associated psychosis patients receiving drug disease s
Bromocriptine associated psychosis patients receiving drug disease
amphetamine cocaine use stroke hemorrhagic ischemic
cocaine use stroke hemorrhagic ischemic
Busulfan induced cystitis hemorrhagic
Busulfan induced cystitis
busulfan induced cystitis hemorrhage
busulfan induced cystitis
cyclophosphamide radiation appearances cystitis
cyclophosphamide radiation cystitis
busulfan tendency induce atypia carcinoma
Pyrazinamide have effects disorders toxicity hyperuricemia
Pyrazinamide have effects disorders hepatic
Pyrazinamide have effects disorders toxicity
lovastatin Efficacy women hypercholesterolemia
lovastatin efficacy evaluate women hypercholesterolemia
creatine elevations symptoms defined rare Myopathy
Lovastatin effective therapy hypercholesterolemia
acetaminophen NSAID g starting diagnosis SAH aneurysmal
acetaminophen g starting diagnosis SAH aneurysmal
ketoprofen receive randomized Patients hemorrhage aneurysmal
ketoprofen receive randomized Patients hemorrhage subarachnoid
ketoprofen receive randomized Patients hemorrhage
ketoprofen receive randomized Patients SAH
ketoprofen NSAID g starting diagnosis SAH
ketoprofen ketoprofen receive randomized Patients hemorrhage aneurysmal
ketoprofen ketoprofen receive randomized Patients hemorrhage subarachnoid
ketoprofen ketoprofen receive randomized Patients hemorrhage
ketoprofen ketoprofen receive randomized Patients SAH
ketoprofen ketoprofen NSAID g starting diagnosis SAH
acetaminophen NSAID ketoprofen receive randomized Patients hemorrhage aneurysmal
acetaminophen NSAID ketoprofen receive randomized Patients hemorrhage subarachnoid
acetaminophen NSAID ketoprofen receive randomized Patients hemorrhage
acetaminophen NSAID ketoprofen receive randomized Patients SAH
acetaminophen NSAID g starting diagnosis SAH
acetaminophen g NSAID ketoprofen receive randomized Patients hemorrhage aneurysmal
acetaminophen g NSAID ketoprofen receive randomized Patients hemorrhage subarachnoid
acetaminophen g NSAID ketoprofen receive randomized Patients hemorrhage
acetaminophen g NSAID ketoprofen receive randomized Patients SAH
acetaminophen g starting diagnosis SAH
ketoprofen NSAID g starting diagnosis SAH aneurysmal
ketoprofen ketoprofen NSAID g starting diagnosis SAH aneurysmal
adenosine diphosphate microM induced aggregation platelet
adenosine diphosphate microM induced aggregation
diphosphate microM induced aggregation platelet
diphosphate microM induced aggregation
acetaminophen group increased aggregation platelet
acetaminophen group increased aggregation
acetaminophen group increased results platelet
acetaminophen group increased results aggregation
Ketoprofen platelet function patients SAH
acetaminophen impaired Ketoprofen platelet function patients SAH
ketoprofen used surgery aneurysms artery
ketoprofen used surgery aneurysms
ketoprofen used pose hemorrhage
dopamine blockade result thought syndrome Neuroleptic
dopamine blockade result thought syndrome malignant
dopamine blockade result thought syndrome
risperidone impart frequency symptoms extrapyramidal
risperidone impart frequency symptoms
Quinidine responsible hepatitis
cytosine treatment patient leukemia acute
cytosine treatment patient leukemia myeloid
cytosine treatment patient leukemia
arabinoside treatment patient leukemia acute
arabinoside treatment patient leukemia myeloid
arabinoside treatment patient leukemia
cytosine arabinoside high toxicity
arabinoside high toxicity
cytosine arabinoside high toxicity recognized reported toxicity
arabinoside high toxicity recognized reported toxicity
cytosine arabinoside toxicity reported recognized toxicity
arabinoside toxicity reported recognized toxicity
cytosine arabinoside toxicity
arabinoside toxicity
cytosine arabinoside high course resulted complained numbness
arabinoside high course resulted complained numbness
methylprednisolone responded worsened development graft
methylprednisolone responded worsened versus
methylprednisolone responded worsened worsened disease -
methylprednisolone responded worsened worsened disease host
methylprednisolone responded worsened worsened disease
methylprednisolone responded worsened resolving neuropathy
Sorafenib induced due infarction myocardial
Sorafenib induced due infarction
nicorandil Addition reduced maintained status stable
nicorandil Addition reduced maintained status angina
acetaminophen overdose
vinorelbine squamous
vinorelbine cell
vinorelbine cell trial esophageal
vinorelbine cell trial esophageal carcinoma
vinorelbine cell administered agent squamous
vinorelbine cell
vinorelbine cell carcinoma esophageal
vinorelbine cell carcinoma
VNB cell administered agent squamous
VNB cell
VNB cell carcinoma esophageal
VNB cell carcinoma
cisplatin pretreated assessable toxicity
VNB tolerated occurred instances toxicity
VNB agent carcinoma esophageal
VNB agent carcinoma squamous
VNB agent carcinoma cell
VNB agent carcinoma
VNB evaluation warranted profile toxicity
fenfluramine users disease valvular
fenfluramine users disease heart
fenfluramine users disease
dexfenfluramine fenfluramine users disease valvular
dexfenfluramine fenfluramine users disease heart
dexfenfluramine fenfluramine users disease
fenfluramine users % had disease valvular
fenfluramine users % had disease
dexfenfluramine fenfluramine users % had disease valvular
dexfenfluramine fenfluramine users % had disease
fenfluramine users abnormalities valvular
fenfluramine users abnormalities
dexfenfluramine fenfluramine users abnormalities valvular
dexfenfluramine fenfluramine users abnormalities
phentermine developed disease valvular
phentermine developed disease heart
phentermine developed disease
fenfluramine receiving patients RESULTS phentermine developed disease valvular
fenfluramine receiving patients RESULTS phentermine developed disease heart
fenfluramine receiving patients RESULTS phentermine developed disease
nitroglycerin effect inducing seems depend stimulation site pain
D treated cirrhosis primary
D treated cirrhosis biliary
D treated cirrhosis
penicillamine case cirrhosis primary
penicillamine case cirrhosis biliary
penicillamine case cirrhosis
D used diseases rheumatologic
D used diseases
penicillamine D used diseases rheumatologic
penicillamine D used diseases
D used limits toxicity
penicillamine D used limits toxicity
D complications one develop dermatomyositis
penicillamine Polymyositis develop dermatomyositis
D receiving developed cirrhosis primary
D receiving developed cirrhosis biliary
D receiving developed cirrhosis
penicillamine therapy D receiving developed cirrhosis primary
penicillamine therapy D receiving developed cirrhosis biliary
penicillamine therapy D receiving developed cirrhosis
D dermatomyositis
penicillamine therapy followed D dermatomyositis
BD mice treatment pre induced convulsions
1063 BD mice treatment pre induced convulsions
BD mice treatment pre induced convulsions
1018 BD mice treatment pre induced convulsions
LR mice treatment pre induced convulsions
132 LR mice treatment pre induced convulsions
BD agonist tolylguanidine o agonist well worsened toxicity
1031 BD agonist tolylguanidine o agonist well worsened toxicity
3 R BD agonist tolylguanidine o agonist well worsened toxicity
R BD agonist tolylguanidine o agonist well worsened toxicity
1 R BD agonist tolylguanidine o agonist well worsened toxicity
-LSB- 2 1 R BD agonist tolylguanidine o agonist well worsened toxicity
2 1 R BD agonist tolylguanidine o agonist well worsened toxicity
3 1 R BD agonist tolylguanidine o agonist well worsened toxicity
4 3 1 R BD agonist tolylguanidine o agonist well worsened toxicity
dichlorophenyl 3 1 R BD agonist tolylguanidine o agonist well worsened toxicity
ethyl -RSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
-RSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
1 1 R BD agonist tolylguanidine o agonist well worsened toxicity
4 1 1 R BD agonist tolylguanidine o agonist well worsened toxicity
diazabicyclo -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
-LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
4 -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
3 -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
0 -RSB- nonane -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
-RSB- nonane -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
nonane -LSB- 1 R BD agonist tolylguanidine o agonist well worsened toxicity
cocaine toxicity
di agonist well worsened toxicity
o agonist well worsened toxicity
tolylguanidine o agonist well worsened toxicity
DTG tolylguanidine o agonist well worsened toxicity
oligodeoxynucleotide shown attenuate effects convulsive
salvianolic A effect infarction myocardial
salvianolic A effect infarction
acid A effect infarction myocardial
acid A effect infarction
A effect infarction myocardial
A effect infarction
salvianolic A potential evaluate isoproterenol induced infarction myocardial
salvianolic A potential evaluate isoproterenol induced infarction
acid A potential evaluate isoproterenol induced infarction myocardial
acid A potential evaluate isoproterenol induced infarction
A potential evaluate isoproterenol induced infarction myocardial
A potential evaluate isoproterenol induced infarction
isoproterenol observed ADP ratio characterized dysfunction respiratory
isoproterenol observed ADP ratio characterized dysfunction
ADP ratio characterized dysfunction respiratory
ADP ratio characterized dysfunction
isoproterenol dysfunction cardiac
isoproterenol dysfunction
salvianolic A Administration attenuated isoproterenol dysfunction injury myocardial
salvianolic A Administration attenuated isoproterenol dysfunction injury
acid A Administration attenuated isoproterenol dysfunction injury myocardial
acid A Administration attenuated isoproterenol dysfunction injury
A Administration attenuated isoproterenol dysfunction injury myocardial
A Administration attenuated isoproterenol dysfunction injury
salvianolic A Administration attenuated isoproterenol dysfunction cardiac
salvianolic A Administration attenuated isoproterenol dysfunction
acid A Administration attenuated isoproterenol dysfunction cardiac
acid A Administration attenuated isoproterenol dysfunction
A Administration attenuated isoproterenol dysfunction cardiac
A Administration attenuated isoproterenol dysfunction
isoproterenol dysfunction injury myocardial
isoproterenol dysfunction injury
salvianolic A damage myocardial
salvianolic A damage
acid A damage myocardial
acid A damage
A damage myocardial
A damage
isoproterenol A damage myocardial
isoproterenol A damage
salvianolic acid has effect isoproterenol induced infarction myocardial
salvianolic acid has effect isoproterenol induced infarction
acid has effect isoproterenol induced infarction myocardial
acid has effect isoproterenol induced infarction
A activity acid has effect isoproterenol induced infarction myocardial
A activity acid has effect isoproterenol induced infarction
Vancomycin curative % patients infection
aminoglycoside receiving patients confined nephrotoxicity
aminoglycoside receiving patients confined nephrotoxicity ototoxicity
vancomycin aminoglycoside receiving patients confined nephrotoxicity
aminoglycoside receiving patients confined occurred Thrombophlebitis
vancomycin constitutes infections
dobutamine infusion managed admitted patient known have cardiomyopathy hypertrophic
dobutamine infusion managed admitted patient known have cardiomyopathy
dobutamine infusion managed admitted failure biventricular
dobutamine infusion managed admitted failure
propofol infusion continued available detect hyperthermia malignant
propofol infusion continued available detect hyperthermia
methylergonovine Effect patients angina variant
methylergonovine Effect patients angina
methylergonovine administration effects studied pectoris angina
methylergonovine administration effects studied pectoris
methylergonovine administration effects studied patients angina variant
methylergonovine administration effects studied patients angina
methylergonovine administration effects studied patients patients pain chest
methylergonovine administration effects studied patients patients pain
methylergonovine dose injection use tests spasm
methylergonovine dose injection use tests have sensitivity angina variant
methylergonovine dose injection use tests have sensitivity angina
debrisoquine polymorphism belonging patients experience reactions adverse
debrisoquine polymorphism belonging patients experience reactions drug
debrisoquine polymorphism belonging patients experience reactions
sparteine phenotype polymorphism belonging patients experience reactions adverse
sparteine phenotype polymorphism belonging patients experience reactions drug
sparteine phenotype polymorphism belonging patients experience reactions
estrogen Characterization tumors adenohypophyseal
estrogen Characterization tumors
DES establishing induced tumor
Amiodarone represents drug cardioversion recent fibrillation atrial
Amiodarone represents drug cardioversion recent fibrillation
Amiodarone represents drug cardioversion recent AF
amiodarone loading initiation experienced fibrillation atrial
amiodarone loading initiation experienced fibrillation
salt angiotensinogen hypertension
Testosterone hypertension
testosterone causes increases BP injury renal
testosterone causes increases BP injury
Testosterone replacement increased BP injury renal
Testosterone replacement increased BP injury
angiotensin system upregulation contributes development hypertension
angiotensin system upregulation contributes development injury renal
angiotensin system upregulation contributes development injury
Testosterone contributes development injury renal
Testosterone contributes development injury
Testosterone contributes development hypertension
pentazocine due myopathy fibrous
pentazocine due myopathy
pentazocine due neuropathy Compression
pentazocine due neuropathy
pentazocine due neuropathy nerve of
pentazocine due neuropathy nerve the
pentazocine due neuropathy nerve radial
pentazocine due neuropathy nerve
pentazocine injection effect Fibrous
pentazocine injection effect myopathy
pentazocine woman 37 fibrous
pentazocine woman 37 fibrous bilaterally myopathy
pentazocine woman 37 showed myopathy fibrous
pentazocine woman 37 showed myopathy
Paracetamol associated coma
Paracetamol associated coma renal
Paracetamol associated coma and
Paracetamol associated coma failure hepatic
Paracetamol associated coma failure
paracetamol ingestion failure acidosis failure acute
paracetamol ingestion failure acidosis failure renal
paracetamol ingestion failure acidosis failure
paracetamol ingestion failure acidosis and
paracetamol ingestion failure hepatic
paracetamol ingestion failure
Penicillamine induced arthritis rheumatoid
Penicillamine induced arthritis
D months presented arthritis rheumatoid
D months presented arthritis
penicillamine treatment woman arthritis rheumatoid
penicillamine treatment woman arthritis
D course case emphasizes need sediment proteinuria
penicillamine treatment emphasizes need sediment proteinuria
hepatitis antigen stick assess examined globulin Hepatitis
hepatitis antigen stick assess examined globulin B
B antigen stick assess examined globulin Hepatitis
B antigen stick assess examined globulin B
surface antigen stick assess examined globulin Hepatitis
surface antigen stick assess examined globulin B
antigen stick assess examined globulin Hepatitis
antigen stick assess examined globulin B
hepatitis antigen stick assess preventing hepatitis type
hepatitis antigen stick assess preventing hepatitis B
hepatitis antigen stick assess preventing hepatitis
B antigen stick assess preventing hepatitis type
B antigen stick assess preventing hepatitis B
B antigen stick assess preventing hepatitis
surface antigen stick assess preventing hepatitis type
surface antigen stick assess preventing hepatitis B
surface antigen stick assess preventing hepatitis
antigen stick assess preventing hepatitis type
antigen stick assess preventing hepatitis B
antigen stick assess preventing hepatitis
HBsAG antigen stick assess examined globulin Hepatitis
HBsAG antigen stick assess examined globulin B
HBsAG antigen stick assess preventing hepatitis type
HBsAG antigen stick assess preventing hepatitis B
HBsAG antigen stick assess preventing hepatitis
gamma synthesis attributed induced tachycardia bradycardia
aminobutyric acid gamma synthesis attributed induced tachycardia bradycardia
acid gamma synthesis attributed induced tachycardia bradycardia
GABA gamma synthesis attributed induced tachycardia bradycardia
gamma synthesis attributed induced doses hypotension
aminobutyric acid gamma synthesis attributed induced doses hypotension
acid gamma synthesis attributed induced doses hypotension
GABA gamma synthesis attributed induced doses hypotension
gamma synthesis attributed induced tachycardia
aminobutyric acid gamma synthesis attributed induced tachycardia
acid gamma synthesis attributed induced tachycardia
GABA gamma synthesis attributed induced tachycardia
isoniazid hypotension doses induced tachycardia
urethane chloralose anaesthetised rats determined induced enhancement isoniazid bradycardia
chloralose anaesthetised rats determined induced enhancement isoniazid bradycardia
hexamethonium increased increased bradycardia
propranolol increased bradycardia
clonidine increased bradycardia
atenolol propranolol increased bradycardia
labetalol propranolol increased bradycardia
pindolol propranolol increased bradycardia
carbachol hexamethonium increased increased bradycardia
angiotensin proteins altered rats syndrome nephrotic
angiotensin proteins altered rats syndrome
angiotensin proteins altered rats syndrome NS
Doxorubicin cardiomyopathy Wilms
Doxorubicin cardiomyopathy Wilms tumor
anthracycline cardiomyopathy
anthracycline cardiomyopathy experienced bed tumor
anthracycline cardiomyopathy experienced children tumor Wilms
anthracycline cardiomyopathy experienced children tumor
doxorubicin bed tumor
doxorubicin bed experienced children tumor Wilms
doxorubicin bed experienced children tumor
doxorubicin interaction fact include fields tumor Wilms
doxorubicin interaction fact include fields tumor
doxorubicin dosage restricted tumor Wilms
doxorubicin dosage restricted tumor
Lamivudine added infection hepatitis
Lamivudine added infection B
Lamivudine added infection
sirolimus replaced transplant acidosis
sirolimus replaced transplant acidosis
tacrolimus suspected acidosis transplant acidosis
tacrolimus suspected acidosis
lamivudine augmented triggered dysfunction mitochondrial
lamivudine augmented triggered dysfunction
tacrolimus triggered dysfunction mitochondrial
tacrolimus triggered dysfunction
ephedrine study placebo induced dysfunction sexual
ephedrine study placebo induced dysfunction
ephedrine has effects dysfunction sexual
ephedrine has effects dysfunction
ephedrine effects study cross controlled measures women sexually
ephedrine effects study cross controlled measures women dysfunctional
magnesium administration preeclampsia
magnesium administration became quadriplegic
magnesium administration became history disease neuromuscular
magnesium administration became history disease
magnesium administration paralysis
magnesium effects sensitive Patients suspected having disorder
magnesium effects sensitive Patients suspected having disorder transmission of
magnesium effects sensitive Patients suspected having disorder transmission neuromuscular
magnesium effects sensitive Patients suspected having disorder transmission
doxorubicin induced cardiotoxicity
fat diet sensitive doxorubicin induced cardiotoxicity
doxorubicin sensitive rats obese
doxorubicin chemotherapy limited life threatening cardiotoxicity
Adriamycin doxorubicin chemotherapy limited life threatening cardiotoxicity
doxorubicin induced cardiotoxicity
doxorubicin sensitizes rats diet feeding intervention induced cardiotoxicity
fat diet feeding intervention induced cardiotoxicity
doxorubicin sensitizes rats diet induces obesity
doxorubicin dose administered day regimen led absence toxicity renal
doxorubicin dose administered day regimen led absence toxicity renal or
doxorubicin dose administered day regimen led absence toxicity renal hepatic
doxorubicin dose administered day regimen led absence toxicity
doxorubicin dose administered day regimen led cardiotoxicity
doxorubicin dose administered day regimen led cardiotoxicity mortality rats obese
doxorubicin dose administered day regimen led cardiotoxicity mortality rats OB
doxorubicinol doxorubicin accumulation change fed revealed OB
Doxorubicin studies revealed OB
doxorubicin accumulation change fed revealed OB
ATP levels drop leading stress revealed sensitized rats OB
ATP levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
ATP ratio accompanied levels drop leading stress revealed sensitized rats OB
ATP ratio accompanied levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
doxorubicin administration ratio accompanied levels drop leading stress revealed sensitized rats OB
doxorubicin administration ratio accompanied levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
AMP decreased oxidation proliferators downregulation proteins uncoupling upregulation leading stress revealed sensitized rats OB
AMP decreased oxidation min min heart OB
ADP ratio accompanied levels drop leading stress revealed sensitized rats OB
ADP ratio accompanied levels drop leading upregulation uncoupling proteins downregulation proliferators oxidation min min heart OB
ATP generation downregulating induced HFD induced sensitized rats obese
doxorubicin sensitized induced HFD induced cardiotoxicity
doxorubicin sensitized rats obese
ATP generation downregulating induced cardiotoxicity
testosterone concentration increased affected hyperprolactinemia
risperidone started occurred fractures
disulfiram overdose
disulfiram intoxication axonal superimposed case palsy
disulfiram intoxication axonal caused polyneuropathy
Diazepam remains ketamine buffers decreases duration hallucinations
vitamin D growth accelerated calcification artery
vitamin D growth accelerated calcification
D growth accelerated calcification artery
D growth accelerated calcification
vitamin treatment growth enhance extent calcification artery
vitamin treatment growth enhance extent calcification
D treatment growth enhance extent calcification artery
D treatment growth enhance extent calcification
Warfarin doses given rats enhance carboxylation protein inhibitor calcification
vitamin treatment growth enhance carboxylation protein inhibitor calcification
D treatment growth enhance carboxylation protein inhibitor calcification
Warfarin weeks Treatment caused 20 rats calcification
phosphate serum relationship was determined explanation association calcification artery
phosphate serum relationship was determined explanation association calcification
phosphate serum relationship was calcification artery
phosphate serum relationship was calcification
phosphate serum relationship was levels induced calcification artery
phosphate serum relationship was levels induced calcification
phosphate levels was determined explanation association calcification artery
phosphate levels was determined explanation association calcification
phosphate levels was calcification artery
phosphate levels was calcification
phosphate levels induced calcification artery
phosphate levels induced calcification
phosphate levels related calcification artery
phosphate levels related calcification
vitamin D synergy examined calcification artery
vitamin D synergy examined calcification
D synergy examined calcification artery
D synergy examined calcification
vitamin D doses known cause calcification
vitamin D doses known cause calcification media of
vitamin D doses known cause calcification media the
vitamin D doses known cause calcification media artery
D doses known cause calcification
D doses known cause calcification media of
D doses known cause calcification media the
D doses known cause calcification media artery
vitamin Warfarin doses known calcification
vitamin Warfarin doses known calcification media of
vitamin Warfarin doses known calcification media the
vitamin Warfarin doses known calcification media artery
K Warfarin doses known calcification
K Warfarin doses known calcification media of
K Warfarin doses known calcification media the
K Warfarin doses known calcification media artery
Warfarin administration increased extent calcification
vitamin D media increased extent calcification
D media increased extent calcification
vitamin dose calcification artery
vitamin dose calcification
D dose calcification artery
D dose calcification
vitamin dose effect parallel elevation calcium suggests induce calcification artery
vitamin dose effect parallel elevation calcium suggests induce calcification
D dose effect parallel elevation calcium suggests induce calcification artery
D dose effect parallel elevation calcium suggests induce calcification
vitamin dose effect dose calcification artery
vitamin dose effect dose calcification
D dose effect dose calcification artery
D dose effect dose calcification
vitamin dose effect dose effect parallel elevation calcium suggests induce calcification artery
vitamin dose effect dose effect parallel elevation calcium suggests induce calcification
D dose effect dose effect parallel elevation calcium suggests induce calcification artery
D dose effect dose effect parallel elevation calcium suggests induce calcification
vitamin D induce suggests calcium elevation parallel effect dose calcification artery
vitamin D induce suggests calcium elevation parallel effect dose calcification
D induce suggests calcium elevation parallel effect dose calcification artery
D induce suggests calcium elevation parallel effect dose calcification
vitamin D induce calcification artery
vitamin D induce calcification
D induce calcification artery
D induce calcification
calcium elevation parallel effect dose calcification artery
calcium elevation parallel effect dose calcification
calcium suggests induce calcification artery
calcium suggests induce calcification
calcium effect induce suggests calcium elevation parallel effect dose calcification artery
calcium effect induce suggests calcium elevation parallel effect dose calcification
calcium effect induce calcification artery
calcium effect induce calcification
calcium had explained inhibits activity protein inhibitor calcification
Warfarin treatment had explained inhibits activity protein inhibitor calcification
Warfarin D synergy explained inhibits activity protein inhibitor calcification
Warfarin inhibits activity protein inhibitor calcification
vitamin D produced calcium had explained inhibits activity protein inhibitor calcification
D produced calcium had explained inhibits activity protein inhibitor calcification
vitamin Warfarin D synergy explained inhibits activity protein inhibitor calcification
D synergy explained inhibits activity protein inhibitor calcification
vitamin D treated rats found sites calcification artery
vitamin D treated rats found sites calcification
D treated rats found sites calcification artery
D treated rats found sites calcification
gamma showed found sites calcification artery
gamma showed found sites calcification
carboxylated gamma showed found sites calcification artery
carboxylated gamma showed found sites calcification
gamma protein required inhibitor calcification
carboxyglutamate residues gamma protein required inhibitor calcification
gamma protein required required sites calcification
carboxyglutamate residues gamma protein required required sites calcification
SRL treated therapy sarcoma cancers carsinom renal
SRL treated therapy sarcoma cancers carsinom cell
SRL treated therapy sarcoma cancers carsinom
SRL treated therapy neoplasia due nephropathy CAN
SRL treated therapy sarcoma nephropathy
SRL treated therapy neoplasia
SRL treated therapy sarcoma cancers tumors intestinal
SRL treated therapy sarcoma cancers tumors
SRL treated therapy sarcoma Kaposi
SRL treated therapy sarcoma Kaposi '
SRL treated therapy sarcoma s
SRL treated therapy sarcoma
SRL treated therapy sarcoma cancers skin
SRL treated therapy sarcoma cancers
SRL treated therapy neoplasia due nephropathy chronic
SRL treated therapy neoplasia due nephropathy allograft
SRL treated therapy neoplasia due nephropathy
heparin therapy thrombophlebitis
DFO other factor ototoxic
DFO role development impairment hearing
DFO role development impairment
oxacillin treated man year developed failure lesions purpuric
oxacillin treated man year developed failure lesions
oxacillin week bacteremia Staphylococcus
oxacillin week bacteremia aureus
oxacillin week bacteremia
amphetamine dose sensitization diet promoting causes sugar
amphetamine dose sensitization diet promoting causes dependency
cyanoacrylate doxorubicin toxicity renal
cyanoacrylate doxorubicin toxicity
doxorubicin toxicity renal
doxorubicin toxicity
adriamycin doxorubicin toxicity renal
adriamycin doxorubicin toxicity
doxorubicin nanoparticle explored rats glomerulonephritis
doxorubicin nanoparticle explored toxicity renal
doxorubicin nanoparticle explored toxicity
DX died given rats rats glomerulonephritis
DX killed toxicity renal
DX killed toxicity
cocaine revealed period METHODS aneurysms
cocaine patients outcome predictors aneurysms
Cocaine use predisposed predisposed aneurysms
nelarabine therapy T
nelarabine therapy T leukaemia cell
nelarabine therapy T leukaemia lymphoblastic
nelarabine therapy T leukaemia
nelarabine therapy T leukaemia and
nelarabine therapy T leukaemia lymphoma
cyclophosphamide nelarabine therapy T
cyclophosphamide nelarabine therapy T leukaemia cell
cyclophosphamide nelarabine therapy T leukaemia lymphoblastic
cyclophosphamide nelarabine therapy T leukaemia
cyclophosphamide nelarabine therapy T leukaemia and
cyclophosphamide nelarabine therapy T leukaemia lymphoma
etoposide nelarabine therapy T
etoposide nelarabine therapy T leukaemia cell
etoposide nelarabine therapy T leukaemia lymphoblastic
etoposide nelarabine therapy T leukaemia
etoposide nelarabine therapy T leukaemia and
etoposide nelarabine therapy T leukaemia lymphoma
nelarabine d combination used children T
nelarabine d combination used children leukaemia cell
nelarabine d combination used children leukaemia
nelarabine d combination used children leukaemia or
nelarabine d combination used children leukaemia lymphoma
AraG nelarabine d combination used children T
AraG nelarabine d combination used children leukaemia cell
AraG nelarabine d combination used children leukaemia
AraG nelarabine d combination used children leukaemia or
AraG nelarabine d combination used children leukaemia lymphoma
cyclophosphamide etoposide d nelarabine d combination used children T
cyclophosphamide etoposide d nelarabine d combination used children leukaemia cell
cyclophosphamide etoposide d nelarabine d combination used children leukaemia
cyclophosphamide etoposide d nelarabine d combination used children leukaemia or
cyclophosphamide etoposide d nelarabine d combination used children leukaemia lymphoma
CPM etoposide d nelarabine d combination used children T
CPM etoposide d nelarabine d combination used children leukaemia cell
CPM etoposide d nelarabine d combination used children leukaemia
CPM etoposide d nelarabine d combination used children leukaemia or
CPM etoposide d nelarabine d combination used children leukaemia lymphoma
etoposide d nelarabine d combination used children T
etoposide d nelarabine d combination used children leukaemia cell
etoposide d nelarabine d combination used children leukaemia
etoposide d nelarabine d combination used children leukaemia or
etoposide d nelarabine d combination used children leukaemia lymphoma
VP etoposide d nelarabine d combination used children T
VP etoposide d nelarabine d combination used children leukaemia cell
VP etoposide d nelarabine d combination used children leukaemia
VP etoposide d nelarabine d combination used children leukaemia or
VP etoposide d nelarabine d combination used children leukaemia lymphoma
cyclophosphamide etoposide giving safety supports monitored toxicity neurological
cyclophosphamide etoposide giving safety supports monitored toxicity
etoposide giving safety supports monitored toxicity neurological
etoposide giving safety supports monitored toxicity
imidazoline modulation hypotension
estrogen modulation hypotension
clonidine effect hypotensive
estrogen modulates effect hypotensive
alpha rats paralleled SDRR activity a
alpha rats paralleled SDRR activity reduced
alpha rats paralleled SDRR activity locomotor
alpha rats paralleled SDRR activity
methyldopa hypotension alpha rats paralleled SDRR activity a
methyldopa hypotension alpha rats paralleled SDRR activity reduced
methyldopa hypotension alpha rats paralleled SDRR activity locomotor
methyldopa hypotension alpha rats paralleled SDRR activity
estrogen downregulates mediated hypotension
estrogen interaction hypotension
rapamycin inhibitors target observed recipients nephropathy chronic
rapamycin inhibitors target observed recipients nephropathy allograft
rapamycin inhibitors target observed recipients nephropathy
sirolimus target observed recipients nephropathy chronic
sirolimus target observed recipients nephropathy allograft
sirolimus target observed recipients nephropathy
dopamine receptors induced hyperactivity
SCH blocked hyperactivity
23390 SCH blocked hyperactivity
fluphenazine SCH blocked hyperactivity
raclopride SCH blocked hyperactivity
SKF agonist had induced hyperactivity
38393 SKF agonist had induced hyperactivity
PHNO induced hyperactivity
apomorphine infusion induced state dyskinetic
apomorphine infusion induced state modification result investigated Using area group patients disease Parkinson
apomorphine infusion induced state modification result investigated Using area group patients disease
azidothymidine erythropoietin colonies Sensitivity treated mice immunodeficient
AZT due determine BM used model AIDS
AZT due determine BM infection
AZT due determine BM leukaemia
phenylhydrazine compared observed degree anaemia
PHZ phenylhydrazine compared observed degree anaemia
PHZ AZT treated degrees anaemia
AZT observed anaemia degree inappropriate reticulocytosis
amisulpride unmasked Pheochromocytoma
tiapride amisulpride unmasked Pheochromocytoma
amisulpride treated patient describe unmasking pheochromocytoma
tiapride amisulpride treated patient describe unmasking pheochromocytoma
nicardipine recovered discontinued CASE man headache
verapamil treatment nicardipine recovered discontinued CASE man hypertension
verapamil treatment nicardipine recovered discontinued CASE man headache
nicardipine recovered discontinued CASE man hypertension
verapamil treatment nicardipine recovered discontinued CASE man headache vomiting
nicardipine recovered discontinued CASE man headache vomiting
benzamide drugs use associated symptoms pheochromocytoma
amisulpride crisis patient pheochromocytoma
tiapride amisulpride crisis patient pheochromocytoma
pegylated alpha patient chronic
pegylated alpha patient hepatitis
pegylated alpha patient C
interferon alpha patient chronic
interferon alpha patient hepatitis
interferon alpha patient C
alpha patient chronic
alpha patient hepatitis
alpha patient C
2 b case parasitosis patient chronic
2 b case parasitosis patient hepatitis
2 b case parasitosis patient C
b case parasitosis patient chronic
b case parasitosis patient hepatitis
b case parasitosis patient C
ribavirin treatment b case parasitosis patient chronic
ribavirin treatment b case parasitosis patient hepatitis
ribavirin treatment b case parasitosis patient C
ribavirin interferon treatment patients chronic
ribavirin interferon treatment patients hepatitis
ribavirin interferon treatment patients C
MPTP dyskinesias
L drugs Effect dopa dyskinesias
dopa dyskinesias
L tested see modified movements dyskinetic
DOPA tested see modified movements dyskinetic
dopamine neurotransmitters acting agents series tested see modified movements dyskinetic
clonidine reduced cost return symptomatology parkinsonian
methysergide clonidine reduced movements dyskinetic
5 methysergide clonidine reduced movements dyskinetic
MDOT clonidine reduced movements dyskinetic
physostigmine clonidine reduced movements dyskinetic
MK MDOT clonidine reduced cost return symptomatology parkinsonian
801 clonidine reduced cost return symptomatology parkinsonian
propranolol MDOT clonidine reduced movements dyskinetic
methysergide clonidine reduced cost return symptomatology parkinsonian
propranolol MDOT clonidine reduced cost return symptomatology parkinsonian
5 methysergide clonidine reduced cost return symptomatology parkinsonian
MDOT clonidine reduced cost return symptomatology parkinsonian
clonidine reduced movements dyskinetic
physostigmine clonidine reduced cost return symptomatology parkinsonian
MK MDOT clonidine reduced movements dyskinetic
801 clonidine reduced movements dyskinetic
yohimbine reduced movements dyskinetic
meperidine yohimbine reduced movements dyskinetic
Baclofen useful monkey form dyskinesia
Baclofen useful monkey form dystonic
Atropine converted movements dystonic
Atropine converted chorea
5 toxicity Cardiac
5 toxicity
fluorouracil toxicity Cardiac
fluorouracil toxicity
5 presented metastasis patient carcinoma colon
5 presented metastasis patient carcinoma
fluorouracil administration metastasis patient carcinoma colon
fluorouracil administration metastasis patient carcinoma
5 administration metastasis patient carcinoma colon
5 administration metastasis patient carcinoma
FU 5 administration metastasis patient carcinoma colon
FU 5 administration metastasis patient carcinoma
5 presented metastasis
fluorouracil administration metastasis
5 administration metastasis
FU 5 administration metastasis
nifedipine resolved pain chest
nifedipine resolved pain
nifedipine resolved similar observed angina Prinzmetal
nifedipine resolved similar observed angina Prinzmetal '
nifedipine resolved similar observed angina s
nifedipine resolved similar observed angina
calcium antagonists used cause due cardiotoxicity
calcium antagonists used cause suggest cardiotoxicity
calcium antagonists used cause spasm coronary
calcium antagonists used cause spasm
5 due cause spasm coronary
5 due cause spasm
FU cause spasm coronary
FU cause spasm
5 prevention used cause spasm coronary
5 prevention used cause spasm
FU cardiotoxicity suggest cause spasm coronary
FU cardiotoxicity suggest cause spasm
5 due cardiotoxicity
FU cause due cardiotoxicity
5 due cause suggest cardiotoxicity
FU cause suggest cardiotoxicity
5 prevention used cause due cardiotoxicity
FU cardiotoxicity suggest cause due cardiotoxicity
5 prevention used cause suggest cardiotoxicity
FU cardiotoxicity
paroxetine treatment day exhibited tremors
paroxetine treatment day exhibited retardation rigidity muscle
paroxetine treatment day exhibited retardation rigidity
paroxetine treatment day exhibited retardation psychomotor
paroxetine treatment day exhibited retardation
alprazolam paroxetine treatment day exhibited tremors
alprazolam paroxetine treatment day exhibited retardation rigidity muscle
alprazolam paroxetine treatment day exhibited retardation rigidity
alprazolam paroxetine treatment day exhibited retardation psychomotor
alprazolam paroxetine treatment day exhibited retardation
GNC H immunotherapy overdose cocaine
GNC H immunotherapy overdose
92 H immunotherapy overdose cocaine
92 H immunotherapy overdose
H immunotherapy overdose cocaine
H immunotherapy overdose
2 H immunotherapy overdose cocaine
2 H immunotherapy overdose
cocaine use continues remains treatment overdose cocaine
cocaine use continues remains treatment overdose
GNC H potential examined using model overdose cocaine
GNC H potential examined using model overdose
92 H potential examined using model overdose cocaine
92 H potential examined using model overdose
H potential examined using model overdose cocaine
H potential examined using model overdose
2 H potential examined using model overdose cocaine
2 H potential examined using model overdose
cocaine toxicity blockade observed H reduced up % death
GNC dose observed H reduced up seizures
92 GNC dose observed H reduced up seizures
H reduced up seizures
2 H reduced up seizures
GNC dose observed blockade toxicity
92 GNC dose observed blockade toxicity
H observed blockade toxicity
2 H observed blockade toxicity
cocaine toxicity
GNC dose observed H reduced up % death
92 GNC dose observed H reduced up % death
H reduced up % death
2 H reduced up % death
cocaine injection post prevented death
GNC H prevented death
92 H prevented death
H prevented death
2 H prevented death
GNC potential support H tool overdose cocaine
GNC potential support H tool overdose
92 GNC potential support H tool overdose cocaine
92 GNC potential support H tool overdose
H tool overdose cocaine
H tool overdose
2 H tool overdose cocaine
2 H tool overdose
Dup 753 prevents development nephrosis
753 prevents development nephrosis
puromycin aminonucleoside development nephrosis
aminonucleoside development nephrosis
blood urea syndromes proteinuria
nitrogen urea syndromes proteinuria
urea syndromes proteinuria
angiotensin II antagonist administration inhibited appearance syndromes nephrotic
angiotensin II antagonist administration inhibited appearance syndromes
II antagonist administration inhibited appearance syndromes nephrotic
II antagonist administration inhibited appearance syndromes
blood urea syndromes nephrotic
blood urea syndromes
nitrogen urea syndromes nephrotic
nitrogen urea syndromes
urea syndromes nephrotic
urea syndromes
Dup administration inhibited appearance syndromes proteinuria hypoalbuminemia
753 Dup administration inhibited appearance syndromes proteinuria hypoalbuminemia
losartan administration inhibited appearance syndromes proteinuria hypoalbuminemia
angiotensin II antagonist administration inhibited appearance syndromes proteinuria
II antagonist administration inhibited appearance syndromes proteinuria
blood urea syndromes proteinuria hypoalbuminemia
nitrogen urea syndromes proteinuria hypoalbuminemia
urea syndromes proteinuria hypoalbuminemia
angiotensin II antagonist administration inhibited appearance syndromes proteinuria hypercholesterolemia
II antagonist administration inhibited appearance syndromes proteinuria hypercholesterolemia
Dup administration inhibited appearance syndromes nephrotic
Dup administration inhibited appearance syndromes
753 Dup administration inhibited appearance syndromes nephrotic
753 Dup administration inhibited appearance syndromes
losartan administration inhibited appearance syndromes nephrotic
losartan administration inhibited appearance syndromes
angiotensin II antagonist administration inhibited appearance syndromes proteinuria hypoalbuminemia
II antagonist administration inhibited appearance syndromes proteinuria hypoalbuminemia
blood urea syndromes proteinuria hypercholesterolemia
nitrogen urea syndromes proteinuria hypercholesterolemia
urea syndromes proteinuria hypercholesterolemia
Dup administration inhibited appearance syndromes proteinuria
753 Dup administration inhibited appearance syndromes proteinuria
losartan administration inhibited appearance syndromes proteinuria
Dup administration inhibited appearance syndromes proteinuria hypercholesterolemia
753 Dup administration inhibited appearance syndromes proteinuria hypercholesterolemia
losartan administration inhibited appearance syndromes proteinuria hypercholesterolemia
puromycin aminonucleoside development system renin induced nephrosis
aminonucleoside development system renin induced nephrosis
angiotensin system renin induced nephrosis
amikacin toxicity
aminoglycosides improved impair infarction
aminoglycosides improved endophthalmitis
vancomycin amikacin treatment toxicity retinal
vancomycin amikacin treatment toxicity
amikacin toxicity treatment endophthalmitis streptococcal
amikacin toxicity treatment endophthalmitis
amikacin treatment endophthalmitis streptococcal
amikacin treatment endophthalmitis
vancomycin amikacin treatment endophthalmitis streptococcal
vancomycin amikacin treatment endophthalmitis
fluorescein confirmed telangiectasis
chloramphenicol beginning undergoing extraction cataract
chloramphenicol treatment report reported cases hypoplasia bone
chloramphenicol treatment report reported cases hypoplasia marrow
chloramphenicol treatment report reported cases hypoplasia
chloramphenicol associated toxicity ocular
chloramphenicol associated toxicity
ifosfamide Hallucinations induced neurotoxicity
ifosfamide effect symptom neurotoxicity
ifosfamide hallucinations occur signs neurotoxicity
haloperidol neuroleptics becomes agitation
ecstasy users deficits Learning
ecstasy users deficits Learning and
ecstasy users deficits memory
ecstasy users deficits
ecstasy users display impairments
ecstasy users display impairments performance in
ecstasy users display impairments performance learning
ecstasy users display impairments performance learning and
ecstasy users display impairments performance learning memory
cannabis users hyperactivity Deficits
cannabis users hyperactivity Deficits learning in
cannabis users hyperactivity Deficits learning
cannabis users hyperactivity Deficits learning and
cannabis users hyperactivity Deficits learning memory
cannabis users hyperactivity
ecstasy revealed task phases analysis hyperactivity
ecstasy related effects neurotoxic
ecstasy effects neurotoxic
prostaglandin synthetase Effect inhibitors induced convulsions
prostaglandins induction seizure
prostaglandins induction effects inhibitors convulsions
PGs prostaglandins induction seizure
PGs prostaglandins induction effects inhibitors convulsions
PGs involved fluorthyl induced convulsions
PGs involved fluorthyl convulsions
azidothymidine induced impairment activity immunodeficiency
Benzylacyclouridine reverses azidothymidine induced suppression marrow
Benzylacyclouridine reverses azidothymidine induced suppression
Benzylacyclouridine reverses azidothymidine induced impairment activity immunodeficiency
azidothymidine vitro inhibition concentrations cells impairment activity immunodeficiency
AZT azidothymidine vitro inhibition concentrations cells impairment activity immunodeficiency
uridine concentrations cells impairment activity immunodeficiency
Urd uridine concentrations cells impairment activity immunodeficiency
benzylacyclouridine ability effect AZT induced anemia
BAU ability effect AZT induced anemia
benzylacyclouridine ability effect AZT induced anemia leukopenia
BAU ability effect AZT induced anemia leukopenia
AZT effect ability assessed toxicities
benzylacyclouridine ability assessed toxicities
BAU ability assessed toxicities
Urd administration associated toxicities
Urd administration associated toxicities assessed ability effect AZT induced anemia leukopenia
Urd administration associated toxicities assessed ability effect AZT induced anemia
Urd catabolism inhibits toxicity
Urd concentration increases inhibits toxicity
Urd manner toxicity
BAU reversed rendered anemic
BAU reversed induced anemia
BAU reversed rendered anemic leukopenic
BAU reversed induced anemia leukopenia
BAU reversed rendered mice increased improved megaloblastosis
AZT administration rendered mice increased improved megaloblastosis
AZT administration water drinking days reversed rendered mice increased improved megaloblastosis
AZT induced reversed rendered mice increased improved megaloblastosis
BAU reduced AZT induced toxicity marrow
BAU reduced AZT induced toxicity
levodopa overflow dyskinesias disease Parkinson
levodopa overflow dyskinesias disease Parkinson '
levodopa overflow dyskinesias disease s
levodopa overflow dyskinesias disease
levodopa therapy complications assessed coordination hand disease Parkinson
levodopa therapy complications assessed coordination hand disease Parkinson '
levodopa therapy complications assessed coordination hand disease s
levodopa therapy complications assessed coordination hand disease
levodopa complications assessed coordination hand disease Parkinson
levodopa complications assessed coordination hand disease Parkinson '
levodopa complications assessed coordination hand disease s
levodopa complications assessed coordination hand disease
levodopa with studied groups patients Parkinson
levodopa with studied groups patients Parkinson '
levodopa with studied groups patients s
levodopa with studied groups patients disease
levodopa with LID + Parkinson
levodopa with LID + Parkinson '
levodopa with LID + s
levodopa with LID + disease
levodopa dyskinesias disease Parkinson
levodopa dyskinesias disease Parkinson '
levodopa dyskinesias disease s
levodopa dyskinesias disease
levodopa assessed lift score Scale Parkinson
levodopa assessed lift score Scale Parkinson '
levodopa assessed lift score Scale s
levodopa assessed lift score Scale Disease
levodopa increased LID Parkinson
levodopa increased LID Parkinson '
levodopa increased LID s
levodopa increased LID disease
mangiferin Role infarction myocardial
mangiferin Role infarction
creatine phosphokinase isoenzymes dehydrogenase activity determined heart caused damage myocardial
creatine phosphokinase isoenzymes dehydrogenase activity determined heart caused damage
uric level activity determined heart caused damage myocardial
uric level activity determined heart caused damage
acid level activity determined heart caused damage myocardial
acid level activity determined heart caused damage
lactate dehydrogenase activity determined heart caused damage myocardial
lactate dehydrogenase activity determined heart caused damage
iron capacity activity determined heart caused damage myocardial
iron capacity activity determined heart caused damage
ISPH injection caused damage myocardial
ISPH injection caused damage
triphenyl chloride test used assay myocardium ischemic
triphenyl chloride test used assay myocardium
tetrazolium chloride test used assay myocardium ischemic
tetrazolium chloride test used assay myocardium
chloride test used assay myocardium ischemic
chloride test used assay myocardium
TTC chloride test used assay myocardium ischemic
TTC chloride test used assay myocardium
mangiferin role analyzed chloride test used assay myocardium ischemic
mangiferin role analyzed chloride test used assay myocardium
Vitamin C dismutase enzymes altered rats MI
C dismutase enzymes altered rats MI
glutathione peroxidase dismutase enzymes altered rats MI
glutathione transferase dismutase enzymes altered rats MI
glutathione activities transferase dismutase enzymes altered rats MI
glutathione levels dismutase enzymes altered rats MI
Vitamin E dismutase enzymes altered rats MI
E dismutase enzymes altered rats MI
superoxide dismutase enzymes altered rats MI
dimethyl sulphoxide ml suspended weight pretreatment given rats MI
sulphoxide ml suspended weight pretreatment given rats MI
mangiferin pretreatment given rats MI
mangiferin administration rose ISPH induced rats MI
mangiferin exerts due MI
ISPH exerts due potential regulated system damage cardiac
ISPH exerts due potential regulated system damage
mangiferin exerts due potential regulated system damage cardiac
mangiferin exerts due potential regulated system damage
quipazine aggressiveness
quipazine aggressiveness induced deprivation REM
quipazine aggressiveness induced deprivation sleep
quipazine aggressiveness induced deprivation
quipazine aggressiveness induced deprivation REMD
apomorphine deprivation REM
apomorphine deprivation sleep
apomorphine deprivation
apomorphine deprivation REMD
apomorphine deprivation induced twitches head
apomorphine deprivation induced twitches
quipazine increased reduced increased induced aggressiveness
quipazine increased reduced increased hr REMD
quipazine increased reduced immediately completing REMD
quipazine hr REMD
apomorphine increased hr REMD
apomorphine increased reduced immediately completing REMD
apomorphine increased reduced increased quipazine hr REMD
apomorphine increased reduced twitches head
apomorphine increased reduced twitches
oestrogen Long increased increase risk cancer breast
oestrogen Long increased increase risk cancer
minoxidil use Pseudoacromegaly
minoxidil resulted patient pseudoacromegaly
minoxidil use effect pseudoacromegaly
WR cisplatin trial amifostine carcinoma breast
WR cisplatin trial amifostine carcinoma
2721 amifostine carcinoma breast
2721 amifostine carcinoma
amifostine carcinoma breast
amifostine carcinoma
cisplatin trial amifostine carcinoma breast
cisplatin trial amifostine carcinoma
Cisplatin has activity line treatment carcinoma breast
Cisplatin has activity line treatment carcinoma
cisplatin observed limited dose e g nephrotoxicity neurotoxicity
cisplatin associated toxicities dose e g nephrotoxicity neurotoxicity
cisplatin observed limited treatment carcinoma breast
cisplatin observed limited treatment carcinoma
cisplatin associated toxicities dose limited treatment carcinoma breast
cisplatin associated toxicities dose limited treatment carcinoma
cisplatin observed limited dose toxicities
cisplatin associated toxicities
amifostine cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity neuropathy
amifostine cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity ototoxicity
amifostine cisplatin trials suggested reduced incidence cisplatin induced nephrotoxicity
amifostine cisplatin conducted carcinoma breast
amifostine cisplatin conducted carcinoma
cisplatin conducted carcinoma breast
cisplatin conducted carcinoma
amifostine addition observed tumor
cisplatin observed tumor effect toxicity
cisplatin observed tumor
amifostine addition observed tumor effect toxicity
dothiepin hydrochloride treatment disorder depressive
dothiepin hydrochloride treatment disorder
hydrochloride treatment disorder depressive
hydrochloride treatment disorder
amitriptyline study placebo treatment outpatients depressed
dothiepin study placebo treatment outpatients depressed
amitriptyline Dothiepin effective alleviating symptoms illness depressive
amitriptyline Dothiepin effective alleviating symptoms illness
Dothiepin effective alleviating symptoms illness depressive
Dothiepin effective alleviating symptoms illness
dothiepin less incidence frequency vision blurred
dothiepin less incidence frequency vision
dothiepin less incidence frequency vision mouth dry
dothiepin less incidence frequency vision mouth
antidepressant drug associated treatment outpatients depressed
amitriptyline effects associated treatment outpatients depressed
Dothiepin found drug associated treatment outpatients depressed
propylthiouracil caused disease Liver
propylthiouracil caused disease
adriamycin effects Cardiotoxic
anthracycline induced cardiomyopathy
anthracycline found resembled lesions myocardial
anthracycline found resembled lesions
adriamycin cardiotoxin consequence leukemia
daunorubicin sarcoma Kaposi
daunorubicin sarcoma Kaposi '
daunorubicin sarcoma s
daunorubicin sarcoma
daunorubicin efficacy assess treatment AIDS
daunorubicin efficacy assess treatment AIDS related sarcoma Kaposi
daunorubicin efficacy assess treatment AIDS related sarcoma Kaposi '
daunorubicin efficacy assess treatment AIDS related sarcoma s
daunorubicin efficacy assess treatment AIDS related sarcoma
daunorubicin agent treatment sarcoma Kaposi
daunorubicin agent treatment sarcoma Kaposi '
daunorubicin agent treatment sarcoma s
daunorubicin agent treatment sarcoma
Mesna adding precise frequency hematuria
Mesna adding infusate patients hematuria
bilirubin mortality predicted presentation encephalopathy
fentanyl reduces pain
fentanyl reduces nausea
fentanyl reduces nausea vomiting
sevoflurane reduces pain
sevoflurane reduces nausea
sevoflurane reduces nausea vomiting
sevoflurane anaesthesia induction advantages occurs nausea postoperative
sevoflurane anaesthesia induction advantages occurs nausea
sevoflurane anaesthesia induction advantages occurs nausea and
sevoflurane anaesthesia induction advantages occurs nausea vomiting
sevoflurane anaesthesia vomiting study examined incidence nausea postoperative
sevoflurane anaesthesia vomiting study examined incidence nausea
sevoflurane anaesthesia vomiting study and
sevoflurane anaesthesia vomiting
sevoflurane anaesthesia vomiting pain
fentanyl Omission reduce did reduce moderate nausea
fentanyl % discharge moderate nausea
fentanyl fentanyl % discharge moderate nausea
fentanyl Omission reduce did reduce incidence vomiting
fentanyl % discharge moderate reduce incidence vomiting
fentanyl fentanyl % discharge moderate reduce incidence vomiting
dexamethasone reduce did reduce incidence nausea postoperative
dexamethasone reduce did reduce incidence nausea
dexamethasone reduce did reduce incidence nausea and
dexamethasone reduce did reduce incidence nausea vomiting
dexamethasone reduce incidence vomiting
dexamethasone reduce moderate nausea
Dexamethasone had effect incidence nausea postoperative
Dexamethasone had effect incidence nausea
Dexamethasone had effect incidence nausea and
Dexamethasone had effect incidence nausea vomiting
fentanyl groups Combining revealed reducing nausea
fentanyl groups Combining revealed reducing nausea prior discharge decreased nausea
fentanyl omission unaffected severity Pain
sevoflurane had reduce increased respiratory
sevoflurane had reduce increased depression
sevoflurane had reduce increased depression hypotension
sevoflurane had reduce increased depression bradycardia
sevoflurane supplement appears exacerbated nausea postoperative
sevoflurane supplement appears exacerbated nausea
sevoflurane supplement appears exacerbated nausea and
sevoflurane supplement appears exacerbated nausea vomiting
sevoflurane supplement appears exacerbated improvement pain postoperative
sevoflurane supplement appears exacerbated improvement pain
fentanyl exacerbated improvement pain postoperative
fentanyl exacerbated improvement pain
acetic acid induced writhing
acid induced writhing
acetic acid paw model edema
acid paw model edema
methotrexate dose induction leukemia meningeal
methotrexate dose induction leukemia
methotrexate regimen high treated developed leukemia acute
methotrexate regimen high treated developed leukemia lymphoblastic
methotrexate regimen high treated developed leukemia
methotrexate concentrations achieve designed regimen high treated developed leukemia acute
methotrexate concentrations achieve designed regimen high treated developed leukemia lymphoblastic
methotrexate concentrations achieve designed regimen high treated developed leukemia
methotrexate regimen high treated disease meningeal
methotrexate regimen high treated disease
methotrexate concentrations achieve designed regimen high treated disease meningeal
methotrexate concentrations achieve designed regimen high treated disease
bilirubin elevations transaminase neutropenia
bilirubin elevations transaminase encountered toxicities
bilirubin elevations transaminase mucositis
methotrexate treatment induction remission relapse leukemia acute
methotrexate treatment induction remission relapse leukemia lymphoblastic
methotrexate treatment induction remission relapse leukemia
